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Abstract: Background: Rucaparib, a poly(ADP-ribose) polymerase inhibitor, 
has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA 
mutation or a high percentage of genome-wide loss of heterozygosity 
(LOH). ARIEL3 evaluated rucaparib versus placebo following response to 
second-line or later platinum-based chemotherapy in patients with high-
grade, recurrent, platinum-sensitive ovarian carcinoma. 
Methods: ARIEL3 is an international, randomised, double-blind, phase 3 
study performed at 87 hospitals and cancer centres. Patients were 
randomised 2:1 to receive oral rucaparib 600 mg twice daily or placebo 
using a computer-generated sequence (block size of six). Patients, 
investigators, site staff, and study sponsor were blinded to assignments. 
The primary endpoint (investigator-assessed progression-free survival) 
was evaluated using an ordered step-down procedure for three nested 
cohorts: (1) BRCA mutant (carcinoma associated with deleterious germline 
or somatic BRCA mutation); (2) homologous recombination deficient (HRD) 
(BRCA mutant or BRCA wild type/LOH high); and (3) intent-to-treat 
population. ARIEL3 is registered with ClinicalTrials.gov, NCT01968213; 
enrolment is complete. 
Findings: Between April 7, 2014, and July 19, 2016, 564 patients were 
randomised, 375 to rucaparib and 189 to placebo. Median progression-free 
survival in patients with a BRCA-mutant carcinoma (n=130, rucaparib; 
n=66, placebo) was 16·6 months versus 5·4 months (p<0·0001), respectively 
(hazard ratio [HR] 0·23; 95% confidence interval [CI] 0·16-0·34); in 
patients with an HRD carcinoma (n=236, rucaparib; n=118, placebo) it was 
13·6 months versus 5·4 months (p<0·0001), respectively (HR 0·32; 95% CI 
0·24-0·42); and in the intent-to-treat population it was 10·8 months and 
5·4 months (p<0·0001), respectively (HR 0·36; 95% CI 0·30-0·45). The most 
common grade 3 or higher adverse events in the safety population (n=372, 
rucaparib; n=189, placebo) were anaemia/decreased haemoglobin (70 [19%], 
rucaparib; one [1%], placebo) and increased alanine or aspartate 
aminotransferase (39 [10%], rucaparib; none, placebo).  
Interpretation: Across all primary analysis groups, rucaparib 
significantly improved progression-free survival in patients with 
platinum-sensitive ovarian cancer who had achieved a response to 
platinum-based chemotherapy. 
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Dear Dr. Spencer: 
 
On behalf of my coauthors, I thank you and the reviewers for providing insightful comments 
on our manuscript entitled “Rucaparib maintenance treatment for recurrent ovarian 
carcinoma after response to platinum therapy (ARIEL3): a phase 3, international, 
randomised, double-blind trial” (THELANCET-D-17-05358). We are grateful to receive an 
opportunity to resubmit our manuscript to The Lancet. 
 
Enclosed please find our point-by-point responses to the reviewers’ comments. Line 
numbers referenced below refer to the tracked version of the manuscript.  
 
Thank you for your consideration. We look forward to receiving your response. 
 
Sincerely, 
 
 
Robert L. Coleman, MD 
 
Reviewer #2 Comment 1: Page 10 '...at regular intervals' bit more detail please. 
Author Response 2.1: We have updated the manuscript to clarify that the independent 
data monitoring committee reviewed the safety and efficacy data from ARIEL3 
approximately every 6 months (lines 204-207): 
“Per the protocol, an independent data monitoring committee monitored enrolment 
and reviewed the safety and efficacy of the trial approximately every 6 months, 
including maturity of progression-free survival events.” 
Reviewer #2 Comment 2: How was the proportionality of hazards verified? Show the 
results for this. 
Author Response 2.2: We thank the reviewer for their inquiry. The Cox proportional 
hazard assumption (ie, constant relative hazard) was verified graphically using log-log 
plots generated using SAS version 9.3 (Cary, NC, USA). 
*Reply to Reviewers Comments
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Reviewer #2 Comment 3: Figure 2 (and S2) are presented well. My preference is to show 
an initial Kaplan-Meier curve over all patients (no treatment) with a 95% confidence interval 
(CI).  
Author Response 2.3: We thank the reviewer for their thoughtful review of the figures 
and their suggestion. We have provided Kaplan-Meier curves of investigator-assessed 
and blinded independent central radiology review–assessed progression-free survival in 
all patients (intent-to-treat population) in the supplementary appendix (figure S6). 
Furthermore, these Kaplan-Meier curves are not stratified by treatment. 
Reviewer #2 Comment 4: Figure 3 (and elsewhere) short on details (e.g., include events). 
X-axis should be redrawn on a log scale (95% CIs symmetric under this transformation).  
Author Response 2.4: We thank the reviewer for their suggestion. We have revised 
Figure 3 to use a log2 scale on the X axis and also provided additional details about the 
cumulative number of events in each arm for all subgroups. This information was added 
in two new columns on the forest plot (figure 3). 
Reviewer #2 Comment 5: Discrepancy in numbers between protocol (Section 6.1) and 
study. Protocol states 'approximately 540' (Section 6.1) with no more than 360 to be 
stratified into subgroups. Whereas 564 were recruited (375 into subgroups). Section 10.8 
makes reference to an independent DMC's monitoring of study size which may explain it.  
Author Response 2.5: We thank the reviewer for this thoughtful comment. Per the 
protocol (Section 6.1), approximately 540 patients were to be enrolled in ARIEL3. A 
minimum of 180 and a maximum of 200 patients with a deleterious BRCA mutation were 
to be enrolled. Additionally, no more than 360 patients without a BRCA mutation 
(referred to as “nbHRD and biomarker negative” in Section 6.1 of the protocol) were to 
be enrolled in ARIEL3.  
The independent data monitoring committee surveyed enrolment of the patients with a 
BRCA mutation and informed the study sponsor (Clovis Oncology, Inc.) when the target 
enrolment number for the BRCA-mutant cohort was anticipated to be reached. Once 
notified, patients who were in the screening process were allowed to complete screening 
and enrol into the study if they met all eligibility criteria. Thus, 196 patients with a BRCA 
mutation were enrolled in ARIEL3, which is within the maximum limit of 200 prespecified 
patients in the protocol. We have clarified this point in the Statistical analysis section 
(lines 288-296): 
“ARIEL3 was designed to enrol approximately 540 patients, including between 180 
and 200 patients with a BRCA mutation in their carcinoma (with no more than 150 
patients with a known deleterious germline BRCA mutation) and no more than 360 
patients without a BRCA mutation in their carcinoma. The independent data 
monitoring committee surveyed enrolment of patients with a BRCA mutation and 
informed the study sponsor (Clovis Oncology, Inc.) when the target enrolment 
number for the BRCA-mutant cohort was anticipated to be reached. Once notified, 
patients who were in the screening process were allowed to complete screening and 
enrol into the study if they met all eligibility criteria.” 
Reviewer #2 Comment 6: I haven't seen your CONSORT Statement (apologies if I've 
missed it). 
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Author Response 2.6: We thank the reviewer for their careful review of our manuscript. 
Per The Lancet’s guidelines, we have ensured that our manuscript conforms to 
CONSORT guidelines and provided our completed check-list with resubmission.   
 
Reviewer #3 Comment 1: Page 23, middle of page: "No cases of Hy's law were observed". 
Not sure what this means 
Author Response 3.1: We thank the reviewer for the comment. As outlined in a 
Guidance for Industry document from the US Department of Health and Human 
Services, Food and Drug Administration, “Hy’s law” is a translation of Dr. Hyman 
Zimmerman’s observation that pure hepatocellular injury sufficient to cause 
hyperbilirubinemia is an indicator of the potential for a drug to cause serious liver injury 
(Department of Health and Human Services. 
www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/Guidances/UC
M174090.pdf). “Hy’s law” was coined by Dr. Robert Temple (Deputy Center Director for 
Clinical Science, Center for the Evaluation of Drug Research and Acting Deputy Director 
of the Office of Drug Evaluation I [ODE-I] at the US Food and Drug Administration) in the 
1980s. 
According to Hy’s law, patients are at risk for hepatocellular injury if they have alanine 
aminotransferase or aspartate aminotransferase levels greater than 3 times the upper 
limit of normal (ULN) at the same time as having bilirubin levels greater than 2 times 
ULN and alkaline phosphatase levels less than 2 times ULN. As noted by Dr. Temple, 
“…Hy’s Law is not a benefit-risk judgment, an automatic trip into oblivion for any drug 
that meets its test. It is a safety biomarker, an indicator of a risk that must be weighed 
against the benefits of a treatment.” (Temple. Pharmacoepidemiology and drug safety. 
2006;15:241-3.) 
In ARIEL3, no patients met the criteria for Hy’s law. Given the context above, we have 
revised the manuscript to clarify our statement (lines 495-499): 
“No cases were considered to meet Hy’s law criteria for drug-induced liver injury (ie, 
alanine aminotransferase or aspartate aminotransferase greater than 3 times the 
upper limit of normal with concomitant bilirubin greater than 2 times the upper limit of 
normal without alkaline phosphatase elevations or another clear reason for the 
elevations).” 
Reviewer #3 Comment 2: Page 23: One should not misinterpret hazard ratios as relative 
risks. For example, the HR 0.44 does not translate in to a 56% reduction in the risk of 
disease progression or death. The HR only refers to risk during a specific timeframe, so 
broad inference should probably be avoided. 
Author Response 3.2: We thank the reviewer for this thoughtful comment. We have 
revised the language in the discussion accordingly (lines 464-471 and 538-545): 
“The prolonged progression-free survival among patients receiving rucaparib in the 
intent-to-treat population (HR 0·36) demonstrates that patients with platinum-
sensitive ovarian carcinoma can derive robust clinical benefit from rucaparib 
maintenance treatment. A similar improvement over placebo (HR 0·35) was seen in 
the secondary endpoint of assessment by BICR review, supporting the validity of the 
benefit observed with rucaparib maintenance treatment.” 
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“Preplanned analysis of progression-free survival in patients with a BRCA wild-
type/LOH-high carcinoma, wherein patients treated with rucaparib had an increase in 
median progression-free survival (HR 0·44) compared with placebo, shows that the 
improvement observed in the HRD cohort was not driven solely by patients with a 
BRCA-mutant carcinoma. The benefit in progression-free survival seen in patients 
with a BRCA wild-type/LOH-high carcinoma (HR 0·44) compared with patients with a 
BRCA wild-type/LOH-low carcinoma (HR 0·58) demonstrates the utility of HRD…” 
Reviewer #3 Comment 3: The authors clearly discuss PARP inhibitor clinical trials of 
relevance, including NOVA and SOLO2. They also appropriately conclude that the results of 
this trial are consistent with what has been published. While they are also correct in the 
statement that direct comparisons cannot be performed, it does little to help the readers 
make PRACTICAL sense of this data. For example, given the availability of niraparib, with 
positive impact on PFS regardless of mBRCA status, what would make rucaparib different?? 
I would suggest that the finding of an objective response rate in this trial population is quite 
interesting and potentially differentiating, including a reported 18% CR rate among those 
who entered with measurable disease. 
Author Response 3.3: We thank the reviewer for sharing this insightful comment and 
agree that the proportion of patients with measurable disease at baseline who achieved 
a complete response is unique to ARIEL3 in the maintenance setting and may be of 
particular interest to clinicians. We have elaborated on this point further in the Discussion 
(lines 532-535): 
“A number of patients with measurable residual disease at study entry showed 
further reduction in carcinoma burden with rucaparib maintenance treatment, 
including conversion to a complete response per RECIST in several patients in the 
nested BRCA-mutant and HRD cohorts and the overall intent-to-treat population.” 
In addition, at the time the ARIEL3 study was designed, we did not know whether the 
treatment effect of a PARP inhibitor would be maintained across all cohorts in the setting 
of a randomised, controlled phase 3 study, including the BRCA wild-type population or 
the intent-to-treat population (at that time, data from NOVA were not available, and 
SOLO2 only evaluated olaparib in patients with tumours with germline BRCA mutations). 
As stated in the manuscript, our findings extend those from the NOVA study and 
demonstrate that rucaparib can provide benefit to patients with tumours associated with 
or without a BRCA mutation vs placebo in the maintenance treatment setting. 
 
Reviewer #4 Comment 1: For Figure 3, under the rucaparib and placebo columns the 
number of patients with the binary yes/no for measurable does not equal the n=375 and 
n=189.  Why are there so many missing values? 
Author Response 4.1: We thank the reviewer for the inquiry. We have updated figure 3 
to accurately reflect the number of patients who did not have measurable disease at 
baseline (234, rucaparib; 123, placebo). The corresponding hazard ratio and 95% 
confidence interval data have been updated to reflect this correction. 
Reviewer #4 Comment 2: For the analysis of the rucaparib vs placebo in figure 3, should 
there not be under bulky lesions actually 3 columns: bulky lesion >2cm, measurable disease 
(n=141 as in table 1), and no measurable disease if the authors want to emphasize how 
rucaparib can benefit patients with partial response and bulky disease as they conclude? 
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Author Response 4.2: We thank the reviewer for this suggestion.  
A total of 207 patients (141, rucaparib; 66, placebo) were assessed by the investigator to 
have measurable disease (ie, target lesion of any size) at baseline. Data for measurable 
disease (yes/no) is presented under the “Measurable disease at baseline (per 
investigator)” heading in figure 3 (see also, response to Reviewer #4 Comment 1).    
As part of a separate assessment, the presence of bulky disease was determined by 
independent radiological review (see Study design and patients, lines 221-224). Bulky 
disease was defined as any target or nontarget lesion greater than 2 cm. Data for bulky 
disease (yes/no) is therefore presented as a separate, distinct subgroup because some 
patients had nontarget lesions that could not be included in the category “Measurable 
disease at baseline.” We have amended the figure to clarify this subtle but important 
point.  
Notably, the hazard ratios and 95% confidence intervals for all of these subgroups (ie, 
patients with bulky disease; patients without bulky disease, inclusive of patients with 
tumours <2 cm; and those with no measurable disease) do not cross unity, showing that 
the benefit of rucaparib vs placebo is maintained in all of these subgroups.  
Reviewer #4 Comment 3: Is there a reason that they did not analyze the time to 
subsequent chemotherapy treatment in their subsequent cohorts? 
Author Response 4.3: Time to subsequent anticancer treatment was an exploratory 
endpoint. As part of long-term follow-up, those data are continuing to be collected.  
At the visit cutoff date (April 15, 2017), median time to first subsequent anticancer 
treatment in the intent-to-treat population was 12·5 months in the rucaparib arm 
(censoring rate, 39%) and 7·4 months (censoring rate, 13%) in the placebo arm. Median 
time to second subsequent anticancer treatment was 22·2 months (censoring rate, 58%) 
and 18·6 months (censoring rate, 48%), respectively.  
Given the amount of censoring in the rucaparib arm, we consider those data to be 
immature. We intend to report those data at a future medical congress once they are 
fully mature. 
Reviewer #4 Comment 4: The paper never mentions the additional cost/benefit ratio by 
adding two testing panels of Foundation Medicine T5 NGS assay and BRCAnalysis CDx test 
in order to stratify patients for rucaparib therapy. Since financial costs are being more 
important considerations in cancer care, it would be beneficial for the authors to 
acknowledge this issue as part of the discussion. 
Author Response 4.4: We agree with the reviewer that the use of two testing panels 
may be burdensome and costly to patients and practitioners. As such, Foundation 
Medicine will be integrating BRCA1/BRCA2 mutational analysis with LOH determination 
into a single test with a cost that will be comparable to the original FoundationFocus 
CDxBRCA companion diagnostic (CoDx). This integrated, all-in-one CoDx will be 
submitted to regulatory agencies in parallel with the ARIEL3 clinical data and will be 
marketed following regulatory review/approval under the name FoundationFocus 
CDxBRCA HRD, with “HRD” reflecting the integration of LOH into the test. We are optimistic 
that this approach will help patients avoid the need to undergo additional, duplicative 
testing that may yield similar/overlapping information. A cost-effectiveness analysis will 
be the subject of a future report.  
Reviewer #4 Comment 5: Minor issue: enrollment is misspelled throughout the text. 
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Author Response 4.5: We thank the reviewer for their comment. Given that The Lancet 
is a British journal, we have used the British spelling “enrolment.” We have also checked 
our spellings of the other forms of the word, and although it may seem inconsistent, they 
are correctly spelled “enrol” and “enrolled” per British convention. 
 
Editorial Point 1: Please indicate after each of the reviewers' points the text changes which 
have been made (if any) and the line number on the revised manuscript at which your 
change can be found. [Line numbers can be added to your word document using the 'page 
layout' tab. Please select continuous numbers.] 
Author Response: We have inserted line numbers to the updated manuscript and 
referenced these in our response to the editorial and reviewer comments. 
Editorial Point 2: When interpreting editorial points made by reviewers, please remember 
we will further edit the final manuscript if accepted] 
Author Response: We have responded to reviewer comments regarding editorial 
points (eg, Reviewer #4 Comment 5) understanding that The Lancet’s editors will 
assist with final editing of the text. 
Editorial Point 3: Please indicate any authors who are full professors 
Author Response: We have provided this information in the updated manuscript 
(lines 12-55).  
Editorial Point 4: For randomised trials please follow the CONSORT reporting guidelines 
 http://www.consort-statement.org  and include a CONSORT checklist. 
Editorial Point 5: Please follow CONSORT for abstracts (eg method of randomisation) 
Author Response: We have ensured that our manuscript, including the Summary, 
conforms to CONSORT guidelines. We have provided the method of randomisation 
and information about blinding to the Summary (lines 75-78): 
“Patients were randomised 2:1 to receive oral rucaparib 600 mg twice daily or 
placebo; using a computer-generated sequence (block size of six). Patients, 
investigators, site staff, and the study sponsor were blinded to assignments.” 
Our completed checklists have been provided with resubmission. 
Editorial Point 6: At the end of the methods section please state the role of the funder in: 
data collection, analysis, interpretation, writing of the manuscript and the decision to submit. 
 Please also state which author(s) had access to all the data, and which author(s) were 
responsible for the decision to submit the manuscript etc. 
Author Response: The role of the funding source is provided (lines 339-342). We 
also indicate that all authors had access to the data and were responsible for the final 
decision to submit the manuscript (lines 342-343). 
Editorial Point 7: Please give 95% confidence intervals for  hazard ratios/ odds ratios 
Author Response: We have ensured that 95% confidence intervals are provided for 
all hazard ratios presented in the results.  
Editorial Point 8: Please limit the summary to pre-defined primary endpoints and safety 
endpoints. 
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Author Response: In the Summary, we have provided the results for the 
prespecified, primary endpoint of investigator-assessed progression-free survival and 
relevant safety data. 
Editorial Point 9: Please report all outcomes specified in the protocol 
Author Response: We have ensured that all outcomes specified in the protocol 
have been addressed in the manuscript. 
Editorial Point 10: Please explain any deviations from the protocol  
Author Response: Major protocol deviations as of the visit cutoff date (April 15, 
2017) have been provided as part of the supplemental appendix (p 5). These 
protocol deviations did not result in the exclusion of patients from the final analysis or 
affect the assessment of primary or secondary endpoints in the study.   
Editorial Point 11: If any exploratory outcomes are reported that were not pre-specified, 
please make it clear that these analyses are post-hoc 
Author Response: All analyses presented in the manuscript were prespecified 
except for a retrospective analysis of investigator-assessed progression-free survival 
in patients with or without prior bevacizumab as part of their penultimate or earlier 
treatment. We have indicated that this analysis was exploratory in the Supplemental 
Methods, Efficacy analysis of subgroups section (appendix, pp 3-4).  
In response to Reviewer #2 Comment 3, we have included a post hoc analysis of 
investigator-assessed and blinded independent central radiology review–assessed 
progression-free survival in all enrolled patients, not stratified by treatment (appendix, 
p 4; figure S6). This analysis was not prespecified and has been indicated as post 
hoc in the text and figure title.   
Editorial Point 12: p-values should be exact to 4 decimal places (eg p<0.0001). Two 
decimals are acceptable in tables for non-significant p-values. 
Editorial Point 13: Please provide absolute numbers to accompany all percentages 
Author Response: We have reviewed the manuscript and ensured that all P values 
are provided to 4 decimal places and that all percentages are accompanied by 
absolute numbers. 
Editorial Point 14: Please provide numbers at risk for Kaplan-Meier plots 
Author Response: Data for patients at risk are provided for all Kaplan-Meier plots. 
Editorial Point 15: Please provide the text, tables and figures in an editable format.  
Editorial Point 16: For figures please consult  
http://download.thelancet.com/flatcontentassets/authors/artwork-guidelines.pdf 
Editorial Point 17: If accepted, only 5-6 non-text items (figures or tables) can be 
accommodated in the print edition; additional material can be provided for a web appendix. 
Author Response: Figures have been developed in accordance with The Lancet’s 
artwork guidelines and have been provided in an editable format. Our manuscript 
currently contains four figures and two tables. 
Editorial Point 18: Please provide a research in context panel with 3 parts:  Systematic 
review (which includes a description of how you searched for evidence and how you 
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assessed the quality of that evidence); the added value of the study; and Interpretation of 
the totality of evidence when added to previous work. 
Author Response: A research in context panel with the three requested sections 
has been provided (lines 101-163). 
Editorial Point 19: If you have not yet done so, please return all signed authorship 
statements and conflict of interest forms.  A paragraph summarizing authors' disclosures 
must be made in the manuscript, please. 
Editorial Point 20: For any personal communication, please provide a letter showing that 
the person agrees to their name being used.  We also require signed statements from any 
named person in the acknowledgements saying that they agree to be acknowledged 
Author Response: All signed authorship statements (TL Author forms), conflict of 
interest forms (ICMJE), and signed acknowledgement letters have been provided 
with resubmission; we have provided combined pdfs containing all authors’ forms for 
each of these categories. 
Editorial Point 21: Please ensure there is a statement of contributions explaining what each 
author contributed at the end of the text 
Author Response: A contributions section is provided at the end of the main text 
(lines 561-568). 
Editorial Point 22: Please ensure that there is a section in the Methods section confirming 
ethics approval and consent from all patients has been obtained. 
Author Response: Confirmation of ethics approval and written consent of patients is 
outlined in the Methods (lines 201-204). 
Editorial Point 23: As corresponding author, please confirm that all authors have seen and 
approved of the final text 
Author Response: I confirm that authors have seen and approved the final text. 
Editorial Point 24: Our production system is not compatible with Endnotes.  Please convert 
to normal text. 
Author Response: Endnote references have been converted to normal text. 
Editorial Point 25: Please note our guideline length for research articles is 3000 words. 
Allowing for additional material requested by reviewers and editors we can allow a little 
leeway but we hope for final manuscript below 3500 words (4500 words for RCTs). 
Author Response: In accordance with the word limit for manuscripts reporting 
randomised controlled trials, our manuscript is currently within the limit of 4500 words 
(final word count: 4440 words). 
Editorial Point 26: Please provide a revised manuscript, a tracked changes version 
showing the changes made, and a point-by-point response to ALL EDITORS' and reviewers' 
comments - typed immediately following each specific point.  
Editorial Point 27: PLEASE do not use boxes for replies. This slows checking and can 
result in a delayed decision. 
Author Response: As requested, we have provided our point-by-point responses to 
all editor and reviewer comments, using tracked changes in the manuscript. 
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Summary 67 
Background: Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer 68 
activity in recurrent ovarian carcinoma harbouring a BRCA mutation or a high 69 
percentage of genome-wide loss of heterozygosity (LOH). ARIEL3 evaluated rucaparib 70 
versus placebo following response to second-line or later platinum-based chemotherapy 71 
in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma. 72 
Methods: ARIEL3 is an international, randomised, double-blind, phase 3 study 73 
performed at 87 hospitals and cancer centres. Patients were randomised 2:1 to receive 74 
oral rucaparib 600 mg twice daily or placebo using a computer-generated sequence 75 
(block size of six). Patients, investigators, site staff, and study sponsor were blinded to 76 
assignments. The primary endpoint (investigator-assessed progression-free survival) 77 
was evaluated using an ordered step-down procedure for three nested cohorts: (1) 78 
BRCA mutant (carcinoma associated with deleterious germline or somatic BRCA 79 
mutation); (2) homologous recombination deficient (HRD) (BRCA mutant or BRCA wild 80 
type/LOH high); and (3) intent-to-treat population. ARIEL3 is registered with 81 
ClinicalTrials.gov, NCT01968213; enrolment is complete. 82 
Findings: Between April 7, 2014, and July 19, 2016, 564 patients were randomised, 83 
375 to rucaparib and 189 to placebo. Median progression-free survival in patients with a 84 
BRCA-mutant carcinoma (n=130, rucaparib; n=66, placebo) was 16·6 months versus 85 
5·4 months (p<0·0001), respectively (hazard ratio [HR] 0·23; 95% confidence interval 86 
[CI] 0·16–0·34); in patients with an HRD carcinoma (n=236, rucaparib; n=118, placebo) 87 
it was 13·6 months versus 5·4 months (p<0·0001), respectively (HR 0·32; 95% CI 0·24–88 
0·42); and in the intent-to-treat population it was 10·8 months and 5·4 months 89 
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(p<0·0001), respectively (HR 0·36; 95% CI 0·30–0·45). The most common grade 3 or 90 
higher adverse events in the safety population (n=372, rucaparib; n=189, placebo) were 91 
anaemia/decreased haemoglobin (70 [19%], rucaparib; one [1%], placebo) and 92 
increased alanine or aspartate aminotransferase (39 [10%], rucaparib; none, placebo).  93 
Interpretation: Across all primary analysis groups, rucaparib significantly improved 94 
progression-free survival in patients with platinum-sensitive ovarian cancer who had 95 
achieved a response to platinum-based chemotherapy. 96 
Funding: Clovis Oncology, Inc. 97 
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Research in context 98 
Evidence before this study 99 
Evidence of the clinical effectiveness of poly(ADP-ribose) polymerase (PARP) inhibitors 100 
as maintenance treatment for platinum-sensitive ovarian carcinoma is limited. In a 101 
search of PubMed (conducted July 31, 2017; search term: (“PARP inhibitor” OR 102 
rucaparib OR olaparib OR niraparib OR veliparib OR talazoparib) AND (ovarian AND 103 
(cancer OR carcinoma)) AND "maintenance"), we found that data have been published 104 
in a PubMed-indexed journal for only three clinical trials, Study 19 (NCT00753545), 105 
NOVA (NCT01847274), and SOLO2 (NCT01874353). Study 19, a randomised, 106 
placebo-controlled, phase 2 study, enrolled patients with platinum-sensitive ovarian 107 
carcinoma who had received at least two prior platinum-based chemotherapies. 108 
Progression-free survival was significantly improved with olaparib maintenance 109 
treatment in the overall population, as well as in patients with a germline or somatic 110 
BRCA mutation. Study 19 data were published prior to the commencement of ARIEL3 111 
and supported the investigation of rucaparib as a maintenance treatment for patients 112 
with recurrent platinum-sensitive ovarian carcinoma in ARIEL3. In late 2016, results 113 
from the NOVA trial provided additional support for the role of a PARP inhibitor as 114 
maintenance treatment. In that randomised, placebo-controlled, phase 3 study, 115 
niraparib demonstrated a significant improvement in progression-free survival when 116 
used as a maintenance treatment in patients with ovarian carcinoma with or without a 117 
germline BRCA mutation who had received at least two prior platinum-based 118 
chemotherapies and had no measurable disease greater than 2 cm. Results from one 119 
other phase 3 study with olaparib maintenance treatment, SOLO2, were published in 120 
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July 2017. That randomised, placebo-controlled study enrolled patients with platinum-121 
sensitive ovarian carcinoma who had received at least two prior platinum-based 122 
chemotherapies and carried a germline mutation in BRCA. Similar to the results seen in 123 
Study 19, progression-free survival was significantly improved with olaparib 124 
maintenance treatment in patients enrolled in SOLO2. 125 
Added value of this study 126 
ARIEL3 enrolled patients with or without a germline or somatic BRCA mutation, and the 127 
size of residual disease was not restricted. Our results show that rucaparib maintenance 128 
treatment significantly improved progression-free survival for patients across all primary 129 
analysis groups for patients with recurrent, platinum-sensitive ovarian carcinoma who 130 
achieved a response to platinum-based therapy, including in the intent-to-treat 131 
population. We demonstrate that rucaparib maintenance treatment can provide clinical 132 
benefit not only to patients with ovarian carcinoma associated with a BRCA mutation, 133 
but also to those with BRCA wild-type ovarian carcinoma. A novel aspect of the ARIEL3 134 
trial was the prospective validation of the tumour-based, next-generation sequencing 135 
(NGS) homologous recombination deficiency (HRD) assay that was initially utilised in 136 
the phase 2 ARIEL2 study. This NGS assay combines mutation analysis of BRCA1 and 137 
BRCA2 genes with measurement of the percentage of genome-wide loss of 138 
heterozygosity (LOH) in the cancer tissue as a biomarker for sensitivity to rucaparib 139 
treatment. ARIEL2 enrolled patients with measurable, recurrent ovarian carcinoma, and 140 
provided initial evidence that patients with carcinomas with high LOH benefited from 141 
rucaparib treatment. The current study (ARIEL3) validated the utility of the HRD assay 142 
overall and LOH assessment in particular in the maintenance treatment setting, where 143 
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rucaparib-treated patients with carcinomas that were BRCA wild type/LOH high also 144 
had improvements in progression-free survival, with a lower hazard ratio than in patients 145 
with carcinomas that were BRCA wild type/LOH low.  146 
Implications of all the available evidence 147 
Combined with the evidence from prior studies, our study supports the use of PARP 148 
inhibitors, such as rucaparib, as maintenance treatment for patients with platinum-149 
sensitive ovarian cancer who achieved a response to platinum-based chemotherapy. 150 
ARIEL3 is the first phase 3 study to prospectively assess progression-free survival in 151 
patients with recurrent ovarian carcinoma associated with HRD as a primary endpoint, 152 
and our results demonstrate that HRD as a predictive biomarker can be an informative 153 
tool for clinicians when making treatment decisions for this patient population. In 154 
addition to PARP inhibitors, the targeted agents bevacizumab and cediranib have 155 
proven useful in extending progression-free survival for patients in this setting. Our 156 
findings strengthen the rationale for continued investigation of targeted therapies, such 157 
as PARP inhibitors, for maintenance treatment as either monotherapy or in combination 158 
with other agents, in an effort to provide the best care for patients with advanced 159 
ovarian cancer.   160 
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Introduction 161 
Ovarian cancer is the eighth leading cause of death from cancer in women worldwide.1 162 
Most patients with advanced stage ovarian carcinoma initially receive platinum-based 163 
chemotherapy and achieve a clinical response; however, the majority of these patients 164 
will ultimately relapse.2 The treatment for initial recurrent disease depends on many 165 
factors, including duration of initial treatment response, antecedent and persistent 166 
adverse events, performance status, histology, location and burden of disease, and, 167 
increasingly, tumour genomics such as BRCA mutation status.3 For patients with 168 
platinum-sensitive recurrent ovarian carcinoma, maintenance treatment with targeted 169 
agents has resulted in greater prolongation of progression-free survival.4-9 However, 170 
clinical benefit is typically transient, hence there is an ongoing pursuit for new therapies 171 
and tools to identify patients who may benefit most from these therapies, as well as to 172 
identify the optimal therapeutic strategy for patients.  173 
The poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib is approved in the United 174 
States for the treatment of patients with deleterious BRCA mutation (germline or 175 
somatic) associated advanced ovarian carcinoma who have been treated with two or 176 
more chemotherapy regimens. Approval of rucaparib was based on the objective 177 
response rate (57 of 106 patients [54%]) observed in a pooled population of patients 178 
with BRCA-mutant high-grade ovarian carcinoma from the Study 10 (CO-338-10; 179 
NCT01482715) and ARIEL2 (CO-338-017; NCT01891344) clinical trials.10,11   180 
In Part 1 of the ARIEL2 trial, rucaparib treatment was found to be efficacious not only in 181 
patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma with a BRCA 182 
 10 
 
mutation, but also in patients with BRCA wild-type carcinomas with high genomic loss of 183 
heterozygosity (LOH),11 a potential marker for homologous recombination deficiency 184 
(HRD) and thus PARP inhibitor activity.12-15 In the current phase 3, randomised, 185 
placebo-controlled study (ARIEL3), our objective was to evaluate the efficacy and safety 186 
of rucaparib versus placebo following response to second-line or later platinum-based 187 
chemotherapy in patients with high-grade, platinum-sensitive ovarian carcinoma 188 
(including fallopian tube and primary peritoneal carcinomas) and to prospectively test 189 
the genomic LOH cutoff discriminator that was optimised based on results of ARIEL2 190 
Part 1 as a predictive biomarker for sensitivity to rucaparib treatment. 191 
 192 
Methods 193 
Study design and patients 194 
ARIEL3 (NCT01968213) was a phase 3, international, randomised, placebo-controlled 195 
study conducted at 87 hospitals and cancer centres in Australia, Belgium, Canada, 196 
France, Germany, Israel, Italy, New Zealand, Spain, United Kingdom, and the United 197 
States. The trial was approved by national or local institutional review boards and was 198 
carried out in accordance with the Declaration of Helsinki and Good Clinical Practice 199 
Guidelines of the International Conference on Harmonisation. Patients provided written 200 
informed consent before participation. Per the protocol, an independent data monitoring 201 
committee monitored enrolment and reviewed the safety and efficacy of the trial 202 
approximately every 6 months, including maturity of progression-free survival events. 203 
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Eligible patients were aged 18 years or older, had platinum-sensitive (ie, documented 204 
radiologic disease progression more than 6 months following the last dose of the 205 
penultimate platinum administered), high-grade serous or endometrioid ovarian, primary 206 
peritoneal, or fallopian tube carcinoma and had received at least two prior platinum-207 
based chemotherapy regimens. Prior treatment with bevacizumab was permitted, with 208 
the exception of bevacizumab maintenance treatment following the most recent 209 
platinum-based regimen. On November 4, 2014, after 91 patients had been 210 
randomised, an amendment was made to the protocol requiring that the most recent 211 
platinum-based regimen was to be administered as a chemotherapy doublet and for a 212 
minimum of four cycles. Patients must have achieved either a complete response by 213 
Response Evaluation Criteria In Solid Tumors version 1·1 (RECIST)16 or a partial 214 
response, defined as either a RECIST partial response or a serologic response per 215 
Gynecologic Cancer InterGroup (GCIG) cancer antigen 125 (CA-125)17 response 216 
criteria, to their last platinum-based regimen. For patients who achieved a partial 217 
response, no restriction was placed on residual carcinoma size at study entry; those 218 
who had persistent lesions greater than 2 cm as defined by independent radiological 219 
review were defined as having “bulky” residual disease. Responses must have been 220 
maintained through the completion of chemotherapy and during the interval period 221 
between completion of chemotherapy and entry into ARIEL3. Additionally, CA-125 was 222 
required to be less than the upper limit of normal. Patients had Eastern Cooperative 223 
Oncology Group Performance Status of 0 to 1 and adequate organ function. Patients 224 
were ineligible if they had symptomatic/untreated central nervous system metastases, 225 
had received anticancer therapy 14 or fewer days before starting the study, or had 226 
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received prior treatment with a PARP inhibitor. A complete list of inclusion and exclusion 227 
criteria is provided in the appendix (p 6), and the full study protocol is available in the 228 
appendix.  229 
Central testing of DNA derived from patient archival tumour tissue samples was 230 
performed to detect mutations in homologous recombination pathway genes (appendix 231 
p 8) and assess genomic LOH using Foundation Medicine’s T5 NGS assay (Cambridge, 232 
MA). Based on retrospective analysis of data from ARIEL2 Part 1, a cutoff of 16% or 233 
greater was prespecified for ARIEL3 as a discriminator for high genomic LOH.11 234 
Germline mutations were identified by BRCAnalysis CDx test (Myriad Genetics, Salt 235 
Lake City, UT). Further details of the tumour tissue testing are provided in the appendix 236 
(p 2).  237 
Randomisation and masking 238 
Within 8 weeks of their last dose of platinum, eligible patients were randomised 2:1 to 239 
receive oral rucaparib (600 mg twice daily) or matched placebo. Randomisation was 240 
computer-generated by Almac Clinical Technologies (Souderton, PA) using a block size 241 
of six. Randomisation stratification factors included: homologous recombination repair 242 
gene mutation status (based on gene mutation only); progression-free interval following 243 
penultimate platinum-based regimen; and best response to most recent platinum-based 244 
regimen (additional details in the appendix p 3). Patients were assigned to the rucaparib 245 
arm or placebo arm in a blinded manner using Almac Clinical Technologies’ interactive 246 
web and voice response system (IXRS®); patients, investigators, site staff, and the 247 
study sponsor were blinded to assignments. To ensure blinding was maintained, 248 
rucaparib and placebo tablets were manufactured to have identical appearances.   249 
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Procedures 250 
Patients received study drug in continuous 28-day cycles until disease progression, 251 
death, or other reason for discontinuation. Dose reductions (in decrements of 120 mg) 252 
were permitted if a patient had a grade 3 or greater or persistent grade 2 adverse event 253 
(additional details in the appendix p 3). Treatment was discontinued for a toxicity-related 254 
treatment interruption lasting more than 14 consecutive days (unless otherwise agreed 255 
upon between the investigator and the study sponsor). 256 
Disease assessments were performed at screening, every 12 weeks during treatment 257 
(and post-treatment for patients who discontinued for any reason other than disease 258 
progression), at discontinuation of treatment, and as clinically indicated. Disease 259 
progression was determined by RECIST. Patients with a complete response at study 260 
entry were only considered to have disease progression if an unequivocal new lesion 261 
was identified. Increased CA-125 levels alone were not considered to indicate disease 262 
progression unless confirmed by RECIST. All computed tomography scans and other 263 
imaging were provided to a blinded, independent central radiology review (BICR). 264 
The National Comprehensive Cancer Network–Functional Assessment of Cancer 265 
Therapy Ovarian Symptom Index 18 (FOSI-18)18 questionnaire was used to assess 266 
patient-reported outcomes at screening and throughout treatment.  Safety was 267 
assessed by monitoring for adverse events, laboratory testing, assessing vital signs and 268 
conducting physical examinations. Adverse events were classified in accordance with 269 
the Medical Dictionary for Drug Regulatory Activities classification system version 18·119 270 
and graded for severity in accordance with the National Cancer Institute Common 271 
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Terminology Criteria for Adverse Events version 4·03.20 Serious adverse events were 272 
classified as defined in the protocol (see appendix).  273 
Outcomes 274 
The primary endpoint was investigator-assessed progression-free survival, defined as 275 
time from randomisation to investigator-assessed disease progression per RECIST or 276 
death. Secondary endpoints included progression-free survival by BICR, patient-277 
reported outcomes as evaluated by time to worsening in the FOSI-18 disease-related 278 
symptoms–physical (DRS-P) subscale (defined as ≥4-point decrease) and total score 279 
(defined as ≥8-point decrease), overall survival, safety, and population pharmacokinetic 280 
modelling. Additional details are available in the appendix (p 3). The secondary 281 
endpoint of population pharmacokinetic modelling will be reported separately. 282 
Statistical analysis 283 
ARIEL3 was designed to enrol approximately 540 patients, including between 180 and 284 
200 patients with a BRCA mutation in their carcinoma (with no more than 150 patients 285 
with a known deleterious germline BRCA mutation) and no more than 360 patients 286 
without a BRCA mutation in their carcinoma. The independent data monitoring 287 
committee surveyed enrolment of patients with a BRCA mutation and informed the 288 
study sponsor (Clovis Oncology, Inc.) when the target enrolment number for the BRCA-289 
mutant cohort was anticipated to be reached. Once notified, patients who were in the 290 
screening process were allowed to complete screening and enrol into the study if they 291 
met all eligibility criteria. These subgroup sizes were designed to result in 90% power to 292 
determine statistical significance between rucaparib and placebo at a one-sided alpha 293 
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level of 0·025 given the following assumptions for median investigator-assessed 294 
progression-free survival for the efficacy analysis cohorts: BRCA mutant (carcinoma 295 
associated with a deleterious germline or somatic BRCA mutation), 12·0 months in the 296 
rucaparib arm versus 6·0 months in the placebo arm (hazard ratio [HR] 0·5); HRD 297 
(includes patients with a BRCA-mutated carcinoma and patients with BRCA wild-298 
type/LOH-high carcinomas), 10·0 versus 6·0 months (HR 0·6); and intent-to-treat 299 
population (all randomised patients), 8·5 versus 6·0 months (HR 0·7). 300 
Classification of HRD status in the carcinoma (based on BRCA mutation and/or LOH) 301 
for the efficacy analysis was determined before database lock and the final efficacy 302 
analysis. Per protocol, the primary analysis was to be performed after the independent 303 
data monitoring committee determined that investigator-assessed disease progression 304 
or death had occurred in at least 70% of expected patients in the BRCA-mutant cohort.  305 
All efficacy analyses were performed for the intent-to-treat population. The efficacy 306 
analyses are presented separately for the nested cohorts: BRCA mutant, HRD, and 307 
intent-to-treat population. The primary endpoint was tested using an ordered step-down 308 
multiple comparisons procedure21 for the three nested cohorts: BRCA mutant, HRD, 309 
and the intent-to-treat population. Investigator-assessed progression-free survival in 310 
patients with a BRCA-mutant carcinoma was tested first at a one-sided 0·025 311 
significance level. Analysis of investigator-assessed progression-free survival in patients 312 
with an HRD carcinoma followed by analysis in the intent-to-treat population was 313 
contingent upon a statistically significant result in the analysis of patients with a BRCA-314 
mutant carcinoma. Analysis of the key secondary endpoints of patient-reported 315 
outcomes and overall survival were to follow in a similar ordered step-down procedure. 316 
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Once statistical significance was not achieved for one test, the statistical significance 317 
was not declared for all subsequent analyses in the ordered step-down procedure. 318 
Progression-free survival by BICR was evaluated as a key stand-alone secondary 319 
endpoint, separate from the step-down procedure described above. Time to 320 
progression-free survival (by investigator and by BICR) and time to worsening in the 321 
FOSI-18 DRS-P subscale were analysed using stratified Kaplan-Meier methodology 322 
where distributions between rucaparib and placebo arms were compared using a 323 
stratified log-rank test. A stratified Cox proportional hazards model was used to estimate 324 
the HR between the arms. Exploratory analyses of progression-free survival were 325 
performed in subgroups based on patient characteristics (eg, randomisation 326 
stratification factors, demographics, disease burden at baseline). For patients with 327 
measurable disease at study entry, the proportion of patients achieving a confirmed 328 
complete or partial response per RECIST as assessed by the investigator was a 329 
prespecified exploratory endpoint of ARIEL3.  330 
Safety, including adverse events and clinical laboratory investigations, was evaluated in 331 
all patients who received at least one dose of protocol-specified treatment.  332 
Statistical analyses were performed using SAS version 9·4 (SAS Institute, Cary, NC). 333 
Additional details are available in the appendix (p 4). 334 
Role of the funding source 335 
The study was designed by the sponsor, Clovis Oncology, Inc., and the coordinating 336 
investigators (RLC and JAL). Data presented herein were collected by the investigators, 337 
analysed by Clovis Oncology, and interpreted by all authors. All authors had access to 338 
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the data and had final responsibility for the decision to submit for publication. Writing 339 
and editorial assistance were supported by the sponsor. 340 
 341 
Results 342 
Between April 7, 2014, and July 19, 2016, 564 patients (intent-to-treat population) were 343 
randomised, 375 to rucaparib and 189 to placebo (figure 1; appendix p 11). At the visit 344 
cutoff date (April 15, 2017), 90 (24%) and 9 (5%) patients in the rucaparib and placebo 345 
arms, respectively, were still receiving treatment. Baseline demographic and clinical 346 
characteristics were generally well balanced between the treatment arms (table 1).  347 
Following the ordered step-down multiple comparisons procedure, the analysis of 348 
investigator-assessed progression-free survival was evaluated first in patients with a 349 
BRCA-mutant carcinoma (130, rucaparib; 66, placebo; appendix p 11). Median time to 350 
progression or death was 16·6 months versus 5·4 months (stratified log-rank p<0·0001) 351 
in the rucaparib and placebo arms, respectively (HR 0·23; 95% confidence interval [CI] 352 
0·16–0·34; p<0·0001) (figure 2). In patients with an HRD carcinoma (236, rucaparib; 353 
118, placebo), median progression-free survival was 13·6 months and 5·4 months 354 
(stratified log-rank p<0·0001), respectively (HR 0·32; 95% CI 0·24–0·42; p<0·0001). 355 
Median progression-free survival in the intent-to-treat population was 10·8 months and 356 
5·4 months (stratified log-rank p<0·0001), respectively (HR 0·36; 95% CI 0·30–0·45; 357 
p<0·0001).    358 
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In a prespecified analysis of the key stand-alone, secondary endpoint of progression-359 
free survival assessed by BICR, results were similar to those of investigator-assessed 360 
progression-free survival for the patients with a BRCA-mutant carcinoma (median 26·8 361 
months vs 5·4 months; HR 0·20; 95% CI 0·13–0·32; p<0·0001), the patients with an 362 
HRD carcinoma (median 22·9 months vs 5·5 months; HR 0·34; 95% CI 0·24–0·47; 363 
p<0·0001), and the intent-to-treat population (median 13·7 months vs 5·4 months; HR 364 
0·35; 95% CI 0·28–0·45; p<0·0001) (figure 2).  365 
Analysis of the secondary endpoint of time to worsening in the FOSI-18 DRS-P 366 
subscale score was assessed in the step-down procedure for the three nested 367 
subgroups. In patients with a BRCA-mutant carcinoma, there was no significant 368 
difference between arms in the time to worsening in the FOSI-18 DRS-P subscale 369 
(stratified log-rank p=0·29) (HR 1·24; 95% CI 0·82–1·86; p=0·30). As statistical 370 
significance was not reached in patients with a BRCA-mutant carcinoma, in accordance 371 
with the prespecified step-down procedure, statistical significance could not be 372 
determined for the remaining secondary analyses.  373 
At the visit cutoff date (April 15, 2017), overall survival data were not mature (123 [22%] 374 
patients had died). A follow-up analysis will be performed when approximately 70% of 375 
the patients have died (≈395 overall survival events).   376 
Preplanned subgroup analyses of investigator-assessed progression-free survival 377 
demonstrated that the progression-free survival benefit for rucaparib versus placebo 378 
was observed across all clinical subgroups, irrespective of presence or absence of 379 
measurable disease or bulky disease (defined as any lesion >2 cm) at baseline, 380 
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response to last platinum-based regimen (complete or partial response), LOH (high, 381 
low, or indeterminate), or BRCA mutation (germline or somatic; BRCA1 or BRCA2) 382 
(figure 3; appendix p 12). Further supporting the efficacy observed in the intent-to-treat 383 
population, in the non-nested subgroups of patients with carcinomas that were BRCA 384 
wild type, a progression-free survival benefit as assessed by the investigator was 385 
observed with rucaparib in patients with LOH-high carcinomas (median 9·7 months vs 386 
5·4 months; HR 0·44; 95% CI 0·29–0·66; p<0·0001) and patients with LOH-low 387 
carcinomas (median 6·7 months vs 5·4 months; HR 0·58; 95% CI 0·40–0·85; p=0·0049) 388 
(figure 4); similar results were also observed in progression-free survival assessed by 389 
BICR (appendix p 13).   390 
The majority of patients (374 [66%]) in ARIEL3 had achieved a partial response to the 391 
platinum-based therapy prior to randomisation. For 207 (37%) of 564 patients with 392 
measurable disease per investigator at study entry, a prespecified exploratory analysis 393 
of confirmed response was conducted. In the subgroup of patients with measurable 394 
disease at study entry with a BRCA-mutant carcinoma, 15 (38%) of 40 in the rucaparib 395 
arm and two (9%) of 23 in the placebo arm achieved a confirmed RECIST response 396 
(appendix p 8). In patients with an HRD carcinoma with measurable disease at 397 
baseline, the objective response was also higher in the rucaparib arm (23 [27%] of 85 398 
patients) than the placebo arm (3 [7%] of 41 patients). A similar result was observed in 399 
the intent-to-treat population among patients with measurable disease at baseline (26 400 
[18%] of 141 patients in the rucaparib arm; 5 [8%] of 66 patients in the placebo arm). 401 
Complete responses were observed in the rucaparib arm in seven (18%), 10 (12%), and 402 
10 (7%) patients with measurable disease at baseline in the nested BRCA-mutant and 403 
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HRD cohorts, and the overall intent-to-treat population, respectively. Only one (2%) 404 
complete response was observed in the placebo arm; this occurred in the intent-to-treat 405 
population.  406 
The safety population included 372 patients who received rucaparib (three patients 407 
were withdrawn prior to receiving rucaparib) and 189 patients who received placebo. 408 
For the safety population, the median (interquartile range) treatment duration was 8·3 409 
(3·4–16·1) months in the rucaparib arm and 5·5 (2·8–8·3) months in the placebo arm. A 410 
treatment-emergent adverse event of any grade occurred in 372 patients (100%) in the 411 
rucaparib arm and 182 patients (96%) in the placebo arm (table 2). The most common 412 
treatment-emergent adverse events (reported in at least 35% of patients in either arm) 413 
included nausea (280 patients [75%] in the rucaparib arm and 69 patients [37%] in the 414 
placebo arm), asthenia or fatigue (258 patients [69%] and 83 patients [44%]), dysgeusia 415 
(146 patients [39%] and 13 patients [7%]), anaemia/decreased haemoglobin (139 416 
patients [37%] and 11 patients [6%]), constipation (136 patients [37%] and 45 patients 417 
[24%]), and vomiting (136 patients [37%] and 28 patients [15%]). Treatment-emergent 418 
adverse events of grade 3 or greater were reported in 209 patients (56%) in the 419 
rucaparib arm and 28 patients (15%) in the placebo arm, the most common of which 420 
were anaemia/decreased haemoglobin (70 patients [19%] and one patient [1%]) and 421 
increase in alanine aminotransferase or aspartate aminotransferase (39 patients [10%] 422 
and no patients). For patients in the rucaparib arm, a decline in haemoglobin level from 423 
baseline generally occurred in the first few cycles (appendix p 14). Elevations in alanine 424 
aminotransferase or aspartate aminotransferase were generally transient, self-limiting, 425 
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and not associated with other signs of liver toxicity (appendix p 15). The frequency of 426 
treatment-emergent adverse events was comparable across the three nested cohorts. 427 
One or more serious adverse events were reported in 78 patients (21%) in the rucaparib 428 
arm and 20 patients (11%) in the placebo arm. The most common serious adverse 429 
events (reported in at least 2% of patients in either arm) included anaemia (16 patients 430 
[4%] in the rucaparib arm and one patient [1%] in the placebo arm), pyrexia (six patients 431 
[2%] and no patients), vomiting (six patients [2%] and two patients [1%]), and small 432 
intestinal obstruction (three patients [1%] and three patients [2%]).  433 
Myelodysplastic syndrome and acute myeloid leukaemia were reported in three patients 434 
(1%) in the rucaparib arm (two had a germline BRCA-mutant carcinoma, and one had a 435 
BRCA wild-type/LOH-low carcinoma). One patient died due to myelodysplastic 436 
syndrome and one due to acute myeloid leukaemia. There were no reports of 437 
myelodysplastic syndrome or acute myeloid leukaemia in the placebo arm.  438 
Treatment interruption due to a treatment-emergent adverse event occurred in 237 439 
(64%) and 19 (10%) patients in the rucaparib and placebo arms, respectively (appendix 440 
p 9). Dose reduction due to a treatment-emergent adverse event occurred in 203 (55%) 441 
and eight (4%) patients in the rucaparib and placebo arms, respectively (appendix p 9). 442 
In the rucaparib and placebo arms, 117 (31%) and six (3%) patients, respectively, had 443 
both a treatment interruption due to a treatment-emergent adverse event and a dose 444 
reduction due to a treatment-emergent adverse event. Of patients who received 445 
rucaparib, 50 (13%) discontinued due to a treatment-emergent adverse event 446 
(excluding disease progression) compared with three (2%) patients in the placebo arm 447 
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(appendix p 10). As of the visit cutoff date, in the rucaparib arm there were four deaths 448 
due to adverse events considered unrelated to treatment by the investigator (two 449 
patients due to progressive disease, one due to cardiac arrest, and one due to 450 
haematophagic histiocytosis) and two deaths considered treatment related by the 451 
investigator (one due to acute myeloid leukaemia and one due to myelodysplastic 452 
syndrome). In the placebo arm, two patients died due to adverse events considered 453 
unrelated to treatment by the investigator (one due to progressive disease and one due 454 
to pulmonary embolism). 455 
 456 
Discussion 457 
In ARIEL3, rucaparib maintenance treatment versus placebo significantly improved 458 
progression-free survival in all primary analysis groups of patients with recurrent ovarian 459 
carcinoma following a complete or partial response to platinum-based therapy. The 460 
prolonged progression-free survival among patients receiving rucaparib in the intent-to-461 
treat population (HR 0·36) demonstrates that patients with platinum-sensitive ovarian 462 
carcinoma can derive robust clinical benefit from rucaparib maintenance treatment. A 463 
similar improvement over placebo (HR 0·35) was seen in the secondary endpoint of 464 
assessment by BICR review, supporting the validity of the benefit observed with 465 
rucaparib maintenance treatment. Furthermore, the lower hazard of disease 466 
progression or death associated with rucaparib in the study was observed across all 467 
prespecified subgroups that were analysed. Analysis of non-nested, non-overlapping 468 
patient subpopulations (ie, BRCA wild-type/LOH-high and BRCA wild-type/LOH-low 469 
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patients) indicate that the statistically significant improvement in progression-free 470 
survival observed in the intent-to-treat population was not driven only by the results in 471 
the nested HRD or BRCA-mutant cohorts.  472 
Patient-reported outcomes were evaluated as a secondary endpoint of ARIEL3 as part 473 
of the step-down procedure, with no significant difference in time to worsening in the 474 
FOSI-18 DRS-P subscale observed between the rucaparib and placebo arms. Further 475 
analyses of the patient-reported health outcome data gathered in ARIEL3 are planned 476 
and will be reported separately.  477 
Overall survival data were not mature at the time of the visit cutoff, with less than 25% 478 
of the events needed for final analysis. Patient follow-up is continuing in a blinded 479 
manner and overall survival will be assessed after about 70% maturity is reached. 480 
As reported in prior studies of rucaparib and other PARP inhibitors,5,6,9-11 481 
gastrointestinal side effects, asthenia or fatigue, and myelosuppression were common 482 
treatment-emergent adverse events in the rucaparib arm. Management of adverse 483 
events included supportive care and dose modifications (including treatment interruption 484 
and/or dose reduction). Common laboratory abnormalities observed in the rucaparib 485 
arm included elevations in alanine aminotransferase, aspartate aminotransferase, and 486 
blood creatinine. Alanine aminotransferase and aspartate aminotransferase were not 487 
associated with abnormal increases in bilirubin or other criteria for drug-induced 488 
hepatotoxicity, and generally resolved over time. No cases were considered to meet 489 
Hy’s law criteria for drug-induced liver injury (ie, alanine aminotransferase or aspartate 490 
aminotransferase greater than 3 times the upper limit of normal with concomitant 491 
bilirubin greater than 2 times the upper limit of normal without alkaline phosphatase 492 
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elevations or another clear reason for the elevations).22,23 Similarly, elevations in 493 
creatinine, which have also been observed with olaparib,24 were self-limiting and 494 
stabilised over time. Creatinine is secreted into urine via renal transporters (eg, MATE1, 495 
MATE2-K, OCT-1, and OCT-2), which have been shown to be inhibited in vitro by 496 
multiple PARP inhibitors, including rucaparib, olaparib, and veliparib.25-27 Patterns of 497 
elevation and stabilisation of these laboratory abnormalities similar to those reported 498 
here were observed in the treatment setting with rucaparib.28,29   499 
The results of ARIEL3 are consistent with those of other placebo-controlled studies of 500 
PARP inhibitors in the maintenance treatment setting, including NOVA (NCT01847274) 501 
with niraparib and Study 19 (NCT00753545) and SOLO2 (NCT01874353) with 502 
olaparib.5,6,9 However, direct comparisons with these other trials cannot be made due to 503 
differences in patient groups analysed (eg, SOLO2 only enrolled patients with a 504 
germline BRCA mutation), definition of HRD (eg, in NOVA, HRD included patients with 505 
somatic mutations in BRCA, as well as those with non-BRCA–related HRD), the method 506 
of primary endpoint assessment (eg, investigator vs BICR), and study design (eg, 507 
residual disease was restricted to <2 cm in NOVA).5,6,9,30  508 
Although having a CA-125 below the upper limit of normal is not a requirement of 509 
response per GCIG CA-125 criteria or a RECIST partial response, ARIEL3 required that 510 
patients have CA-125 below the upper limit of normal prior to study entry; this eligibility 511 
requirement was intended to ensure that patients had controlled disease at study entry. 512 
Similar restrictions on CA-125 levels were included in the enrolment criteria of other 513 
studies investigating PARP inhibitors in the maintenance treatment setting, although it is 514 
unknown how many patients in these studies had CA-125 levels greater than the upper 515 
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limit of normal at study entry.5,6,9 Furthermore, it is not known whether inclusion of 516 
patients with CA-125 levels exceeding the upper limit of normal affects the efficacy of 517 
PARP inhibitors in the maintenance treatment setting. 518 
Although ARIEL3 extends the findings of previous studies of PARP inhibitors in this 519 
setting, there are some important differences between ARIEL3 and other studies in the 520 
maintenance treatment setting. Notably, patients in ARIEL3 with carcinomas associated 521 
with a germline or somatic BRCA mutation were both included in the three nested 522 
cohorts (BRCA mutant, HRD, and intent-to-treat population), a feature that is unique to 523 
ARIEL3 among clinical trials in this setting. In addition, ARIEL3 did not restrict 524 
enrolment based on target lesion size for patients with residual disease (partial 525 
response to prior platinum). A number of patients with measurable residual disease at 526 
study entry showed further reduction in carcinoma burden with rucaparib maintenance 527 
treatment, including conversion to a complete response per RECIST in several patients 528 
in the nested BRCA-mutant and HRD cohorts and the overall intent-to-treat population.  529 
Additionally, ARIEL3 is the first phase 3 study to prospectively assess the primary 530 
endpoint of progression-free survival in patients with recurrent ovarian carcinoma 531 
associated with HRD. Preplanned analysis of progression-free survival in patients with a 532 
BRCA wild-type/LOH-high carcinoma, wherein patients treated with rucaparib had an 533 
increase in median progression-free survival (HR 0·44) compared with placebo, shows 534 
that the improvement observed in the HRD cohort was not driven solely by patients with 535 
a BRCA-mutant carcinoma. The benefit in progression-free survival seen in patients 536 
with a BRCA wild-type/LOH-high carcinoma (HR 0·44) compared with patients with a 537 
BRCA wild-type/LOH-low carcinoma (HR 0·58) demonstrates the utility of HRD, in 538 
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particular high genomic LOH as defined by Foundation Medicine’s T5 assay, as a 539 
predictive biomarker for sensitivity to rucaparib treatment. Based on our findings, HRD 540 
assessment may be an informative tool for clinicians making treatment decisions for 541 
patients with BRCA wild-type associated platinum-sensitive ovarian carcinoma. 542 
However, response to rucaparib was also clearly observed in the cohort of patients with 543 
carcinomas that were BRCA wild type/LOH low, with more than 30% of patients in the 544 
rucaparib arm achieving benefit of more than a year’s duration compared with less than 545 
10% in the placebo arm. Therefore, the biomarker does not appear to be sufficiently 546 
precise to predict lack of benefit on an individual basis. 547 
In summary, rucaparib improved progression-free survival in women with platinum-548 
sensitive ovarian carcinoma following a complete or partial response to second-line or 549 
later platinum-based chemotherapy. Treatment-emergent adverse events in the 550 
rucaparib arm were generally managed with dose modifications and were not 551 
associated with increased mortality or morbidity compared with the placebo arm.  552 
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Figure legends 728 
Figure 1: CONSORT diagram 729 
*A full description of protocol deviations is provided in the appendix (p 5); these protocol 730 
deviations are reported as of the visit cutoff date (April 15, 2017) and did not result in 731 
the exclusion of patients or data from any efficacy or safety analyses in the study. 732 
 733 
Figure 2: Investigator-assessed and blinded independent central radiology 734 
review–assessed progression-free survival  735 
Kaplan-Meier estimates of progression-free survival as assessed by the investigator (A–736 
C) and by BICR (D–F) in the rucaparib (blue) and placebo (red) arms for patients with a 737 
BRCA-mutant carcinoma (A, D), patients with an HRD carcinoma (B, E), and the intent-738 
to-treat population (C, F). BICR=blinded independent central radiology review. 739 
CI=confidence interval. HR=hazard ratio. HRD=homologous recombination deficient. 740 
NR=not reached. 741 
 742 
Figure 3: Investigator-assessed progression-free survival in subgroups of the 743 
intent-to-treat population 744 
CA-125=cancer antigen 125. CI=confidence interval. CR=complete response. 745 
GCIG=Gynecologic Cancer InterGroup. HR=hazard ratio. LOH=loss of heterozygosity. 746 
PR=partial response. RECIST=Response Evaluation Criteria In Solid Tumors version 747 
1·1. *By local germline test, central germline test, or tumour testing. †Tumour sample 748 
was not evaluable for percent of genomic LOH due to low tumour content or low 749 
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aneuploidy. ‡Prior treatment with bevacizumab was permitted as part of penultimate or 750 
earlier treatment. 751 
 752 
Figure 4: Investigator-assessed progression-free survival in patients with a BRCA 753 
wild-type carcinoma  754 
Kaplan-Meier estimates of progression-free survival as assessed by the investigator in 755 
the rucaparib (blue) and placebo (red) arms for patients with a BRCA wild-type 756 
carcinoma with LOH high (A) and LOH low (B). CI=confidence interval. HR=hazard 757 
ratio. LOH=loss of heterozygosity. 758 
 759 
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Summary 67 
Background: Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has demonstrated 68 
anticancer activity in patients with recurrent ovarian carcinoma that harboursharbouring 69 
a BRCA mutation or has a high percentage of genome-wide loss of heterozygosity 70 
(LOH). ARIEL3 evaluated rucaparib versus placebo following response to second-line 71 
or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-72 
sensitive ovarian carcinoma. 73 
Methods: ARIEL3 is an international, randomised, double-blind, phase 3 study 74 
performed at 87 hospitals and cancer centres in which. Patients were randomised 75 
patients2:1 to receive oral rucaparib 600 mg twice daily or placebo using a computer-76 
generated sequence (block size of six). Patients, investigators, site staff, and study 77 
sponsor were blinded to assignments. The primary endpoint (investigator-assessed 78 
progression-free survival) was evaluated using an ordered step-down procedure for 79 
three nested cohorts: (1) BRCA mutant (carcinoma associated with deleterious germline 80 
or somatic BRCA mutation); (2) homologous recombination deficient (HRD) (BRCA 81 
mutant or BRCA wild type/LOH high); and (3) intent-to-treat population. ARIEL3 is 82 
registered with ClinicalTrials.gov, NCT01968213; enrolment is complete. 83 
Findings: Between April 7, 2014, and July 19, 2016, 564 patients (intent-to-treat 84 
population) were randomised, 375 to rucaparib and 189 to placebo. Median 85 
progression-free survival in patients with a BRCA-mutant carcinoma (n=130, rucaparib; 86 
n=66, placebo) was 16·6 months versus 5·4 months (p<0·0001), respectively (hazard 87 
ratio [HR] 0·23; 95% confidence interval [CI] 0·16–0·34); in patients with an HRD 88 
carcinoma (n=236, rucaparib; n=118, placebo) it was 13·6 months versus 5·4 months 89 
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(p<0·0001), respectively (HR 0·32; 95% CI 0·24–0·42); and in the intent-to-treat 90 
population it was 10·8 months and 5·4 months (p<0·0001), respectively (HR 0·36; 95% 91 
CI 0·30–0·45). The most common grade 3 or higher treatment-emergent adverse 92 
events in the safety population (n=372, rucaparib; n=189, placebo) were 93 
anaemia/decreased haemoglobin (70 [19%], rucaparib; one [1%], placebo) and 94 
increased alanine aminotransferase or aspartate aminotransferase (39 [10%], 95 
rucaparib; none, placebo).  96 
Interpretation: Across all primary analysis groups, rucaparib significantly improved 97 
progression-free survival in patients with platinum-sensitive ovarian cancer who had 98 
achieved a response to platinum-based chemotherapy. 99 
Funding: Clovis Oncology, Inc. 100 
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Research in context 101 
Evidence before this study 102 
Evidence of the clinical effectiveness of poly(ADP-ribose) polymerase (PARP) inhibitors 103 
as maintenance treatment for platinum-sensitive ovarian carcinoma is limited. In a 104 
search of PubMed (conducted July 31, 2017; search term: (“PARP inhibitor” OR 105 
rucaparib OR olaparib OR niraparib OR veliparib OR talazoparib) AND (ovarian AND 106 
(cancer OR carcinoma)) AND "maintenance"), we found that data have been published 107 
in a PubMed-indexed journal for only three clinical trials, Study 19 (NCT00753545), 108 
NOVA (NCT01847274), and SOLO2 (NCT01874353). Study 19, a randomised, 109 
placebo-controlled, phase 2 study, enrolled patients with platinum-sensitive ovarian 110 
carcinoma who had received at least two prior platinum-based chemotherapies. 111 
Progression-free survival was significantly improved with olaparib maintenance 112 
treatment in the overall population, as well as in patients with a germline or somatic 113 
BRCA mutation. Study 19 data were published prior to the commencement of ARIEL3 114 
and supported the investigation of rucaparib as a maintenance treatment for patients 115 
with recurrent platinum-sensitive ovarian carcinoma in ARIEL3. In late 2016, results 116 
from the NOVA trial provided additional support for the role of a PARP inhibitor as 117 
maintenance treatment. In that randomised, placebo-controlled, phase 3 study, 118 
niraparib demonstrated a significant improvement in progression-free survival when 119 
used as a maintenance treatment in patients with ovarian carcinoma with or without a 120 
germline BRCA mutation who had received at least two prior platinum-based 121 
chemotherapies and had no measurable disease greater than 2 cm. Results from one 122 
other phase 3 study with olaparib maintenance treatment, SOLO2, were published in 123 
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July 2017. That randomised, placebo-controlled study enrolled patients with platinum-124 
sensitive ovarian carcinoma who had received at least two prior platinum-based 125 
chemotherapies and carried a germline mutation in BRCA. Similar to the results seen in 126 
Study 19, progression-free survival was significantly improved with olaparib 127 
maintenance treatment in patients enrolled in SOLO2. 128 
Added value of this study 129 
ARIEL3 enrolled patients with or without a germline or somatic BRCA mutation, and the 130 
size of residual disease was not restricted. Our results show that rucaparib maintenance 131 
treatment significantly improved progression-free survival for patients across all primary 132 
analysis groups for patients with recurrent, platinum-sensitive ovarian carcinoma who 133 
achieved a response to platinum-based therapy, including in the intent-to-treat 134 
population. We demonstrate that rucaparib maintenance treatment can provide clinical 135 
benefit not only to patients with ovarian carcinoma associated with a BRCA mutation, 136 
but also to those with BRCA wild-type ovarian carcinoma. A novel aspect of the ARIEL3 137 
trial was the prospective validation of the tumour-based, next-generation sequencing 138 
(NGS) homologous recombination deficiency (HRD) assay that was initially utilised in 139 
the phase 2 ARIEL2 study. This NGS assay combines mutation analysis of BRCA1 and 140 
BRCA2 genes with measurement of the percentage of genome-wide loss of 141 
heterozygosity (LOH) in the carcinomacancer tissue as a biomarker for sensitivity to 142 
rucaparib treatment. ARIEL2 enrolled patients with measurable, recurrent ovarian 143 
carcinoma, and provided initial evidence that patients with carcinomas with high LOH 144 
benefited from rucaparib treatment. The current study (ARIEL3) validated the utility of 145 
the HRD assay overall and LOH assessment in particular in the maintenance treatment 146 
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setting, where rucaparib-treated patients with carcinomas that were BRCA wild 147 
type/LOH high also had improvements in progression-free survival, with a lower hazard 148 
ratio than in patients with carcinomas that were BRCA wild type/LOH low.  149 
Implications of all the available evidence 150 
Combined with the evidence from prior studies, our study supports the use of PARP 151 
inhibitors, such as rucaparib, as maintenance treatment for patients with platinum-152 
sensitive ovarian cancer who achieved a response to platinum-based chemotherapy, 153 
including patients who have bulky residual disease.. ARIEL3 is the first phase 3 study to 154 
prospectively assess progression-free survival in patients with recurrent ovarian 155 
carcinoma associated with HRD as a primary endpoint, and our results demonstrate 156 
that HRD as a predictive biomarker can be an informative tool for clinicians when 157 
making treatment decisions for this patient population. In addition to PARP inhibitors, 158 
the targeted agents bevacizumab and cediranib have proven useful in extending 159 
progression-free survival for patients in this setting. Our findings strengthen the 160 
rationale for continued investigation of targeted therapies, such as PARP inhibitors, for 161 
maintenance treatment as either monotherapy or in combination with other agents, in an 162 
effort to provide the best care for patients with advanced ovarian cancer.   163 
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Introduction 164 
Ovarian cancer is the eighth leading cause of death from cancer in women worldwide.1 165 
Most patients with advanced stage ovarian carcinoma initially receive platinum-based 166 
chemotherapy and achieve a clinical response; however, the majority of these patients 167 
will ultimately relapse.2 The treatment for initial recurrent disease depends on many 168 
factors, including duration of initial treatment response, antecedent and persistent 169 
adverse events, performance status, histology, location and burden of disease, and, 170 
increasingly, tumour genomics such as BRCA mutation status.3 For patients with 171 
platinum-sensitive recurrent ovarian carcinoma, maintenance treatment with targeted 172 
agents has resulted in greater prolongation of progression-free survival.4-9 However, 173 
clinical benefit is typically transient, hence there is an ongoing pursuit for new therapies 174 
and tools to identify patients who may benefit most from these therapies, as well as to 175 
identify the optimal therapeutic strategy for patients.  176 
The poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib is approved in the United 177 
States for the treatment of patients with deleterious BRCA mutation (germline or 178 
somatic) associated advanced ovarian carcinoma who have been treated with two or 179 
more chemotherapy regimens. Approval of rucaparib was based on the objective 180 
response rate (54%, n=57 of 106) patients [54%]) observed in a pooled population of 181 
patients with BRCA-mutant high-grade ovarian carcinoma from the Study 10 (CO-338-182 
10; NCT01482715) and ARIEL2 (CO-338-017; NCT01891344) clinical trials.10,11   183 
In Part 1 of the ARIEL2 trial, rucaparib treatment was found to be efficacious not only in 184 
patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma with a BRCA 185 
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mutation, but also in patients with BRCA wild-type carcinomas with high genomic loss of 186 
heterozygosity (LOH),11 a potential marker for homologous recombination deficiency 187 
(HRD) and thus PARP inhibitor activity.12-15 In the current phase 3, randomised, 188 
placebo-controlled study (ARIEL3), our objective was to evaluate the efficacy and safety 189 
of rucaparib versus placebo following response to second-line or later platinum-based 190 
chemotherapy in patients with high-grade, platinum-sensitive ovarian carcinoma 191 
(including fallopian tube and primary peritoneal carcinomas) and to prospectively test 192 
the genomic LOH cutoff discriminator that was optimised based on results of ARIEL2 193 
Part 1 as a predictive biomarker for sensitivity to rucaparib treatment. 194 
 195 
Methods 196 
Study design and patients 197 
ARIEL3 (NCT01968213) was a phase 3, international, randomised, placebo-controlled 198 
study conducted at 87 hospitals and cancer centres in Australia, Belgium, Canada, 199 
France, Germany, Israel, Italy, New Zealand, Spain, United Kingdom, and the United 200 
States. The trial was approved by national or local institutional review boards and was 201 
carried out in accordance with the Declaration of Helsinki and Good Clinical Practice 202 
Guidelines of the International Conference on Harmonisation. Patients provided written 203 
informed consent before participation. Per the protocol, an independent data monitoring 204 
committee monitored enrolment and reviewed the safety and efficacy of the trial at 205 
regular intervalsapproximately every 6 months, including maturity of progression-free 206 
survival events. 207 
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Eligible patients were aged 18 years or older, had platinum-sensitive (ie, documented 208 
radiologic disease progression more than 6 months following the last dose of the 209 
penultimate platinum administered), high-grade serous or endometrioid ovarian, primary 210 
peritoneal, or fallopian tube carcinoma , and had received at least two prior platinum-211 
based chemotherapy regimens. Prior treatment with bevacizumab was permitted, with 212 
the exception of bevacizumab maintenance treatment following the most recent 213 
platinum-based regimen. On November 4, 2014, after 91 patients had been 214 
randomised, an amendment was addedmade to the protocol requiring that the most 215 
recent platinum-based regimen was to be administered as a chemotherapy doublet and 216 
for a minimum of four cycles. Patients must have achieved either a complete response 217 
by Response Evaluation Criteria In Solid Tumors version 1·1 (RECIST)1616 or a partial 218 
response, defined as either a RECIST partial response or a serologic response per 219 
Gynecologic Cancer InterGroup (GCIG) cancer antigen 125 (CA-125)17 response 220 
criteria, to their last platinum-based regimen. For patients who achieved a partial 221 
response, no restriction was placed on residual carcinoma size at study entry; those 222 
who had persistent lesions greater than 2 cm as defined by independent radiological 223 
review were defined as having “bulky” residual disease. Responses must have been 224 
maintained through the completion of chemotherapy and during the interval period 225 
between completion of chemotherapy and entry into ARIEL3. Additionally, CA-125 was 226 
required to be less than the upper limit of normal. Patients had Eastern Cooperative 227 
Oncology Group Performance Status of 0 to 1 and adequate organ function. Patients 228 
were ineligible if they had symptomatic/untreated central nervous system metastases, 229 
had received anticancer therapy 14 or fewer days before starting the study, or had 230 
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received prior treatment with a PARP inhibitor. A complete list of inclusion and exclusion 231 
criteria is provided in the appendix (p 6), and the full study protocol is available in the 232 
appendix.  233 
Central testing of DNA derived from patient archival tumour tissue samples was 234 
performed to detect mutations in homologous recombination pathway genes (appendix 235 
p 8) and assess genomic LOH using Foundation Medicine’s T5 NGS assay (Cambridge, 236 
MA). Based on retrospective analysis of data from ARIEL2 Part 1, a cutoff of 16% or 237 
greater for high genomic LOH was prespecified for ARIEL3 as a discriminator for high 238 
genomic LOH.11 Germline mutations were identified by BRCAnalysis CDx test (Myriad 239 
Genetics, Salt Lake City, UT). Further details of the tumour tissue testing are provided 240 
in the appendix (p 2).  241 
Randomisation and masking 242 
Within 8 weeks of their last dose of platinum, eligible patients were randomised 2:1 to 243 
receive oral rucaparib (600 mg twice daily) or matched placebo. Randomisation was 244 
computer-generated by Almac Clinical Technologies (Souderton, PA) using a block size 245 
of six. Randomisation stratification factors included: homologous recombination repair 246 
gene mutation status (based on gene mutation only); progression-free interval following 247 
penultimate platinum-based regimen; and best response to most recent platinum-based 248 
regimen (additional details in the appendix p 3). Patients were assigned to the rucaparib 249 
arm or placebo arm in a blinded manner using Almac Clinical Technologies’ interactive 250 
web and voice response system (IXRS®); patients, investigators, site staff, and the 251 
study sponsor were blinded to assignments. To ensure blinding was maintained, 252 
rucaparib and placebo tablets were manufactured to have identical appearances.   253 
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Procedures 254 
Patients received study drug in continuous 28-day cycles until disease progression, 255 
death, or other reason for discontinuation. Dose reductions (in decrements of 120 mg) 256 
were permitted if a patient had a grade 3 or greater or persistent grade 2 adverse event 257 
(additional details in the appendix p 3). Treatment was discontinued for a toxicity-related 258 
treatment interruption lasting more than 14 consecutive days (unless otherwise agreed 259 
upon between the investigator and the study sponsor). 260 
Disease assessments were performed at screening, every 12 weeks during treatment 261 
(and post-treatment for patients who discontinued for any reason other than disease 262 
progression), at discontinuation of treatment, and as clinically indicated. Disease 263 
progression was determined by RECIST. Patients with a complete response at study 264 
entry were only considered to have disease progression if an unequivocal new lesion 265 
was identified. Increased CA-125 levels alone were not considered to indicate disease 266 
progression unless confirmed by RECIST. All computed tomography scans and other 267 
imaging were provided to a blinded, independent central radiology review (BICR). 268 
The National Comprehensive Cancer Network–Functional Assessment of Cancer 269 
Therapy Ovarian Symptom Index 18 (FOSI-18)18 questionnaire was used to assess 270 
patient-reported outcomes at screening and throughout treatment.  Safety was 271 
assessed by monitoring for adverse events, laboratory testing, assessing vital signs and 272 
conducting physical examinations. Adverse events were classified in accordance with 273 
the Medical Dictionary for Drug Regulatory Activities classification system version 18·119 274 
and graded for severity in accordance with the National Cancer Institute Common 275 
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Terminology Criteria for Adverse Events version 4·03.2020 Serious adverse events were 276 
classified as defined in the protocol (see appendix).  277 
Outcomes 278 
The primary endpoint was investigator-assessed progression-free survival, defined as 279 
time from randomisation to investigator-assessed disease progression per RECIST or 280 
death. Secondary endpoints included progression-free survival by BICR, patient-281 
reported outcomes as evaluated by time to worsening in the FOSI-18 disease-related 282 
symptoms–physical (DRS-P) subscale (defined as ≥4-point decrease) and total score 283 
(defined as ≥8-point decrease), overall survival, safety, and population pharmacokinetic 284 
modelling. Additional details are available in the appendix (p 3). The secondary 285 
endpoint of population pharmacokinetic modelling will be reported separately. 286 
Statistical analysis 287 
ARIEL3 was designed to enrol approximately 540 patients, including between 180 and 288 
200 patients with a BRCA mutation in their carcinoma (with no more than 150 patients 289 
with a known deleterious germline BRCA mutation) and no more than 360 patients 290 
without a BRCA mutation in their carcinoma. The independent data monitoring 291 
committee surveyed enrolment of patients with a BRCA mutation and informed the 292 
study sponsor (Clovis Oncology, Inc.) when the target enrolment number for the BRCA-293 
mutant cohort was anticipated to be reached. Once notified, patients who were in the 294 
screening process were allowed to complete screening and enrol into the study if they 295 
met all eligibility criteria. These subgroup sizes were designed to result in 90% power to 296 
determine statistical significance between rucaparib and placebo at a one-sided alpha 297 
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level of 0·025 given the following assumptions for median investigator-assessed 298 
progression-free survival for the efficacy analysis cohorts: BRCA mutant (carcinoma 299 
associated with a deleterious germline or somatic BRCA mutation), 12·0 months in the 300 
rucaparib arm versus 6·0 months in the placebo arm (hazard ratio [HR] 0·5); HRD 301 
(includes patients with a BRCA-mutated carcinoma and patients with BRCA wild-302 
type/LOH-high carcinomas), 10·0 versus 6·0 months (HR 0·6); and intent-to-treat 303 
population (all randomised patients), 8·5 versus 6·0 months (HR 0·7). 304 
Classification of HRD status in the carcinoma (based on BRCA mutation and/or LOH) 305 
for the efficacy analysis was determined before database lock and the final efficacy 306 
analysis. Per protocol, the primary analysis was to be performed after the independent 307 
data monitoring committee determined that investigator-assessed disease progression 308 
or death had occurred in at least 70% of expected patients in the BRCA-mutant cohort.  309 
All efficacy analyses were performed for the intent-to-treat population. The efficacy 310 
analyses are presented separately for the nested cohorts: BRCA mutant, HRD, and 311 
intent-to-treat population. The primary endpoint was tested using an ordered step-down 312 
multiple comparisons procedure21,2221 for the three nested cohorts: BRCA mutant, HRD, 313 
and the intent-to-treat population. Investigator-assessed progression-free survival in 314 
patients with a BRCA-mutant carcinoma was tested first at a one-sided 0·025 315 
significance level. Analysis of investigator-assessed progression-free survival in patients 316 
with an HRD carcinoma followed by analysis in the intent-to-treat population was 317 
contingent upon a statistically significant result in the analysis of patients with a BRCA-318 
mutant carcinoma. Analysis of the key secondary endpoints of patient-reported 319 
outcomes and overall survival were to follow in a similar ordered step-down procedure. 320 
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Once statistical significance was not achieved for one test, the statistical significance 321 
was not declared for all subsequent analyses in the ordered step-down procedure. 322 
Progression-free survival by BICR was evaluated as a key stand-alone secondary 323 
endpoint, separate from the step-down procedure described above. Time to 324 
progression-free survival (by investigator and by BICR) and time to worsening in the 325 
FOSI-18 DRS-P subscale were analysed using stratified Kaplan-Meier methodology 326 
where distributions between rucaparib and placebo arms were compared using a 327 
stratified log-rank test. A stratified Cox proportional hazards model was used to estimate 328 
the HR between the arms. Exploratory analyses of progression-free survival were 329 
performed in subgroups based on patient characteristics (eg, randomisation 330 
stratification factors, demographics, disease burden at baseline). For patients with 331 
measurable disease at study entry, the proportion of patients achieving a confirmed 332 
complete or partial response per RECIST as assessed by the investigator was ana 333 
prespecified exploratory endpoint of ARIEL3.  334 
Safety, including adverse events and clinical laboratory investigations, was evaluated in 335 
all patients who received at least one dose of protocol-specified treatment.  336 
Statistical analyses were performed using SAS version 9·4 (SAS Institute, Cary, NC). 337 
Additional details are available in the appendix (p 4). 338 
Role of the funding source 339 
The study was designed by the sponsor, Clovis Oncology, Inc., and the coordinating 340 
investigators (RLC and JAL). Data presented herein were collected by the investigators, 341 
analysed by Clovis Oncology, and interpreted by all authors. All authors had access to 342 
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the data and had final responsibility for the decision to submit for publication. Writing 343 
and editorial assistance were supported by the sponsor. 344 
 345 
Results 346 
Between April 7, 2014, and July 19, 2016, 564 patients (intent-to-treat population) were 347 
randomised, 375 to rucaparib and 189 to placebo (figure 1; appendix p 11). At the visit 348 
cutoff date (April 15, 2017), 90 (24%) and 9 (5%) patients in the rucaparib and placebo 349 
arms, respectively, were still receiving treatment. Baseline demographic and clinical 350 
characteristics were generally well balanced between the treatment arms (table 1).  351 
Following the ordered step-down multiple comparisons procedure, the analysis of 352 
investigator-assessed progression-free survival was evaluated first in patients with a 353 
BRCA-mutant carcinoma (130, rucaparib; 66, placebo; appendix p 11). Median time to 354 
progression or death was 16·6 months versus 5·4 months (stratified log-rank p<0·0001) 355 
in the rucaparib and placebo arms, respectively (HR 0·23; 95% confidence interval [CI] 356 
0·16–0·34; p<0·0001) (figure 2). In patients with an HRD carcinoma (236, rucaparib; 357 
118, placebo), median progression-free survival was 13·6 months and 5·4 months 358 
(stratified log-rank p<0·0001), respectively (HR 0·32; 95% CI 0·24–0·42; p<0·0001). 359 
Median progression-free survival in the intent-to-treat population was 10·8 months and 360 
5·4 months (stratified log-rank p<0·0001), respectively (HR 0·36; 95% CI 0·30–0·45; 361 
p<0·0001).    362 
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In a prespecified analysis of the key stand-alone, secondary endpoint of progression-363 
free survival assessed by BICR, results were similar to those of investigator-assessed 364 
progression-free survival for the patients with a BRCA-mutant carcinoma (median 26·8 365 
months vs 5·4 months; HR 0·20; 95% CI 0·13–0·32; p<0·0001), the patients with an 366 
HRD carcinoma (median 22·9 months vs 5·5 months; HR 0·34; 95% CI 0·24–0·47; 367 
p<0·0001), and the intent-to-treat population (median 13·7 months vs 5·4 months; HR 368 
0·35; 95% CI 0·28–0·45; p<0·0001) (figure 2).  369 
Analysis of the secondary endpoint of time to worsening in the FOSI-18 DRS-P 370 
subscale score was assessed in the step-down procedure for the three nested 371 
subgroups. In patients with a BRCA-mutant carcinoma, there was no significant 372 
difference between arms in the time to worsening in the FOSI-18 DRS-P subscale 373 
(stratified log-rank p=0·29) (HR 1·24; 95% CI 0·82–1·86; p=0·30). As statistical 374 
significance was not reached in patients with a BRCA-mutant carcinoma, in accordance 375 
with the prespecified step-down procedure, statistical significance could not be 376 
determined for the remaining secondary analyses.  377 
At the visit cutoff date (April 15, 2017), overall survival data were not mature (123 378 
[21·822%] patients had died). A follow-up analysis will be performed when 379 
approximately 70% of the patients have died. (≈395 overall survival events).   380 
Preplanned subgroup analyses of investigator-assessed progression-free survival 381 
demonstrated that the progression-free survival benefit for rucaparib versus placebo 382 
was observed across all clinical subgroups, irrespective of presence or absence of 383 
measurable disease or bulky disease (defined as any lesion >2 cm) at baseline, 384 
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response to last platinum-based regimen (complete or partial response), LOH (high, 385 
low, or indeterminate), or BRCA mutation (germline or somatic; BRCA1 or BRCA2) 386 
(figure 3; appendix p 12). Further supporting the efficacy observed in the intent-to-treat 387 
population, in the non-nested subgroups of patients with carcinomas that were BRCA 388 
wild type, a progression-free survival benefit as assessed by the investigator was 389 
observed with rucaparib in patients with LOH-high carcinomas (median 9·7 months vs 390 
5·4 months; HR 0·44; 95% CI 0·29–0·66; p<0·0001) and patients with LOH-low 391 
carcinomas (median 6·7 months vs 5·4 months; HR 0·58; 95% CI 0·40–0·85; p=0·0049) 392 
(figure 4); similar results were also observed in progression-free survival assessed by 393 
BICR (appendix p 13).   394 
The majority of patients (374 [66%]) in ARIEL3 had achieved a partial response to the 395 
platinum-based therapy prior to randomisation. For 207 (37%) of 564 patients with 396 
measurable disease per investigator at study entry, a prespecified exploratory analysis 397 
of confirmed response was conducted. In the subgroup of patients with measurable 398 
disease at study entry with a BRCA-mutant carcinoma, 15 (38%) of 40 in the rucaparib 399 
arm and two (9%) of 23 in the placebo arm achieved a confirmed RECIST response 400 
(appendix p 8). In patients with an HRD carcinoma with measurable disease at 401 
baseline, the objective response was also higher in the rucaparib arm (23 [27%] of 85 402 
patients) than the placebo arm (3 [7%] of 41 patients). A similar result was observed in 403 
the intent-to-treat population among patients with measurable disease at baseline (26 404 
[18%] of 141 patients in the rucaparib arm; 5 [8%] of 66 patients in the placebo arm). 405 
Complete responses were observed in the rucaparib arm in seven (18%), 10 (12%), and 406 
10 (7%) patients with measurable disease at baseline in the nested BRCA-mutant and 407 
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HRD cohorts, and the overall intent-to-treat population, respectively. Only one (2%) 408 
complete response was observed in the placebo arm; this occurred in the intent-to-treat 409 
population.  410 
The safety population included 372 patients who received rucaparib (three patients 411 
were withdrawn prior to receiving rucaparib) and 189 patients who received placebo. 412 
For the safety population, the median (interquartile range) treatment duration was 8·3 413 
(3·4–16·1) months in the rucaparib arm and 5·5 (2·8–8·3) months in the placebo arm. A 414 
treatment-emergent adverse event of any grade occurred in 372 patients (100%) in the 415 
rucaparib arm and 182 patients (96%) in the placebo arm (table 2). The most common 416 
treatment-emergent adverse events (reported in at least 35% of patients in either arm) 417 
included nausea (280 patients [75%] in the rucaparib arm and 69 patients [37%] in the 418 
placebo arm), asthenia or fatigue (258 patients [69%] and 83 patients [44%]), dysgeusia 419 
(146 patients [39%] and 13 patients [7%]), anaemia/decreased haemoglobin (139 420 
patients [37%] and 11 patients [6%]), constipation (136 patients [37%] and 45 patients 421 
[24%]), and vomiting (136 patients [37%] and 28 patients [15%]). Treatment-emergent 422 
adverse events of grade 3 or greater were reported in 209 patients (56%) in the 423 
rucaparib arm and 28 patients (15%) in the placebo arm, the most common of which 424 
were anaemia/decreased haemoglobin (70 patients [19%] and one patient [1%]) and 425 
increase in alanine aminotransferase or aspartate aminotransferase (39 patients [10%] 426 
and no patients). For patients in the rucaparib arm, a decline in haemoglobin level from 427 
baseline generally occurred in the first few cycles (appendix p 14). Elevations in alanine 428 
aminotransferase or aspartate aminotransferase were generally transient, self-limiting, 429 
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and not associated with other signs of liver toxicity (appendix p 15). The frequency of 430 
treatment-emergent adverse events was comparable across the three nested cohorts. 431 
One or more serious adverse events were reported in 78 patients (21%) in the rucaparib 432 
arm and 20 patients (11%) in the placebo arm. The most common serious adverse 433 
events (reported in at least 2% of patients in either arm) included anaemia (16 patients 434 
[4%] in the rucaparib arm and one patient [1%] in the placebo arm), pyrexia (six patients 435 
[2%] and no patients), vomiting (six patients [2%] and two patients [1%]), and small 436 
intestinal obstruction (three patients [1%] and three patients [2%]).  437 
Myelodysplastic syndrome and acute myeloid leukaemia were reported in three patients 438 
(1%) in the rucaparib arm (two had a germline BRCA-mutant carcinoma, and one had a 439 
BRCA wild-type/LOH-low carcinoma). One patient died due to myelodysplastic 440 
syndrome and one due to acute myeloid leukaemia. There were no reports of 441 
myelodysplastic syndrome or acute myeloid leukaemia in the placebo arm.  442 
Treatment interruption due to a treatment-emergent adverse event occurred in 237 443 
(64%) and 19 (10%) patients in the rucaparib and placebo arms, respectively (appendix 444 
p 9). Dose reduction due to a treatment-emergent adverse event occurred in 203 (55%) 445 
and eight (4%) patients in the rucaparib and placebo arms, respectively (appendix p 9). 446 
In the rucaparib and placebo arms, 117 (31%) and six (3%) patients, respectively, had 447 
both a treatment interruption due to a treatment-emergent adverse event and a dose 448 
reduction due to a treatment-emergent adverse event. Of patients who received 449 
rucaparib, 50 (13%) discontinued due to a treatment-emergent adverse event 450 
(excluding disease progression) compared with three (2%) of patients in the placebo 451 
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arm (appendix p 10). As of the visit cutoff date, in the rucaparib arm there were four 452 
deaths due to adverse events considered unrelated to treatment by the investigator (two 453 
patients due to progressive disease, one due to cardiac arrest, and one due to 454 
haematophagic histiocytosis) and two deaths considered treatment related by the 455 
investigator (one due to acute myeloid leukaemia and one due to myelodysplastic 456 
syndrome). In the placebo arm, two patients died due to adverse events considered 457 
unrelated to treatment by the investigator (one due to progressive disease and one due 458 
to pulmonary embolism). 459 
 460 
Discussion 461 
In ARIEL3, rucaparib maintenance treatment versus placebo significantly improved 462 
progression-free survival in all primary analysis groups of patients with recurrent ovarian 463 
carcinoma following a complete or partial response to platinum-based therapy. The 63% 464 
reduction in risk of diseaseprolonged progression or death observed-free survival 465 
among patients receiving rucaparib in the intent-to-treat population (HR 0·36) 466 
demonstrates that patients with platinum-sensitive ovarian carcinoma can derive robust 467 
clinical benefit from rucaparib maintenance treatment. A similar reduction (65%) in risk 468 
of disease progression or deathimprovement over placebo (HR 0·35) was seen in the 469 
secondary endpoint of assessment by BICR review, supporting the validity of the benefit 470 
observed with rucaparib maintenance treatment. Furthermore, the lower riskhazard of 471 
disease progression or death associated with rucaparib in the study was observed 472 
across all prespecified subgroups that were analysed. Analysis of non-nested, non-473 
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overlapping patient subpopulations (ie, BRCA wild-type/LOH-high and BRCA wild-474 
type/LOH-low patients) indicate that the statistically significant improvement in 475 
progression-free survival observed in the intent-to-treat population was not driven only 476 
by the results in the nested HRD or BRCA-mutant cohorts.  477 
Patient-reported outcomes were evaluated as a secondary endpoint of ARIEL3 as part 478 
of the step-down procedure, with no significant difference in time to worsening in the 479 
FOSI-18 DRS-P subscale observed between the rucaparib and placebo arms. Further 480 
analyses of the patient-reported health outcome data gathered in ARIEL3 are planned 481 
and will be reported separately.  482 
Overall survival data were not mature at the time of the visit cutoff, with less than 25% 483 
of the events needed for final analysis. Patient follow-up is continuing in a blinded 484 
manner and overall survival will be assessed after about 70% maturity is reached. 485 
As reported in prior studies of rucaparib and other PARP inhibitors,5,6,9-11,23 486 
gastrointestinal side effects, asthenia or fatigue, and myelosuppression were common 487 
treatment-emergent adverse events in the rucaparib arm. Management of adverse 488 
events included supportive care and dose modifications (including treatment interruption 489 
and/or dose reduction). Common laboratory abnormalities observed in the rucaparib 490 
arm included elevations in alanine aminotransferase, aspartate aminotransferase, and 491 
blood creatinine. Alanine aminotransferase and aspartate aminotransferase were not 492 
associated with abnormal increases in bilirubin or other criteria for drug-induced 493 
hepatotoxicity, and generally resolved over time. No cases of Hy’s law were 494 
observed.No cases were considered to meet Hy’s law criteria for drug-induced liver 495 
injury (ie, alanine aminotransferase or aspartate aminotransferase greater than 3 times 496 
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the upper limit of normal with concomitant bilirubin greater than 2 times the upper limit 497 
of normal without alkaline phosphatase elevations or another clear reason for the 498 
elevations).22,23 Similarly, elevations in creatinine, which have also been observed with 499 
olaparib,24 were self-limiting and stabilised over time. Creatinine is secreted into urine 500 
via renal transporters (eg, MATE1, MATE2-K, OCT-1, and OCT-2), which have been 501 
shown to be inhibited in vitro by multiple PARP inhibitors, including rucaparib, olaparib, 502 
and veliparib.25-27 Patterns of elevation and stabilisation of these laboratory 503 
abnormalities similar to those reported here were observed in the treatment setting with 504 
rucaparib.28,29   505 
The results of ARIEL3 are consistent with those of other placebo-controlled studies of 506 
PARP inhibitors in the maintenance treatment setting, including NOVA (NCT01847274) 507 
with niraparib and Study 19 (NCT00753545) and SOLO2 (NCT01874353) with 508 
olaparib.5,6,9 However, direct comparisons with these other trials cannot be made due to 509 
differences in patient groups analysed (eg, SOLO2 only enrolled patients with a 510 
germline BRCA mutation), definition of HRD (eg, in NOVA, HRD included patients with 511 
somatic mutations in BRCA, as well as those with non-BRCA–related HRD), the method 512 
of primary endpoint assessment (eg, investigator vs BICR), and study design (eg, 513 
residual disease was restricted to <2 cm in NOVA).5,6,9,30  514 
Although having a CA-125 below the upper limit of normal is not a requirement of 515 
response per GCIG CA-125 criteria or a RECIST partial response, ARIEL3 required that 516 
patients have CA-125 below the upper limit of normal prior to study entry; this eligibility 517 
requirement was intended to ensure that patients had controlled disease at study entry. 518 
Similar restrictions on CA-125 levels were included in the enrolment criteria of other 519 
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studies investigating PARP inhibitors in the maintenance treatment setting, although it is 520 
unknown how many patients in these studies had CA-125 levels greater than the upper 521 
limit of normal at study entry.5,6,9 Furthermore, it is not known whether inclusion of 522 
patients with CA-125 levels exceeding the upper limit of normal affects the efficacy of 523 
PARP inhibitors in the maintenance treatment setting. 524 
Although ARIEL3 extends the findings of previous studies of PARP inhibitors in this 525 
setting, there are some important differences between ARIEL3 and other studies in the 526 
maintenance treatment setting. Notably, patients in ARIEL3 with carcinomas associated 527 
with a germline or somatic BRCA mutation were both included in the three nested 528 
cohorts (BRCA mutant, HRD, and intent-to-treat population), a feature that is unique to 529 
ARIEL3 among clinical trials in this setting. In addition, ARIEL3 did not restrict 530 
enrolment based on target lesion size for patients with residual disease (partial 531 
response to prior platinum). A number of patients with measurable residual disease at 532 
study entry showed further reduction in carcinoma burden with rucaparib maintenance 533 
treatment, including conversion to a complete response per RECIST. in several patients 534 
in the nested BRCA-mutant and HRD cohorts and the overall intent-to-treat population.  535 
Additionally, ARIEL3 is the first phase 3 study to prospectively assess the primary 536 
endpoint of progression-free survival in patients with recurrent ovarian carcinoma 537 
associated with HRD. Preplanned analysis of progression-free survival in patients with a 538 
BRCA wild-type/LOH-high carcinoma, wherein patients treated with rucaparib had a 539 
56% decreasean increase in risk of diseasemedian progression or death-free survival 540 
(HR 0·44) compared with placebo, shows that the improvement observed in the HRD 541 
cohort was not driven solely by patients with a BRCA-mutant carcinoma. The lower risk 542 
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of diseasebenefit in progression or death-free survival seen in patients with a BRCA 543 
wild-type/LOH-high carcinoma (HR 0·44) compared with patients with a BRCA wild-544 
type/LOH-low carcinoma (HR 0·58) demonstrates the utility of HRD, in particular high 545 
genomic LOH as defined by Foundation Medicine’s T5 assay, as a predictive biomarker 546 
for sensitivity to rucaparib treatment. Based on our findings, HRD assessment may be 547 
an informative tool for clinicians making treatment decisions for patients with BRCA 548 
wild-type associated platinum-sensitive ovarian carcinoma. However, response to 549 
rucaparib was also clearly observed in the cohort of patients with carcinomas that were 550 
BRCA wild type/LOH low, with more than 30% of patients in the rucaparib arm 551 
achieving benefit of more than a year’s duration compared with less than 10% in the 552 
placebo arm. Therefore, the biomarker does not appear to be sufficiently precise to 553 
predict lack of benefit on an individual basis. 554 
In summary, rucaparib improved progression-free survival in women with platinum-555 
sensitive ovarian carcinoma following a complete or partial response to second-line or 556 
later platinum-based chemotherapy. Treatment-emergent adverse events in the 557 
rucaparib arm were generally managed with dose modifications and were not 558 
associated with increased mortality or morbidity compared with the placebo arm.  559 
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Figure legends 746 
Figure 1: CONSORT diagram 747 
*A full description of protocol deviations is provided in the appendix (p 5); these protocol 748 
deviations are reported as of the visit cutoff date (April 15, 2017) and did not result in 749 
the exclusion of patients or data from any efficacy or safety analyses in the study. 750 
 751 
Figure 2: Investigator-assessed and blinded independent central radiology 752 
review–assessed progression-free survival  753 
Kaplan-Meier estimates of progression-free survival as assessed by the investigator (A–754 
C) and by BICR (D–F) in the rucaparib (blue) and placebo (red) arms for patients with a 755 
BRCA-mutant carcinoma (A, D), patients with an HRD carcinoma (B, E), and the intent-756 
to-treat population (C, F). BICR=blinded independent central radiology review. 757 
CI=confidence interval. HR=hazard ratio. HRD=homologous recombination deficient. 758 
NR=not reached. 759 
 760 
Figure 3: Investigator-assessed progression-free survival in subgroups of the 761 
intent-to-treat population 762 
CA-125=cancer antigen 125. CI=confidence interval. CR=complete response. 763 
GCIG=Gynecologic Cancer InterGroup. HR=hazard ratio. LOH=loss of heterozygosity. 764 
PR=partial response. RECIST=Response Evaluation Criteria In Solid Tumors version 765 
1·1. *By local germline test, central germline test, or tumour testing. †Tumour sample 766 
was not evaluable for percent of genomic LOH due to low tumour content or low 767 
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aneuploidy. ‡Prior treatment with bevacizumab was permitted as part of penultimate or 768 
earlier treatment. 769 
 770 
Figure 4: Investigator-assessed progression-free survival in patients with a BRCA 771 
wild-type carcinoma  772 
Kaplan-Meier estimates of progression-free survival as assessed by the investigator in 773 
the rucaparib (blue) and placebo (red) arms for patients with a BRCA wild-type 774 
carcinoma with LOH high (A) and LOH low (B). CI=confidence interval. HR=hazard 775 
ratio. LOH=loss of heterozygosity. 776 
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Table 1: Baseline patient and disease characteristics in the intent-to-treat 
population 
Characteristic Rucaparib 
(n=375)
 
Placebo 
(n=189)
 
Age (years) 61·0 (53·0–67·0) 62·0 (53·0–68·0) 
Race   
White 302 (81%) 149 (79%) 
Non-white 26 (7%) 13 (7%) 
Unknown 47 (13%) 27 (14%) 
ECOG Performance Status   
0 280 (75%) 136 (72%) 
1 95 (25%) 53 (28%) 
Diagnosis
 
  
Epithelial ovarian cancer 312 (83%) 159 (84%) 
Fallopian tube cancer 32 (9%) 10 (5%) 
Primary peritoneal cancer 31 (8%) 19 (10%) 
High-grade serous adenocarcinoma* 0 1 (1%) 
Histology   
Serous 357 (95%) 179 (95%) 
Endometrioid 16 (4%) 7 (4%) 
Mixed 1 (<1%) 3 (2%) 
Transitional 1 (<1%) 0 
BRCA mutation in the carcinoma   
BRCA mutant 130 (35%) 66 (35%) 
BRCA1 80 (21%) 37 (20%) 
BRCA2 50 (13%) 29 (15%) 
Germline 82 (22%) 48 (25%) 
Somatic 40 (11%) 16 (8%) 
Unknown
†
 8 (2%) 2 (1%) 
BRCA wild type 245 (65%) 123 (65%) 
LOH high 106 (28%) 52 (28%) 
LOH low 107 (29%) 54 (29%) 
LOH indeterminate
‡
 32 (9%) 17 (9%) 
Number of prior chemotherapy regimens  2 (2–3) 2 (2–3) 
2 231 (62%) 124 (66%) 
≥3 144 (38%) 65 (34%) 
Prior bevacizumab use
§
 83 (22%) 43 (23%) 
Number of platinum-based regimens 2 (2–3) 2 (2–3) 
2 236 (63%) 126 (67%) 
≥3 139 (37%) 63 (33%) 
Measurable disease at baseline (per investigator) 141 (38%) 66 (35%) 
Bulky disease (any lesion >2 cm) at baseline (per 
independent radiological review) 
71 (19%) 29 (15%) 
Randomisation stratification factors   
Table 1
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HRR gene mutation status   
BRCA mutant 130 (35%) 66 (35%) 
Mutation in other, non-BRCA HRR gene 28 (7%) 15 (8%) 
No mutation detected in BRCA or HRR gene 217 (58%) 108 (57%) 
Time to progression with penultimate platinum 
(months) 
13·8 (10·0–22·3) 14·6 (10·7–24·0) 
6 to <12 months 151 (40%) 76 (40%) 
≥12 months 224 (60%) 113 (60%) 
Response to last platinum    
CR per RECIST  126 (34%) 64 (34%) 
PR per RECIST or serologic response per 
GCIG CA-125 criteria 
249 (66%)  125 (66%) 
Data are median (interquartile range) or n (%). CA-125=cancer antigen 125. CR=complete 
response. ECOG=Eastern Cooperative Oncology Group. GCIG=Gynecologic Cancer InterGroup. 
HRR=homologous recombination repair. LOH=loss of heterozygosity. PR=partial response. 
RECIST=Response Evaluation Criteria In Solid Tumors version 1·1. *Per patient records, origin was 
fallopian tube and/or ovary. 
†
Tumour sample was BRCA mutant by Foundation Medicine’s T5 next-
generation sequencing assay, but a blood sample was not available for central germline testing. 
‡
Tumour sample was not evaluable for percent of genomic LOH due to low tumour content or low 
aneuploidy. 
§
Prior treatment with bevacizumab was permitted as part of penultimate or earlier 
treatment. 
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Table 2: Treatment emergent adverse events of any grade reported in ≥10% of 
patients in either arm in the safety population 
 Rucaparib 
(n=372) 
Placebo 
(n=189) 
 Any  
grade 
Grade 
1–2 
Grade 
3 
Grade 
4 
Any  
grade 
Grade 
1–2 
Grade 
3 
Grade 
4 
At least one AE 372 (100%)* 163 (44%) 179 (48%) 24 (6%) 182 (96%)
†
 154 (81%) 24 (13%) 2 (1%) 
Blood and lymphatic system disorders 
Anaemia; decreased 
haemoglobin 
139 (37%) 69 (19%) 67 (18%) 3 (1%) 11 (6%) 10 (5%) 0 1 (1%) 
Neutropenia; neutrophil count 
decreased 
67 (18%) 42 (11%) 19 (5%) 6 (2%) 9 (5%) 7 (4%) 1 (1%) 1 (1%) 
Thrombocytopenia; platelet 
count decreased 
104 (28%) 85 (23%) 13 (3%) 6 (2%) 5 (3%) 5 (3%) 0 0 
Gastrointestinal disorders 
Abdominal distension 41 (11%) 41 (11%) 0 0 22 (12%) 22 (12%) 0 0 
Abdominal pain 111 (30%) 102 (27%) 9 (2%) 0 49 (26%) 48 (25%) 1 (1%) 0 
Abdominal pain (upper) 52 (14%) 50 (13%) 2 (1%) 0 10 (5%) 10 (5%) 0 0 
Constipation 136 (37%) 129 (35%) 7 (2%) 0 45 (24%) 43 (23%) 2 (1%) 0 
Diarrhoea 118 (32%) 116 (31%) 2 (1%) 0 41 (22%) 39 (21%) 2 (1%) 0 
Dyspepsia 54 (15%) 53 (14%) 1 (<1%) 0 9 (5%) 9 (5%) 0 0 
Nausea 280 (75%) 266 (72%) 14 (4%) 0 69 (37%) 68 (36%) 1 (1%) 0 
Vomiting 136 (37%) 121 (33%) 15 (4%) 0 28 (15%) 26 (14%) 2 (1%) 0 
General disorders and administration site conditions 
Asthenia; fatigue 258 (69%) 233 (63%) 25 (7%) 0 83 (44%) 78 (41%) 5 (3%) 0 
Oedema peripheral 39 (10%) 38 (10%) 1 (<1%) 0 14 (7%) 14 (7%) 0 0 
Pyrexia 44 (12%) 44 (12%) 0 0 8 (4%) 8 (4%) 0 0 
Infections and infestations 
Upper respiratory tract 
infection 
41 (11%) 41 (11%) 0 0 6 (3%) 4 (2%) 2 (1%) 0 
Investigations 
Increase in alanine 
aminotransferase or aspartate 
aminotransferase
‡
 
126 (34%) 87 (23%) 39 (10%) 0 7 (4%) 7 (4%) 0 0 
Increase in blood creatinine 57 (15%) 56 (15%) 1 (<1%) 0 3 (2%) 3 (2%) 0 0 
Metabolism and nutrition disorders 
Decreased appetite 87 (23%) 85 (23%) 2 (1%) 0 26 (14%) 26 (14%) 0 0 
Hypomagnesaemia 40 (11%) 39 (10%) 1 (<1%) 0 11 (6%) 11 (6%) 0 0 
Musculoskeletal and connective tissue disorders 
Arthralgia 57 (15%) 55 (15%) 2 (1%) 0 24 (13%) 24 (13%) 0 0 
Back pain 45 (12%) 45 (12%) 0 0 28 (15%) 28 (15%) 0 0 
Nervous system disorders 
Dizziness 54 (15%) 54 (15%) 0 0 15 (8%) 14 (7%) 1 (1%) 0 
Dysgeusia 146 (39%) 146 (39%) 0 0 13 (7%) 13 (7%) 0 0 
Headache 67 (18%) 66 (18%) 1 (<1%) 0 30 (16%) 29 (15%) 1 (1%) 0 
Psychiatric disorders 
Insomnia 53 (14%) 53 (14%) 0 0 15 (8%) 15 (8%) 0 0 
Respiratory, thoracic and mediastinal disorders 
Cough 54 (15%) 54 (15%) 0 0 25 (13%) 25 (13%) 0 0 
Dyspnoea 50 (13%) 50 (13%) 0 0 14 (7%) 14 (7%) 0 0 
Skin and subcutaneous tissue disorders 
Photosensitivity reaction 64 (17%) 62 (17%) 2 (1%) 0 1 (1%) 1 (1%) 0 0 
Pruritus 47 (13%) 47 (13%) 0 0 19 (10%) 19 (10%) 0 0 
Rash 46 (12%) 45 (12%) 1 (<1%) 0 17 (9%) 17 (9%) 0 0 
Data are n (%); the safety population includes all patients who received at least one dose of protocol-specified treatment. 
AE=adverse event. *Includes six patients with a grade 5 treatment-emergent adverse event. 
†
Includes two patients with a grade 5 
Table 2
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treatment-emergent adverse event. 
‡
Elevations were transient, self-limiting, and not associated with other signs of liver toxicity. 
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1 SYNOPSIS 
Protocol Number CO-338-014 
Title A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of 
Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in 
Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial 
Ovarian, Primary Peritoneal, or Fallopian Tube Cancer 
Study Phase Phase 3 
Introduction  Rucaparib is an orally available, small molecule inhibitor of poly (adenosine 
diphosphate [ADP]-ribose) polymerase (PARP) being developed for treatment of 
ovarian cancer associated with homologous recombination deoxyribonucleic acid 
(DNA) repair deficiency.  The safety and efficacy of rucaparib has been evaluated 
in several Phase 1 and Phase 2 studies. 
Normal cells repair single-strand breaks (SSBs) in DNA primarily through base 
excision repair (BER).  While there are several variations of BER, all pathways rely 
on PARP enzymes, of which PARP-1 is the best characterized.  SSBs that are not 
repaired result in stalled replication forks and the development of double-strand 
breaks (DSBs), which are in turn primarily repaired by homologous recombination 
DNA repair, a complex process involving multiple proteins, including those 
encoded by breast cancer susceptibility gene 1 and 2 (BRCA1 and BRCA2), as well 
as many others. 
Homologous recombination pathway defects, either as an initiating event or late 
event in the carcinogenetic process, may be responsible for the genetic instability 
observed in many cancers.  An analysis of the Cancer Genome Atlas (TCGA), 
which examined molecular changes in high-grade serous ovarian cancer (HGSOC), 
estimated that approximately 50% of patients with HGSOC have homologous 
recombination deficiency (HRD).1  Drivers of HRD include: 
1. Germline mutations in the BRCA1 and BRCA2 genes (gBRCA).  These are 
the strongest known hereditary factors for epithelial ovarian cancer (EOC), 
accounting for up to 15% of all EOC.2, 3  These patients carry heterozygous 
deleterious mutations in their germline DNA and develop tumors when the 
remaining wild-type functional allele is inactivated (i.e., “second hit”). 
2. Somatic BRCA1/2 mutations (sBRCA) (approximately 6 – 8% of HGSOC 
patients)1, 4 
3. Mutation in a homologous recombination gene other than BRCA1/2 
(approximately 16% of HGSOC patients).1  Nonclinical studies by several 
groups have identified RAD proteins (e.g. RAD51, RAD51C, RAD52, 
RAD54L),5, 6, 7, 8 Fanconi Anemia proteins (e.g. FANCA, FANCC, 
FANCD2),9, 10, 11 and many others (e.g. ATM, ATR, CHEK1, CHEK2)12, 13, 
14, 15 as being involved in homologous recombination. 
4. Functional silencing of homologous recombination genes, such as through 
BRCA promoter methylation (approximately 10% of HGSOC patients)1 or 
other mechanisms 
Inhibition of DNA damage repair in cancer cells, which are intrinsically genetically 
unstable, represents an attractive opportunity for the development of new therapies.  
Given the overlap in various DNA repair pathways, inhibition of a single pathway is 
unlikely to have a significant effect, whereas inhibition of multiple DNA repair 
pathways may lead to cell death, a concept known as synthetic lethality.  Normal  
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Introduction 
(cont) 
cells, with only one DNA repair pathway affected by inhibition of PARP, still have 
an intact DNA repair pathway that can compensate, whereas cancer cells with pre-
existing HRD that are treated with a PARP inhibitor develop critically DNA repair 
deficiency and enter apoptosis.  This concept of synthetic lethality has been 
demonstrated in landmark in vitro and in vivo studies16, 17as well as in several 
clinical trials that evaluated a single agent PARP inhibitor for the treatment of 
relapsed ovarian cancer and metastatic breast cancer with or without an associated 
germline BRCA mutation.18, 19, 20, 21, 22, 23, 24 In vitro studies have also shown that cells 
deficient in or depleted of homologous recombination proteins other than BRCA1/2 
have been associated with PARP inhibitor sensitivity.25, 26, 27, 28   It is possible that the 
24% ORR observed in ovarian cancer patients without evidence of a gBRCA1/2 
mutation and treated with olaparib21 was due to HRD driven by a sBRCA1/2 
mutation or by an alteration in another key homologous recombination gene. 
Clinical activity in HGSOC has also been observed with switch maintenance PARP 
inhibitor therapy following response to platinum-based chemotherapy.   Patients 
with platinum-sensitive relapsed ovarian cancer who achieved a response to another 
regimen of platinum-based chemotherapy followed by olaparib as switch 
maintenance treatment experienced a statistically significant improvement in 
median PFS (8.3 months) compared to patients who received  placebo as 
maintenance therapy (4.8 months); hazard ratio (HR) of 0.35 (95% CI, 0.25 – 
0.49).29  Patients with a BRCA mutation derived the most benefit (median PFS 11.2 
vs 4.3 months; HR=0.18; 95% CI 0.11-0.31; P<0.00001).30  It should be noted that 
the outcomes of sBRCA + gBRCA mutant patients were the same as gBRCA mutant 
patients alone, suggesting that, for stratification and analysis purposes in the present 
study, it is appropriate to not differentiate between germline and somatic mutations.   
Patients without a BRCA mutation also experienced significant benefit from 
treatment with olaparib (HR=0.53; 95% CI 0.33-0.84; P=0.007), suggesting that 
patients with DNA repair defects in genes other than BRCA are likely contributing 
to the overall PFS result.30 
The purpose of this study is to evaluate progression-free survival (PFS) of patients 
with platinum-sensitive, relapsed high-grade epithelial ovarian, fallopian tube, or 
primary peritoneal cancer who receive rucaparib or placebo as switch maintenance 
therapy following a response to platinum-based chemotherapy.  Prior to final 
analysis, patients will be placed into molecularly defined subgroups of HRD based 
on the Final Clinical Trial Assay (FCTA).  It is anticipated that rucaparib will 
provide therapeutic benefit and increase PFS in patients with HRD.   
Study Overview 
 
This is a randomized, international, double-blind, placebo-controlled Phase 3 study 
evaluating rucaparib maintenance therapy in advanced ovarian cancer.  The primary 
endpoint is PFS by Response Evaluation Criteria in Solid Tumors (RECIST) v1.131  
as assessed by the investigator.  Risk/benefit will be assessed regularly by an 
Independent Data Monitoring Committee that will have access to unblinded 
datasets. 
This study will enroll patients with platinum-sensitive, high-grade serous or 
endometrioid epithelial ovarian, primary peritoneal, or fallopian tube cancer who 
achieved either a complete response (CR) by RECIST v1.1 or a partial response 
(PR), defined as either a RECIST v1.1 PR or a cancer antigen 125 (CA-125) 
response by Gynecologic Cancer Intergroup (GCIG) criteria,32 to their last 
platinum-based regimen.  All responses will require CA-125 that is within the upper 
limit of normal (ULN). 
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Study Overview 
(cont’d) 
 
 
 
 
 
 
During the screening phase, each patient will have archival tumor tissue analyzed 
for mutations in homologous recombination pathway genes.  Genes of interest will 
be sequenced using Foundation Medicine’s next generation sequencing (NGS) test, 
which examines a panel of cancer-related genes, including BRCA1/2 and other 
homologous recombination pathway genes.  Patients will be stratified into one of 
three HRD subgroups (BRCA1/2 mutation in tumor tissue [tBRCA], HRD due to 
mutation in a homologous recombination gene other than BRCA1/2 [nonBRCA 
HRD (nbHRD)], or biomarker negative) for randomization based on the results 
obtained with Foundation Medicine’s Initial Clinical Trial Assay (ICTA)  
(Appendix A).  Enrollment of patients known a priori to harbor a gBRCA mutation 
classified as deleterious (pathogenic), suspected deleterious, or equivalent, on the 
most recent assessment, will be limited to 150.  Enrollment of patients with a BRCA 
gene mutation detected in tumor tissue (tBRCA), including those known to harbor a 
gBRCA mutation, will be limited to 200.  Once this cap is reached, newly screened 
patients identified as having a BRCA mutation in tumor tissue will be offered 
treatment in another study. 
The complete results of the Foundation Medicine NGS test, which examines exons 
of 287 genes as well as introns of 19 genes, will be provided to all patients who opt 
to receive this information and provide appropriate consent.  Tumor tissue results 
for the BRCA genes will be provided to patients upon availability.  Results for the 
remainder of the gene panel will be provided to patients upon study treatment 
discontinuation.  In the event a mutation associated with hereditary cancer or other 
syndrome is detected in tumor tissue, the patient will be referred by the investigator 
for genetic counseling and potential germline testing per institutional guidelines. If 
the patient chooses to have germline BRCA testing, this result will be entered into 
the clinical trial database.   
Mutations detected in tumor tissue may be somatic or germline; however, the NGS 
test will not distinguish between the two.  A blood sample will therefore be 
collected for all patients and stored.  Prior to final efficacy analysis, genomic DNA 
may be subjected to exploratory analysis in order to determine whether any 
mutation identified is of germline or somatic origin. 
Tumor DNA will also be assessed by the NGS test to detect the presence of 
genomic scars.33, 34, 35, 36 Analysis of specific genomic scarring patterns may identify 
tumors with HRD regardless of the underlying mechanism(s).  The extent of 
genomic scarring and its utility in predicting clinical outcome with rucaparib will be 
assessed in a Phase 2 study (CO-338-017) that will be initiated in parallel with this 
Phase 3 study, but will be completed earlier.  The insights from study CO-338-017 
will be applied prospectively to the analysis of this Phase 3 study. 
The FCTA analysis plan (gene mutation and/or genomic scarring) and classification 
of HRD subgroups will be finalized and locked down prior to the completion of the 
Phase 3 study and applied prospectively to the primary efficacy analysis.  The 
Sponsor will remain blinded to all tumor tissue and germline test results until the 
primary efficacy analysis is conducted. 
Number of 
Patients 
Approximately 540 patients will be enrolled.  A minimum of 180 and a maximum 
of 200 patients with a deleterious tBRCA mutation will be enrolled.  Enrollment of 
patients with a known deleterious gBRCA mutation documented in their medical 
record will not exceed 150.  There is no minimum number of patients required for 
each of the nbHRD and biomarker negative subgroups; however, no more than 360 
total patients will be randomized for stratification into these subgroups combined. 
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Number of Sites This is a multicenter, multinational study.  Patients will be enrolled from 
approximately 90 – 100 study sites. 
Study Duration Q4 2013 – Q4 2016 
Study Objectives The primary objective of this study is: 
• To evaluate PFS by RECIST, as assessed by the investigator, in 
molecularly-defined HRD subgroups 
The secondary objectives of this study are: 
• To evaluate PFS by RECIST, as assessed by independent radiology review 
(IRR), in molecularly-defined HRD subgroups 
• To evaluate patient-reported outcome (PRO) of disease-related symptoms 
utilizing the disease-related symptoms – physical (DRS–P) subscale of the 
National Comprehensive Cancer Network-Functional Assessment of Cancer 
Therapy (NCCN-FACT) FACT-Ovarian Symptom Index 18 (FOSI-18)  
• To evaluate PRO utilizing the complete FOSI-18 
• To evaluate survival benefit 
• To evaluate safety 
• To determine the population pharmacokinetics (PK) of rucaparib 
The exploratory objectives of this study are: 
• To evaluate the relationship between cancer antigen 125 (CA-125) levels 
and invPFS 
• To evaluate PFS2 (PFS on the subsequent line of treatment) 
• To evaluate overall response rate (ORR) 
• To evaluate duration of response (DOR) 
• To evaluate PRO utilizing the Euro-Quality of Life 5D (EQ-5D) 
• To explore the relationship between rucaparib exposure, efficacy, and safety 
Study Population Inclusion Criteria 
All patients enrolling into the study must meet all of the following inclusion criteria: 
1. Have signed an Institutional Review Board/Independent Ethics Committee-
approved informed consent form prior to any study-specific evaluation 
2. Be ≥18 years of age at the time the informed consent form is signed 
3. Have a histologically confirmed diagnosis of high-grade serous or endometrioid 
epithelial ovarian, fallopian tube, or primary peritoneal cancer 
− For mixed histology, >50% of the primary tumor must be confirmed to be 
high-grade serous or endometrioid 
4. Received prior platinum-based therapy and have platinum-sensitive disease (i.e. 
documented radiologic disease progression >6 months following the last dose of 
the penultimate platinum administered) 
− Received ≥2 prior platinum-based treatment regimens, including platinum-
based regimen that must have been administered immediately prior to 
maintenance therapy in this trial.  In addition, up to 1 non-platinum is 
permitted. 
− There is no upper limit on the number of prior platinum-based regimens that 
may have been received, but the patient must have been sensitive to the 
penultimate platinum-based regimen administered. 
Clovis Oncology, Inc.   Clinical Protocol 
Oral rucaparib (CO-338) CO-338-014 
 September 9, 2013 
 Page 16 Confidential 
Study Population 
(cont’d) 
− If both neoadjuvant and adjuvant treatment were administered pre/post any 
debulking surgery, this will be considered 1 treatment regimen 
− Prior continuous (e.g. bevacizumab) or switch maintenance therapy 
following any prior treatment regimen is permitted  
5.    Achieved best response of either CR (defined as complete radiologic response 
by RECIST) or PR (defined as partial response by RECIST and/or a GCIG CA-
125 response) to the most recent platinum-based regimen administered (4 cycles 
minimum) and maintained response through completion of chemotherapy 
− All responses require that CA-125 be <ULN.  Response must have been 
maintained to permit entry into the study.   
− All disease assessments performed prior to and during this chemotherapy 
regimen must be adequately documented in the patient’s medical record 
6.   Have sufficient archival formalin-fixed paraffin-embedded (FFPE) tumor tissue 
(1 x 4 µm section for hematoxylin and eosin [H&E] stain and approximately 8 
to 12 x 10 µm sections, or equivalent) available for planned analyses.   
− The most recently collected tumor tissue should be provided, if available 
− Submission of a tumor block is preferred; if sections are provided, these 
must all be from the same tumor sample. 
− Sample must be received at the central laboratory at least 3 weeks prior to 
planned start of treatment in order to enable stratification for randomization 
7.  Have CA-125 measurement <ULN 
8.  Have ECOG performance status of 0 to 1 
9.  Have adequate organ function confirmed by the following laboratory values 
obtained within 14 days of the first dose of study drug: 
a. Bone Marrow Function 
− Absolute neutrophil count (ANC) ≥1.5 × 109/L 
− Platelets >100 × 109/L  
− Hemoglobin ≥9 g/dL 
b. Hepatic Function 
− Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 
× ULN; if liver metastases, then ≤5 × ULN 
− Bilirubin ≤1.5 × ULN 
c. Renal Function  
− Serum creatinine ≤1.5 × ULN or estimated glomerular filtration rate 
(GFR) ≥45 mL/min using the Cockcroft Gault formula 
Exclusion Criteria 
Patients will be excluded from participation if any of the following criteria apply: 
1. History of a prior malignancy except: 
a. Curatively treated non-melanoma skin cancer 
b. Breast cancer treated curatively >3 years ago, or other solid tumor treated 
curatively >5 years ago, without evidence of recurrence 
c.  Synchronous endometrioid endometrial cancer (Stage 1A G1/G2) 
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Study Population 
(cont’d) 
2. Prior treatment with any PARP inhibitor, including oral or intravenous rucaparib.  
Patients who previously received iniparib are eligible. 
3. Required drainage of ascites during the final 2 cycles of the last platinum-based 
regimen and/or during the period between the last dose of chemotherapy of that 
regimen and randomization to maintenance treatment in this study 
4. Symptomatic and/or untreated central nervous system (CNS) metastases.  
Patients with asymptomatic previously treated CNS metastases are eligible 
provided they have been clinically stable for at least 4 weeks. 
5. Prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder 
or defect that would interfere with absorption of study drug 
6. Known human immunodeficiency virus (HIV) or acquired immunodeficiency 
syndrome (AIDS)-related illness, or history of chronic hepatitis B or C.   
7. Pregnant or breast feeding.  Women of childbearing potential must have a 
negative serum pregnancy test <3 days prior to first dose of study drug 
8. Received treatment with chemotherapy, radiation, hormones, antibody therapy or 
other immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, or 
experimental drugs ≤14 days prior to first dose of study drug and/or ongoing 
adverse effects from such treatment > NCI CTCAE Grade 1 
9. Received administration of strong CYP1A2 or CYP3A4 inhibitors ≤7 days prior 
to first dose of study drug or have on-going requirements for these medications 
(Appendix F) 
10. Non-study related minor surgical procedure ≤5 days, or major surgical procedure 
≤21 days, prior to first dose of study drug;  in all cases, the patient must be 
sufficiently recovered and stable before treatment administration 
11. Presence of any other condition that may increase the risk associated with study 
participation or interfere with the interpretation of study results, and, in the 
opinion of the investigator, would make the patient inappropriate for the study 
Pregnancy is an exclusion criterion and women of childbearing potential must not 
be considering getting pregnant during the study. 
Patients of reproductive potential must practice an effective method of 
contraception during treatment and for 6 months following the last study drug dose. 
No waivers of these inclusion or exclusion criteria will be granted by the 
investigator and the sponsor or its designee for any patient enrolled into the study. 
Study Treatment 
 
Eligible patients will be randomized 2:1 to receive rucaparib (600 mg bid) or 
placebo.  Randomization will occur by a central randomization procedure using an 
Interactive Voice Response System/Interactive Web Response System 
(IVRS/IWRS).  The following will be included as randomization stratification 
factors at study entry to ensure treatment groups are balanced:  
• HRD classification (tBRCA, nbHRD, or biomarker negative) by the ICTA 
(Appendix A). 
• Interval between completion of the penultimate platinum-based regimen and 
disease progression (6 to 12 or >12 months) by radiologic assessment 
• Best response to the most recent platinum-based regimen (CR [defined as 
complete radiologic response by RECIST or PR [defined as partial response by 
RECIST and/or a GCIG CA-125 response]).  All responses require that CA-125 
be <ULN. 
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Study Treatment 
(cont’d) 
Randomization to study treatment must occur within 8 weeks following a patient’s 
last dose of platinum-based chemotherapy.  
Study drug will be taken orally twice daily (12 hours apart) with at least 8 oz   (240 
mL) of water.  Study drug may be taken with an empty stomach or with food. 
Patients will take study drug twice daily for continuous 28-day cycles until disease 
progression by RECIST as assessed by the investigator, or other reason for 
discontinuation.  Treatment interruptions and/or dose reductions are permitted in the 
event of unacceptable toxicity. 
Withdrawal 
Criteria 
A patient must be discontinued from treatment with study drug if any of the 
following apply: 
• Consent withdrawal at the patient’s own request or at the request of their legally 
authorized representative 
• Progression of patient’s underlying disease by RECIST as assessed by the 
investigator 
• Any event, adverse or otherwise, that, in the opinion of the investigator, would 
pose an unacceptable safety risk to the patient 
• An intercurrent illness that, in the opinion of the investigator, would affect 
assessments of the clinical status to a significant degree and requires 
discontinuation of therapy 
Disease 
Assessments for 
Efficacy 
Efficacy measures will include clinical examination, CA-125 measurement, and 
appropriate imaging (CT scans of the chest, abdomen, and pelvis with appropriate 
slice thickness per RECIST); other studies (magnetic resonance imaging [MRI], 
X-ray, positron emission tomography [PET], and ultrasound) may be performed if 
required.  Disease assessment will be performed at screening, at the end of every 12 
weeks of treatment, at discontinuation of treatment, and as clinically indicated. 
Disease progression will be determined by RECIST (Appendix B).  Patients with a 
CR at study entry will only be considered to have disease progression if a new 
lesion is identified.  Patients who meet GCIG CA-125 criteria (Appendix C) for 
disease progression should have a radiologic assessment by RECIST.  If the 
radiologic assessment does not confirm disease progression, patients should 
continue on treatment and be assessed by RECIST per the protocol schedule. 
Patients who discontinued treatment for reason other than disease progression or 
death should continue to have tumor scans and CA-125 measurement performed at 
12 (± 2) week intervals until disease progression, as assessed by the investigator.  
Safety 
Assessments 
Safety assessments will include adverse events (AEs), hematology, serum 
chemistry, vital signs, body weight, concomitant medications/procedures, ECOG 
performance status (Appendix D), and study drug modifications.  
Statistical 
Procedures 
 
Sample Size Justification 
The total enrollment planned is 540 patients.  A minimum of 180 and a maximum of 
200 patients with a deleterious tBRCA mutation will be enrolled.  Enrollment of 
patients with a known deleterious gBRCA mutation documented in their medical 
record will not exceed 150.  There is no minimum number of patients required for 
each of the nbHRD and biomarker negative subgroups; however, no more than 360 
total patients will be randomized for stratification into these subgroups combined.  
Prior to final efficacy analysis, HRD classification will be determined by the FCTA 
that will evaluate homologous recombination gene mutations and/or extent of  
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Statistical 
Procedures 
(cont’d) 
genomic scarring in tumor tissue. 
The table below provides estimated sample sizes and power calculations. 
Group Hazard 
Ratio 
Cumulative 
N  
Minimum 
Number of 
Events 
(70%) 
Median PFS   
Placebo vs 
Rucaparib 
(months) 
Power One-
sided 
Alpha 
tBRCA  0.50 180 126 6 vs 12 90% 0.025 
All HRD 
(tBRCA + 
nbHRD) 
0.60 300 210 6 vs 10 90% 0.025 
ITT 
Population 
(tBRCA + 
nbHRD + 
Biomarker 
Negative) 
0.70 540 378 6 vs 8.5 90% 0.025 
Analysis Populations 
Safety: The safety population will consist of all patients who received at least one 
dose of protocol-specified treatment. 
Intent-to-treat (ITT): The ITT population will consist of all randomized patients.  
Response evaluable:  The response evaluable population will consist of all patients 
who have measurable or evaluable disease at study entry, received at least one dose 
of study drug, and who had at least one post-baseline disease assessment. 
General Statistical Considerations 
Quantitative variables will be summarized using descriptive statistics.  For variables 
registered on a continuous scale, the following will be presented: N, mean, standard 
deviation, median, minimum and maximum.  Categorical variables will be 
presented using frequencies and percentages.  The Kaplan-Meier methodology will 
be used to summarize time-to-event variables.  The stratified hazard ratio from the 
Cox proportional hazards model will be used to estimate the HR between the 
randomized treatment groups.  The primary and key secondary endpoints will be 
tested among the tBRCA subgroup, all HRD subgroup, and all randomized patients, 
using an ordered step-down multiple comparisons procedure.  Investigator 
determined PFS (invPFS) in the tBRCA subgroup will be tested first at a one-sided 
0.025 significance level.  If invPFS in the tBRCA subgroup is statistically 
significant, then irrPFS in the tBRCA subgroup will be tested at a one-sided 0.025 
significance level and if significant, invPFS and irrPFS will be tested in the all HRD 
subgroup followed by invPFS and irrPFS in all randomized patients.  Continuing in 
an ordered step-down manner, the PRO of disease symptoms utilizing the DRS-P 
subscale of the FOSI-18 will be tested at the one-sided 0.025 significance level in 
the tBRCA, all HRD, and all randomized patients subgroups and then for the 
remaining key secondary endpoints of PRO utilizing the FOSI-18 total score and 
OS.  Once statistical significance is not achieved for one test the statistical 
significance will not be declared for all subsequent analyses in the ordered step-
down procedure. 
Primary Efficacy Analysis 
The primary efficacy analysis for the study is investigator-determined PFS (invPFS) 
by RECIST.  Investigator-determined PFS is defined as the time from  
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Statistical 
Procedures 
(cont’d) 
randomization to disease progression, according to RECIST v1.1 criteria as assessed 
by the investigator, or death due to any cause, whichever occurs first.  The 
stratification factors included in the primary analysis of invPFS will be HRD 
classification (tBRCA, nbHRD or biomarker negative), interval between completion 
of penultimate platinum regimen and disease progression (6 to 12 months or >12 
months) by radiologic assessment, and best response to the most recent platinum-
based regimen (either CR [defined as complete radiologic response by RECIST] or 
PR [defined as partial response by RECIST and/or a GCIG CA-125 response]).  All 
responses require that CA-125 be <ULN. 
Tumor HRD status by the FCTA will be determined after randomization, but before 
the final efficacy analysis, so that the primary endpoint (PFS in molecularly defined 
subgroups) can be assessed prospectively. 
Secondary Efficacy Analyses 
Secondary efficacy endpoints include: 
• PFS by RECIST v1.1 as assessed by IRR 
• PRO of disease-related symptoms as measured by the DRS-P subscale score of 
the FOSI-18 
• PRO as measured by the total score of the FOSI-18 
• OS 
PFS for secondary efficacy analysis is defined as the time from randomization to 
disease progression, according to RECIST v1.1 criteria as assessed by IRR, or death 
due to any cause, whichever occurs first.   
The time to an event in PRO of worsening of disease symptoms will be defined as 
the time from randomization to a 4-point reduction in the FOSI-18 DRS−P subscale 
score.  Similarly, an event in worsening of PRO utilizing the FOSI-18 total score 
will be defined as the time from randomization to an 8-point reduction in the total 
score. 
OS, time to death from any cause, is defined as the number of days from the date of 
randomization to the date of death (due to any cause).  Patients without a known 
date of death will be censored on the date the patient was last known to be alive. 
Safety Analysis 
Data from all patients who receive at least one dose of study drug will be included 
in the safety analyses.  AEs, clinical laboratory information, vital signs, ECOG 
performance status, body weight, and concomitant medications / procedures will be 
tabulated and summarized. 
AEs will be summarized overall, with separate summaries for serious AEs, AEs 
leading to treatment discontinuation or death, and CTCAE Grade 3 or higher AEs. 
Independent Data Monitoring Committee (IDMC) 
No formal efficacy interim analyses for early stopping are planned.   
An IDMC will meet to review the efficacy and safety data from this study.  The 
IDMC will: 
• Review efficacy and safety of rucaparib compared to placebo to ensure the 
study is beneficial to patients;  
• Ensure the study is conducted in a high quality manner; and 
• Monitor the size of the tBRCA subgroup and known gBRCA subgroup 
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2 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
AAG alpha-1 acid glycoprotein 
ADP adenosine diphosphate 
AE adverse event 
AIDS acquired immunodeficiency syndrome 
ALP alkaline phosphatase 
ALT alanine aminotransferase 
ANC absolute neutrophil count 
AST aspartate aminotransferase 
AUC area under the curve 
BER 
BID 
base excision repair 
twice a day 
BRCA1 breast cancer susceptibility gene 1 
BRCA2 breast cancer susceptibility gene 2 
BUN 
CA-125 
blood urea nitrogen 
cancer antigen 125 
CFR Code of Federal Regulations 
Cmax maximum concentration 
CNS central nervous system 
CR complete response  
CRO contract research organization  
CT computed tomography 
CTCAE Common Terminology Criteria for Adverse Events (version 4.0) 
CYP cytochrome P450 
DLT dose-limiting toxicity  
DNA deoxyribonucleic acid 
DOR duration of response 
DSB double-strand break 
DRS−P disease-related symptoms−physical 
ECG electrocardiogram 
ECOG Eastern Cooperative Oncology Group 
eCRF electronic case report form 
EDC electronic data capture 
EOC epithelial ovarian cancer 
EQ-5D Euro-Quality of Life 5D 
EQ-VAS Euro-Quality Visual Analogue Scale 
FCTA Final Clinical Trial Assay 
FDA Food and Drug Administration 
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FFPE formalin-fixed paraffin-embedded 
FOSI-18 FACT-Ovarian Symptom Index 18 
GALT gut-associated lymphoid tissue 
gBRCA germline BRCA 
GCIG Gynecologic Cancer InterGroup 
GCP 
h 
hERG 
Good Clinical Practice 
hour 
human ether-a-go-go-related gene 
HGSOC high grade serous ovarian cancer 
HIPAA Health Information Portability and Accountability Act 
HIV human immunodeficiency virus 
HR hazard ratio 
HRD homologous recombination deficiency 
ICH International Conference on Harmonization 
ICTA Initial Clinical Trial Assay 
ICxx concentration where maximum response is inhibited by XX% 
IDMC Independent Data Monitoring Committee 
IEC Independent Ethics Committee 
INR international normalized ratio 
invPFS disease progression according to RECIST v1.1 as assessed by the investigator, or 
death from any cause 
IRB Institutional Review Board  
IRR independent radiology review 
ITT Intent-to-treat 
irrPFS disease progression according to RECIST v1.1, as assessed by IRR, or death from 
any cause  
IVRS/IWRS Interactive Voice Response System/Interactive Web Response System 
LOH loss of heterozygosity 
MedDRA 
Min 
MRI 
Medical Dictionary for Drug Regulatory Activities 
minute 
magnetic resonance imaging 
MTD maximum tolerated dose 
mut mutant 
nbHRD non-BRCA homologous recombination deficiency 
NCCN-FACT National Comprehensive Cancer Network-Functional Assessment of Cancer 
NCI National Cancer Institute 
NGS next generation sequencing 
NOAEL no-observed-adverse-effect level 
ORR overall response rate 
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OS overall survival 
PARP poly (adenosine diphosphate [ADP]-ribose) polymerase 
PD progressive disease 
PET positron emission tomography 
PLD PEGylated liposomal doxorubicin 
PFS progression-free survival 
PFS2 second event of progression-free survival 
P-gp P-glycoprotein 
PID poly (adenosine diphosphate [ADP]-ribose) polymerase inhibiting dose 
PK pharmacokinetic(s) 
PR partial response 
PRO patient-reported outcome 
PS performance status 
QD once a day 
RECIST Response Evaluation Criteria in Solid Tumors Version 1.1 
SAE serious adverse event 
SAS statistical analysis software 
SD stable disease 
SNP single-nucleotide polymorphism 
SOC system organ class 
SOP Standard operating procedure 
SSB single-strand break 
SUSAR suspected unexpected serious adverse reaction 
TCGA The Cancer Genome Atlas 
TEAE treatment-emergent adverse events 
Tmax time to maximum concentration 
TMZ temozolomide 
unk unknown 
UV ultraviolet 
WBC white blood cell 
WT wild type 
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3 INTRODUCTION 
3.1 Ovarian Cancer 
3.1.1 General Overview 
Ovarian cancer is the second most common gynecologic malignancy worldwide and the leading 
cause of death attributed to gynecological cancer.37, 38After initial therapy, most women will have 
a progression-free interval of approximately 1.5 to 2 years, depending on the extent of post-
operative residual disease and response to chemotherapy.39  Relapse still occurs, however, in the 
majority of cases, and only 10−30% of women experience long-term survival.39  Advanced stage 
disease is associated with a 5-year survival rate of only 30−40%.37 
Approximately 90% of ovarian tumors are surface epithelial in origin, and the papillary serous 
histology subtype accounts for approximately 75%, of which the large majority (70%) is high-
grade.39  The site of origin of epithelial ovarian cancer (EOC) remains unclear.  Some studies 
suggest that serous EOC and primary peritoneal cancer (PPC) arise from the fallopian tube 
epithelium40, 41; however, other studies suggest an origin within stem cells of the ovarian surface 
epithelium.39, 42  EOC, PPC and fallopian tube cancer behave very similarly, and are therefore 
treated in the same way. 
The median age at presentation of EOC is 60 years.  Many women present with advanced disease 
and therefore have a poor prognosis. 
3.1.2  Treatment of Ovarian Cancer 
The standard approach to treatment of advanced ovarian cancer is cytoreductive surgery (either 
at time of diagnosis or interval debulking following 2 – 3 cycles of neoadjuvant chemotherapy), 
with the goal of minimizing residual tumor to no visible residual disease, a major prognostic 
indicator for improved survival.  Six to eight cycles of platinum- and taxane-based chemotherapy 
is the global standard of care.  If initial cytoreduction is not performed, interval debulking 
surgery is considered.  This surgery may be carried out after three or four cycles of primary 
chemotherapy, followed by three further cycles of chemotherapy.  Platinum analogues, such as 
carboplatin and cisplatin, are the most active agents, mediating their effects through the 
formation of inter- and intra-strand cross-links with deoxyribonucleic acid (DNA).43, 44 
The choice of treatment for relapsed disease is based on the treatment-free interval relative to last 
therapy administered and chemotherapy agents used. As many patients experience multiple 
relapses, prognosis and response to therapy decreases as the interval between last chemotherapy 
exposure and disease relapse shortens. The treatment-free, or specifically the platinum-free 
interval, provides further prognostic information for patients, as therapeutic options lessen and 
survival shortens as a patient’s tumor becomes less responsive to platinum-based therapy.  
Platinum-based regimens dominate ovarian cancer therapy and define treatment groups.44  In 
general, patients whose disease progresses during treatment with a platinum-based regimen are 
considered to have platinum-refractory disease; patients whose disease relapses within 6 months 
after the last platinum agent was administered are considered to have platinum-resistant disease; 
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and patients whose disease relapses more than 6 months after the last platinum-based therapy 
was administered are considered to have platinum-sensitive disease. These classifications are 
clinical, and not based on a mechanistic definition of platinum sensitivity or resistance. 
PARP inhibitor monotherapy has elicited objective responses in patients with platinum-sensitive 
disease as well as in patients with platinum-resistant disease, although response rates are higher 
in the former population.21, 22, 23  This indicates that using platinum-sensitivity alone as a 
selection marker for PARP inhibitor therapy is not a very effective tool, although it is a 
reasonable place to begin predictive biomarker development.  
Maintenance therapy following a response to standard treatment provides an opportunity to 
extend the disease-free period.  Maintenance strategies evaluated to date for ovarian cancer have 
focused on the prolonged use of single-agent chemotherapy, antiangiogenesis agents, hormonal 
therapy, vaccines, and intraperitoneal chemotherapy.  The OCEANS study evaluated carboplatin 
and gemcitabine with or without bevacizumab as part of the initial treatment and then as 
maintenance in women with platinum-sensitive ovarian, primary peritoneal, or fallopian tube 
cancer who were in their first relapse following primary chemotherapy.  The addition of 
bevacizumab resulted in a statistically significant improvement in PFS (median 12.4 vs 8.4 
months; HR=0.484 [95% CI, 0.388 to 0.605; log-rank P<0.00001]).45  The PFS benefit of 
bevacizumab administered together with chemotherapy followed by single agent bevacizumab 
maintenance treatment compared to chemotherapy alone and placebo maintenance was further 
established in two front-line Phase 3 studies, GOG-218 (HR=0.717 [95% CI, 0.625 to 0.824; log-
rank P<0.001])46 and ICON-7 (HR=0.81 [95% CI, 0.70 to 0.94; log-rank P<0.04]).47  Based on 
these trials, the European Medicines Agency approved bevacizumab, in combination with 
carboplatin and paclitaxel, for front-line treatment of advanced (International Federation of 
Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian-tube, 
or primary peritoneal cancer, and, in combination with carboplatin and gemcitabine, for 
treatment of first recurrence of platinum-sensitive epithelial ovarian, fallopian-tube or primary 
peritoneal cancer in women who have not received prior therapy with bevacizumab or other 
vascular-endothelial-growth-factor (VEGF) inhibitors or VEGF-receptor-targeted agents. 
3.1.3 Homologous Recombination Deficiency 
DNA is constantly damaged by both endogenous and exogenous (environmental) assaults.  A 
common type of DNA damage is the formation of DNA single-strand breaks (SSBs).  During 
normal cell cycling, DNA is replicated and replication forks are eventually stalled by persistent 
SSBs.  If stalled replication forks are not rapidly repaired, they can often degenerate and form 
DNA double-strand breaks (DSBs), which are highly likely to be lethal to the cell.   
Normal cells repair single-strand breaks (SSBs) in DNA primarily through base excision repair 
(BER).  While there are several variations of BER, all pathways rely on PARP enzymes, of 
which PARP1 is the best characterized.  SSBs that are not repaired result in stalled replication 
forks and the development of double-strand breaks (DSBs), which are in turn primarily repaired 
by homologous recombination DNA repair, a complex process involving multiple proteins, 
including those encoded by breast cancer susceptibility gene 1 and 2 (BRCA1 and BRCA2),  
among others. 
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If either the BER or homologous recombination pathway is rendered non-functional, the 
remaining functional pathway can compensate to ensure ongoing DNA repair and cell cycling.  
For example, when the BRCA-associated homologous recombination pathway is lost or 
dysfunctional, repair shifts towards the BER repair pathway that is dependent on PARP 
enzymes.  In contrast, in the setting in which both repair pathways (BER and homologous 
recombination) are rendered non-functional, the cell dies.  This concept, where a defect in either 
of two pathways can be withstood by a cell, but defects in both are lethal, is referred to as 
synthetic lethality.  This type of lethality can arise from a variety of different interactions.  In the 
case of DNA damage repair, dual non-functionality can be achieved by enzymatic inhibition of 
PARP in the context of a genetic mutation in the BRCA1 or BRCA2 genes. 
Synthetic lethality has been demonstrated in landmark in vitro and in vivo studies as well as in 
several clinical trials that evaluated a single agent PARP inhibitor for the treatment of relapsed 
ovarian cancer and metastatic breast cancer.  Bryant and colleagues showed that cell lines and a 
tumor xenograft deficient in homologous recombination (via a defect in a BRCA or other 
homologous recombination gene) were highly sensitive to PARP inhibition.16  This study also 
showed that synthetic lethality could be achieved regardless of whether the mutation was in 
BRCA1 or BRCA2.  In a parallel set of experiments, Farmer and colleagues illustrated that 
chemical inhibition of PARP1 was more potent in homozygous BRCA-deficient cell lines than in 
heterozygous mutant or wild-type cell lines.17 These findings were also supported by a BRCA2-
deficient murine model.  Taken together, these studies provided support for the treatment of 
patients with a BRCA-deficient tumor with a PARP inhibitor. 
3.1.4 Role of HRD in Ovarian Cancer 
Homologous recombination pathway defects, either as an initiating event or late event in the 
carcinogenetic process, may be responsible for the genetic instability observed in many cancers.  
An analysis of the Cancer Genome Atlas (TCGA), which examined molecular changes 
associated with high-grade serous ovarian cancer (HGSOC), estimated that approximately 50% 
of patient with HGSOC have homologous recombination deficiency (HRD).1  Drivers of HRD in 
ovarian cancer include: 
1. Germline mutations in the BRCA1 and BRCA2 genes (gBRCA).  These are the strongest 
known hereditary factors for epithelial ovarian cancer (EOC), accounting for up to 15% 
of all EOC.2, 3  These patients carry heterozygous deleterious mutations in their germline 
DNA and develop tumors when the remaining wild-type functional allele is inactivated 
(i.e., “second hit”). 
 
2. Somatic BRCA1/2 mutations (sBRCA) (approximately 6 – 8% of HGSOC patients)1, 4 
 
3. Mutation in a homologous recombination gene other than BRCA1/2 (approximately 16% 
of HGSOC patients).1  Nonclinical studies by several groups have identified RAD 
proteins (e.g. RAD51, RAD51C, RAD52, RAD54L),5, 6, 7, 8 Fanconi Anemia proteins (e.g. 
FANCA, FANCC, FANCD2),9, 10, 11 and many others (e.g. ATM, ATR, CHEK1, 
CHEK2)12, 13, 14, 15 as being involved in homologous recombination. 
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4. Functional silencing of homologous recombination genes, such as through BRCA 
promoter methylation (approximately 10% of HGSOC patients)1 or other mechanisms 
All patients in the TCGA HGSOC study received platinum-based therapy.  In general, patients 
identified as having defects in homologous recombination pathway genes were more sensitive to 
platinum-based treatment.  This differential survival effect is hypothesized to be related to 
improved response to platinum-based therapies in patients whose tumors have evidence of HRD, 
since attenuation of platinum’s pharmacodynamic effect (DNA cross-linking) is also mediated 
by DNA repair. 
3.2 PARP Inhibitors 
PARP inhibitors have been evaluated in the clinic for the past decade.  Olaparib (AZD-2281), the 
most advanced investigational PARP inhibitor, has demonstrated compelling Phase 2 clinical 
activity, both in treatment and maintenance settings, in relapsed, HGSOC patients (both germline 
BRCA mutant and wild-type) and in metastatic breast cancer patients with a gBRCA mutation. 
The concept of synthetic lethality was exploited in two proof-of-concept clinical studies with 
olaparib in patients with BRCA-associated tumor types. These studies evaluated the efficacy and 
safety of continuous oral dosing with olaparib in women with either relapsed ovarian cancer or 
advanced breast cancer and a gBRCA mutation.19, 20  In these patients, who had received a median 
of three prior chemotherapy regimens, encouraging overall response rates of 33% and 41%, were 
observed, in gBRCA ovarian and gBRCA breast cancer, respectively. In a third study, olaparib 
treatment was associated with a greater overall response rate (ORR) in patients with gBRCA-
associated ovarian cancer compared with the patients in the non-gBRCA associated cohort (41% 
vs 24%, respectively).21  In a fourth study that evaluated olaparib versus PEGylated liposomal 
doxorubicin (PLD) in patients with a gBRCA mutation and relapsed ovarian cancer, the efficacy 
of olaparib was consistent with that observed in previous studies.22 
Activity in HGSOC has also been observed with PARP inhibitor switch maintenance therapy 
following response to platinum-based chemotherapy.29, 30  Patients with platinum-sensitive 
relapsed ovarian cancer who achieved a response to another regimen of platinum-based 
chemotherapy followed by olaparib as switch maintenance treatment experienced a statistically 
significant improvement in median PFS (8.3 months) compared to patients who received  
placebo as maintenance therapy (4.8 months); hazard ratio of 0.35 (95% CI, 0.25 – 0.49).29  
Patients with a BRCA mutation derived the most benefit (median PFS 11.2 vs 4.3 months; 
HR=0.18; 95% CI 0.11-0.31; P<0.00001).30  It should be noted that the outcomes of sBRCA + 
gBRCA mutant patients were the same as gBRCA mutant patients alone, suggesting that, for 
stratification and analysis purposes in the present study, it is appropriate to not differentiate 
between germline and somatic mutations.   Patients without a BRCA mutation also experienced 
significant benefit from treatment with olaparib (HR=0.53; 95% CI 0.33-0.84; P=0.007).30  
Niraparib (MK-4827) has exhibited clinical activity in a Phase 1 study in both BRCA-mutated 
ovarian cancer (8 RECIST PRs) and sporadic ovarian cancer (5 RECIST PRs and/or GCIG CA-
125 responses).23  In a Phase 1 evaluation of BMN 673, 11 of 17 BRCA-mutated ovarian cancer 
patients treated at doses ≥100 µg/day exhibited a RECIST and/or CA-125 response.24 
Taken together, these data support the potential role for the PARP inhibitor rucaparib in the 
treatment of patients with BRCA-associated ovarian cancer.  Furthermore, the 24% ORR and HR 
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of 0.53 in the non-BRCA cohorts described above21,30 suggests that the clinical utility of PARP 
inhibitors can be extended to a larger patient group.  Patients with HRD due to defects in 
homologous recombination genes other than BRCA, i.e., nbHRD, may be part of this larger 
group. 
3.3 Rucaparib 
Rucaparib (formerly known as AG-014447 and PF-01367338) refers to the free base. The 
camphorsulfonic acid salt form (also referred to as camsylate salt) CO-338 (formerly known as 
PF-01367338-BW) will be used in this clinical trial. 
Rucaparib is a small molecule inhibitor of PARP1 and PARP2.  Nonclinical evaluation has 
demonstrated exquisite sensitivity of BRCA1 and BRCA2 homozygous mutant cell lines to 
rucaparib and provides a rationale for the clinical assessment of rucaparib as monotherapy in 
patients with hereditary deficiencies of BRCA1 and/or BRCA2.  Rucaparib has also shown 
antitumor activity as a single agent in the MDA-MB-436 (BRCA1 mutant) xenograft mouse 
model.  The activity of rucaparib in these nonclinical experiments was similar to that of olaparib. 
The details of these and other nonclinical experiments are provided in the Investigator’s 
Brochure. 
3.3.1 Nonclinical Experience 
3.3.1.1 Rucaparib Absorption, Distribution, Metabolism, and Excretion 
The pharmacokinetics (PK) and toxicokinetics of rucaparib (as camsylate salt) following oral 
administration, the intended route of administration in humans, was evaluated in the mouse, rat, 
and dog. The time at which the peak plasma concentrations were observed (Tmax) occurred at 1–3 
hours post dose in the mouse and dog, with the rat generally exhibiting a later Tmax (4–8 hours). 
The oral bioavailability was 17%, 36%, and 62%, respectively, in the mouse (50 mg/kg), rat 
(100 mg/kg), and dog (20 mg/kg).  In the rat and dog, there were no marked gender-related 
differences and no accumulation after repeat oral administration. A less than dose-proportional 
increase in exposure was observed in the rat and dog when rucaparib was administered as a 
suspension in 0.5% methylcellulose; however, a greater than dose-proportional increase in 
exposure was observed in the 1-month dog toxicity study when rucaparib was administered in 
capsules.      
In vitro plasma protein binding studies in mouse, rat, and dog plasma showed moderate binding 
and ranged from 49.5% to 73%.  Plasma protein binding in humans ranged from 55% to 75%.   
Recombinant cytochrome P450 (CYP) studies indicated that CYP2D6, CYP1A2, and to a lesser 
extent, CYP3A4, have the ability to metabolize rucaparib.  Rucaparib moderately inhibited 
CYP1A2, CYP2C19, and CYP2C8.  In addition, rucaparib showed mixed inhibition of CYP2C9.  
Based on bi-directional experiments of digoxin transport carried out using Caco-2 cells, it was 
determined that rucaparib is a moderate P-glycoprotein (P-gp) inhibitor.  Patients taking dixogin 
should have their dixogin levels monitored regularly according to standard institutional practices. 
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Quantitative whole body autoradiography studies in Long Evans rats showed [14C] rucaparib 
radioequivalents were rapidly and widely distributed to tissues following IV administration, 
consistent with a large volume of distribution.  At 2 minutes after dosing, highest concentrations 
were found in kidney, lung, thyroid gland, heart, stomach mucosa, liver adrenal glands, spleen, 
and blood.  Little radioactivity was present in brain; levels were undetectable at 15 minutes after 
dosing.  Activity was undetectable in most tissues by 96 hours after dosing, however levels in the 
choroid/retina declined more slowly, and persistent radioactivity was also found in hair follicles 
through 192 hours, indicating that drug equivalents have high affinity and long half-life in 
pigmented tissues.  High levels of radioactivity were observed in ureters, bladder, and bile ducts, 
indicating both renal and biliary routes eliminated drug equivalents.   
3.3.1.2 Multiple-Dose Toxicity Studies 
Rucaparib was evaluated in both rat and dog in oral and IV infusion toxicity studies.  Only the 
multiple-dose toxicity studies utilizing the oral formulation are summarized below.  Details of all 
other toxicity studies are provided in the Investigator’s Brochure. 
Target organs identified in studies where rucaparib was administered orally include the 
hematopoietic system and gastrointestinal tract.  No cardiovascular findings were noted in any of 
the oral toxicity studies. 
Multiple-Dose Oral Toxicity in Rats 
Administration of rucaparib camsylate salt via oral gavage was generally well-tolerated in the rat 
up to 1000 mg/kg/day for 7 days and up to 150 mg/kg/day for 28 days.  Decreases in body 
weight gain and food consumption were noted in both studies.  In the 7-day study, target organs 
identified microscopically were bone marrow, spleen, and thymus.  Minimal to mild bone 
marrow hypocellularity was noted in all dose groups.  The no-observed-adverse-effect-level 
(NOAEL) was established at 500 mg/kg/day. 
In the 28-day study, there were 3 rucaparib-related deaths at 500 mg/kg/day immediately after 
blood collection on Day 28 (n=1) or Day 29 (first day of recovery phase (n=2).  These deaths 
likely resulted from the marked anemia identified hematologically.  Other rucaparib-related 
clinical signs at 500 mg/kg/day included thinning haircoat and pale eyes.  Identified target organs 
included bone marrow, spleen, lymphoid tissue (thymus, gut-associated-lymphoid tissue 
[GALT], and lymph nodes), and cecum (at 500 mg/kg/day only).  Following cessation of 
rucaparib dosing, most findings reversed.  In this study, the severe toxic dose in 10% of the 
animals (STD10) was 500 mg/kg/day and the NOAEL was 50 mg/kg/day. 
Multiple-Dose Oral Toxicity in Dogs 
Oral gavage administration of the camsylate salt form of rucaparib to dogs for 7 days resulted in 
gastrointestinal clinical signs at the 80 mg/kg/day high-dose group.  Hematopoietic effects of 
decreased reticulocytes were noted in mid- to high-dose groups and leukopenia was exhibited in 
all treatment groups.  Lymphoid atrophy occurred in both sexes and in all treatment groups.  
Decreased bone marrow cellularity was seen in both sexes (males at all doses; females at 80 
mg/kg/day).  A 7-day repeat-dose toxicity study using oral capsules in dogs was repeated in 
order to characterize the toxicity of a new lot of rucaparib camsylate.  Similar to the results of the 
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prior 7-day study in dog, gastrointestinal clinical findings were noted at 80 mg/kg/day. Vomiting 
was observed throughout the dosing phase for males as well as liquid and/or mucoid feces in 
both genders. Decreased food consumption was observed at 80 mg/kg/day that correlated with 
the body weight loss that was considered adverse.  Decreases in erythroid, platelet, and leukocyte 
parameters were observed primarily at 80 mg/kg/day and occasionally at 20 or 5 mg/kg/day.  
These data indicated that the drug targeted multiple bone marrow lineages in a dose-related 
pattern. 
Rucaparib camsylate salt in capsules was administered orally to dogs for 30 consecutive days 
with a 29-day recovery.  Gastrointestinal clinical signs were noted at ≥ 5 mg/kg/day, with 
decrease in food consumption at 75 mg/kg/day.  Adverse hematological changes (decrease in 
erythroid, myeloid, and megokaryocytic lineages) occurred at ≥ 20 mg/kg/day.  Effects were 
fully reversible.  The NOAEL in this study was 5 mg/kg/day. 
Rucaparib camsylate in capsules was also given orally to dogs at doses of 3, 15/10, 40/30/20 
mg/kg/day for 91 consecutive days with a 29-day recovery period.  Body weight losses and 
inappetance observed at the high dose in both sexes during the first quarter of the dosing phase 
were considered adverse and resulted in dose reductions (40 to 30 to 20 mg/kg/day for toxicity 
and 15 to 10 mg/kg day in order to maintain multiples of exposures for optimal testing of dose 
response) for the remainder of the study.  Clinical pathology findings were indicative of bone 
marrow toxicity; these changes were non-progressive over time suggesting potential adaptation 
to these initial effects.  Hematological findings at 40/30/20 mg/kg/day correlated with erythroid 
atrophy of the bone marrow detected microscopically.  By Day 29 of recovery, most effects 
reversed. The highest non-severely toxic dose (HNSTD) for this study was 20 mg/kg/day for 
male dogs.  No HNSTD was established for female dogs.  The NOAEL was 10 and 20 
mg/kg/day for male and female dogs, respectively. 
3.3.1.3 Additional Observations 
In vitro genetic toxicology assays demonstrated oral rucaparib to be clastogenic.  Bacterial 
mutagenicity data for rucaparib were clearly negative in four microbial tester strains, both with 
and without metabolic activation, and equivocal in a fifth tester strain.   
In an in vitro assay for human ether-a-go-go-related gene (hERG) activity, the IC50 and IC20 for 
the inhibitory effects of rucaparib (50% inhibitory concentration and 20% inhibitory 
concentration) on hERG potassium currents were 24 µM (7761 ng/mL) and 7 µM (2264 ng/mL), 
respectively.  These values are 9-fold and 2.6-fold higher, respectively, than the mean unbound 
steady state plasma concentration (858 ng/mL) observed to date in humans at a dose of 600 mg 
BID rucaparib administered orally. 
Effects on appearance and behavior, motor activity, body temperature, and a number of 
neurofunctional tests and reflexes were evaluated in rats.  A dose of 50 mg/kg of rucaparib 
administered via IV infusion (mean Cmax=13629 ng/mL) resulted in a significant reduction in 
motor activity compared with vehicle-treated animals; however, there were no effects on 
neurofunctional or reflex testing at this dose.  The plasma concentration measured at this dose is 
4.7-fold above the mean steady state plasma concentration (2880 ng/mL) observed to date in 
humans at a dose of 600 mg BID rucaparib administered orally. 
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Administration of rucaparib to Long-Evans rats orally at doses up to 750 mg/kg/dose, followed 
by a single exposure to solar-simulated ultraviolet radiation approximately 4 hours after the final 
dose elicited no skin or ocular reactions indicative of phototoxicity.  The no-observed-effect-
level (NOEL) for phototoxicity was >750 mg/kg/day. 
3.3.2 Clinical Experience   
The early clinical program assessed safety and efficacy of rucaparib in patients with 
malignancies commonly treated with chemotherapeutic agents. Initially, the IV formulation of 
rucaparib was administered in combination with a variety of chemotherapies; later, the oral 
formulation of rucaparib was administered in combination with chemotherapy and as a 
monotherapy.  The oral formulation as monotherapy is the focus of current development efforts. 
3.3.2.1 Rucaparib Monotherapy 
Clovis-sponsored study CO-338-010 is a 2-part, open-label, safety, PK, and preliminary efficacy 
study of oral rucaparib administered daily for continuous 21-day cycles.  Part 1 is a Phase 1 
portion in patients with any solid tumor, including lymphoma, who have progressed on standard 
treatment.  The primary objective of Part 1 is to determine the optimal monotherapy dose for 
orally administered rucaparib.  Part 2 is a Phase 2 portion in patients with platinum-sensitive 
relapsed ovarian cancer with evidence of a gBRCA mutation who have received at least 2, but no 
more than 4, prior regimens. The primary objective of Part 2 is to assess the overall objective 
response rate by Response Evaluation Criteria in Solid Tumors (RECIST). 
Study CO-338-010 was initiated in Q4 2011.  As of 9 September 2013, 52 patients (median age 
51 yrs [range 21−71]; 47 female; 26 breast cancer, 18 ovarian/peritoneal cancer, 8 other tumor) 
have been treated at dose levels of 40, 80, 160, 300, and 500 mg once daily (QD), and 240, 360, 
480, 600, and 840 mg twice daily (BID) rucaparib administered continuously.  One of 6 patients 
treated with 360 mg BID rucaparib experienced a dose-limiting toxicity (DLT) of Common 
Toxicity Criteria for Adverse Events (CTCAE) Grade 3 nausea despite maximal intervention in 
Cycle 1 of treatment.  No DLTs were observed during Cycle 1 in the 480 (n=9), 600 (n=5), and 
840 mg BID (n=3) cohorts; however, similar to other PARP inhibitors, non-DLT 
myelosuppression was observed beyond Cycle 1.  The dose of 600 mg BID rucaparib was 
selected as the recommended dose for Phase 2 and Phase 3 studies based on the overall safety & 
tolerability, PK, and clinical activity profile. 
Twenty-one patients are ongoing and 31 patients have discontinued.  Reasons for discontinuation 
include disease progression (n=27), adverse event unrelated to study treatment (n=2), withdrawal 
of consent (n=1), eligibility criteria violation (n=1).  No patient discontinued rucaparib due to a 
treatment-related adverse event.   
The median number of cycles administered is 3 (range 1–21+).  Twenty-four patients have 
received ≥4 cycles of treatment.  Nine patients have had their dose of rucaparib escalated.  Six 
patients had their dose of rucaparib reduced due to a treatment-related AE.  Events leading to 
dose reduction included: Grade 3 thrombocytopenia (n=1, rucaparib reduced from 480 to 360 mg 
BID), Grade 3 anemia (n=1, rucaparib reduced from 600 to 480 mg BID), Grade 3 nausea (n=1, 
rucaparib reduced from 360 to 240 mg BID), Grade 2 neutropenia (n=2 total, rucaparib reduced 
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from 600 to 480 mg BID [n=1] and from 500 to 300 mg QD [n=1]), and a constellation of Grade 
1-2 gastrointestinal toxicities and inability to ingest 14 x 60 mg tablets (n=1; rucaparib reduced 
from 840 to 480 mg BID).  Four patients experienced a retreatment delay between cycles. One 
patient was delayed due Grade 3 thrombocytopenia.  One patient was delayed due to Grade 3 
thrombocytopenia and Grade 3 anemia.  Two patients were delayed due to Grade 2 neutropenia. 
As of 9 September 2013, safety data are available for 52 treated patients.   Treatment-related 
adverse events (AEs) (all grades) reported in ≥5 patients include nausea (n=13, 26%), fatigue 
(n=10, 20%), vomiting (n=9, 18%), decreased appetite (n=6, 12%), and diarrhea (n=6, 12%).  
Mild to moderate (Grade 1 – 2) elevations of ALT and/or AST have been reported in patients 
treated at higher doses, primarily 480, 600, and 840 mg BID.  These elevations were not 
accompanied by any changes in bilirubin levels and were either transient, and resolved to within 
normal ranges, or stabilized.  Patients were asymptomatic and no dosing modifications were 
required.  Grade 1 – 2 photosensitivity of skin has also been reported.   
Overall, treatment-related Grade 3 events have been minimal and no Grade 4 events have been 
reported.  Grade 3 related events include anemia (n=2, 4%), thrombocytopenia (n=2, 4%), 
neutropenia (n=1, 2%), fatigue (n=1, 2%), and nausea (n=1, 2%).  As has been observed with 
rucaparib and other PARP inhibitors, myelosuppression may be delayed and observed after a 
period of continuous dosing.  Three patients died within 30 days of last dose of study drug; all 
deaths were assessed as due to disease progression and not related to rucaparib.   
To date, one patient (breast cancer, gBRCA mutation) has achieved a RECIST CR and 6 patients 
(2 ovarian cancer, 3 breast cancer, 1 pancreatic cancer; all with gBRCA mutation) have achieved 
a RECIST PR during the dose escalation phase (n=2 at 300 mg QD; n=1 at 360 mg BID; n=2 at 
480 mg BID; and n=1 at 600 mg BID).  The duration of the PR for one of the breast cancer 
patient was 5.1 months; all other patients with a CR or PR are still ongoing.  An additional 12 
patients (7 ovarian cancer, 4 breast cancer, 1 colorectal; 9 with gBRCA mutation 2 with unknown 
gBRCA status, 1 gBRCA wild-type) achieved a best response of stable disease (SD) >12 wks.  
Three patients with ovarian cancer and a gBRCA mutation have achieved prolonged stable 
disease and are ongoing at 62, 32, and 30 weeks.  An additional 6 ovarian cancer patients are 
ongoing at less than 12 weeks of treatment.  The overall disease control rates (CR or PR or 
SD>12 weeks and CR or PR or SD>24 weeks) to date in all evaluable ovarian cancer patients 
across all dose levels are 91% (10/11) and 50% (5/10), respectively (Table 1). 
Table 1. Disease Control of Ovarian Cancer Patients Treated with 
Rucaparib in Study CO-338-010 
BRCA Status  Disease Control Rate (%) (CR, PR, or SD>12 weeks) 
Disease Control Rate (%) 
(CR, PR, or SD>24 weeks) 
gBRCA mutation 100 (9/9) 63 (5/8) 
gBRCA unknown 100 (1/1)  0 (0/1) 
gBRCA wild-type 0 (0/1)  0 (0/1) 
Overall  91 (10/11)  50 (5/10) 
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After once daily oral administration of rucaparib for 15 days, steady state Cmax and AUC0-24 
generally increased dose proportionally.  Tmax and t1/2 were independent of dose.  Steady state 
exposure increased by an average of 89%, consistent with accumulation expected for a 
compound exhibiting a t1/2 of approximately 17 hours administered once daily.  Following BID 
oral administration of rucaparib for 15 days, steady state Cmax and AUC0-24 generally increased 
dose proportionally.  Moreover, BID dosing delivered a lower Cmax with a low peak to trough 
plasma concentration variation.  The target trough level of 2 µM was achieved in 100% of 
patients (n=14) at ≥240 mg BID with low inter-patient variability (<4-fold) within each dose 
group.  Steady state trough levels also exhibited low intra-patient variability (24% CV). No 
sporadically high exposures were observed.  The effect of food on rucaparib PK was evaluated at 
40 mg (n=3) and 300 mg (n=6) doses administered once daily.  There was no food effect; 
patients may take rucaparib on an empty stomach or with food. 
Study A4991014 
Clovis-sponsored study A4991014 is an ongoing Phase 1, open-label, multicenter, dose 
escalation study.  The primary objectives are to determine the safety and PK of rucaparib when 
administered in combination with different chemotherapeutic regimens in adult patients with 
advanced solid tumors.  The study was initially designed to explore escalating doses of IV 
rucaparib (as phosphate salt) in combination with different chemotherapeutic regimens, but was 
subsequently amended to evaluate the oral formulation of rucaparib in combination with 
carboplatin; all other treatment arms were discontinued.   
As of 28 August 2013, a total of 84 patients (median age=54.5 [range 20-76]; 54 female; 36 
ECOG PS=0) have been treated in this study.  Of these, 52 patients were treated with IV and/or 
oral rucaparib on Days 1–3 in combination with various chemotherapeutic regimens.  Thirty-two 
patients have been treated with escalating doses of oral rucaparib (Days 1 – 14) in combination 
with carboplatin. 
Oral rucaparib doses of 80, 120, 180, 240, and 360 mg were administered with AUC3 
carboplatin, followed by 360 mg rucaparib with AUC4, and subsequently AUC5, carboplatin.  
Two of 5 patients treated with AUC5 carboplatin and 360 mg rucaparib experienced a dose-
limiting toxicity (Grade 4 thrombocytopenia and Grade 3 neutropenia in 1 patient; Grade 4 
thrombocytopenia and Grade 4 neutropenia in 1 patient) in Cycle 1 of treatment.  Evaluation of 
240 mg rucaparib in combination with AUC5 carboplatin is nearly complete.  To date, 1 of 5 
patients treated with that dose combination has experienced DLT of Grade 4 thrombocytopenia.  
The 6th patient in the cohort is currently completing Cycle 1 of treatment. 
As of 28 August 2013, safety data is available for 32 patients treated with oral rucaparib 
(14 days) and carboplatin.  Adverse events (all grades) occurring in ≥25% of patients include 
nausea (n=21, 66%), fatigue (n=17, 53%), anemia (n=15, 47%), vomiting (n=15, 47%), 
constipation (n=14, 44%), thrombocytopenia (n=13, 41%), abdominal pain (n=11, 34%), 
decreased appetite (n=10, 31%), neutropenia (n=9, 28%), and diarrhea (n=9, 28%), Two patients 
treated with oral rucaparib and carboplatin died within 30 days of last dose of study drug; both 
deaths were assessed as due to disease progression and not related to study drugs. 
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To date, 3 patients have achieved a RECIST PR.   One patient (ovarian cancer, gBRCAwt, AUC3 
carboplatin and 180 mg rucaparib) had a PR of 5.1 months duration.  One patient (breast cancer, 
gBRCA2mut, AUC5 carboplatin and 360 mg rucaparib) had a PR of 3 months duration.  One 
patient (ovarian cancer, gBRCA1mut, AUC5 carboplatin and 240 mg rucaparib) achieved a PR at 
the end of Cycle 2 and is currently ongoing in Cycle 3.  Two ovarian cancer patients                  
(1 gBRCAunk, 1 gBRCAwt) discontinued carboplatin (after 4 and 8 cycles, respectively) and 
continued on rucaparib (additional 4 and 25+ cycles, respectively).  Overall disease control rate 
(CR, PR, or SD>12 weeks) in ovarian cancer patients across all dose levels was 60% (6/10). 
After a single oral administration, rucaparib was rapidly absorbed with Cmax achieved within 4 
hours.  Cmax and AUC0-∞ increased in an approximately dose-proportional manner.  Apparent 
terminal half-life (t1/2) ranged from 13 to 21 hours.  The absolute bioavailability of the rucaparib 
immediate-release tablet was dose-independent and was estimated to be 36%.  Rucaparib 
exposure was not meaningfully changed by carboplatin co-administration. 
Study A4991002 and A4991005 
Further details of these studies are provided in the Investigator’s Brochure. 
3.4 Rationale for Study 
In vitro studies have shown that cells deficient in BRCA1/2 as well as cells deficient in or 
depleted of homologous recombination proteins other than BRCA1/2 have been associated with 
PARP inhibitor sensitivity in vitro.16, 17, 25, 26, 27, 28  Clinical data have shown that ovarian cancer 
patients with and without evidence of a gBRCA mutation benefit from treatment with a PARP 
inhibitor18, 19, 20, 21, 22 and that maintenance treatment with a PARP inhibitor following a response 
to platinum-based treatment increases PFS in patients with ovarian cancer.29, 30  While patients 
with a BRCA mutation derived the most benefit, patients without evidence of a BRCA mutation 
also derived significant benefit.21, 30  The purpose of this study is to evaluate PFS of patients with 
platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, fallopian tube, or 
primary peritoneal cancer who receive rucaparib or placebo as switch maintenance therapy 
following a response to platinum-based chemotherapy in order to identify the patients most 
likely to benefit from treatment with rucaparib.  It is anticipated that rucaparib will provide 
therapeutic benefit and increase PFS in patients with HRD associated with a BRCA gene 
mutation or other HR gene alteration. 
Patients will be stratified into one of 3 HRD subgroups (tBRCA, nbHRD, and biomarker 
negative) (Appendix A) by Foundation Medicine’s ICTA, which will determine HRD status 
through analysis of homologous recombination gene mutations in tumor tissue.  Tumor DNA 
will also be assessed to detect the presence of genomic scars.33, 34, 35, 36  Analysis of specific 
genomic scarring patterns may identify tumors with HRD regardless of the underlying 
mechanism(s).  Homologous recombination gene mutation analysis and genomic scarring will 
also be assessed in a Phase 2 study (CO-338-017) that will be initiated in parallel with this Phase 
3 study.  The insights from study CO-338-017 will be applied prospectively to the analysis of 
this Phase 3 trial.  The FCTA analysis plan (gene mutation and/or genomic scarring) and 
classification of HRD subgroups will be finalized and locked down prior to the completion of the 
Phase 3 study and applied prospectively to the analysis of this Phase 3 study. 
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4 STUDY OBJECTIVES 
4.1 Objectives and Endpoints 
This is a double-blind efficacy study of oral rucaparib in patients with platinum-sensitive, 
relapsed high-grade serous or endometrioid epithelial ovarian, fallopian tube, or primary 
peritoneal cancer who receive rucaparib or placebo as switch maintenance therapy following a 
response to platinum-based chemotherapy. 
Primary, secondary, and exploratory objectives and endpoints are shown in Table 2. 
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 Table 2. Primary, Secondary, and Exploratory Objectives and Endpoints  
 Primary Objectives Primary Endpoints 
 1. To evaluate PFS by RECIST, as assessed by 
the investigator, in molecularly-defined HRD 
subgroups 
1. Disease progression according to RECIST 
Version 1.1 (v1.1), as assessed by the 
investigator, or death from any cause (invPFS), 
in molecularly defined subgroups 
 Secondary Objectives Secondary Endpoints 
 1. To evaluate PFS by RECIST, as assessed by 
independent radiology review (IRR), in 
molecularly-defined HRD subgroups 
1. Disease progression according to RECIST v1.1, 
as assessed by IRR, or death from any cause 
(irrPFS), in molecularly defined subgroups 
 2. To evaluate patient-reported outcome (PRO) 
of disease related symptoms utilizing the 
disease-related symptoms – physical 
(DRS−P) subscale of the National 
Comprehensive Cancer Network-Functional 
Assessment of Cancer Therapy 
(NCCN-FACT) FACT-Ovarian Symptom 
Index 18 (FOSI-18) 
2. Time to a 4-point decrease in the DSR−P 
subscale of the FOSI-18 
 3. To evaluate PRO utilizing the complete 
FOSI-18 
3. Time to an 8-point decrease in the total score of 
the FOSI-18 
 4. To evaluate survival benefit 4. OS 
 5. To evaluate safety  5. Incidence of AEs, clinical laboratory 
abnormalities, and dose modifications 
 6. To determine the population PK of rucaparib 6. Individual model parameter estimates of 
rucaparib and covariates identification 
 Exploratory Objectives Exploratory Endpoints 
 1. To evaluate the relationship between cancer 
antigen 125 (CA-125) levels and invPFS 
1. Association between the change from baseline in 
CA-125 measurements  and invPFS 
 2. To evaluate PFS2 (PFS on the subsequent 
line of treatment) 
2. Time to the next event of disease progression or 
death, as assessed by the investigator 
 3. To evaluate ORR 3. ORR per RECIST v1.1, as assessed by both 
investigator and IRR, in patients with 
measureable disease at study entry 
 4. To evaluate duration of response (DOR) 4. DOR per RECIST Version 1.1, as assessed by 
both investigator and IRR 
 5. To evaluate PRO utilizing the Euro-Quality 
of Life 5D (EQ-5D) 
5. PRO as measured by the total score on the 
EQ-5D 
 6. To explore the relationship between 
rucaparib exposure, efficacy, and safety 
6. Rucaparib PK, invPFS, irrPFS, CA-125, AEs, 
clinical laboratory abnormalities, and dose 
modifications 
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5 STUDY DESIGN 
5.1 Overall Study Design and Plan 
This is a double-blind efficacy study of oral rucaparib in patients with platinum-sensitive, 
high-grade serous or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer 
who receive rucaparib or placebo as switch maintenance therapy following a response to 
platinum-based chemotherapy. 
5.1.1 Screening Phase 
All patients will undergo screening assessments within 90 days prior to randomization.   
The study will enroll patients with platinum-sensitive (defined as disease with confirmed 
radiologic relapse >6 months after the last dose of the penultimate platinum regimen received), 
high-grade serous or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer 
who achieved a response to platinum-based chemotherapy administered for relapsed disease.  
Patients must have received ≥2 prior platinum-based treatment regimens, inclusive of the 
regimen that must have been administered immediately prior to maintenance therapy in this trial.  
There is no limit on the number of prior platinum-regimens that may have been received, but the 
patient must have been sensitive to the penultimate platinum regimen received.  In addition, up 
to 1 prior non-platinum regimen is permitted.  Prior continuous or switch maintenance therapy 
may have been administered with any prior treatment.  For the last chemotherapy course prior to 
study entry, patients must have received a platinum-based regimen (minimum 4 cycles) and have 
achieved a CR (defined as complete radiologic response by RECIST [Appendix A] or PR 
(defined as partial response by RECIST [Appendix A] and/or a GCIG CA-125 response 
[Appendix C].  All responses require that CA-125 be <ULN.  The response must be maintained 
to permit entry into the study.   
Screening assessments will include demographics and medical history, prior treatments for 
serous or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer (and other 
malignancies, if applicable), prior and current medications and procedures, 12 lead 
electrocardiogram (ECG), ECOG performance status, central laboratory hematology, serum 
chemistry, and CA-125 measurement, serum pregnancy (for women of childbearing potential 
only), urinalysis, physical examination, height, weight, and vital signs measurements, adverse 
events, and radiologic assessment by CT or MRI.  PRO will be collected using the FOSI-18 and 
EQ-5D instruments.   
Germline BRCA mutation results should be obtained for all patients who are known to have been 
tested prior to enrollment in order to determine whether any mutation was reported and if so, 
whether the mutation was classified as deleterious / pathogenic or other.  Enrollment of patients 
with a gBRCA mutation classified as deleterious (i.e., pathogenic), suspected deleterious, or the 
equivalent, on the most recent assessment by a testing laboratory will be limited to 150.  Patients 
with a BRCA mutation detected in tumor tissue (tBRCA) will be limited to 200.  Once this cap is 
reached, newly screened patients identified as having a BRCA mutation in tumor tissue will be 
offered treatment in another study. 
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The complete results of the Foundation Medicine NGS test, which examines exons of 287 genes 
as well as introns of 19 genes, will be provided to all patients who opt to receive this information 
and provide appropriate consent.  Results for the BRCA genes will be provided to patients upon 
availability.  Results for the remainder of the gene panel will be provided to patients upon 
treatment discontinuation.  In the event a mutation associated with hereditary cancer or other 
syndrome is detected in tumor tissue, the patient will be referred by the investigator for genetic 
counseling and potential germline testing per institutional guidelines. If the patient chooses to 
have germline BRCA testing, this result will be entered into the clinical trial database.  The 
Sponsor will remain blinded to all NGS test results, including all tBRCA results, until the 
primary efficacy analysis is conducted. 
Mutations detected in tumor tissue may be somatic or germline; however, the NGS test will not 
distinguish between the two.  A blood sample will therefore be collected for all patients and 
stored.  Prior to final efficacy analysis, genomic DNA may be subjected to exploratory analysis 
in order to determine whether any mutation identified is of germline or somatic origin.  This data 
will be generated in a research setting and will not be provided to the investigator or patient. 
Enrollment will require Clovis (or designee) review of eligibility, including, but not limited to: 
• a list of all prior cancer therapies and dates administered; 
• documentation supporting platinum sensitivity; 
• documentation supporting a RECIST or GCIG CA-125 response to most recent platinum-
based treatment; 
•  local gBRCA test result if patient has previously been tested; and 
•  confirmation that sufficient tumor tissue was submitted for HRD stratification for 
randomization and storage for potential bridging to a validated companion diagnostic 
test. 
5.1.2 Randomization 
Randomization to study treatment must occur within 8 weeks following a patient’s last dose of 
platinum-based chemotherapy, and is described in more detail in Section 7.2.  Study treatment 
must be initiated within 3 days of randomization. 
5.1.3 Double-Blind Treatment Phase 
During the double-blind treatment phase (continuous 28-day treatment cycles), patients will be 
monitored for safety and efficacy.  Assessments will include AEs, physical examination, vital 
signs and weight measurement, central laboratory hematology, serum chemistry, including 
alpha-1 acid glycoprotein (AAG) analysis on days where a blood sample is taken for PK, and 
CA-125 measurement, serum or urine pregnancy for women of childbearing potential, 
concomitant medications, therapies and procedures, disease status assessment, study drug 
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administration and accountability, and PRO.  ECGs and urinalysis will be performed as clinically 
indicated.  Blood samples will also be collected for population PK. 
Patients will be assessed for disease status per RECIST v1.1 at the end of every 3 cycles 
(12 weeks) of treatment.  Patients experiencing disease progression by RECIST v1.1, as assessed 
by the investigator, will be discontinued from treatment and enter follow-up.  Disease 
progression will only be determined by RECIST v1.1.  Patients with a CR at study entry will 
only be considered to have disease progression if a new lesion is identified.  Patients who meet 
GCIG CA-125 criteria for disease progression should have a radiologic assessment and be 
assessed by RECIST v1.1.  If the radiologic assessment does not confirm disease progression, 
patients should continue on treatment and be assessed by RECIST v1.1 per the protocol schedule 
of assessments. 
All CT scans (and other imaging, as appropriate) performed during the treatment period and at 
treatment discontinuation will be collected for IRR. 
Patients will be continuously monitored for safety.  An Independent Data Monitoring Committee 
(IDMC) with multidisciplinary representation will evaluate safety in compliance with a 
prospective charter. 
5.1.4 Treatment Discontinuation 
Upon treatment discontinuation, regardless of reason, patients will have a Treatment 
Discontinuation visit.  Assessments will include AEs, physical examination, vital signs and 
weight measurements, central laboratory hematology, serum chemistry, and CA-125 
measurement, serum pregnancy (for women of childbearing potential only), concomitant 
medications, therapies and procedures, disease status assessment, study drug accountability, and 
PRO.  Additionally, all patients discontinued from treatment will be followed for 28 days 
following the last dose of study drug for the collection of AEs and PRO.  An optional tumor 
biopsy will be collected from patients who experience disease progression and provide 
appropriate consent. 
5.1.5 Follow-Up Phase 
After the Treatment Discontinuation visit, all patients will be followed for AEs up to 28-days 
after last dose of study drug.  Patients will also be followed for survival, subsequent treatments, 
and monitoring for secondary malignancy every 12 weeks until death, loss to follow-up, 
withdrawal of consent, or study closure.   
Patients who discontinued treatment for reason other than disease progression or death should 
continue to have tumor scans and CA-125 measurement performed at 12 (± 2) week intervals 
until disease progression by RECIST v1.1, as assessed by the investigator. 
5.2 Study Schema 
An overview of the study design is provided in Figure 1.   
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5.3 End of Study 
The trial will close when the required number of PFS events has been observed.  Upon formal 
closure of the study, individual patients who are continuing to benefit from treatment with 
rucaparib at the time of study closure, and who do not meet any of the criteria for withdrawal, 
will have the option of entering an extension protocol in which they can continue to receive 
rucaparib. 
5.4 Discussion of Study Design 
This is a multicenter, randomized, double-blind, placebo-controlled study. 
Sponsor personnel (with the exception of individuals responsible for clinical supply chain), 
investigator and clinical site staff, and patient will all be blinded to study treatment to avoid bias 
in the interpretation of the efficacy and safety results.  To avoid bias between treatment groups, 
patients will be randomized to treatment with active drug or placebo with stratification according 
to HRD classification, interval between completion of penultimate platinum-based regimen and 
disease progression by radiologic assessment, and best response to platinum regimen received 
immediately before initiation of maintenance therapy.   
PFS by RECIST will be assessed by the investigator for the primary endpoint (invPFS) and by a 
blinded independent radiologist for the secondary endpoint (irrPFS). 
Risk/benefit will be assessed regularly by an IDMC that will have access to unblinded datasets. 
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6 STUDY POPULATION 
6.1 Number of Patients and Sites 
Approximately 540 patients with platinum-sensitive, relapsed, high-grade serous or endometrioid 
epithelial ovarian, fallopian tube, or primary peritoneal cancer will be enrolled at approximately 
90 – 100 study sites.  A minimum of 180 and a maximum of 200 patients with a deleterious 
tBRCA mutation will be enrolled.  Enrollment of patients with a known deleterious gBRCA 
mutation documented in their medical record will not exceed 150.  There is no minimum number 
of patients required for each of the nbHRD and biomarker negative subgroups; however, no 
more than 360 total patients will be randomized for stratification into these subgroups combined. 
6.2 Inclusion Criteria 
All patients enrolling into the study must meet all of the following inclusion criteria: 
1. Have signed an Institutional Review Board/Independent Ethics Committee-approved 
informed consent form prior to any study-specific evaluation 
2. Be ≥18 years of age at the time the informed consent form is signed 
3. Have a histologically confirmed diagnosis of high-grade serous or endometrioid epithelial 
ovarian, fallopian tube, or primary peritoneal cancer  
− For mixed histology, >50% of the primary tumor must be confirmed to be high-grade 
serous or endometrioid 
4. Received prior platinum-based therapy and have platinum-sensitive disease (i.e., documented 
radiologic disease progression >6 months following the last dose of the penultimate platinum 
administered) 
− Received ≥2 prior platinum-based treatment regimens, including the platinum-based 
regimen that must have been administered immediately prior to maintenance therapy in 
this trial.  In addition, up to 1 non-platinum regimen is permitted. 
o There is no limit on the number of prior platinum-based regimens that may have been 
received; the patient must have been sensitive to the penultimate platinum-based 
regimen administered. 
o If both neoadjuvant and adjuvant treatment were administered pre/post any debulking 
surgery, this will be considered 1 treatment regimen 
o Prior continuous (e.g. bevacizumab) or switch maintenance therapy following any 
prior treatment regimen is permitted 
5. Achieved best response of either CR (defined as complete radiologic response by RECIST) 
or PR (defined as partial response by RECIST and/or a GCIG CA-125 response) to the most 
recent platinum-based regimen administered (4 cycles minimum) and maintained response 
through completion of chemotherapy 
− All responses require that CA-125 be <ULN.  Response must have been maintained to 
permit entry into the study. 
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− All disease assessments performed prior to and during this chemotherapy regimen must 
be adequately documented in the patient’s medical record 
6. Have sufficient archival formalin-fixed paraffin-embedded (FFPE) tumor tissue (1 x 4 µm 
section for hematoxylin and eosin [H&E] stain and approximately 8 – 12 x 10 µm sections, 
or equivalent) available for planned analyses. 
− The most recently collected tumor tissue sample should be provided, if available.   
− Submission of a tumor block is preferred; if sections are provided, these must all be from 
the same tumor sample. 
− Sample must be received at the central laboratory at least 3 weeks prior to planned start 
of treatment in order to enable stratification for randomization. 
7. Have CA-125 measurement that is < ULN 
8. Have ECOG performance status of 0 to 1 
9. Have adequate organ function confirmed by the following laboratory values obtained within 
14 days of the first dose of study drug: 
− Bone Marrow Function 
o Absolute neutrophil count (ANC) ≥1.5 × 109/L 
o Platelets >100 × 109/L  
o Hemoglobin ≥9 g/dL 
− Hepatic Function 
o Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × ULN; if 
liver metastases, then ≤5 × ULN 
o Bilirubin ≤1.5 × ULN 
− Renal Function  
o Serum creatinine ≤1.5 × ULN or estimated glomerular filtration rate (GFR) ≥45 
mL/min using the Cockcroft Gault formula 
 
6.3 Exclusion Criteria 
Patients will be excluded from participation if any of the following criteria apply: 
1. History of a prior malignancy except: 
a. Curatively treated non-melanoma skin cancer 
b. Breast cancer treated curatively >3 years ago, or other solid tumor treated curatively >5 
years ago, without evidence of recurrence 
c. Synchronous endometrioid endometrial cancer (Stage 1A G1/G2) 
2. Prior treatment with any PARP inhibitor, including oral or intravenous rucaparib.  Patients 
who previously received iniparib are eligible. 
3. Required drainage of ascites during the final 2 cycles of their last platinum-based regimen 
and/or during the period between the last dose of chemotherapy of that regimen and 
randomization to maintenance treatment in this study 
Clovis Oncology, Inc.   Clinical Protocol 
Oral rucaparib (CO-338) CO-338-014 
 September 9, 2013 
 Page 44 Confidential 
4. Symptomatic and/or untreated central nervous system (CNS) metastases.  Patients with 
asymptomatic previously treated CNS metastases are eligible provided they have been 
clinically stable for at least 4 weeks. 
5. Prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect 
that would interfere with absorption of study drug 
6. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome 
(AIDS)-related illness, or history of chronic hepatitis B or C 
7. Pregnant or breast feeding.  Women of childbearing potential must have a negative serum 
pregnancy test <3 days prior to first dose of study drug 
8. Received treatment with chemotherapy, radiation, hormones, antibody therapy or other 
immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, or experimental 
drugs ≤14 days prior to first dose of study drug and/or ongoing adverse effects from such 
treatment > NCI CTCAE Grade 1 
9. Received administration of strong CYP1A2 or CYP3A4 inhibitors ≤7 days prior to first dose 
of study drug or have on-going requirements for these medications (Appendix F) 
10. Non-study related minor surgical procedure ≤5 days, or major surgical procedure ≤21 days, 
prior to first dose of study drug;  in all cases, the patient must be sufficiently recovered and 
stable before treatment administration 
11. Presence of any other condition that may increase the risk associated with study participation 
or may interfere with the interpretation of study results, and, in the opinion of the 
investigator, would make the patient inappropriate for entry into the study 
6.4 Patients of Reproductive Potential 
Pregnancy is an exclusion criterion and women of childbearing potential must not be considering 
getting pregnant during the study.  Female patients who are more than 2 years postmenopausal or 
have had a hysterectomy and/or bilateral oophorectomy will not be considered of childbearing 
potential.  Female patients of childbearing potential must have a negative serum pregnancy test 
result less than 3 days prior to administration of the first dose of study drug.  A serum or urine 
pregnancy test (investigator’s discretion) must be performed within 72 hours prior to Day 1 of 
every subsequent cycle during the treatment phase. A serum pregnancy test will be performed at 
the End of Treatment visit.  All pregnancy testing will be performed by the local laboratory. 
Female patients of reproductive potential must practice an effective method of contraception 
during treatment and for 6 months following the last dose of study drug.  Adequate contraception 
is defined as double-barrier method (i.e., condom in combination with a diaphragm, 
cervical/vault cap, or intrauterine device).  Oral, injectable, implant, or patch forms of 
contraception are not permitted as potential drug-drug interactions between oral rucaparib and 
these forms of birth control has not yet been evaluated. 
Patients will be instructed to notify the investigator if pregnancy is discovered either during or 
within 6 months of completing treatment with study drug.   
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6.5 Waivers of Inclusion/Exclusion Criteria 
No waivers of these inclusion or exclusion criteria will be granted by the investigator and the 
sponsor or its designee for any patient enrolling into the study.   
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Randomization to study treatment must occur within 8 weeks following a patient’s last dose of 
platinum-based chemotherapy.  Study treatment must be initiated within 3 days of 
randomization. 
7.3 Preparation and Administration of Protocol-Specified Treatment 
The investigator or designee will be responsible for distributing study drug to all patients.  Study 
drug will be assigned by the IVRS/IWRS according to the patient’s randomization assignment.  
The system must be accessed at each dispensation in order to retrieve the bottle number 
appropriate to the patient’s treatment.  Study sites should follow local guidelines for the handling 
of oral cytotoxic drugs. 
All patients will ingest study drug twice a day.  Patients may take study drug on an empty 
stomach or with food (with a regular meal or within 30 minutes after a regular meal).  Each dose 
should be taken with at least 8 oz (240 mL) of room temperature water.  Tablets should be 
swallowed whole.   
Patients should take study drug doses as close to 12 hours apart as possible, preferably at the 
same times every day.  If a patient misses a dose (i.e., does not take it within 4 hours of the 
scheduled time), she should skip the missed dose and resume taking study drug with their next 
scheduled dose.  Missed or vomited doses should not be made up. 
A sufficient number of tablets will be provided to the patient to last until the next scheduled visit.  
Patients will be instructed to record daily doses taken or not taken in an electronic dosing diary, 
and will be instructed to bring their study drug tablets, all containers (empty, partially used, 
and/or unopened), and electronic dosing diary to the next scheduled visit for reconciliation by 
site personnel.  The electronic dosing diary is a Class 1 listed (i.e., approved) device. 
7.3.1 Dietary Restrictions 
All patients participating in the study should be instructed not to consume grapefruit, grapefruit 
juice, or any of the CYP1A2 or CYP3A4 inhibitors noted in Appendix F for 7 days prior to their 
first scheduled dose of oral rucaparib or placebo and for the duration of their participation on the 
study.   
7.4 Starting Dose and Dose Modifications of Protocol-Specified Treatment 
7.4.1 Starting Dose 
The starting dose in this study will be 600 mg rucaparib or matched placebo, bid. 
7.4.2 Dose Modification Criteria  
The dose of study drug should be reduced if any of the following are observed: 
• Grade 3 or 4 hematologic toxicity  
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• Grade 3 or 4 non-hematologic toxicity (except for alopecia, nausea, vomiting, or diarrhea 
adequately controlled with systemic antiemetic/antidiarrheal medication administered in 
standard doses according to the study center routines) 
• In addition, and at the discretion of the investigator, the dose of rucaparib may be held 
and/or reduced for Grade 2 toxicity not adequately controlled by concomitant 
medications and/or supportive care. 
Treatment with study drug should be held until the toxicity resolves to ≤CTCAE Grade 2.  Twice 
daily dosing may then be resumed at either the same dose or a lower dose, per investigator 
discretion.  If treatment is resumed at the same dose, and the patient experiences the same 
toxicity, the dose should be reduced following resolution of the event to ≤CTCAE Grade 2.  If 
the patient continues to experience toxicity, additional dose reduction steps are permitted.  If a 
patient continues to experience toxicity despite two dose reduction steps (i.e., to a dose of 360 
mg BID rucaparib or placebo), or if dosing with study drug is interrupted for >14 consecutive 
days due to toxicity, treatment should be discontinued, unless otherwise agreed between the 
investigator and the sponsor. 
Dose reduction steps are presented in Table 3. 
Dose re-escalation upon resolution of toxicity to ≤CTCAE Grade 1 is permitted upon agreement 
between the investigator and Sponsor. 
Table 3. Dose Reduction Steps 
Starting Dose 600 mg BID 
Dose Level -1 480 mg BID 
Dose Level -2 360 mg BID 
 
7.4.3 Criteria for Re-Treatment 
A new cycle of treatment may begin if: 
• ANC ≥1.0 x 109/L 
• Platelet count ≥100 x 109/L 
• Non-hematologic toxicities have returned to baseline or ≤CTCAE Grade 1 severity (or, at 
the investigator’s discretion, ≤CTCAE Grade 2 severity if not considered a safety risk for 
the patient) 
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7.5 Accountability of Protocol-Specified Treatment 
Study personnel will maintain accurate records of study drug receipt, dispensation, use, return, 
destruction, and reconciliation.  An IVRS/IWRS will be used to manage study drug inventory at 
all sites.  In order to function properly, and to ensure patients receive the correct study drug 
according to the treatment assigned at randomization, the system will require real-time entry of 
study drug receipt, dispensation, or destruction, etc. by study personnel at the study center. 
The site is responsible for the return or destruction of study drug as required.  Any study drug 
accidentally or deliberately destroyed must be accounted for.  All study drug containers must be 
accounted for prior to their destruction at the study center, according to institutional procedures 
for disposal of cytotoxic drugs.  Unused study drug containers should be destroyed on-site if 
possible.  Destruction of damaged or expired study drug at the site requires prior approval by the 
sponsor.  If destruction on site is not possible, supply should be returned to the drug depot.   
During the course of the study and at completion of the study, the number of study drug 
containers received, dispensed, returned, and destroyed must be reconciled.    
7.6 Blinding/Masking of Treatment 
Active and placebo tablets will be identical in appearance and supplied in identical containers.  
The medication labeling will ensure that no staff member or patient will be able to identify 
whether the tablets are placebo or contain active medication. 
Patients will take the equivalent number of active or placebo tablets according to the treatment 
assignment and scheduled dose. 
In the event of a medical emergency, an individual patient’s treatment assignment may be 
unblinded using IVRS/IWRS.  The module to unblind treatment assignment is accessible only to 
specific authorized study personnel.  AEs per se are not a reason to break the treatment code.  
Unblinding should only occur for medical emergencies that require explicit knowledge of the 
treatment administered in order to determine the next course of action.  The IVRS/IWRS vendor 
operates a 24-hour/365-day helpline as a back-up in the rare event the electronic system in 
unavailable when unblinding is required. 
The study will not be unblinded for overall safety evaluation. 
7.7 Treatment Compliance 
Documentation of dosing will be recorded in a study specific electronic dosing diary provided by 
the sponsor (or designee).  Study site personnel will review dosing information with the patient 
(or legally authorized representative) on scheduled clinic visit days, providing instructions 
regarding dose, dose frequency and the number of tablets to be taken for each dose.  Patients (or 
legally authorized representative) will be instructed to record dosing information for study drug 
taken at home in the electronic dosing diary and to bring the electronic dosing diary and all 
unused tablets with them to scheduled clinic visits.  A compliance check and tablet count will be 
performed by study personnel during clinic visits.  Every effort should be made to ensure 
patients complete the electronic dosing diary and return their study drug containers at the end of 
each cycle of treatment.  
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8 PRIOR AND CONCOMITANT THERAPIES 
Patients who have received prior treatment with a PARP inhibito,r including IV or oral 
rucaparib, are not eligible to participate in this study.  Patients having received prior treatment 
with iniparib are eligible. 
During the study, supportive care (e.g., antiemetics; analgesics for pain control) may be used at 
the investigator’s discretion and in accordance with institutional procedures.   
All procedures performed (e.g., thoracentesis, etc.) and medications used during the study must 
be documented on the eCRF.   
8.1 Anticancer or Experimental Therapy 
No other anticancer therapies (including chemotherapy, radiation, hormonal treatment, antibody 
or other immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, or other 
experimental drugs) of any kind will be permitted while the patient is participating in the study.  
Prior treatment with such therapies between the completion of platinum-based therapies and the 
initiation of maintenance treatment is not permitted. 
8.2 Hematopoietic Growth Factors and Blood Products 
Erythropoietin, darbepoetin alfa, and/or hematopoietic colony-stimulating factors for treatment 
of cytopenias should be administered according to institutional guidelines.  Transfusion 
thresholds for blood product support will be in accordance with institutional guidelines. 
8.3 CYP450 Isoenzyme Inhibitors, Inducers, and Substrates 
The plasma concentrations of rucaparib may be increased in the presence of co-administered 
potent CYP1A2 or CYP3A4 inhibitors.  Therefore, strong CYP1A2 and CYP3A4 inhibitors are 
excluded.  Moderate inhibitors are permitted at the discretion of the Investigator in the event a 
suitable alternative cannot be found.   
The plasma concentrations of rucaparib may be reduced in the presence of co-administered 
potent CYP1A2 or CYP3A4 inducers.  Therefore, strong CYP1A2 and CYP3A4 inducers are 
excluded.  Moderate inducers are permitted at the discretion of the Investigator in the event a 
suitable alternative cannot be found. 
In addition, CYP1A2 is known to be induced in chronic smokers.  Smokers are not excluded 
from the study; however, smoking status should be assessed and recorded in the source 
documents and eCRF.   
A list of CYP1A2 and CYP3A4 inhibition / induction medications to be avoided or used with 
caution is provided in Appendix F. 
Because rucaparib was shown to be a moderate inhibitor of CYP1A2, CYP2C8, CYP2C9, and 
CYP2C19 in vitro, caution should also be exercised in patients receiving rucaparib and requiring 
concomitant medication with CYP substrates that have a narrow therapeutic range, such as 
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phenytoin, S-mephenytoin, theophylline, tizanidine, and warfarin (Coumadin), as rucaparib doses 
≥480 mg might increase the plasma concentrations of these medication.  Other susceptible 
medications should be used with caution and plasma levels and/or pharmacodynamic surrogates 
monitored as appropriate. 
8.4 Bisphosphonates 
Bisphosphonates are permitted. 
8.5 Anticoagulants 
Caution should be exercised in patients receiving oral rucaparib and concomitant warfarin 
(Coumadin) as rucaparib showed a mixed inhibition of CYP2C9 in vitro.  If appropriate, low 
molecular weight heparin should be considered as an alternative treatment.  Patients taking 
warfarin should have international normalized ratio (INR) monitored regularly per standard 
clinical practice. 
8.6 Other Concomitant Medications 
Therapies considered necessary for the patient’s well-being may be given at the discretion of the 
investigator and should be documented on the eCRF.  Other concomitant medications, except for 
analgesics, chronic treatments for concomitant medical conditions, or agents required for 
life-threatening medical problems, should be avoided.  Herbal and complementary therapies 
should not be encouraged because of unknown side effects and potential drug interactions, but 
any taken by the patient should be documented appropriately on the eCRF. 
Because rucaparib is a P-gp inhibitor in vitro, caution should be exercised in patients receiving 
rucaparib and requiring concomitant treatment with digoxin.  Patients taking digoxin should have 
their digoxin levels monitored regularly according to standard institutional practices. 
Oral, injectable, implant, or patch forms of contraception are not permitted as potential drug-drug 
interactions between oral rucaparib and these forms of birth control has not yet been evaluated. 
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9 STUDY PROCEDURES 
9.1 Schedule of Assessments 
Table 4 summarizes the procedures and assessments to be performed for all patients. 
All procedures and assessments are to be completed within ±3 day of the scheduled time point. 
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Table 4. Schedule of Assessments 
l = Includes hemoglobin, hematocrit, WBC and differential (with ANC), and platelet count.  Blood will be analyzed by a central laboratory.  A duplicate sample may 
be collected and analyzed by the local laboratory for immediate treatment decisions. 
m = Includes total protein, albumin, creatinine or estimated GFR using the Cockcroft Gault formula, BUN or urea, total bilirubin, ALP, ALT, AST, total cholesterol, 
glucose, sodium, potassium, chloride, CO2, calcium, and phosphorus.  Blood will be analyzed by a central laboratory.  A duplicate sample may be collected and 
analyzed by the local laboratory for immediate treatment decisions. 
n = Women of childbearing potential must have a negative serum pregnancy test result <3 days prior to the first dose of study drug.  A serum or urine pregnancy test 
(investigator’s discretion) must be performed <3 days prior to Day 1 of every cycle during the treatment phase.  A serum pregnancy test must be performed at the 
treatment discontinuation visit.  All tests will be performed by a local laboratory. 
o = Includes dipstick for protein, glucose, blood, pH, and ketones.  If dipstick findings abnormal, perform microscopic evaluation to assess abnormal findings.  
Urinalysis to be repeated as clinically indicated.   
p = CA-125 measurement should be performed at Screening, on Cycle 1, Day 1, at the same time disease assessment scans are performed, and as clinically indicated.  
All CA-125 measurements will be performed by a central laboratory. 
q = Randomization to study treatment must occur within 8 weeks following a patient’s last dose of platinum-based chemotherapy.  Randomization will occur by a 
central randomization procedure using an IVRS/IWRS.  Patients will be stratified based on HRD classification (tBRCA, nbHRD or biomarker negative), interval 
between completion of penultimate platinum regimen and disease progression (6 to 12 or > 12 months) by radiologic assessment, and best response (RECIST CR, 
RECIST PR, or GCIG CA-125 response) to most recent platinum regimen.  All responses require that CA-125 be <ULN. 
r = AEs that occur after first dose through to 28 days after last dose of study drug will be recorded. 
s = Ongoing SAEs will be followed to resolution. 
t = PK samples to be collected on Day 15 of Cycle 1 (in morning or afternoon, after dose taken earlier in day), on Day 1 of Cycle 2 (prior to dosing), on Day 15 of 
Cycle 2 (in morning or afternoon, after dose taken earlier in day), and on Day 1 of Cycle 4 and Cycle 7 (prior to dosing).  At least one morning post-dose sample 
and one afternoon post-dose sample must be taken for each patient. 
u = Serum AAG sample to be collected on the same day as the PK sample.  Sample should be collected at the same time as the hematology and serum chemistry 
samples for central laboratory testing. 
v = An optional tumor biopsy may be collected from patients at time of disease progression.  Additional consent is required.  Refer to the Pathology Charter for 
detailed sample handling instructions. 
w = All patients discontinued from treatment, regardless of reason, should be followed for subsequent treatments, secondary malignancy, and survival every 12 weeks 
until death, loss to follow-up, withdrawal of consent from study, or closure of the study.  Follow-up can be performed via the telephone.  Diagnosis of any 
secondary malignancy requires appropriate documentation (i.e., laboratory and/or pathology reports). 
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9.2 Screening Phase 
Following written informed consent, and unless otherwise specified, the following assessments 
will be performed prior to randomization.  Assessments performed within the specified windows, 
but prior to patient signing informed consent, are acceptable only if confirmed to have been 
standard of care. 
Up to 90 days prior to randomization: 
• Medical history, including demographic information (birth date, race, gender, etc.) and 
smoking status, and oncology history, including date of diagnosis for ovarian, primary 
peritoneal, or fallopian tube cancer (and other malignancy, if applicable), prior treatments 
received, dates of administration, best response achieved, date of progression and how 
assessed, radiology reports, and gBRCA mutation status (if known) 
• FFPE archival tumor tissue sample.  Sufficient archival FFPE tumor tissue (enough for         
1 x 4 µm section for H&E and approximately 8 to 12 x 10 µm sections, or equivalent) for 
planned analyses should be provided.  Refer to the Pathology Charter for detailed sample 
handling instructions.  
o The most recently collected tumor tissue sample should be provided, if available.   
o Submission of a tumor block preferred; if sections are provided, these must all be 
from the same tumor sample. 
o Sample must be submitted to the central laboratory at least 3 weeks prior to 
planned start of treatment in order to enable stratification for randomization 
Up to 28 days prior to randomization: 
• PRO collected using the FOSI-18 and EQ-5D instruments 
• Physical examination by body system, including height and weight 
• Vital signs (blood pressure, pulse, and temperature) 
• 12-lead ECG 
• Prior and concomitant medications and any surgical procedures  
• Disease assessment/tumor scans: tumor assessments should consist of clinical examination 
and appropriate imaging techniques (including CT scans of the chest, abdomen, and pelvis 
with appropriate slice thickness per RECIST; other studies (magnetic resonance imaging 
[MRI], X-ray, positron emission tomography [PET], and ultrasound) may be performed if 
required.  The same methods used to detect lesions at baseline are to be used to follow 
lesions throughout the clinical study.  If a patient has known brain metastases, this disease 
should be evaluated at each required assessment. 
• ECOG performance status (Appendix D) 
Up to 14 days prior to randomization: 
• Hematology (hemoglobin, hematocrit, white blood cell [WBC] and differential [with ANC], 
and platelet count 
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• Serum chemistry (total protein, albumin, creatinine, or estimated GFR using the Cockcroft 
Gault formula, blood urea nitrogen [BUN] or urea, total bilirubin, ALP, ALT, AST, glucose, 
sodium, potassium, chloride, CO2, calcium, and phosphorus) and total cholesterol 
• Urinalysis performed on freshly voided clean sample (dipstick for protein, glucose, blood, 
pH, and ketones) ≤14 days prior to the first dose of study drug.  If dipstick findings are 
abnormal based on investigator judgment, then a microscopic evaluation will be performed to 
assess the abnormal findings 
• CA-125 measurement 
Up to 3 days prior to first dose of study drug: 
• Serum pregnancy test for women of childbearing potential 
9.3 Treatment Phase 
9.3.1 Day 1 of Cycles 1 and 2 
The following procedures/assessments will be completed before study drug is administered: 
• PRO using the FOSI-18 and EQ-5D instruments 
• Physical examination 
• Weight 
• Vital Signs 
• Concomitant medications and procedures 
• ECOG performance status (Appendix D) 
• Hematology  
• Serum chemistry 
• Urine or serum pregnancy for women of childbearing potential (Cycle 2 only) 
• CA-125 measurement 
• Blood sample for storage (Cycle 1 only) 
• Study drug dispensation 
• AE monitoring 
• Plasma PK sample (prior to first dose taken that day) (Cycle 2 only; see Section 9.5.1) 
• Serum sample for AAG sample (Cycle 2 only) 
Study drug will be dispensed to the patient in sufficient quantity to last until the next treatment 
cycle.  Patients will ingest study drug twice daily at about the same times every day, as close to 
12 hours apart as possible.  Each dose of study drug should be taken with at least 8 oz (240 mL) 
of room temperature water.  Patients may take study drug on an empty stomach or with food 
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(with a regular meal or within 30 minutes after a regular meal).  Patients will record dosing 
information in their electronic dosing diary. 
Patients will be instructed to refrain from taking their first dose of study drug at home on the day 
of their clinic visits because certain assessments must be performed prior to dosing. 
9.3.2 Day 15 of Cycles 1 and 2 
The following procedures will be completed: 
• Concomitant medications and procedures 
• Hematology 
• Serum chemistry 
• AE monitoring 
• Plasma PK sample (in morning or afternoon following the first dose of study drug taken this 
day; see Section 9.5.1) 
• Serum sample for AAG analysis (note: sample can be collected at the same time as 
hematology and serum chemistry)  
Patients will ingest study drug twice daily at about the same times every day, at close to 12 hours 
apart as possible.  Each dose of study drug should be taken with at least 8 oz (240 mL) of room 
temperature water.  Patients may take study drug on an empty stomach or with food (with a 
regular meal or within 30 minutes after a regular meal).  Patients will record dosing information 
in their electronic dosing diary. 
9.3.3 Day 1 of Cycles 3 and Beyond 
The following procedures will be completed before study drug is administered: 
• PRO using the FOSI-18 and EQ-5D instruments 
• Physical examination 
• Weight 
• Vital signs 
• Concomitant medications and procedures 
• Disease assessment/tumor scans at the end of every 3rd cycle of treatment (within 7 days 
prior to the start of the next cycle) 
• ECOG performance status (Appendix D) 
• Hematology 
• Serum chemistry 
• Urine or serum pregnancy for women of childbearing potential 
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• CA-125 measurement 
• AE monitoring 
• Plasma PK sampling (prior to the first dose of study drug taken this day; Cycles 4 and 7 only; 
see Section 9.5.1) 
• Serum sample for AAG analysis (note: sample can be collected at the same time as 
hematology and serum chemistry) (Cycles 4 and 7 only) 
Study drug will be dispensed to the patient in sufficient quantity to last until the next clinic visit.  
A single dose of study drug will be administered during the current clinic visit with at least 8 oz 
(240 mL) of room temperature water.  Patients may take study drug on an empty stomach or with 
food (with a regular meal or within 30 minutes after a regular meal).  Patient will record dosing 
information in their electronic dosing diary. 
Patients will continue dosing with study drug at home on an empty stomach or with food (with a 
regular meal or within 30 minutes after a regular meal), taking doses twice daily at about the 
same times every day.  Study drug should be taken with at least 8 oz (240 mL) of room 
temperature water.  Patients will record dosing information in their electronic dosing diary. 
9.4 Post-Treatment Phase 
9.4.1 Treatment Discontinuation 
Upon treatment discontinuation, regardless of the reason, patients will have a Treatment 
Discontinuation visit. The following procedures will be performed: 
• PRO using the FOSI-18 and EQ-5D instruments 
• Physical examination 
• Weight 
• Vital signs 
• 12-lead ECG 
• Concomitant medications and procedures 
• Tumor scans (using the same methodology as was used at screening) if reason for treatment 
discontinuation was other than disease progression based on radiologic assessment 
• ECOG performance status (Appendix D) 
• Hematology 
• Serum chemistry 
• Serum pregnancy test for women of childbearing potential 
• CA-125 measurement 
• AE monitoring 
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• Optional tumor tissue biopsy collection at time of disease progression/treatment 
discontinuation (requires additional consent).  Tumor tissue will be processed locally as 
FFPE tissue.  Refer to the Pathology Charter for detailed sample handling instructions. 
9.4.2 28-day Follow-up 
The following procedures will be performed for all patients at 28 (±3) days after the last dose of 
study drug: 
• PRO collected using the FOSI-18 and EQ-5D instruments 
• Disease assessment for patients who discontinued treatment for reason other than disease 
progression or death.  Tumor scans and CA-125 measurement should continue to be 
performed at 12 (±2) week intervals until disease progression, as assessed by the investigator.  
• CA-125 measurement 
• AE monitoring 
9.4.3 Long-term Follow-up 
• Disease assessment for patients who discontinued treatment for reason other than disease 
progression or death.  Tumor scans and CA-125 measurement should continue to be 
performed at 12 (±2) week intervals until disease progression, as assessed by the investigator.  
• Subsequent treatments, secondary malignancy monitoring, and overall survival information 
will be collected for all patients every 12 weeks until death, loss to follow-up, withdrawal of 
consent from study, or closure of the study.  Follow-up can be performed via the telephone.  
Diagnosis of any secondary malignancy requires appropriate documentation (i.e., laboratory 
and/or pathology reports). 
9.5 Methods of Data Collection 
Hematology, serum chemistry, urinalysis, and assays described below will be performed 
centrally.  Serum and/or urine pregnancy, if applicable, will be performed locally.  Please refer to 
the Pathology Charter and/or Laboratory Manual for details on collecting and processing all 
samples that will be sent to central/core laboratories. 
9.5.1 Pharmacokinetic Evaluations and AAG Measurement 
For all patients, 4 mL blood samples for rucaparib population PK analysis will be drawn at the 
following time points: 
• Day 15 of Cycle 1 (in morning or afternoon, after dose taken earlier in the day) 
• Day 1 of Cycle 2 (before first dose taken that day) 
• Day 15 of Cycle 2 (in morning or afternoon, after dose taken earlier in the day) 
• Day 1 of Cycle 4 and 7 (before first dose taken that day) 
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At least one morning post-dose sample and one afternoon post-dose sample must be taken for 
each patient. 
Serum samples for AAG analysis will be collected on the same day as PK samples. 
Central laboratories will be used for bioanalysis of plasma rucaparib levels and AAG 
measurement.  Please refer to the laboratory manual for details on collection and processing of 
blood PK samples. 
9.5.2 Biomarker Analysis – FFPE Tumor Tissue 
Archival tumor tissue must be located during the screening process and submitted to the central 
laboratory as soon as possible for determination of HRD status.  Archival tumor tissue is 
required for HRD stratification for randomization and for storage for potential bridging to a 
validated companion diagnostic test.    
9.5.3 Biomarker Analysis – Blood 
A blood sample collected prior to first dose of study drug will be stored.  Prior to final analysis, 
genomic DNA may be analyzed in an exploratory fashion in order to determine whether the 
mutation is germline or somatic.   
9.5.4 Safety Evaluations 
9.5.4.1 Adverse Event Assessment 
The investigator is responsible for assessing the safety of the patients and for compliance with 
the protocol to ensure study integrity.  Patients will be monitored for AEs during study 
participation, beginning after the first dose of study drug and until 28 days after the last dose of 
study drug.  Any ongoing serious adverse events (SAEs) will be followed until resolution or 
stabilization.  AEs and laboratory abnormalities will be graded according to the NCI CTCAE 
grading system (Version 4.0) and recorded on the eCRF. 
Complete details for monitoring AEs, including the definition of drug-related AEs, are provided 
in Section 10. 
9.5.4.2 Prior and concomitant medications 
Prior concomitant medications will be recorded during screening and concomitant medications 
will be collected from study entry until the Treatment Discontinuation visit. 
9.5.4.3 Clinical Laboratory Investigations 
With the exception of samples for serum pregnancy, all other samples collected will be analyzed 
by a central laboratory; a duplicate sample may be collected and analyzed by the local laboratory 
for immediate treatment decisions. The panels of laboratory tests to be performed are shown 
below: 
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Hematology:  Hemoglobin, hematocrit, WBC and differential (with ANC), and platelet count at 
screening (to be performed ≤14 days prior to the first dose of study drug), at clinic visits during 
treatment, and at the Treatment Discontinuation visit.  Hematology results must be reviewed by 
the investigator prior to the start of treatment with oral rucaparib or placebo. 
Clinical Chemistry:  Total protein, albumin, creatinine, or estimated GFR using the Cockcroft 
Gault formula, BUN or urea, total bilirubin, alkaline phosphatase (ALP), ALT, AST, total 
cholesterol, glucose, sodium, potassium, chloride, CO2, calcium, and phosphorus at screening (to 
be performed ≤14 days prior to the first dose of study drug), on Day 1 of each cycle during 
treatment, and at the Treatment Discontinuation visit.  Clinical chemistry results must be 
reviewed by the Investigator prior to the start of initial treatment with study drug. 
Urinalysis:  Performed on freshly voided clean sample by dipstick for protein, glucose, blood, 
pH, and ketones per the schedule of evaluations.  If dipstick findings are abnormal, then a 
microscopic evaluation will be performed to assess the abnormal findings.  Urinalysis will be 
performed at screening only, but may be repeated if clinically indicated.   
Laboratory reports will be reviewed by the investigator or delegated physician who will then 
comment on out-of-range parameters and assess clinical significance.  Clinically significant 
abnormalities and associated panel results, as well as results of any additional tests performed as 
follow-up to the abnormalities, will be documented on the eCRF as an AE per the criteria 
specified in Section 10.4. 
9.5.4.4 Vital Signs 
Vital signs will include blood pressure, pulse, and body temperature.  Vital signs will be 
performed at most study visits.   
9.5.4.5 12-Lead Electrocardiograms 
For all patients, 12-lead ECGs will be taken at screening (within 28 days prior to first rucaparib 
dose) and at Treatment Discontinuation 
The following will be measured or calculated: heart rate, PR, QRS, QT, QTc, and rhythm.  The 
investigator will analyze the ECGs locally and assess the results as normal or abnormal 
(clinically significant or not clinically significant). 
ECGs will be repeated as clinically indicated. 
9.5.4.6 Body Weight and Height 
Height will be measured during the Screening visit only.  Weight will be measured per 
institutional guidelines at Screening, on Day 1 of each cycle, and at the End of Treatment visit.   
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9.5.4.7 Physical Examinations 
Physical examinations will include an assessment of all the major body systems.  Physical 
examinations will be performed at screening (complete) and at most study visits (limited as 
appropriate).  
9.5.4.8 ECOG Performance Status 
ECOG performance status (Appendix D) will be assessed at screening, on Day 1 of each cycle, 
and at the Treatment Discontinuation visit.  ECOG performance status should be assessed by the 
same study personnel at each visit, if possible.  Care will be taken to accurately score 
performance status, especially during screening for study eligibility purposes.  Additional 
consideration should be given to borderline ECOG performance status to avoid enrolling patients 
with significant impairment. 
9.5.5 Efficacy Evaluations 
9.5.5.1 Disease Assessments 
Tumor assessment measurements will be performed at screening, at the end of every 12 weeks of 
treatment, at discontinuation of treatment, and as clinically indicated. 
Disease assessment will comprise clinical examination and appropriate imaging techniques (CT 
scans of the chest, abdomen, and pelvis with appropriate slice thickness per RECIST); other 
studies (MRI, X-ray, PET, and ultrasound) may be performed if required. If a patient has known 
brain metastases, this disease should be evaluated at each required assessment.  The same 
methods used to detect lesions at baseline are to be used to follow the same lesions throughout 
the clinical study.  Investigators should perform scans of the anatomical sites that, in their 
judgment, are appropriate to assess based on each patient’s tumor status.   
Tumor response will be interpreted using RECIST v1.1 (Appendix B).  Disease progression will 
only be determined by RECIST v1.1.  Patients with a CR at study entry will only be considered 
to have disease progression if a new lesion is identified.  Patients who meet GCIG CA-125 
criteria for disease progression should have a radiologic assessment and be assessed by RECIST.  
If the radiologic assessment does not confirm disease progression, patients should continue on 
treatment and continue to be assessed by RECIST per the protocol schedule of assessments. 
Patients who discontinued treatment for reason other than disease progression or death should 
continue to have tumor scans and CA-125 measurement performed at 12 (± 2) week intervals 
until disease progression, as assessed by the investigator. 
9.5.5.2 Tumor Markers 
CA-125 measurement will be performed at screening, on Day 1 of Cycle 1, at the end of every 
12 weeks of treatment (i.e. at the same time as disease assessment scans are performed), at 
discontinuation of treatment, and as clinically indicated.  All CA-125 measurements will be 
performed by a central laboratory. 
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9.5.6 Patient-Reported Outcomes 
PRO utilizing the FOSI-18 and EQ-5D instruments (see Appendix E) will be assessed at 
screening, on Day 1 of every treatment cycle, at treatment discontinuation, and at the 28-day 
follow-up visit.  Patients will complete the instruments on an electronic device before any other 
scheduled study procedures are performed and dosing occurs (if applicable).  The electronic 
device is a Class 1 listed (i.e. approved) device. 
9.5.7 Appropriateness of Measurements 
The assessments planned in the protocol are widely used and recognized as reliable, accurate and 
relevant. 
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10 ADVERSE EVENT MANAGEMENT 
10.1 Definition of an Adverse Event 
An AE is any untoward medical occurrence, including the exacerbation of a pre-existing 
condition, in a patient administered a pharmaceutical product.  The pharmaceutical product does 
not necessarily have a causal relationship with the AE.  Anticipated fluctuations of pre-existing 
conditions, including the disease under study, that do not represent a clinically significant 
exacerbation or worsening are not considered AEs. 
For the purposes of this study, disease progression of the patient’s tumor with new or worsening 
symptoms must be documented as an AE.  However, disease progression documented solely by 
radiographic evidence with no new or worsening symptoms will not require reporting as an AE.   
It is the responsibility of the investigator to document all AEs that occur during the study.  AEs 
should be elicited by asking the patient a nonleading question (e.g., “Have you experienced any 
new or changed symptoms since we last asked/since your last visit?”).  AEs will be reported on 
the AE eCRF.  Symptoms reported spontaneously by the patient during the physical examination 
will also be documented on the AE eCRF. 
10.2 Definition of a Serious Adverse Event 
An SAE is any untoward medical occurrence that occurs at any dose (including after informed 
consent is given and prior to dosing) that: 
• Results in death. 
• Is immediately life-threatening (i.e., the patient is at risk of death at the time of the event; it 
does not refer to an event that hypothetically might have caused death if it were more 
severe). 
• Requires in-patient hospitalization or prolongation of existing hospitalization. 
• Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions. 
• Results in a congenital anomaly or birth defect. 
• Is an important medical event based upon appropriate medical judgment; it may jeopardize 
the patient or may require intervention to prevent one of the other outcomes noted above. 
10.3 Exceptions to Serious Adverse Event Reporting 
The following are not considered SAEs and therefore are not required to be reported to the 
Sponsor: 
• Pre-planned or elective hospitalization, including social and/or convenience situations (e.g., 
respite care). 
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• Overdose of study drug or concomitant medication, unless there is an AE that meets SAE 
criteria (e.g., hospitalization), as a direct consequence of the overdose.  This should be 
entered as Overdose - followed by the appropriate AE/SAE term. 
• Progression of the patient’s underlying cancer (disease progression) documented solely on 
radiographic evidence with no new or worsening symptoms.  (Note: disease progression 
manifested with clinical signs/symptoms should be documented as an AE on the eCRF). 
10.4 Clinical Laboratory Assessments and Other Abnormal Assessments as Adverse 
Events and Serious Adverse Events 
It is the responsibility of the Investigator to assess the clinical significance of all abnormal 
laboratory values as defined by the list of reference ranges from the local laboratory.  In some 
cases, significant change in laboratory values within the normal range may require similar 
assessment. 
An abnormal value that is not already associated with an AE is to be recorded as an AE only if 
one of the following criteria is met: 
• It resulted in treatment modification (reduction of dose, interruption of dosing, or permanent 
discontinuation of study drug) 
• It required intervention / management 
• It is suggestive of organ toxicity 
• The Investigator considers it to be clinically significant 
10.5 Pregnancy 
If a patient becomes pregnant during the course of the study, study drug dosing should be held 
immediately. 
Pregnancy is not considered to be an AE or SAE; however, all pregnancies must be reported to 
the Sponsor using the Clinical Pregnancy Report form within the same timelines as for as SAE. 
All pregnancies should be followed through to outcome whenever possible.  Once the outcome 
of a pregnancy is known, the Clinical Pregnancy Outcome Report form should be completed and 
submitted to the Sponsor. 
10.6 Recording of Adverse Events and Serious Adverse Events 
All AEs, serious and non-serious, will be fully documented on the appropriate eCRF. For each 
AE, the Investigator must provide duration (start and end dates or ongoing), intensity, 
relationship to study drug, and indicate whether specific action or therapy was required. 
Any AE/SAE that occurs from the time informed consent is obtained until 28 days after last dose 
of study drug administration will be collected, documented and reported to the Sponsor by the 
Investigator according to the specific definitions and instructions detailed within this protocol, 
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whether dosing has occurred or not. After the 28-day window, only SAEs assessed as related to 
study drug should be reported.  If a patient is determined to be a screen failure, no further AEs/ 
SAEs are required to be reported once that determination has been made, with the exception of 
AEs/SAEs deemed related to a protocol-specified procedure. 
All SAEs, regardless of relationship to study drug, must be reported to the Sponsor/designee 
within 24 hours of the Investigator’s knowledge. This should be done by faxing or emailing the 
completed SAE report to the Sponsor/designee contact provided on the SAE report form. 
Investigators must follow patients with SAEs until the event has resolved or the condition has 
stabilized.  If the patient is lost to follow-up with an ongoing SAE, this should be captured 
accordingly on a follow-up SAE report.   
10.6.1 Intensity of Adverse Events 
Severity refers to the intensity of an AE.  The severity of each AE will be categorized using the 
NCI CTCAE, Version 4.0 (http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.0_2009-05-
29_QuickReference_8.5x11.pdf).48  
For any term that is not specifically listed in the CTCAE, intensity should be assigned a grade of 
1-5 using the following CTCAE guidelines:  
• Mild (Grade 1): mild or asymptomatic symptoms; clinical or diagnostic observations 
only; intervention not indicated 
• Moderate (Grade 2): limiting age-appropriate instrumental activities of daily living; 
minimal, local or noninvasive intervention indicated 
• Severe (Grade 3): limiting self-care activities of daily living; hospitalization indicated 
• Life threatening (Grade 4): life-threatening consequences; urgent intervention indicated 
• Fatal (Grade 5): results in death 
 
10.6.2 Causal Relationship of Adverse Events to Investigational Medicinal Products 
Medical judgment should be used to determine the cause of the AE considering all relevant 
factors such as but not limited to:  the disease under study, concurrent disease, concomitant 
medication, relevant history, pattern of the AE, temporal relationship to the study medication, 
dechallenge or rechallenge. 
Not Related 
To Study Drug 
An AE that is clearly due to extraneous causes (e.g., concurrent disease, concomitant 
medication, disease under study, etc.) 
An AE that does not follow a reasonable temporal sequence from administration of 
the study drug. 
An AE that does not reappear or worsen when study drug is restarted. 
An AE for which an alternative explanation is likely, but not clearly identifiable. 
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Related to 
Study Drug 
An AE that is difficult to assign to alternative causes. 
An AE that follows a strong or reasonable temporal sequence from administration of 
study drug. 
An AE that could not be reasonably explained by the patient’s clinical state, 
concurrent disease, or other concomitant therapy administered to the patient. 
An AE that is confirmed with a positive rechallenge or supporting laboratory data. 
  
10.6.3 Outcome  
The investigator will record the outcome for each AE according to the following criteria: 
Outcome 
• Recovered/Resolved 
• Recovered/Resolved with sequelae 
• Ongoing 
• Death 
• Unknown/Lost to follow-up 
10.7 Regulatory Aspects of Adverse Event Reporting 
SAEs and pregnancy must be reported to the safety contract research organization (CRO) within 
24 hours of knowledge of the event, according to the procedures below.  It is important that the 
investigator provide an assessment of relationship of the SAE to study treatment at the time of 
the initial report.  The SAE Report form must be used for reporting SAEs, the Clinical Pregnancy 
Report form must be used for reporting pregnancies, and the Clinical Pregnancy Outcome Report 
form must be used for reporting the outcome of any pregnancy. 
All SAEs, irrespective of relationship to study treatment, and pregnancies must be reported 
within 24 hours of knowledge of the event by facsimile (fax) or email to: 
PRA International 
 
  
Region(s) Fax Number Email Address 
North America:           
All Other Regions:       
   
Additional information should be reported via email or fax to the appropriate contact above.  
Further details on SAE/pregnancy reporting can be found in the investigator’s file.  
For urgent SAE-related questions, or when guidance is required from a safety specialist, 
investigational sites should call the following telephone numbers: 
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PRA International 
Region(s) Telephone Number 
North America  
All Other Regions:  
 
Clovis Oncology, Inc. (Clovis Oncology), or its designee is responsible for submitting reports of 
AEs associated with the use of the drug that are both serious and unexpected to FDA, according 
to 21 Code of Federal Regulations (CFR) 312.32, to the European regulatory authorities 
according to the European Commission Clinical Trials Directive (2001/20/EC); and to other 
regulatory authorities, according to national law and/or local regulations.  All investigators 
participating in ongoing clinical studies with the study medication will receive copies of these 
reports for prompt submission to their IRB or IEC.  In accordance with the European 
Commission Clinical Trials Directive (2001/20/EC), Clovis Oncology or its designee will notify 
the relevant ethics committees in concerned member states of applicable suspected unexpected 
serious adverse reactions (SUSARs) as individual notifications or through periodic line listings. 
Clovis Oncology or its designee will submit all safety updates and periodic reports to the 
regulatory authorities as required by applicable regulatory requirements. 
10.8 Independent Data Monitoring Committee 
No formal efficacy interim analyses are planned. 
An Independent Data Monitoring Committee (IDMC) will be established to review safety and 
efficacy data in compliance with a prospective charter.  The IDMC will be comprised of medical 
oncologists with experience in treating women with ovarian cancer and a statistician, all of 
whom are not otherwise involved in the study as investigators.  The IDMC responsibilities, 
authorities, and procedures will be documented in the IDMC charter, which will be endorsed and 
signed by the IDMC prior to the first data review meeting. 
The IDMC will: 
• Review safety and efficacy of rucaparib compared with placebo to ensure the study is 
beneficial to patients 
• Ensure the study is conducted in a high quality manner 
• Monitor the size of the tBRCA subgroup and the known gBRCA group 
Following data review, the IDMC will recommend continuation, revision, or termination of the 
study and/or continuing or halting enrollment into a particular subgroup.  The IDMC will meet at 
least semi-annually after sufficient data has been collected.    The IDMC chairperson may 
convene formal IDMC meeting if there are safety concerns.  The Sponsor can also request an 
IDMC review of safety data. 
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11 STATISTICAL METHODS 
11.1 Analysis Populations 
The following analysis populations are defined for the study: 
Safety Table Population – The safety population will consist of all patients who received at 
least one dose of protocol-specified treatment. 
Intent-to-treat (ITT) Population − The ITT population will consist of all randomized patients. 
Response Evaluable Population − The response evaluable population will consist of all patients 
evaluable for response by RECIST (Appendix B).  Patients evaluable for a RECIST response 
must have at least one measureable target lesion at baseline and at least one post-baseline tumor 
assessment. 
11.2 Statistical Methods 
11.2.1 General Considerations 
Variables registered on a continuous scale will be presented using the following descriptive 
statistics: N, mean, standard deviation, median, minimum and maximum.  Continuous variables 
may also be presented using frequencies and percentages among appropriate categorizations.  
Categorical variables will be presented using frequencies and percentages.  The Kaplan-Meier 
methodology will be used to summarize time-to-event variables.  The number of patients with 
events and the number of censored patients will also be presented.  The stratified logrank test 
will be used to compare the time-to-event distributions between the randomized treatment 
groups.  In addition, the Cox proportional hazards model will be used to estimate the HR 
between the randomized treatment groups. 
The primary and key secondary endpoints will be tested among the tBRCA and all HRD 
subgroups, and all randomized patients, using an ordered step-down multiple comparisons 
procedure.  Investigator determined PFS (invPFS) in the tBRCA subgroup will be tested first at a 
one-sided 0.025 significance level.  If invPFS in the tBRCA subgroup is statistically significant 
then irrPFS in the tBRCA subgroup will be tested at a one-sided 0.025 significance level and if 
significant, invPFS and irrPFS will be tested in the all HRD subgroup followed by invPFS and 
irrPFS in all randomized patients.  Continuing in an ordered step-down manner, the PRO of 
disease symptoms utilizing the FOSI-18 DRS-P subscale will be tested at the one-sided 0.025 
significance level in the tBRCA, all HRD, and all randomized patients subgroups and then for 
the remaining key secondary endpoints of PRO utilizing the FOSI-18 total score and OS.  Once 
statistical significance is not achieved for one test the statistical significance will not be declared 
for all subsequent analyses in the ordered step-down procedure.  
All data will be used to their maximum possible extent but without any imputations for missing 
data. 
All statistical analyses will be conducted with the SAS® System, version 9.1 or higher.    
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Unless otherwise specified, baseline is defined as the last measurement on or prior to the first 
day of study drug administration. 
11.2.2 Patient Disposition  
Patient disposition (analysis population allocation, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency counts, and the corresponding 
percentages. 
11.2.3 Baseline Characteristics  
All demographic and baseline characteristics will be summarized for the safety population. 
The following variables will be summarized with frequency tabulations: 
• Time since diagnosis of HGSOC (months):  > 12-24, > 24 
• Baseline laboratory parameters:  graded based on CTCAE 
• HRD status for stratification at randomization:  tBRCA, nbHRD, biomarker negative 
• Interval between completion of penultimate platinum regimen and disease progression (6 
to 12 months of >12 months) by radiologic assessment 
• Best response to most recent platinum-based regimen (CR [defined as complete 
radiologic response by RECIST with normalization of CA-125] or PR [defined as partial 
radiologic response by RECIST and/or a GCIG CA-125 response]).  All responses 
require that CA-125 be <ULN. 
Descriptive statistics may also be used to summarize the continuous variables.   
11.2.4 Efficacy Analyses  
All efficacy evaluations will be conducted using the ITT population. 
11.2.4.1 Primary Efficacy Analysis 
The primary efficacy endpoint for the study is invPFS by RECIST.  Investigator-determined PFS 
is defined as the time from randomization to disease progression, according to RECIST v1.1 
criteria (Appendix B), as assessed by the investigator, or death due to any cause, in molecularly 
defined subgroups.  The stratification factors included in the primary analysis of invPFS will be 
as follows: 
• HRD classification (tBRCA or nbHRD or biomarker negative) 
• Interval between completion of penultimate platinum regimen and disease progression (6 
to 12 months or >12 months) by radiologic assessment 
• Best response to the most recent platinum-based regimen (CR [defined as complete 
radiologic response by RECIST with normalization of CA-125] or PR [defined as partial 
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response by RECIST and/or a GCIG CA-125 response]).  All responses required that CA-
125 be <ULN. 
Tumor HRD status by the FCTA will be determined after randomization, but before the final 
efficacy analysis, so that the primary endpoint (PFS in molecularly defined subgroups) can be 
assessed prospectively. 
11.2.4.2 Secondary Efficacy Analyses 
Secondary efficacy endpoints are: 
• Disease progression according to RECIST v1.1, as assessed by IRR, or death from any 
cause (irrPFS), in molecularly defined subgroups 
• Time to a 4-point decrease in the FOSI-18 DSR−P subscale 
• Time to an 8-point decrease in the FOSI-18 total score 
• OS 
irrPFS 
PFS for secondary efficacy analysis is defined as the time from randomization to disease 
progression, according to RECIST v1.1 criteria as assessed by IRR, or death due to any cause, 
whichever occurs first.   
PRO of disease-related symptoms as measured by the FOSI-18 DRS−P subscale 
The time to an event in PRO of worsening of disease symptoms will be defined as the time from 
randomization to a 4-point reduction in the FOSI-18 DRS-P subscale.  Patients without a 4-point 
reduction will be censored on the date of their last PRO evaluation.   
PRO as measured by the total score of the FOSI-18 
An event in worsening of PRO utilizing the complete FOSI-18 instrument will be defined as the 
time from randomization to an 8-point reduction in the total score.  Patients without an 8-point 
reduction will be censored on the date of their last PRO evaluation. 
Overall survival 
Overall survival (OS) is defined as the number of days from the date of randomization to the date 
of death (due to any cause).  Patients without a known date of death will be censored on the date 
the patient was last known to be alive. 
11.2.5 Safety Analyses  
Safety endpoints are incidence of AEs, clinical laboratory abnormalities, and dose modifications. 
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Data from all patients who receive at least one dose of study drug will be included in the safety 
analyses.  AEs, clinical laboratory information, vital signs, ECG results, ECOG performance 
status, body weight, and concomitant medications/procedures will be tabulated and summarized. 
11.2.5.1 Adverse Events 
AEs will be classified using the Medical Dictionary for Drug Regulatory Activities (MedDRA) 
classification system.  The severity of the toxicities will be graded according to the NCI CTCAE 
whenever possible. Only treatment-emergent adverse events (TEAEs) will be collected: TEAEs 
are defined as AEs with onset date on or after the date of first dose of study medication until the 
date of the last study medication dose plus 28 days.   
The number and percentage of patients who experienced TEAEs for each system organ class 
(SOC) and preferred term will be presented.  Multiple instances of the TEAE in each SOC and 
multiple occurrences of the same preferred term are counted only once per patient.  The number 
and percentage of patients with at least one TEAE will also be summarized.   
Separate tables will be presented as follows: 
• All TEAEs 
• TEAEs by CTCAE grade 
• Grade 3 or greater TEAEs 
• Serious TEAEs 
• TEAEs with an outcome of death 
• TEAEs leading to discontinuation of study medication 
• TEAEs resulting in interruption/delay of study medication 
• TEAEs resulting in dose reduction of study medication 
If a patient experiences multiple occurrences of the same AE with different toxicity grades, the 
patient will be counted once for the maximum (most severe) toxicity grade.  AEs with a missing 
toxicity grade will be presented in the summary table with a toxicity grade of “Missing.”  For 
each toxicity grade, the number and percentage of patients with at least one TEAE of the given 
grade will be summarized.    
11.2.5.2 Clinical Laboratory Evaluations 
Clinical laboratory evaluations include the continuous variables for hematology, serum 
chemistry, and urinalysis.  The laboratory values will be presented in SI units.  The on-treatment 
period will be defined as the time from the first dose of study drug to 28 days after the last dose 
of study drug.  Laboratory values collected during the on-treatment period will be included in the 
summary tables.  The laboratory values collected after the on-treatment period will only be 
presented in the data listings.   
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The summary of laboratory data will include shift tables based on CTCAE for shifts in grade 
from baseline to maximum, minimum and last value during the on-treatment period.   
Supporting laboratory data including normal ranges and abnormal laboratory flags will be 
provided using by-patient listings.  Separate listings will be produced for clinically significant 
laboratory abnormalities (i.e., those that meet Grade 3 or 4 criteria according to CTCAE). 
11.2.5.3 Vital Sign Measurements 
The on-treatment period will be defined as the time from the first dose of study drug to 28 days 
after the last dose of study drug.  Vital sign measurements collected during the on-treatment 
period will be included in the summary tables.  The vital sign measurements collected after the 
on-treatment period will only be presented in the data listings.   
The summary of vital sign data will include descriptive statistics (N, mean, SD, minimum, 
median, third quartile and maximum) of the maximum, minimum and last value during the on-
treatment period.  Summaries using descriptive statistics (N, mean, SD, minimum, median and 
maximum) of the change from baseline to the maximum, minimum, and last value during the on-
treatment period will also be given.   
11.2.6 Population PK Analysis 
The PK endpoint is individual model parameter estimates of rucaparib and covariates 
identification. 
A specific population PK data analysis plan will be developed that will outline the detailed 
approach to data handling, model development and diagnostics, individual model parameter 
estimation, exploration of covariate effects, and final model evaluation techniques. 
11.2.7 Exploratory Analyses 
The endpoints for the exploratory analyses are: 
• Change from baseline in CA-125 measurements by the central laboratory 
• PFS2 (PFS on the subsequent line of treatment) defined as the time from randomization to 
the second event of disease progression or death, as assessed by the investigator 
• ORR per RECIST v1.1, as assessed by both investigator and IRR, in patients with 
measureable disease at study entry 
• DOR per RECIST Version 1.1, as assessed by both investigator and IRR 
• PRO as measured by the EQ-5D total score 
• Rucaparib PK, invPFS, irrPFS, CA-125, AEs, clinical laboratory abnormalities, and dose 
modifications 
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11.2.7.1 Change from Baseline in CA-125 
Analyses of changes and/or percent changes from baseline will be analyzed for each scheduled 
pos-tbaseline visit and for the final visit for the CA-125 measurements from the central 
laboratory.  Patients that do not have both a baseline measurement and at least one post-baseline 
measurement will not be included. 
At a given visit, the change and/or percent change from baseline will be compared between the 
randomized treatment groups using an ANCOVA using the treatment as a categorical factor and 
baseline measurement for the parameter as a continuous covariate. 
The association between the change from baseline to the end of Cycle 2 in CA-125 
measurements and invPFS will be evaluated using a Cox proportional hazards model.  A 
measure of CA-125 kinetics such as the rate of change from baseline in CA-125 may also be 
associated with invPFS using a Cox model. 
11.2.7.2 Progression Free Survival 2 (PFS2) 
The second event of PFS, PFS2, is defined as the time from randomization to the second event of 
disease progression as assessed by the investigator, or death due to any cause.  The first event of 
disease progression will be captured as the primary endpoint in this study and thus the second 
event will be the next event of disease progression as assessed by the investigator.  This second 
event of PFS may be a documented event per RECIST guidelines or may be an event of 
symptomatic progression.   
11.2.7.3 Overall Response Rate 
ORR is defined as a best response of CR or PR using the RECIST v1.1 criteria (Appendix B), as 
assessed by both investigator and IRR, in patients with measurable disease at study entry.  ORR 
will be summarized with frequencies and percentages in the safety population.  Patients who are 
not evaluable for a RECIST response will be considered to have experienced disease 
progression.    
11.2.7.4 Duration of Response 
The DOR is measured from the time measurement criteria are met for CR/PR per RECIST v1.1 
criteria (Appendix B), as assessed by both investigator and IRR, until the first date that recurrent 
or PD is objectively documented.  The DOR will be summarized with descriptive statistics.  
Only patients with a response will be included in the summary. 
11.2.7.5 Patient Reported Outcome EQ-5D 
Analyses of changes and/or percent changes from baseline will be analyzed for each scheduled 
postbaseline visit and for the final visit for the EQ-5D instrument and the EQ VAS.  Patients that 
do not have both a baseline measurement and at least one postbaseline measurement will not be 
included. 
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At a given visit, the change and/or percent change from baseline will be compared between the 
randomized treatment groups using an ANCOVA using the treatment as a categorical factor and 
baseline measurement for the parameter as a continuous covariate. 
11.2.7.6 Relationship between Rucaparib Exposure and Efficacy and Safety 
The primary endpoint of invPFS will be presented for subgroups of patients defined by levels of 
rucaparib exposure.  These analyses are exploratory in nature so the definition of relevant 
subgroups may be data-driven.   
11.3 Interim Analysis 
No formal interim efficacy analyses will be performed. 
11.4 Sample Size Considerations 
The total enrollment planned is 540 patients.  A minimum of 180 and a maximum of 200 patients 
with a deleterious tBRCA mutation will be enrolled.  Enrollment of patients with a known 
deleterious gBRCA mutation documented in their medical record will not exceed 150.  There is 
no minimum number of patients required for each of the nbHRD and biomarker negative 
subgroups; however, no more than 360 total patients will be randomized for stratification into 
these subgroups combined.  Prior to final efficacy analysis, HRD classification will be 
determined by the FCTA, which will evaluate homologous recombination gene mutations and/or 
extent of genomic scarring in tumor tissue. 
Table 5 below provides estimated sample sizes and power calculations. 
 
Table 5.          Estimated Sample Sizes and Power Calculations 
Group Hazard 
Ratio 
Cumulative 
N  
Minimum 
Number of 
Events 
(70%) 
Median PFS   
Placebo vs 
Rucaparib 
(months) 
Power One-
sided 
Alpha 
BRCA HRD  0.50 180 126 6 vs 12 90% 0.025 
All HRD 
(BRCA + 
nbHRD) 
0.60 300 210 6 vs 10 90% 0.025 
ITT Population 
(BRCA + 
nbHRD + 
Biomarker 
Negative) 
0.70 540 378 6 vs 8.5 90% 0.025 
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The study will end after 70% of the patients in the tBRCA subgroup have an observed event of 
investigator-determined disease progression or death.  If the minimum number of tBRCA 
patients are enrolled, then the study will end following the 126th event of investigator-determined 
disease progression or death.  Similarly, if the maximum number of tBRCA patients are enrolled, 
then the study will end following the 140th event of investigator-determined disease progression 
or death.  The IDMC will inform the Sponsor when the required number of PFS events have 
been observed in order to ensure the Sponsor remains blinded to which patients are in the tBRCA 
subgroup.  If the nbHRD and/or biomarker negative subgroups have observed events of invPFS 
in fewer than 60% of the patients, the IDMC may recommend that the study continue for up to 6 
more months if it is likely that the nbHRD and biomarker negative subgroups will observe 
enough additional events of PFS to reach 60%.  
Following the collection of the required number of PFS events, the outstanding queries for all 
visits and events prior to the data cutoff date will be resolved and the database will be locked 
before the blind break and subsequent primary analysis.    
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12 PATIENT DISPOSITION 
12.1 Removal of patients from therapy or assessment 
A patient must be discontinued from treatment with study drug if any of the following apply: 
• Consent withdrawal at the patient’s own request or at the request of their legally 
authorized representative 
• Progression of patient’s underlying disease by RECIST as assessed by the investigator 
• Any event, adverse or otherwise, that, in the opinion of the investigator, would pose an 
unacceptable safety risk to the patient 
• An intercurrent illness that, in the opinion of the investigator, would affect assessments of 
the clinical status to a significant degree and requires discontinuation of therapy 
The sponsor may discontinue the trial early for any of the reasons noted in Section 13.6. 
12.2 Procedures for discontinuation 
The sponsor (or designee) should be notified of all study terminations as soon as possible.  The 
date and reason for cessation of study drug must be documented in the eCRF and source 
documents.  To the extent possible, end-of-study procedures should be performed on all patients 
who receive study drug.  The Treatment Discontinuation visit should occur 28 (±3) days 
following the last dose of study drug.  Patients will be followed for 28 days after the last dose of 
study drug for safety; those with ongoing SAEs will be followed until either resolution or 
stabilization has been determined. 
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13 STUDY ADMINISTRATION 
13.1 Regulatory and Ethical Considerations 
This study will be conducted in compliance with the protocol; Good Clinical Practices (GCPs), 
including International Conference on Harmonization (ICH) Technical Requirements for 
Registration of Pharmaceuticals for Human Use Guidelines; Food and Drug Administration 
(FDA) regulatory requirements; and in accordance with the ethical principles of the Declaration 
of Helsinki.   
13.1.1 Regulatory Authority Approvals 
The sponsor or designee will submit the study protocol plus all relevant study documents to 
concerned regulatory agencies for approval prior to the study start.  No patient will be admitted 
to the study until appropriate regulatory approval of the study protocol has been received. 
Each investigator must complete a Form FDA 1572 (or equivalent) and provide the completed 
form according to written instructions to the sponsor (or designee).  Each investigator must 
submit to the sponsor (or designee) financial disclosure information according to national law 
and/or local regulations. 
U.S.-generated data will be handled in accordance with the Health Information Portability and 
Accountability Act (HIPAA).  The trial will be registered at www.clinicaltrials.gov, EudraCT, 
and other applicable trial registry systems as appropriate. 
13.1.2 Independent Ethics Committee/Institutional Review Board 
This protocol and any material to be provided to the patient (such as advertisements, patient 
information sheets, drug dosing diaries, or descriptions of the study used to obtain informed 
consent) will be submitted by the investigator to an IEC/IRB.  This also applies to protocol 
amendments.   
Clovis Oncology will supply relevant data for the investigator to submit the study protocol and 
additional study documents to the IEC/IRB.  The principal investigator will submit the study 
protocol for review and approval by an IEC/IRB, according to national law and/or local 
regulations, and will provide the IEC/IRB with all appropriate materials.   
Verification of the IEC’s/IRB’s unconditional approval of the study protocol and the written 
informed consent form will be transmitted to Clovis Oncology.  This approval must refer to the 
study by exact study protocol title and number, identify the documents reviewed, and state the 
date of the review. 
No patient will be admitted to the study until appropriate IEC/IRB approval of the study protocol 
has been received, the investigator has obtained the signed and dated informed consent form, and 
the sponsor is notified.   
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The principal investigator will submit appropriate reports on the progress of the study to the 
IEC/IRB at least annually in accordance with applicable national law and/or local regulations 
and in agreement with the policy established by the IEC/IRB and sponsor.   
The IEC/IRB must be informed by the principal investigator of all subsequent study protocol 
amendments and of SAEs or SUSARs occurring during the study that are likely to affect the 
safety of the patients or the conduct of the study. 
13.2 Confidentiality of Information 
The investigator must assure that patients’ anonymity is strictly maintained and that their 
identities are protected from unauthorized parties.  Only patient initials and an identification code 
(i.e., not names) should be recorded on any form submitted to the sponsor and the IRB.  The 
investigator must record all screened and enrolled patients in the eCRF.  The investigator must 
have a list where the identity of all treated patients can be found. 
The investigator agrees that all information received from Clovis Oncology, including, but not 
limited to, the Investigator’s Brochure, this protocol, eCRFs, the protocol-specified treatment, 
and any other study information, remain the sole and exclusive property of the sponsor during 
the conduct of the study and thereafter.  This information is not to be disclosed to any third party 
(except employees or agents directly involved in the conduct of the study or as required by law) 
without prior written consent from the sponsor.  The investigator further agrees to take all 
reasonable precautions to prevent the disclosure by any employee or agent of the study center to 
any third party or otherwise into the public domain. 
13.3 Patient Informed Consent 
All information about the clinical study, including the patient information and the informed 
consent form, is prepared and used for the protection of the human rights of the patient according 
to ICH GCP guidelines and the Declaration of Helsinki. 
It is the responsibility of the investigator to obtain signed informed consent forms from each 
patient participating in this study after adequate explanation of the aims, methods, objectives, 
and potential hazards of the study and prior to undertaking any study-related procedures.   
The informed consent form, prepared by the investigator with the assistance of the sponsor, must 
be approved along with the study protocol by the IEC/IRB and be acceptable to the sponsor. 
The patient must be provided with the patient information and informed consent form consistent 
with the study protocol version used and approved by the relevant IEC/IRB.  The informed 
consent form must be in a language fully comprehensible to the prospective patient.  Patients 
(and/or relatives, guardians, or legal representatives, if necessary) must be given sufficient time 
and opportunity to inquire about the details of the study and to discuss and decide on their 
participation in the study with the investigator concerned.  The patient and the person explaining 
about the study and with whom they discuss the informed consent will sign and date the 
informed consent form.  A copy of the signed informed consent form will be retained by the 
patient and the original will be filed in the investigator file unless otherwise agreed.   
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13.4 Study Monitoring 
On behalf of Clovis Oncology, a CRO monitor will contact and visit the investigator at the study 
center prior to the entry of the first patient (unless Clovis or the CRO has worked with the center 
recently in which case this initial visit maybe waived) and at predetermined appropriate intervals 
during the study until after the last patient is completed.  The monitor will also perform a study 
closure visit.  Visits may also be conducted by Clovis Oncology personnel. 
In accordance with ICH GCP guidelines, the investigator must ensure provision of sufficient 
time, reasonable space, and adequate qualified personnel for the monitoring visits.  The visits are 
for the purpose of verifying adherence to the study protocol and the completeness, consistency, 
and accuracy of data entered on the eCRF and other documents.   
The investigator will make all source data (i.e., the various study records, the eCRFs, laboratory 
test reports, other patient records, drug accountability forms, and other pertinent data) available 
for the monitor and allow access to them throughout the entire study period.  Monitoring is done 
by comparing the relevant site records of the patients with the entries on the eCRF (i.e., source 
data verification).  It is the monitor’s responsibility to verify the adherence to the study protocol 
and the completeness, consistency, and accuracy of the data recorded on the eCRFs.   
By agreeing to participate in the study, the investigator agrees to cooperate with the monitor to 
ensure that any problems detected in the course of the monitoring visits are resolved.  Contact 
information for the study monitor is located in the investigator file.  Representatives from Clovis 
Oncology may also contact and visit the investigators and monitor data during the study.   
13.5 Case Report Form 
The data will be collected using an electronic data capture (EDC) system by remote data entry on 
eCRFs.  Sites will receive training on the EDC system.  All users will be supplied with unique 
login credentials. 
Prior to study start, the investigator will prepare a list showing the signature and handwritten 
initials of all individuals authorized to make or change entries on eCRFs.  This “study center 
personnel and delegation list” must be kept current throughout the study. 
For each patient enrolled, an eCRF should be completed and reviewed by the principal 
investigator or co-investigator within a reasonable time period (<2 weeks) after data collection.  
This also applies to records for those patients who fail to complete the study.  If a patient 
withdraws from the study, the reason must be noted on the eCRF.  If a patient is withdrawn from 
the study because of a treatment-limiting AE, thorough efforts should be made to clearly 
document the outcome. 
All laboratory data and investigator observations on the results and any other clinically 
significant test results must be documented on eCRFs. 
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Full information regarding electronic data capture and completing eCRFs is included in the 
investigator files.  All questions or comments related to electronic capture should be directed to 
the assigned monitor. 
13.6 Study Termination and Site Closure 
Both the sponsor and the investigator reserve the right to terminate the study at any time.  Should 
this be necessary, both parties will arrange discontinuation procedures.  In terminating the study, 
Clovis Oncology and the investigator will assure that adequate consideration is given to the 
protection of the patients’ interests. 
Clovis Oncology reserves the right to discontinue the study at any time for medical or 
administrative reasons.  When feasible, a 30 day written notification will be given. 
The entire study will be stopped if: 
• The protocol-specified treatment is considered too toxic to continue the study 
• Evidence has emerged that, in the opinion of the sponsor or the investigator(s), makes the 
continuation of the study unnecessary or unethical 
• The stated objectives of the study are achieved 
• The sponsor discontinues the development of oral rucaparib 
Regardless of the reason for termination, all data available for the patient at the time of 
discontinuation of follow-up must be recorded on the eCRF.  All reasons for discontinuation of 
treatment must be documented.  In terminating the study, the investigator will ensure that 
adequate consideration is given to the protection of the patients’ interests. 
13.7 Modification of the Study Protocol 
Protocol amendments, except when necessary to eliminate an immediate hazard to patients, must 
be made only with the prior approval of Clovis Oncology.  Agreement from the investigator must 
be obtained for all protocol amendments and amendments to the informed consent document.  
The IEC/IRB must be informed of all amendments and give approval prior to their 
implementation.  The sponsor will submit any study protocol amendments to the concerned 
regulatory authorities for approval and keep the investigator(s) updated as detailed in the ICH 
GCP guidelines. 
13.8 Retention of Study Documents 
The study site will maintain a study file, which should contain, at minimum, the Investigator’s 
Brochure, the protocol and any amendments, drug accountability records, correspondence with 
the IEC/IRB and Clovis Oncology, and other study-related documents. 
The investigator agrees to keep records and those documents that include (but are not limited to) 
the identification of all participating patients, medical records, study-specific source documents, 
source worksheets, all original signed and dated informed consent forms, copies of all eCRFs, 
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query responses, and detailed records of drug disposition to enable evaluations or audits from 
regulatory authorities and Clovis Oncology or its designees. 
The investigator shall retain records required to be maintained for a period of 5 years following 
the date a marketing application in an ICH region is approved for the drug for the indication for 
which it is being investigated or, if no application is to be filed or if the application is not 
approved for such indication, until at least 5 years after the investigation is discontinued.  
However, these documents should be retained for a longer period if required by the applicable 
regulatory requirement(s) or if needed by Clovis Oncology.  In addition, the investigator must 
make provision for the patients’ medical records to be kept for the same period of time. 
No data should be destroyed without the agreement of Clovis Oncology.  Should the investigator 
wish to assign the study records to another party or move them to another location, Clovis 
Oncology must be notified in writing of the new responsible person and/or the new location.  
Clovis Oncology will inform the investigator, in writing, when the trial-related records are no 
longer needed. 
Patients’ medical records and other original data will be archived in accordance with the 
archiving regulations or facilities of the investigational site. 
13.9 Clinical Study Report 
A clinical study report will be prepared under the responsibility and supervision of Clovis 
Oncology and signed by the sponsor’s chief medical officer, thereby indicating their agreement 
with the analyses, results, and conclusions of the clinical study report.   
13.10 Study Publication 
The results of this study will be published and/or presented at scientific meetings in a timely 
manner.  Any formal publication of study results will be a collaborative effort between the 
sponsor and the investigator(s). All data generated from this study are the property of Clovis 
Oncology and shall be held in strict confidence along with all information furnished by Clovis 
Oncology.  Independent analysis and/or publication of these data by the investigator(s) or any 
member of their staff are not permitted without the prior written consent of Clovis Oncology.  
Written permission to the investigator will be contingent on the review by Clovis Oncology of 
the statistical analysis and manuscript, and will provide for nondisclosure of Clovis Oncology 
confidential or proprietary information.  In all cases, the parties agree to submit all manuscripts 
or abstracts to all other parties 30 days prior to submission.  This will enable all parties to protect 
proprietary information and to provide comments based on information that may not yet be 
available to other parties.  The sponsor may request a delay in publication if there are important 
intellectual property concerns relating to publication, but does not have the right to suppress 
publication of the study results indefinitely. 
Result of this pivotal study will also be posted to www.clinicaltrials.gov within 30 days of 
marketing approval for rucaparib in the US and to EudraCT within one year of the end of the 
trial. 
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13.11 Quality Assurance Audits 
An audit visit to clinical centers may be conducted by a quality control auditor appointed by 
Clovis Oncology.  The purpose of an audit, which is independent of and separate from routine 
monitoring or quality control functions, is to evaluate trial conduct and compliance with the 
protocol, standard operating procedures (SOPs), ICH GCPs, and the applicable regulatory 
requirements.  The investigator and the sponsor may also be subject to an inspection by FDA, 
European Regulatory authorities, or other applicable regulatory authorities at any time.  The 
auditor and regulatory authorities will require authorization from the investigator to have direct 
access to the patients’ medical records.  It is important that the investigator(s) and their staff 
cooperate with the auditor or regulatory authorities during this audit or inspection.  
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15.1 Appendix A 
List of Homologous Recombination Genes for HRD Stratification by the ICTA   
 
tBRCA nbHRD Biomarker-negative 
BRCA1 
BRCA2 
ATM 
ATR 
ATRX 
BARD1 
BLM 
BRIP1 
CHEK1 
CHEK2 
FANCA 
FANCC 
FANCD2 
FANCE 
FANCF 
FANCG 
FANCI 
FANCL 
FANCM 
MRE11A 
NBN 
PALB2 
RAD50 
RAD51 
RAD51B 
RAD51C 
RAD51D 
RAD52 
RAD54L 
RPA1 
Genes not included in 
the tBRCA or nbHRD 
groups 
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15.2 Appendix B 
Response Evaluation Criteria in Solid Tumors Criteria 
The RECIST guidelines (Version 1.1) are described in Eisenhauer (2009)31 and at 
http://www.eortc.be/Recist/Default.htm.  A short summary is given below. 
Measurable Disease: 
Tumor lesions:  measurable lesions are defined as those that can be accurately measured in at 
least one dimension (longest diameter to be recorded) with the following: 
• A minimum size of 10 mm by CT scan (CT scan thickness no greater than 5 mm). 
• A minimum size of 10 mm caliper measurement by clinical exam (lesions that cannot be 
accurately measured with calipers should be recorded as nonmeasurable). 
• A minimum size of 20 mm by chest X-ray. 
All tumor measurements must be recorded n millimeters (or decimal fractions of centimeters). 
Malignant lymph nodes:  to be considered pathologically enlarged and measurable, a lymph node 
must be ≥15 mm in short axis when assessed by CT scan (CT scan slice thickness recommended 
to be not greater than 5 mm).  At baseline and in follow-up, only the short axis will be measured 
and followed.   
Nonmeasurable Disease: 
All other lesions (or sites of disease), including small lesions (longest diameter <10 mm or 
pathological lymph nodes with ≥10 to <15 mm short axis), as well as truly nonmeasurable 
lesions, are considered nonmeasurable disease.  Lesions considered truly nonmeasurable include 
leptomeningeal disease, ascites, pleural/pericardial effusions, inflammatory breast disease, 
lymphangitic involvement of skin and lung, and abdominal masses/abdominal organomegaly 
identified by physical exam that is not measurable by reproducible imaging techniques.   
Bone Lesions 
Bone lesions, cystic lesion, and lesions previously treated with local therapy require particular 
comment.  Bone scan, PET scan, or plain films are not considered adequate imaging techniques 
to measure bone lesions.  However, these techniques can be used to confirm the presence or 
disappearance of bone lesions. 
Lytic bone lesions or mixed lytic–blastic lesions with identifiable soft tissue components that can 
be evaluated by cross-sectional imaging techniques such as CT or MRI can be considered as 
measurable lesions if the soft tissue component meets the definition of measurability described 
above. 
Blastic bone lesions are nonmeasurable. 
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Cystic Lesions 
Lesions that meet the criteria for radiographically defined simple cysts should not be considered 
as malignant lesions (neither measurable nor nonmeasurable) because they are, by definition, 
simple cysts. 
Cystic lesions thought to represent cystic metastases can be considered as measurable lesions if 
they meet the definition of measurability described above.  However, if noncystic lesions are 
present in the same patient, these are preferred as target lesions. 
Lesions with Prior Local Treatment 
Tumor lesions situated in a previous irradiated area or in an area subjected to other locoregional 
therapy are usually not considered measurable unless there has been demonstrated progression in 
the lesion. 
Target Lesions 
All measurable lesions up to a maximum of two lesions per organ and five lesions in total, 
representative of all involved organs, should be identified as target lesions and recorded and 
measured at baseline.  Target lesions should be selected on the basis of their size (lesions with 
the longest diameter) and their suitability for accurate repeated measurements (either by imaging 
techniques or clinically).  A sum of the longest diameter (LD) for all target lesions will be 
calculated and reported as the baseline sum LD.  The baseline sum LD will be used as reference 
by which to characterize the objective tumor response.   
Non target Lesions 
RECIST criteria require unequivocal quantification of the changes in tumor size for adequate 
interpretation of the sum of target lesions.  Consequently, when the boundaries of the primary are 
difficult to delineate, this tumor should not be considered a target lesion. 
Guidelines for Evaluation of Measurable Disease 
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up.  Imaging-based evaluation is 
preferred to evaluation by clinical examination when both methods have been used to assess the 
antitumor effect of a treatment. 
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Evaluation of Target Lesions 
Complete Response Disappearance of all target lesions.  Any pathological lymph nodes 
(whether target or nontarget) must have reduction in short axis to <10 mm. 
Partial Response At least a 30% decrease in the sum of the LD of target lesions, taking as 
reference the baseline sum LD. 
Stable Disease Neither sufficient shrinkage to qualify for partial response nor sufficient 
increase to qualify for PD, taking as reference the smallest sum LD since 
the treatment started. 
Progressive Disease At least a 20% increase in the sum of the LD of target lesions, taking as 
reference the smallest sum on study (this includes the baseline sum if that 
is the smallest on study).  In addition to the relative increase of 20%, the 
sum must also demonstrate an absolute increase of at least 5 mm.  The 
appearance of one or more new lesions is also considered progression. 
  
Evaluation of Nontarget Lesions 
Complete Response Disappearance of all nontarget lesions and normalization of tumor marker 
level. 
Stable Disease/Incomplete 
Response 
Persistence of one or more nontarget lesion(s) or/and maintenance of 
tumor marker level above the normal limits. 
Progressive Disease Appearance of one or more new lesions and/or unequivocal progression of 
existing nontarget lesions. 
  
If tumor markers are initially above the institutional ULN, they must normalize for a patient to 
be considered a complete responder.   
Evaluation of Best Overall Response 
The best overall response is the best response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for PD the smallest measurements recorded 
since the treatment started).  The patient’s best response assignment will depend on the 
achievement of both measurement and confirmation criteria.   
Evaluation of Best Overall Response 
Target Lesions Nontarget Lesions New Lesions Overall Response 
CR CR No CR 
CR Non-CR/non-PD No PR 
CR Not evaluated No PR 
PR Non-PD or not 
evaluated 
No PR 
SD Non-PD or not 
evaluated 
No SD 
Not Evaluated Non-PD No NE 
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Evaluation of Best Overall Response 
Target Lesions Nontarget Lesions New Lesions Overall Response 
PD Any Yes or No PD 
Any PD Yes or No PD 
Any Any Yes PD 
NE = Not evaluable. 
   
Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be classified as having 
symptomatic deterioration.  Every effort should be made to document the objective progression, 
even after discontinuation of treatment. 
In some circumstances, it may be difficult to distinguish residual disease from normal tissue.  
When the evaluation of CR depends on this determination, it is recommended that the residual 
lesion be investigated (fine needle aspiration/biopsy) prior to confirming the complete response 
status. 
Confirmatory Measurement/Duration of Response 
Confirmation 
CT scans are required at screening and at the end of every 3rd cycle of treatment. 
Duration of Overall Response 
The duration of overall response is measured from the time measurement criteria are met for CR 
or PR (whichever is first recorded) until the first date that recurrent or PD is objectively 
documented (taking as reference for PD the smallest measurements recorded since the treatment 
started). 
The duration of overall CR is measured from the time measurement criteria are first met for CR 
until the first date that recurrent disease is objectively documented. 
Duration of Stable Disease 
SD is measured from the start of the treatment until the criteria for progression are met, taking as 
reference the smallest measurements recorded since the treatment started. 
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15.3 Appendix C   
Gynecological Cancer Intergroup (GCIG) Guidelines  
GCIG Guidelines for Response Using CA-12532 
GCIG CA 125 definitions are available at http://gcig.igcs.org/CA-125.html.   
To be evaluable for response by CA-125 requires two pretreatment samples at least twice the 
upper limit of normal and at least two additional samples after the start of treatment.   
A response to CA-125 has occurred if after two elevated levels before therapy there is at least a 
50% decrease that is confirmed by a fourth sample.  The four samples must satisfy the following 
criteria: 
1. The two pretreatment samples must both be at least twice the upper limit of normal and at 
least 1 day but not more than 3 months apart; 
2. At least one of the two pretreatment samples should be within 1 week of starting 
treatment; 
3. The third sample must be ≤ 50% of the second sample; 
4. The confirmatory fourth sample must be ≥ 21 days after sample 3 and ≤ 110% of 
sample 3; 
5. Any intervening samples between samples 2 and 3 and between samples 3 and 4 must be 
≤ 110% of the previous sample unless considered to be increasing because of tumor lysis. 
Patients are not evaluable by CA-125 if they have received mouse antibodies or if there has been 
medical or surgical interference with their peritoneum or pleura during the previous 28 days.  
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15.4 Appendix D 
Eastern Cooperative Oncology Group (ECOG) Performance Status Scale 
ECOG Performance Status 
0 Fully active, able to carry on all predisease performance without restriction. 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature (e.g., light house work or office work). 
2 Ambulatory and capable of all self care but unable to carry out any work activities.  Up and 
about more than 50% of waking hours. 
3 Capable of only limited self care; confined to bed or chair more than 50% of waking hours. 
4 Completely disabled.  Cannot carry on any self care.  Totally confined to bed or chair. 
5 Dead. 
 
In the event performance status is assessed by the Karnofsky Performance Status scale, the 
following conversion chart applies. 
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Karnofsky Performance Status ECOG Performance 
Status 
General Description Score Specific Description Score 
Able to carry on 
normal activity and to 
work; no special care 
needed 
100 Normal; no complaints; no 
evidence of disease 
0 
90 Able to carry on normal activity; 
minor signs or symptoms of 
disease 
1 
80 Normal activity with effort; some 
signs or symptoms of disease 
Unable to work; able 
to live at home and 
care for most personal 
needs; varying amount 
of assistance needed 
70 Cares for self, unable to carry on 
normal activity or to do active 
work 
2 
60 Requires occasional assistance, 
but is able to care for most of 
personal needs 
50 Requires considerable assistance 
and frequent medical care 
3 
Unable to care for self; 
requires equivalent of 
institutional or 
hospital care; disease 
may be progressing 
rapidly 
40 Disabled; requires special care 
and assistance 
30 Severely disabled; hospital 
admission is indicated although 
death not imminent 
4 
20 Very sick; hospital admission 
necessary; active supportive 
treatment necessary 
10 Moribund; fatal processes 
progressing rapidly 
0 Dead 5 
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15.5 Appendix E  
National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy 
(NCCN-FACT) FACT - Ovarian Symptom Index (FOSI-18) instrument (NCCN-FACT 
FOSI-18) – English Version 
Sample form and background available at: http://www.facit.org/FACITOrg/Questionnaires .  
Patients will complete the instrument on an electronic device.  This device is a Class 1 listed 
(i.e., approved) device. 
Below is a list of statements that other people with your illness have said are important.  
Please circle or mark one number per line to indicate your response as it applies to  
the past 7 days. 
  
 
Not at 
all 
A little 
bit 
Some-
what 
Quite 
a bit 
Very 
much 
       GP1 I have a lack of energy...................................  0 1 2 3 4 
GP4 I have pain .....................................................  0 1 2 3 4 
GP6 I feel ill ..........................................................  0 1 2 3 4 
O3 I have cramps in my stomach area ................  0 1 2 3 4 
HI7 I feel fatigued .................................................  0 1 2 3 4 
Cx6 I am bothered by constipation .......................  0 1 2 3 4 
O1 I have swelling in my stomach area ..............  0 1 2 3 4 
C3 I have control of my bowels ..........................  0 1 2 3 4 
GF5 I am sleeping well ..........................................  0 1 2 3 4 
GE6 I worry that my condition will get worse ......  0 1 2 3 4 
GP2 I have nausea .................................................  0 1 2 3 4 
B5 I am bothered by hair loss .............................  0 1 2 3 4 
GP5 I am bothered by side effects of treatment ....  0 1 2 3 4 
O2 I have been vomiting .....................................  0 1 2 3 4 
BMT15 I am bothered by skin problems ....................  0 1 2 3 4 
BMT5 I am able to get around by myself .................  0 1 2 3 4 
GF3 I am able to enjoy life ....................................  0 1 2 3 4 
GF7 I am content with the quality of my life 
right now ........................................................  
 
0 
 
1 
 
2 
 
3 
 
4 
 
D
R
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P 
T
S
E 
F 
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D
R
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E 
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Euro-QoL5D (EQ-5D) – English Version for the US 
By placing a checkmark in one box in each group below, please indicate which statements best 
describe your own health state today. 
Mobility 
I have no problems in walking about   
I have some problems in walking about   
I am confined to bed   
Self-Care 
I have no problems with self-care   
I have some problems washing or dressing myself   
I am unable to wash or dress myself   
Usual Activities (e.g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities   
I have some problems with performing my usual activities   
I am unable to perform my usual activities   
Pain/Discomfort 
I have no pain or discomfort   
I have moderate pain or discomfort   
I have extreme pain or discomfort   
Anxiety/Depression 
I am not anxious or depressed   
I am moderately anxious or depressed   
I am extremely anxious or depressed   
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15.6 Appendix F 
Inhibitors and Inducers of CYP1A2 and CYP3A 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm09
3664.htm#classInhibit 
 
CYP Enzyme Strong Inhibitor (Avoid) Moderate Inhibitor (Caution) 
CYP1A2 
Ciprofloxacin 
Enoxacin 
Fluvoxamine 
Methoxsalen 
Mexiletine 
Phenylpropanolamine 
Thiabendazole 
Zileuton 
CYP3A 
Boceprevir 
Clarithromycin 
Conivaptan 
Grapefruit juice 
Indinavir 
Itraconazole 
Ketoconazole 
Lopinavir/Ritonavir 
Mibefradil 
Nefazodone 
Nelfinavir 
Posaconazole 
Ritonavir  
Saquinavir 
Telaprevir 
Telithromycin 
Voriconazole 
Amprenavir 
Aprepitant 
Atazanavir 
Ciprofloxacin 
Darunavir/Ritonavir 
Diltiazem 
Erythromycin 
Fluconazole 
Fosamprenavir 
Grapefruit juice* 
Imatinib 
Verapamil 
 
 
* The effect of grapefruit juice varies widely among brands and is concentration-, dose-, and preparation-
dependent. Patients should be instructed to avoid grapefruit juice in this study.  
 
CYP Enzyme Strong Inducer (Avoid) Moderate Inducer (Caution) 
CYP1A2 
N/A Montelukast 
Phenytoin 
Smoking 
CYP3A 
Avasimibe 
Carbamazepine 
Phenytoin 
Rifampin 
St. John’s Wort 
Bosentan 
Efavirenz 
Etravirine 
Modafinil 
Nafcillin 
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1 SYNOPSIS 
Protocol Number CO-338-014 
Title A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of 
Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in 
Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial 
Ovarian, Primary Peritoneal, or Fallopian Tube Cancer 
Study Phase Phase 3 
Introduction  Rucaparib is an orally available, small molecule inhibitor of poly (adenosine 
diphosphate [ADP]-ribose) polymerase (PARP)-1, PARP-2, and PARP-3 and is 
being developed for treatment of ovarian cancer associated with homologous 
recombination deoxyribonucleic acid (DNA) repair deficiency. The safety and 
efficacy of rucaparib has been evaluated in several Phase 1 and Phase 2 studies. 
Normal cells repair single-strand breaks (SSBs) in DNA primarily through base 
excision repair (BER). While there are several variations of BER, all pathways 
rely on PARP enzymes, of which PARP-1 is the best characterized. SSBs that are 
not repaired result in stalled replication forks and the development of double-
strand breaks (DSBs), which are in turn primarily repaired by homologous 
recombination DNA repair, a complex process involving multiple proteins, 
including those encoded by breast cancer susceptibility gene 1 and 2 (BRCA1 and 
BRCA2), as well as many others. 
Homologous recombination pathway defects, either as an initiating event or late 
event in the carcinogenetic process, may be responsible for the genetic instability 
observed in many cancers. An analysis of the Cancer Genome Atlas (TCGA), 
which examined molecular changes in high-grade serous ovarian cancer 
(HGSOC), estimated that approximately 50% of patients with HGSOC have 
homologous recombination deficiency (HRD).1 Drivers of HRD include: 
1. Germline mutations in the BRCA1 and BRCA2 genes (gBRCA). These are the 
strongest known hereditary factors for epithelial ovarian cancer (EOC), 
accounting for up to 15% of all EOC.2, 3 These patients carry heterozygous 
deleterious mutations in their germline DNA and develop tumors when the 
remaining wild-type functional allele is inactivated (i.e. “second hit”). 
2. Somatic BRCA1/2 mutations (sBRCA) (6 – 8% of HGSOC patients)1, 4 
3. Mutation in a homologous recombination gene other than BRCA1/2 
(approximately 16% of HGSOC patients).1 Nonclinical studies by several 
groups have identified RAD proteins (eg, RAD51, RAD51C, RAD52, 
RAD54L),5-8 Fanconi Anemia proteins (eg, FANCA, FANCC, FANCD2),9-11 
and many others (eg, ATM, ATR, CHEK1, CHEK2)12-15 as being involved in 
homologous recombination. 
4. Functional silencing of homologous recombination genes, such as through 
BRCA promoter methylation (approximately 10% of HGSOC patients)1 or 
other mechanisms 
Inhibition of DNA damage repair in cancer cells, which are intrinsically 
genetically unstable, represents an attractive opportunity for the development of 
new therapies. Given the overlap in various DNA repair pathways, inhibition of a 
single pathway is unlikely to have a significant effect, whereas inhibition of 
multiple DNA repair pathways may lead to cell death, a concept known as 
synthetic lethality. Normal cells, with only one DNA repair pathway affected  
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Introduction 
(cont) 
by inhibition of PARP, still have an intact DNA repair pathway that can 
compensate, whereas cancer cells with pre-existing HRD that are treated with a 
PARP inhibitor develop critically DNA repair deficiency and enter apoptosis. This 
concept of synthetic lethality has been demonstrated in landmark in vitro and 
in vivo studies16, 17 as well as in several clinical trials that evaluated a single agent 
PARP inhibitor for the treatment of relapsed ovarian cancer and metastatic breast 
cancer with or without an associated germline BRCA mutation.18-24 In vitro studies 
have also shown that cells deficient in or depleted of homologous recombination 
proteins other than BRCA1/2 have been associated with PARP inhibitor 
sensitivity.25-28 It is possible that the 24% ORR observed in olaparib-treated 
ovarian cancer patients without evidence of a gBRCA1/2 mutation21 was due to 
HRD driven by a sBRCA1/2 mutation or by an alteration in another key 
homologous recombination gene. 
Clinical activity in HGSOC has also been observed with switch maintenance 
PARP inhibitor therapy following response to platinum-based chemotherapy. 
Patients with platinum-sensitive relapsed ovarian cancer who achieved a response 
to another regimen of platinum-based chemotherapy followed by olaparib as 
switch maintenance treatment experienced a statistically significant improvement 
in median PFS (8.3 months) compared to patients who received placebo as 
maintenance therapy (4.8 months); hazard ratio (HR) of 0.35 (95% CI, 0.25 – 
0.49).29 Patients with a BRCA mutation derived the most benefit (median PFS 11.2 
vs 4.3 months; HR=0.18; 95% CI 0.11-0.31; P<0.00001).30 It should be noted that 
the outcomes of sBRCA + gBRCA mutant patients were the same as gBRCA 
mutant patients alone, suggesting that, for stratification and analysis purposes in 
the present study, it is appropriate to not differentiate between germline and 
somatic mutations. Patients without a BRCA mutation also experienced significant 
benefit from treatment with olaparib (HR=0.53; 95% CI 0.33-0.84; P=0.007), 
suggesting that patients with DNA repair defects in genes other than BRCA are 
likely contributing to the overall PFS result.30  
The purpose of this study is to evaluate progression-free survival (PFS) of patients 
with platinum-sensitive, relapsed high-grade epithelial ovarian, fallopian tube, or 
primary peritoneal cancer who receive rucaparib or placebo as switch maintenance 
therapy following a response to platinum-based chemotherapy. Prior to final 
analysis, patients will be placed into molecularly defined subgroups of HRD based 
on the Final Clinical Trial Assay (FCTA). It is anticipated that rucaparib will 
provide therapeutic benefit and increase PFS in patients with HRD.  
Study Overview This is a randomized, international, double-blind, placebo-controlled Phase 3 
study evaluating rucaparib maintenance therapy in advanced ovarian cancer. The 
primary endpoint is PFS by Response Evaluation Criteria in Solid Tumors 
(RECIST) v1.131 as assessed by the investigator. Risk/benefit will be assessed 
regularly by an Independent Data Monitoring Committee that will have access to 
unblinded datasets. 
This study will enroll patients with platinum-sensitive, high-grade serous or 
endometrioid epithelial ovarian, primary peritoneal, or fallopian tube cancer who 
achieved either a complete response (CR) by RECIST v1.1 or a partial response 
(PR), defined as either a RECIST v1.1 PR or a cancer antigen 125 (CA-125) 
response by Gynecologic Cancer Intergroup (GCIG) criteria,32 to their last 
platinum-based regimen. All responses will require CA-125 that is within the  
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Study Overview 
(cont)  
upper limit of normal (ULN). During the screening phase, each patient will have 
archival tumor tissue analyzed for mutations in homologous recombination 
pathway genes. Genes of interest will be sequenced using Foundation Medicine’s 
next generation sequencing (NGS) test, which examines a panel of cancer-related 
genes, including BRCA1/2 and other homologous recombination pathway genes. 
Patients will be stratified into one of three HRD subgroups (BRCA1/2 mutation in 
tumor tissue [tBRCA], HRD due to mutation in a homologous recombination gene 
other than BRCA1/2 [nonBRCA HRD (nbHRD)], or biomarker negative) for 
randomization based on the results obtained with Foundation Medicine’s Initial 
Clinical Trial Assay (ICTA) (Appendix A). Enrollment of patients known a priori 
to harbor a gBRCA mutation classified as deleterious (pathogenic), suspected 
deleterious, or equivalent, on the most recent assessment, will be limited to 150. 
Enrollment of patients with a BRCA gene mutation detected in tumor tissue 
(tBRCA), including those known to harbor a gBRCA mutation, will be limited to 
200. Once this cap is reached, newly screened patients identified as having a 
BRCA mutation in tumor tissue will be offered treatment in another study. 
The complete results of the Foundation Medicine NGS test, which examines exons 
of 287 genes as well as introns of 19 genes, will be provided to all patients who 
opt to receive this information and provide appropriate consent. Tumor tissue 
results for the BRCA genes will be provided to patients who consent to receive this 
information upon availability. Results for the remainder of the gene panel will be 
provided to consenting patients upon study treatment discontinuation. Results are 
to be disclosed to consenting patients by the study physician as part of an overall 
clinical discussion. In the event a mutation associated with hereditary cancer or 
other syndrome is detected in tumor tissue, the patient will be referred by the 
investigator for genetic counseling and potential germline testing per institutional 
guidelines. If the patient chooses to have germline BRCA testing, this result will 
be entered into the clinical trial database.  
Mutations detected in tumor tissue may be somatic or germline; however, the 
NGS test will not distinguish between the two. A blood sample will therefore be 
collected for all patients and stored. Prior to final efficacy analysis, genomic DNA 
may be subjected to exploratory analysis in order to determine whether any 
mutation identified is of germline or somatic origin. 
Tumor DNA will also be assessed by the NGS test to detect the presence of 
genomic scars.33-36 Analysis of specific genomic scarring patterns may identify 
tumors with HRD regardless of the underlying mechanism(s). The extent of 
genomic scarring and its utility in predicting clinical outcome with rucaparib will 
be assessed in a Phase 2 study (CO-338-017) that will be initiated in parallel with 
this Phase 3 study, but will be completed earlier. The insights from study 
CO-338-017 will be applied prospectively to the analysis of this Phase 3 study. 
The FCTA analysis plan (gene mutation and/or genomic scarring) and 
classification of HRD subgroups will be finalized and locked down prior to the 
completion of the Phase 3 study and applied prospectively to the primary efficacy 
analysis. The Sponsor will remain blinded to all tumor tissue and germline test 
results until the primary efficacy analysis is conducted. 
 
  
Clovis Oncology, Inc.   Clinical Protocol 
Oral rucaparib (CO-338) CO-338-014 
 7 July 2016  
Amendment 3 15 
 
Number of 
Patients 
Approximately 540 patients will be enrolled. A minimum of 180 and a maximum 
of 200 patients with a deleterious tBRCA mutation will be enrolled. Enrollment of 
patients with a known deleterious gBRCA mutation documented in their medical 
record will not exceed 150. There is no minimum number of patients required for 
each of the nbHRD and biomarker negative subgroups; however, no more than 
360 total patients will be randomized for stratification into these subgroups 
combined. 
Number of Sites This is a multicenter, multinational study. Patients will be enrolled from 
approximately 90 – 100 study sites. 
Study Duration Q4 2013 – Q2 2017 
Study Objectives The primary objective of this study is: 
• To evaluate PFS by RECIST, as assessed by the investigator, in 
molecularly-defined HRD subgroups 
The secondary objectives of this study are: 
• To evaluate patient-reported outcome (PRO) of disease-related symptoms 
utilizing the disease-related symptoms – physical (DRS–P) subscale of the 
National Comprehensive Cancer Network-Functional Assessment of 
Cancer Therapy (NCCN-FACT) FACT-Ovarian Symptom Index 18 
(FOSI-18)  
• To evaluate PRO utilizing the complete FOSI-18 
• To evaluate survival benefit 
• To evaluate PFS by RECIST, as assessed by independent radiology 
review (IRR), in molecularly-defined HRD subgroups  
• To evaluate safety 
• To determine the population pharmacokinetics (PK) of rucaparib 
The exploratory objectives of this study are: 
• To evaluate the relationship between cancer antigen 125 (CA-125) levels 
and invPFS 
• To evaluate PFS2 (PFS on the subsequent line of treatment) 
• To evaluate overall response rate (ORR) 
• To evaluate duration of response (DOR) 
• To evaluate PRO utilizing the Euro-Quality of Life 5D (EQ-5D) 
• To explore the relationship between rucaparib exposure, efficacy, and 
safety 
Study Population Inclusion Criteria 
All patients enrolling into the study must meet all of the following inclusion 
criteria: 
1. Have signed an Institutional Review Board/Independent Ethics Committee-
approved informed consent form prior to any study-specific evaluation 
2. Be 18 years of age at the time the informed consent form is signed 
3. Have a histologically confirmed diagnosis of high-grade (Grade 2 or 3) serous 
or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer 
 For mixed histology, >50% of the primary tumor must be confirmed to be 
high-grade serous or endometrioid 
 Grade 2 tumors classified under a 3-tier system should be re-reviewed by 
local pathology and confirmed as high-grade under the 2-tier system  
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Study Population 
(cont) 
4. Received prior platinum-based therapy and have platinum-sensitive disease 
(i.e. documented radiologic disease progression >6 months following the last 
dose of the penultimate platinum administered) 
 Received ≥2 prior platinum-based treatment regimens, including platinum-
based regimen that must have been administered immediately prior to 
maintenance therapy in this trial. In addition, up to 1 non-platinum 
chemotherapy regimen is permitted. Prior hormonal therapy is permitted; 
this treatment will not be counted as a non-platinum regimen.  
 There is no upper limit on the number of prior platinum-based regimens 
that may have been received, but the patient must have been sensitive to the 
penultimate platinum-based regimen administered. 
 If both neoadjuvant and adjuvant treatment were administered pre/post any 
debulking surgery, this will be considered 1 treatment regimen 
 Prior maintenance therapy following a prior treatment regimen is 
permitted, with the exception of the regimen received immediately prior to 
maintenance in this study. No anticancer therapy is permitted to be 
administered as maintenance treatment in the interval period between 
completion of the most recent platinum-based therapy and initiation of 
study drug in this trial. 
5. Achieved best response of either CR or PR to the most recent platinum-based 
regimen administered and is randomized to study treatment within 8 weeks of 
the last dose of platinum received.  
 The most recent platinum-based regimen must have been a chemotherapy 
doublet. The choice of the platinum and the 2nd chemotherapy agent is per 
Investigator’s discretion. 
 A minimum of 4 cycles of platinum chemotherapy must have been 
administered. There is no cap on the maximum number of cycles; however, 
additional cycles of treatment administered following completion of 
therapy for the specific purpose of enabling patient eligibility and 
randomization within 8 weeks of the last platinum dose is not permitted. 
 A CR is defined as a complete radiologic response per RECIST v1.1, i.e. 
absence of any detectable disease and CA-125 <ULN.* 
 A PR is defined as either a partial response per RECIST v1.1 (if disease 
was measurable prior to chemotherapy) or a serologic response per GCIG 
CA-125 response criteria (if disease was not measurable according to 
RECIST v1.1).* 
o CA-125 must also be <ULN for all responses classified as a PR 
 R0 surgery (no visible tumor) or R1 surgery (residual disease <1 cm) as a 
component of the most recent treatment regimen is not permitted. The 
response assessment must be determined solely in relation to the 
chemotherapy regimen administered. The presence of measurable disease 
or CA-125 > 2 x ULN immediately prior to the chemotherapy regimen is 
required. 
Clovis Oncology, Inc.   Clinical Protocol 
Oral rucaparib (CO-338) CO-338-014 
 7 July 2016  
Amendment 3 17 
 
Study Population 
(cont)  
 Responses must have been maintained through the completion of 
chemotherapy and during the interval period between completion of 
chemotherapy and entry in the study. 
 All disease assessments performed prior to and during this chemotherapy 
regimen must be adequately documented in the patient’s medical record 
6. Have sufficient archival formalin-fixed paraffin-embedded (FFPE) tumor 
tissue (1 x 4 µm section for hematoxylin and eosin [H&E] stain and 
approximately 8 to 12 x 10 µm sections, or equivalent) available for planned 
analyses. 
 The most recently collected tumor tissue should be provided, if available 
 Submission of a tumor block is preferred; if sections are provided, these 
must all be from the same tumor sample. 
 Sample must be received at the central laboratory at least 3 weeks prior 
to start of treatment in order to enable stratification for randomization 
7. Have CA-125 measurement that is < ULN 
8. Have ECOG performance status of 0 to 1 
9. Have adequate organ function confirmed by the following laboratory values 
obtained within 14 days of the first dose of study drug: 
 Bone Marrow Function 
o Absolute neutrophil count (ANC)  1.5 × 109/L 
o Platelets > 100 × 109/L  
o Hemoglobin  9 g/dL 
 Hepatic Function 
o Aspartate aminotransferase (AST) and alanine aminotransferase 
(ALT)  3 × ULN; if liver metastases, then  5 × ULN 
o Bilirubin  1.5 × ULN (< 2 x ULN if hyperbilirubinemia is due to 
Gilbert’s syndrome) 
 Renal Function  
o Serum creatinine  1.5 × ULN or estimated glomerular filtration rate 
(GFR) ≥ 45 mL/min using the Cockcroft Gault formula 
* Note: It is acceptable for sites to utilize local and contemporaneous clinical 
imaging reports to record lesion measurement history and define a burden of 
disease according to RECIST; it is not a requirement to re-read radiological 
scans to collect this data. 
Exclusion Criteria 
Patients will be excluded from participation if any of the following criteria apply: 
1. History of a prior malignancy except: 
 Curatively treated non-melanoma skin cancer 
 Breast cancer treated curatively > 3 years ago, or other solid tumor treated 
curatively > 5 years ago, without evidence of recurrence 
 Synchronous endometrioid endometrial cancer (Stage 1A G1/G2) 
2. Prior treatment with any PARP inhibitor, including oral or intravenous 
rucaparib. Patients who previously received iniparib are eligible. 
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Study Population 
(cont) 
3. Required drainage of ascites during the final 2 cycles of their last platinum-
based regimen and/or during the period between the last dose of chemotherapy 
of that regimen and randomization to maintenance treatment in this study 
4. Symptomatic and/or untreated central nervous system (CNS) metastases. 
Patients with asymptomatic previously treated CNS metastases are eligible 
provided they have been clinically stable for at least 4 weeks. 
5. Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that 
would, in the opinion of the Investigator, interfere with absorption of study 
drug 
6. Known human immunodeficiency virus (HIV) or acquired immunodeficiency 
syndrome (AIDS)-related illness, or history of chronic hepatitis B or C 
7. Pregnant or breast feeding. Women of childbearing potential must have a 
negative serum pregnancy test ≤ 3 days prior to first dose of study drug. 
8. Received treatment with chemotherapy, radiation, antibody therapy or other 
immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, or 
experimental drugs 14 days prior to first dose of study drug and/or ongoing 
adverse effects from such treatment > NCI CTCAE Grade 1, with the exception 
of Grade 2 non-hematologic toxicity such as alopecia, peripheral neuropathy 
and related effects of prior chemotherapy that are unlikely to be exacerbated by 
treatment with study drug 
 Ongoing hormonal treatment for previously treated breast cancer is 
permitted 
 Refer also to inclusion criteria #4 for guidelines pertaining to prior 
maintenance therapy 
9. Received administration of strong CYP1A2 or CYP3A4 inhibitors  7 days 
prior to first dose of study drug or have on-going requirements for these 
medications (Appendix F) 
10. Non-study related minor surgical procedure 5 days, or major surgical 
procedure ≤21 days, prior to first dose of study drug; in all cases, the patient 
must be sufficiently recovered and stable before treatment administration 
11. Presence of any other condition that may increase the risk associated with 
study participation or may interfere with the interpretation of study results, and, 
in the opinion of the investigator, would make the patient inappropriate for 
entry into the study 
Pregnancy is an exclusion criterion and women of childbearing potential must not 
be considering getting pregnant during the study. 
Female patients of reproductive potential must practice a highly effective method 
of contraception (failure rate < 1% per year) with their male partners during 
treatment and for 6 months following the last study drug dose. 
 No waivers of these inclusion or exclusion criteria will be granted by the 
investigator and the sponsor or its designee for any patient enrolled into the study. 
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Study Treatment  Eligible patients will be randomized 2:1 to receive rucaparib (600 mg bid) or 
placebo. Randomization will occur by a central randomization procedure using an 
Interactive Voice Response System/Interactive Web Response System 
(IVRS/IWRS). The following will be included as randomization stratification 
factors at study entry to ensure treatment groups are balanced:  
• HRD classification (tBRCA, nbHRD, or biomarker negative) by the ICTA 
(Appendix A). 
• Interval between completion of the penultimate platinum-based regimen and 
disease progression (6 to 12 or >12 months) by radiologic assessment 
• Best response to the most recent platinum-based regimen (CR [defined as 
complete radiologic response by RECIST or PR [defined as partial response 
by RECIST and/or a GCIG CA-125 response]). All responses require that 
CA-125 be <ULN. 
Randomization to study treatment must occur within 8 weeks following a patient’s 
last dose of platinum-based chemotherapy. Study drug will be taken orally twice 
daily (12 hours apart) with at least 8 oz (240 mL) of water. Study drug may be 
taken with an empty stomach or with food. 
Patients will take study drug twice daily for continuous 28-day cycles until disease 
progression by RECIST as assessed by the investigator, or other reason for 
discontinuation. Treatment interruptions and/or dose reductions are permitted in 
the event of unacceptable toxicity. 
Withdrawal 
Criteria 
A patient must be discontinued from treatment with study drug if any of the 
following apply: 
• Consent withdrawal at the patient’s own request or at the request of their 
legally authorized representative 
• Progression of patient’s underlying disease by RECIST as assessed by the 
investigator 
• Any event, adverse or otherwise, that, in the opinion of the investigator, would 
pose an unacceptable safety risk to the patient 
• An intercurrent illness that, in the opinion of the investigator, would affect 
assessments of the clinical status to a significant degree and requires 
discontinuation of therapy 
• A positive pregnancy test at any time during the study 
Disease 
Assessments for 
Efficacy 
Efficacy measures will include clinical examination, CA-125 measurement, and 
appropriate imaging (CT scans of the chest, abdomen, and pelvis with appropriate 
slice thickness per RECIST); other studies (magnetic resonance imaging [MRI], 
X-ray, positron emission tomography [PET], and ultrasound) may be performed if 
required. Disease assessment will be performed at screening, at the end of every 12 
calendar weeks after start of treatment on Day 1 of Cycle 1, at discontinuation of 
treatment, and as clinically indicated. 
Disease progression will be determined by RECIST (Appendix B). Patients with a 
CR at study entry will only be considered to have disease progression if a new 
lesion is identified. Patients who meet GCIG CA-125 criteria (Appendix C) for 
disease progression should have a radiologic assessment by RECIST. If the 
radiologic assessment does not confirm disease progression, patients should 
continue on treatment and be assessed by RECIST per the protocol schedule.  
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Disease 
Assessments for 
Efficacy (cont) 
Patients who discontinued treatment for reason other than disease progression or 
death should continue to have tumor scans performed at 12-week intervals (up to 1 
week prior is permitted) until disease progression, as assessed by the investigator. 
Safety 
Assessments 
Safety assessments will include adverse events (AEs), hematology, serum 
chemistry, vital signs, body weight, concomitant medications/procedures, ECOG 
performance status (Appendix D), and study drug modifications.  
Statistical 
Procedures  
Sample Size Justification 
The total enrollment planned is 540 patients. A minimum of 180 and a maximum 
of 200 patients with a deleterious tBRCA mutation will be enrolled. Enrollment of 
patients with a known deleterious gBRCA mutation documented in their medical 
record will not exceed 150. There is no minimum number of patients required for 
each of the nbHRD and biomarker negative subgroups; however, no more than 
360 total patients will be randomized for stratification into these subgroups 
combined. Prior to final efficacy analysis, HRD classification will be determined 
by the FCTA that will evaluate homologous recombination gene mutations and/or 
extent of genomic scarring in tumor tissue. 
The table below provides estimated sample sizes and power calculations. 
Group Hazard 
Ratio 
Cumulative 
N  
Minimum 
Number of 
Events 
(70%) 
Median PFS 
Placebo vs 
Rucaparib 
(months) 
Power One-
sided 
Alpha 
tBRCA  0.50 180 126 6 vs 12 90% 0.025 
All HRD 
(tBRCA + 
nbHRD) 
0.60 300 210 6 vs 10 90% 0.025 
ITT 
Population 
(tBRCA + 
nbHRD + 
Biomarker 
Negative) 
0.70 540 378 6 vs 8.5 90% 0.025 
Analysis Populations 
Safety: The safety population will consist of all patients who received at least one 
dose of protocol-specified treatment. 
Intent-to-treat (ITT): The ITT population will consist of all randomized patients.  
Response evaluable: The response evaluable population will consist of all patients 
who have measurable or evaluable disease at study entry, received at least one 
dose of study drug, and who had at least one post-baseline disease assessment. 
General Statistical Considerations 
Quantitative variables will be summarized using descriptive statistics. For 
variables registered on a continuous scale, the following will be presented: N, 
mean, standard deviation, median, minimum and maximum. Categorical variables 
will be presented using frequencies and percentages. The Kaplan-Meier 
methodology will be used to summarize time-to-event variables. The stratified 
hazard ratio from the Cox proportional hazards model will be used to estimate the 
HR between the randomized treatment groups. The primary and key secondary 
endpoints will be tested among the tBRCA subgroup, all HRD subgroup, and all 
randomized patients, using an ordered step-down multiple comparisons procedure.  
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Statistical 
Procedures 
(cont) 
Investigator determined PFS (invPFS) in the tBRCA subgroup will be tested first 
at a one-sided 0.025 significance level. If invPFS in the tBRCA subgroup is 
statistically significant, then invPFS will be tested in the all HRD subgroup 
followed by invPFS in all randomized patients. Continuing in an ordered step-
down manner, the PRO of disease symptoms utilizing the DRS-P subscale of the 
FOSI-18 will be tested at the one-sided 0.025 significance level in the tBRCA, all 
HRD, and all randomized patients subgroups and then for the remaining key 
secondary endpoints of PRO utilizing the FOSI-18 total score and OS. Once 
statistical significance is not achieved for one test the statistical significance will 
not be declared for all subsequent analyses in the ordered step-down procedure. 
PFS by IRR will be evaluated as a stand-alone secondary endpoint. 
Primary Efficacy Analysis 
The primary efficacy analysis for the study is investigator-determined PFS 
(invPFS) by RECIST. Investigator-determined PFS is defined as the time 
from randomization to disease progression, according to RECIST v1.1 
criteria as assessed by the investigator, or death due to any cause, 
whichever occurs first. The stratification factors included in the primary 
analysis of invPFS will be HRD classification (tBRCA, nbHRD or biomarker 
negative), interval between completion of penultimate platinum regimen and 
disease progression (6 to 12 months or >12 months) by radiologic assessment, and 
best response to the most recent platinum-based regimen (either CR [defined as 
complete radiologic response by RECIST] or PR [defined as partial response by 
RECIST and/or a GCIG CA-125 response]). All responses require that CA-125 be 
<ULN. 
Tumor HRD status by the FCTA will be determined after randomization, but 
before the final efficacy analysis, so that the primary endpoint (PFS in molecularly 
defined subgroups) can be assessed prospectively. 
Secondary Efficacy Analyses 
Secondary efficacy endpoints include: 
• PRO of disease-related symptoms as measured by the DRS-P subscale score of 
the FOSI-18 
• PRO as measured by the total score of the FOSI-18 
• OS 
• PFS by RECIST v1.1 as assessed by IRR 
The time to an event in PRO of worsening of disease symptoms will be defined as 
the time from randomization to a 4-point reduction in the FOSI-18 DRSP 
subscale score. Similarly, an event in worsening of PRO utilizing the FOSI-18 
total score will be defined as the time from randomization to an 8-point reduction 
in the total score. 
OS, time to death from any cause, is defined as the number of days from the date 
of randomization to the date of death (due to any cause). Patients without a known 
date of death will be censored on the date the patient was last known to be alive. 
PFS for secondary efficacy analysis is defined as the time from randomization to 
disease progression, according to RECIST v1.1 criteria as assessed by IRR, or 
death due to any cause, whichever occurs first.  
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Statistical 
Procedures 
(cont)  
Safety Analysis 
Data from all patients who receive at least one dose of study drug will be included 
in the safety analyses. AEs, clinical laboratory information, vital signs, ECOG 
performance status, body weight, and concomitant medications / procedures will 
be tabulated and summarized. 
AEs will be summarized overall, with separate summaries for serious AEs, AEs 
leading to treatment discontinuation or death, and CTCAE Grade 3 or higher AEs. 
Independent Data Monitoring Committee (IDMC) 
No formal efficacy interim analyses for early stopping are planned.  
An IDMC will meet to review the efficacy and safety data from this study. The 
IDMC will: 
• Review efficacy and safety of rucaparib compared to placebo to ensure the 
study is beneficial to patients;  
• Ensure the study is conducted in a high quality manner; and 
• Monitor the size of the tBRCA subgroup and known gBRCA subgroup 
Clovis Oncology, Inc.   Clinical Protocol 
Oral rucaparib (CO-338) CO-338-014 
 7 July 2016  
Amendment 3 23 
 
2 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
AAG alpha-1 acid glycoprotein 
ADP adenosine diphosphate 
AE adverse event 
AESI adverse event of special interest 
AIDS acquired immunodeficiency syndrome 
ALP alkaline phosphatase 
ALT alanine aminotransferase 
AML acute myeloid leukemia 
ANC absolute neutrophil count 
AST aspartate aminotransferase 
AUC area under the curve 
AUCR ratio of the area under the curve 
BCRP breast cancer resistance protein 
BER base excision repair 
BID twice a day 
BRCA1 breast cancer susceptibility gene 1 
BRCA2 breast cancer susceptibility gene 2 
BUN blood urea nitrogen 
CA-125 cancer antigen 125 
CFR Code of Federal Regulations 
Cmax maximum concentration 
CNS central nervous system 
CR complete response  
CRO contract research organization  
CT computed tomography 
CTCAE Common Terminology Criteria for Adverse Events (version 4.03) 
CYP cytochrome P450 
DLT dose-limiting toxicity  
DNA deoxyribonucleic acid 
DOR duration of response 
DSB double-strand break 
DRSP disease-related symptomsphysical 
ECG electrocardiogram 
ECOG Eastern Cooperative Oncology Group 
eCRF electronic case report form 
EDC electronic data capture 
EOC epithelial ovarian cancer 
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EQ-5D Euro-Quality of Life 5D 
FCTA Final Clinical Trial Assay 
FDA Food and Drug Administration 
FFPE formalin-fixed paraffin-embedded 
FOSI-18 FACT-Ovarian Symptom Index 18 
GALT gut-associated lymphoid tissue 
gBRCA germline BRCA 
GCIG Gynecologic Cancer InterGroup 
FSH follicle-stimulating hormone 
GCP Good Clinical Practice 
GFR glomerular filtration rate 
h hour 
Hct hematocrit 
HDL high-density lipoprotein 
hERG human ether-a-go-go-related gene 
Hgb hemoglobin  
HGSOC high grade serous ovarian cancer 
HIPAA Health Information Portability and Accountability Act 
HIV human immunodeficiency virus 
HR hazard ratio 
HRD homologous recombination deficiency 
ICH International Conference on Harmonization 
ICTA Initial Clinical Trial Assay 
ICxx concentration where maximum response is inhibited by XX% 
IDMC Independent Data Monitoring Committee 
IEC Independent Ethics Committee 
INR international normalized ratio 
invPFS disease progression according to RECIST v1.1 as assessed by the investigator, or 
death from any cause 
IRB Institutional Review Board  
IRR independent radiology review 
irrPFS disease progression according to RECIST v1.1 as assessed by independent 
radiology review, or death from any cause 
ITT Intent-to-treat 
IVRS/IWRS Interactive Voice Response System/Interactive Web Response System 
LDL low-density lipoprotein 
LOH loss of heterozygosity 
MATE multidrug and toxin extrusion transporter 
MCV mean corpuscular volume 
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MCH mean corpuscular hemoglobin 
MCHC mean corpuscular hemoglobin concentration 
MDS Myelodysplastic Syndrome 
MedDRA Medical Dictionary for Drug Regulatory Activities 
Min minute 
MRI magnetic resonance imaging 
MTD maximum tolerated dose 
mut mutant 
nbHRD non-BRCA homologous recombination deficiency 
NCCN-FACT National Comprehensive Cancer Network-Functional Assessment of Cancer 
NCI National Cancer Institute 
NGS next generation sequencing 
NOAEL no-observed-adverse-effect level 
OCT organic cation transporter 
ORR overall response rate 
OS overall survival 
PARP poly (adenosine diphosphate [ADP]-ribose) polymerase 
PD progressive disease 
PET positron emission tomography 
PLD PEGylated liposomal doxorubicin 
PFS progression-free survival 
PFS2 second event of progression-free survival 
P-gp P-glycoprotein 
PID poly (adenosine diphosphate [ADP]-ribose) polymerase inhibiting dose 
PK pharmacokinetic(s) 
PR partial response 
PRO patient-reported outcome 
PS performance status 
QD once a day 
QoL quality of life 
RBC red blood cell 
RECIST Response Evaluation Criteria in Solid Tumors Version 1.1 
SAE serious adverse event 
SAS statistical analysis software 
sBRCA somatic breast cancer gene 1 or 2 mutation 
SD stable disease 
SNP single-nucleotide polymorphism 
SOC system organ class 
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SOP Standard operating procedure 
SSB single-strand break 
SUSAR suspected unexpected serious adverse reaction 
tBRCA tumor tissue alteration in BRCA1 or BRCA2, includes gBRCA and sBRCA 
TCGA The Cancer Genome Atlas 
TEAE treatment-emergent adverse events 
Tmax time to maximum concentration 
TMZ temozolomide 
UGT uridinediphosphate-glucuronosyletransferase 
ULN upper limit of normal 
unk unknown 
UV ultraviolet 
WBC white blood cell 
WOCBP women of child-bearing potential 
WT wild type 
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3 INTRODUCTION 
3.1 Ovarian Cancer 
3.1.1 General Overview 
Ovarian cancer is the second most common gynecologic malignancy worldwide and the leading 
cause of death attributed to gynecological cancer.37, 38 After initial therapy, most women will 
have a progression-free interval of approximately 1.5 to 2 years, depending on the extent of post-
operative residual disease and response to chemotherapy.39 Relapse still occurs, however, in the 
majority of cases, and only 1030% of women experience long-term survival.39 Advanced stage 
disease is associated with a 5-year survival rate of only 3040%.37  
Approximately 90% of ovarian tumors are surface epithelial in origin, and the papillary serous 
histology subtype accounts for approximately 75%, of which the large majority (70%) is 
high-grade.39 The site of origin of epithelial ovarian cancer (EOC) remains unclear. Some studies 
suggest that serous EOC and primary peritoneal cancer (PPC) arise from the fallopian tube 
epithelium;40, 41 however, other studies suggest an origin within stem cells of the ovarian surface 
epithelium.39, 42 EOC, PPC and fallopian tube cancer behave very similarly, and are therefore 
treated in the same way. 
The median age at presentation of EOC is 60 years. Many women present with advanced disease 
and therefore have a poor prognosis. 
3.1.2  Treatment of Ovarian Cancer 
The standard approach to treatment of advanced ovarian cancer is cytoreductive surgery (either 
at time of diagnosis or interval debulking following 2 – 3 cycles of neoadjuvant chemotherapy), 
with the goal of minimizing residual tumor to no visible residual disease, a major prognostic 
indicator for improved survival. Six to eight cycles of platinum- and taxane-based chemotherapy 
is the global standard of care. If initial cytoreduction is not performed, interval debulking surgery 
is considered. This surgery may be carried out after three or four cycles of primary 
chemotherapy, followed by three further cycles of chemotherapy. Platinum analogues, such as 
carboplatin and cisplatin, are the most active agents, mediating their effects through the 
formation of inter- and intra-strand cross-links with deoxyribonucleic acid (DNA).43, 44  
The choice of treatment for relapsed disease is based on the treatment-free interval relative to last 
therapy administered and chemotherapy agents used. As many patients experience multiple 
relapses, prognosis and response to therapy decreases as the interval between last chemotherapy 
exposure and disease relapse shortens. The treatment-free, or specifically the platinum-free 
interval, provides further prognostic information for patients, as therapeutic options lessen and 
survival shortens as a patient’s tumor becomes less responsive to platinum-based therapy.  
Platinum-based regimens dominate ovarian cancer therapy and define treatment groups.44 In 
general, patients whose disease progresses during treatment with a platinum-based regimen are 
considered to have platinum-refractory disease; patients whose disease relapses within 6 months 
after the last platinum agent was administered are considered to have platinum-resistant disease; 
Clovis Oncology, Inc.   Clinical Protocol 
Oral rucaparib (CO-338) CO-338-014 
 7 July 2016  
Amendment 3 28 
 
and patients whose disease relapses more than 6 months after the last platinum-based therapy 
was administered are considered to have platinum-sensitive disease. These classifications are 
clinical, and not based on a mechanistic definition of platinum sensitivity or resistance. 
PARP inhibitor monotherapy has elicited objective responses in patients with platinum-sensitive 
disease as well as in patients with platinum-resistant disease, although response rates are higher 
in the former population.21-23 This indicates that using platinum-sensitivity alone as a selection 
marker for PARP inhibitor therapy is not a very effective tool, although it is a reasonable place to 
begin predictive biomarker development.  
Maintenance therapy following a response to standard treatment provides an opportunity to 
extend the disease-free period. Maintenance strategies evaluated to date for ovarian cancer have 
focused on the prolonged use of single-agent chemotherapy, antiangiogenesis agents, hormonal 
therapy, vaccines, and intraperitoneal chemotherapy. The OCEANS study evaluated carboplatin 
and gemcitabine with or without bevacizumab as part of the initial treatment and then as 
maintenance in women with platinum-sensitive ovarian, primary peritoneal, or fallopian tube 
cancer who were in their first relapse following primary chemotherapy. The addition of 
bevacizumab resulted in a statistically significant improvement in PFS (median 12.4 vs 8.4 
months; HR=0.484 [95% CI, 0.388 to 0.605; log-rank P<0.00001]).45 The PFS benefit of 
bevacizumab administered together with chemotherapy followed by single agent bevacizumab 
maintenance treatment compared to chemotherapy alone and placebo maintenance was further 
established in two front-line Phase 3 studies, GOG-218 (HR=0.717 [95% CI, 0.625 to 0.824; log-
rank P<0.001])46 and ICON-7 (HR=0.81 [95% CI, 0.70 to 0.94; log-rank P<0.04]).47 Based on 
these trials, the European Medicines Agency approved bevacizumab, in combination with 
carboplatin and paclitaxel, for front-line treatment of advanced (International Federation of 
Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian-tube, 
or primary peritoneal cancer, and, in combination with carboplatin and gemcitabine, for 
treatment of first recurrence of platinum-sensitive epithelial ovarian, fallopian-tube or primary 
peritoneal cancer in women who have not received prior therapy with bevacizumab or other 
vascular-endothelial-growth-factor (VEGF) inhibitors or VEGF-receptor-targeted agents. 
3.1.3 Homologous Recombination Deficiency 
DNA is constantly damaged by both endogenous and exogenous (environmental) assaults. A 
common type of DNA damage is the formation of DNA single-strand breaks (SSBs). During 
normal cell cycling, DNA is replicated and replication forks are eventually stalled by persistent 
SSBs. If stalled replication forks are not rapidly repaired, they can often degenerate and form 
DNA double-strand breaks (DSBs), which are highly likely to be lethal to the cell.  
Normal cells repair single-strand breaks (SSBs) in DNA primarily through base excision repair 
(BER). While there are several variations of BER, all pathways rely on PARP enzymes, of which 
PARP1 is the best characterized. SSBs that are not repaired result in stalled replication forks and 
the development of double-strand breaks (DSBs), which are in turn primarily repaired by 
homologous recombination DNA repair, a complex process involving multiple proteins, 
including those encoded by breast cancer susceptibility gene 1 and 2 (BRCA1 and BRCA2), 
among others. 
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If either the BER or homologous recombination pathway is rendered non-functional, the 
remaining functional pathway can compensate to ensure ongoing DNA repair and cell cycling. 
For example, when the BRCA-associated homologous recombination pathway is lost or 
dysfunctional, repair shifts towards the BER repair pathway that is dependent on PARP 
enzymes. In contrast, in the setting in which both repair pathways (BER and homologous 
recombination) are rendered non-functional, the cell dies. This concept, where a defect in either 
of two pathways can be withstood by a cell, but defects in both are lethal, is referred to as 
synthetic lethality. This type of lethality can arise from a variety of different interactions. In the 
case of DNA damage repair, dual non-functionality can be achieved by enzymatic inhibition of 
PARP in the context of a genetic mutation in the BRCA1 or BRCA2 genes. 
Synthetic lethality has been demonstrated in landmark in vitro and in vivo studies as well as in 
several clinical trials that evaluated a single agent PARP inhibitor for the treatment of relapsed 
ovarian cancer and metastatic breast cancer. Bryant and colleagues showed that cell lines and a 
tumor xenograft deficient in homologous recombination (via a defect in a BRCA or other 
homologous recombination gene) were highly sensitive to PARP inhibition.16 This study also 
showed that synthetic lethality could be achieved regardless of whether the mutation was in 
BRCA1 or BRCA2. In a parallel set of experiments, Farmer and colleagues illustrated that 
chemical inhibition of PARP1 was more potent in homozygous BRCA-deficient cell lines than in 
heterozygous mutant or wild-type cell lines.17 These findings were also supported by a 
BRCA2-deficient murine model. Taken together, these studies provided support for the treatment 
of patients with a BRCA-deficient tumor with a PARP inhibitor. 
3.1.4 Role of HRD in Ovarian Cancer 
Homologous recombination pathway defects, either as an initiating event or late event in the 
carcinogenetic process, may be responsible for the genetic instability observed in many cancers. 
An analysis of the Cancer Genome Atlas (TCGA), which examined molecular changes 
associated with high-grade serous ovarian cancer (HGSOC), estimated that approximately 50% 
of patient with HGSOC have homologous recombination deficiency (HRD).1 Drivers of HRD in 
ovarian cancer include: 
1. Germline mutations in the BRCA1 and BRCA2 genes (gBRCA). These are the strongest 
known hereditary factors for epithelial ovarian cancer (EOC), accounting for up to 15% 
of all EOC.2, 3 These patients carry heterozygous deleterious mutations in their germline 
DNA and develop tumors when the remaining wild-type functional allele is inactivated 
(i.e. “second hit”). 
2. Somatic BRCA1/2 mutations (sBRCA) (approximately 6 – 8% of HGSOC patients)1, 4  
3. Mutation in a homologous recombination gene other than BRCA1/2 (approximately 16% 
of HGSOC patients).1 Nonclinical studies by several groups have identified RAD 
proteins (eg, RAD51, RAD51C, RAD52, RAD54L),5-8 Fanconi Anemia proteins (eg, 
FANCA, FANCC, FANCD2),9-11 and many others (eg, ATM, ATR, CHEK1, CHEK2)12-
15 as being involved in homologous recombination. 
4. Functional silencing of homologous recombination genes, such as through BRCA 
promoter methylation (approximately 10% of HGSOC patients)1 or other mechanisms 
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Mutations in the BRCA genes in the tumor can be detected through next-generation sequencing 
(NGS). A possible approach to identify non-BRCA patients with HRD is to detect genomic scars 
within the tumor, which arise from the use of error-prone DNA repair pathways when HRR is 
compromised. Through a series of experiments and data analyses, the Sponsor has determined 
that a potential method for identifying patients who may be sensitive to rucaparib is to assess 
genomic scarring by quantifying the extent of loss of heterozygosity across the tumor genome 
(tumor genomic LOH). One of the main advantages of detecting tumor genomic LOH is that it 
can identify HRD tumors regardless of the underlying mechanisms, which include both known 
(i.e. BRCA mutations) and unknown genomic mechanisms.33, 36  
3.2 PARP Inhibitors 
PARP inhibitors have been evaluated in the clinic for the past decade. Olaparib (AZD-2281), the 
most advanced investigational PARP inhibitor, has demonstrated compelling Phase 2 clinical 
activity, both in treatment and maintenance settings, in relapsed, HGSOC patients (both germline 
BRCA mutant and wild-type) and in metastatic breast cancer patients with a gBRCA mutation. 
The concept of synthetic lethality was exploited in two proof-of-concept clinical studies with 
olaparib in patients with BRCA-associated tumor types. These studies evaluated the efficacy and 
safety of continuous oral dosing with olaparib in women with either relapsed ovarian cancer or 
advanced breast cancer and a gBRCA mutation.19, 20 In these patients, who had received a median 
of three prior chemotherapy regimens, encouraging overall response rates of 33% and 41%, were 
observed, in gBRCA ovarian and gBRCA breast cancer, respectively. In a third study, olaparib 
treatment was associated with a greater overall response rate (ORR) in patients with gBRCA-
associated ovarian cancer compared with the patients in the non-gBRCA associated cohort (41% 
vs 24%, respectively).21 In a fourth study that evaluated olaparib versus PEGylated liposomal 
doxorubicin (PLD) in patients with a gBRCA mutation and relapsed ovarian cancer, the efficacy 
of olaparib was consistent with that observed in previous studies.22  
Activity in HGSOC has also been observed with PARP inhibitor switch maintenance therapy 
following response to platinum-based chemotherapy.29, 30 Patients with platinum-sensitive 
relapsed ovarian cancer who achieved a response to another regimen of platinum-based 
chemotherapy followed by olaparib as switch maintenance treatment experienced a statistically 
significant improvement in median PFS (8.3 months) compared to patients who received placebo 
as maintenance therapy (4.8 months); hazard ratio of 0.35 (95% CI, 0.25 – 0.49).29 Patients with 
a BRCA mutation derived the most benefit (median PFS 11.2 vs 4.3 months; HR=0.18; 95% CI 
0.11-0.31; P<0.00001).30 It should be noted that the outcomes of sBRCA + gBRCA mutant 
patients were the same as gBRCA mutant patients alone, suggesting that, for stratification and 
analysis purposes in the present study, it is appropriate to not differentiate between germline and 
somatic mutations. Patients without a BRCA mutation also experienced significant benefit from 
treatment with olaparib (HR=0.53; 95% CI 0.33-0.84; P=0.007).30  
Niraparib (MK-4827) has exhibited clinical activity in a Phase 1 study in both BRCA-mutated 
ovarian cancer (8 RECIST PRs) and sporadic ovarian cancer (5 RECIST PRs and/or GCIG CA-
125 responses).23 In a Phase 1 evaluation of BMN 673, 11 of 17 BRCA-mutated ovarian cancer 
patients treated at doses ≥100 µg/day exhibited a RECIST and/or CA-125 response.24  
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Taken together, these data support the potential role for the PARP inhibitor rucaparib in the 
treatment of patients with BRCA-associated ovarian cancer. Furthermore, the 24% ORR and HR 
of 0.53 in the non-BRCA cohorts described above21, 30 suggests that the clinical utility of PARP 
inhibitors can be extended to a larger patient group. Patients with HRD due to defects in 
homologous recombination genes other than BRCA, i.e. nbHRD, may be part of this larger 
group. 
3.3 Rucaparib 
Rucaparib (formerly known as AG-014447 and PF-01367338) refers to the free base. The 
camphorsulfonic acid salt form (also referred to as camsylate salt) CO-338 (formerly known as 
PF-01367338-BW) will be used in this clinical trial. 
Rucaparib is a small molecule inhibitor of PARP-1, PARP-2, and PARP-3. Nonclinical 
evaluation has demonstrated exquisite sensitivity of BRCA1 and BRCA2 homozygous mutant cell 
lines to rucaparib and provides a rationale for the clinical assessment of rucaparib as 
monotherapy in patients with hereditary deficiencies of BRCA1 and/or BRCA2. Rucaparib has 
also shown antitumor activity as a single agent in the MDA-MB-436 (BRCA1 mutant) xenograft 
mouse model. The activity of rucaparib in these nonclinical experiments was similar to that of 
olaparib. 
The details of these and other nonclinical experiments are provided in the Investigator’s 
Brochure. 
3.3.1 Nonclinical Experience 
3.3.1.1 Rucaparib Absorption, Distribution, Metabolism, and Excretion 
The pharmacokinetics (PK) and toxicokinetics of rucaparib (as camsylate salt) following oral 
administration, the intended route of administration in humans, was evaluated in the mouse, rat, 
and dog. The time at which the peak plasma concentrations were observed (Tmax) occurred at 1–
3 hours post dose in the mouse and dog, with the rat generally exhibiting a later Tmax (4–8 hours). 
The oral bioavailability was 17%, 36%, and 62%, respectively, in the mouse (50 mg/kg), rat 
(100 mg/kg), and dog (20 mg/kg). In the rat and dog, there were no marked gender-related 
differences and no accumulation after repeat oral administration. A less than dose-proportional 
increase in exposure was observed in the rat and dog when rucaparib was administered as a 
suspension in 0.5% methylcellulose; however, a greater than dose-proportional increase in 
exposure was observed in the 1-month dog toxicity study when rucaparib was administered in 
capsules.  
In vitro plasma protein binding studies in mouse, rat, and dog plasma showed moderate binding 
and ranged from 49.5% to 73%. Plasma protein binding in humans ranged from 55% to 75%.  
Recombinant cytochrome P450 (CYP) studies indicated that CYP2D6, and to a lesser extent, 
CYP1A2 and CYP3A4, have the ability to metabolize rucaparib.  
In vitro studies indicated that rucaparib reversibly inhibited (in order of decreasing potency) 
CYP1A2, CYP2C19, CYP2C9, CYP3A, CYP2C8, and CYP2D6. Rucaparib demonstrated 
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concentration-dependent induction of CYP1A2 and down-regulation of CYP3A4 and CYP2B6 at 
clinically relevant concentrations in a hepatocyte incubation study. No time-dependent CYP 
inhibition was observed. Rucaparib also moderately inhibited uridinediphosphate-
glucuronosyletransferase (UGT)1A1. Based on in vitro CYP interaction data, the drug-drug 
interaction (DDI) potential of rucaparib as a CYP inhibitor and/ or inducer was assessed by 
calculating the ratio of AUC (AUCR) of CYP substrate drugs in the presence and absence of 
rucaparib at target clinical exposures (600 mg BID) using the mechanistic static modeling.48, 49 
AUCR allows a conservative estimation of the magnitude of DDIs. Based on this analysis, the 
DDI potential for rucaparib was estimated to be moderate (AUCR 2 to 5) for CYP3A 
(AUCR=5.0), CYP1A2 (AUCR=2.9), CYP2C8 (AUCR=2.6), and CYP2D6 (AUCR=2.3); but 
appeared to be strong (AUCR > 5) for CYP2C19 (AUCR=11) and CYP2C9 (AUCR=5.2). 
Clinical implication of CYP3A downregulation was unknown and thus not considered in the 
modeling; however, downregulation could further increase AUCR for CYP3A and result in 
elevated exposures of drugs that are CYP3A substrates.  
Rucaparib is a substrate for both P-glycoprotein (P-gp) and breast cancer resistance protein 
(BCRP). In vitro data indicate rucaparib is a potent inhibitor of multidrug and toxin extrusion 
transporter (MATE)-1 and MATE2-K (efflux transporters on renal tubule cells), and moderate 
inhibitor of organic cation transporter (OCT)1, BCRP, and P-gp.  
Quantitative whole body autoradiography studies in Long Evans rats showed [14C] rucaparib 
radioequivalents were rapidly and widely distributed to tissues following IV administration, 
consistent with a large volume of distribution. At 2 minutes after dosing, highest concentrations 
were found in kidney, lung, thyroid gland, heart, stomach mucosa, liver adrenal glands, spleen, 
and blood. Little radioactivity was present in brain; levels were undetectable at 15 minutes after 
dosing. Activity was undetectable in most tissues by 96 hours after dosing, however levels in the 
choroid/retina declined more slowly, and persistent radioactivity was also found in hair follicles 
through 192 hours, indicating that drug equivalents have high affinity and long half-life in 
pigmented tissues. High levels of radioactivity were observed in ureters, bladder, and bile ducts, 
indicating both renal and biliary routes eliminated drug equivalents.  
3.3.1.2 Multiple-Dose Toxicity Studies 
Rucaparib was evaluated in both rat and dog in oral and IV infusion toxicity studies. Only the 
multiple-dose toxicity studies utilizing the oral formulation are summarized below. Details of all 
other toxicity studies are provided in the Investigator’s Brochure. 
Target organs identified in studies where rucaparib was administered orally include the 
hematopoietic system and gastrointestinal tract. No cardiovascular findings were noted in any of 
the oral toxicity studies. 
Multiple-Dose Oral Toxicity in Rats 
Administration of rucaparib camsylate salt via oral gavage was generally well-tolerated in the rat 
up to 1000 mg/kg/day for 7 days and up to 150 mg/kg/day for 28 days. Decreases in body weight 
gain and food consumption were noted in both studies. In the 7-day study, target organs 
identified microscopically were bone marrow, spleen, and thymus. Minimal to mild bone 
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marrow hypocellularity was noted in all dose groups. The no-observed-adverse-effect-level 
(NOAEL) was established at 500 mg/kg/day. 
In the 28-day study, there were 3 rucaparib-related deaths at 500 mg/kg/day immediately after 
blood collection on Day 28 (n=1) or Day 29 (first day of recovery phase (n=2). These deaths 
likely resulted from the marked anemia identified hematologically. Other rucaparib-related 
clinical signs at 500 mg/kg/day included thinning haircoat and pale eyes. Identified target organs 
included bone marrow, spleen, lymphoid tissue (thymus, gut-associated-lymphoid tissue 
[GALT], and lymph nodes), and cecum (at 500 mg/kg/day only). Following cessation of 
rucaparib dosing, most findings reversed. In this study, the severe toxic dose in 10% of the 
animals (STD10) was 500 mg/kg/day and the NOAEL was 50 mg/kg/day. 
Rucaparib camsylate in capsules was also given orally to rats at doses of 10, 40, and 
100 mg/kg/day for 91 consecutive days with a 28-day recovery period. Decreased body weight 
and body weight gain were observed for animals given ≥40 mg/kg/day. At the end of the 
recovery phase, mean body weight was still lower for males given 100 mg/kg/day and females 
given ≥40 mg/kg/day. Hematological findings included decreases in red blood cell mass 
parameters in animals given ≥40 mg/kg/day (which correlated with decreased bone marrow 
hypocellularity), and decreases in reticulocytes, white blood cells (WBC) and absolute 
lymphocytes at ≥40 mg/kg/day. The latter changes correlated with the microscopic findings of 
decreased lymphocytes in the mandibular lymph nodes and gut-associated lymphoid tissue. All 
effects were reversible. Microscopically, bone marrow hypocellularity at 100 mg/kg/day and 
minimally decreased lymphocytes in lymphoid tissues at ≥40 mg/kg/day were noted and were 
completely reversed at the end of the recovery period. The NOAEL was established to be 
100 mg/kg/day. 
Multiple-Dose Oral Toxicity in Dogs 
Oral gavage administration of the camsylate salt form of rucaparib to dogs for 7 days resulted in 
gastrointestinal clinical signs at the 80 mg/kg/day high-dose group. Hematopoietic effects of 
decreased reticulocytes were noted in mid- to high-dose groups and leukopenia was exhibited in 
all treatment groups. Lymphoid atrophy occurred in both sexes and in all treatment groups. 
Decreased bone marrow cellularity was seen in both sexes (males at all doses; females at 
80 mg/kg/day). A 7-day repeat-dose toxicity study using oral capsules in dogs was repeated in 
order to characterize the toxicity of a new lot of rucaparib camsylate. Similar to the results of the 
prior 7-day study in dog, gastrointestinal clinical findings were noted at 80 mg/kg/day. Vomiting 
was observed throughout the dosing phase for males as well as liquid and/or mucoid feces in 
both genders. Decreased food consumption was observed at 80 mg/kg/day that correlated with 
the body weight loss that was considered adverse. Decreases in erythroid, platelet, and leukocyte 
parameters were observed primarily at 80 mg/kg/day and occasionally at 20 or 5 mg/kg/day. 
These data indicated that the drug targeted multiple bone marrow lineages in a dose-related 
pattern. 
Rucaparib camsylate salt in capsules was administered orally to dogs for 30 consecutive days 
with a 29-day recovery. Gastrointestinal clinical signs were noted at ≥5 mg/kg/day, with 
decrease in food consumption at 75 mg/kg/day. Adverse hematological changes (decrease in 
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erythroid, myeloid, and megokaryocytic lineages) occurred at ≥20 mg/kg/day. Effects were fully 
reversible. The NOAEL in this study was 5 mg/kg/day. 
Rucaparib camsylate in capsules was also given orally to dogs at doses of 3, 15/10, 
40/30/20 mg/kg/day for 91 consecutive days with a 29-day recovery period. Body weight losses 
and inappetance observed at the high dose in both sexes during the first quarter of the dosing 
phase were considered adverse and resulted in dose reductions (40 to 30 to 20 mg/kg/day for 
toxicity and 15 to 10 mg/kg day in order to maintain multiples of exposures for optimal testing of 
dose response) for the remainder of the study. Clinical pathology findings were indicative of 
bone marrow toxicity; these changes were non-progressive over time suggesting potential 
adaptation to these initial effects. Hematological findings at 40/30/20 mg/kg/day correlated with 
erythroid atrophy of the bone marrow detected microscopically. By Day 29 of recovery, most 
effects reversed. The highest non-severely toxic dose (HNSTD) for this study was 20 mg/kg/day 
for male dogs. No HNSTD was established for female dogs. The NOAEL was 10 and 
20 mg/kg/day for male and female dogs, respectively. 
3.3.1.3 Additional Observations 
In vitro genetic toxicology assays demonstrated oral rucaparib to be clastogenic. Bacterial 
mutagenicity data for rucaparib were clearly negative in four microbial tester strains, both with 
and without metabolic activation, and equivocal in a fifth tester strain.  
In an in vitro assay for human ether-a-go-go-related gene (hERG) activity, the IC50 and IC20 for 
the inhibitory effects of rucaparib (50% inhibitory concentration and 20% inhibitory 
concentration) on hERG potassium currents were 24 µM (7761 ng/mL) and 7 µM (2264 ng/mL), 
respectively. These values are 9-fold and 2.6-fold higher, respectively, than the mean unbound 
steady state plasma concentration (858 ng/mL) observed to date in humans at a dose of 600 mg 
BID rucaparib administered orally. 
Effects on appearance and behavior, motor activity, body temperature, and a number of 
neurofunctional tests and reflexes were evaluated in rats. A dose of 50 mg/kg of rucaparib 
administered via IV infusion (mean Cmax=13629 ng/mL) resulted in a significant reduction in 
motor activity compared with vehicle-treated animals; however, there were no effects on 
neurofunctional or reflex testing at this dose. The plasma concentration measured at this dose is 
4.7-fold above the mean steady state plasma concentration (2880 ng/mL) observed to date in 
humans at a dose of 600 mg BID rucaparib administered orally. 
Administration of rucaparib to Long-Evans rats orally at doses up to 750 mg/kg/dose, followed 
by a single exposure to solar-simulated ultraviolet radiation approximately 4 hours after the final 
dose elicited no skin or ocular reactions indicative of phototoxicity. The no-observed-effect-level 
(NOEL) for phototoxicity was >750 mg/kg/day. 
3.3.2 Clinical Experience 
The early clinical program assessed safety and efficacy of rucaparib in patients with 
malignancies commonly treated with chemotherapeutic agents. Initially, the IV formulation of 
rucaparib was administered in combination with a variety of chemotherapies; later, the oral 
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formulation of rucaparib was administered in combination with chemotherapy and as a 
monotherapy. The oral formulation as monotherapy is the focus of current development efforts. 
More information regarding the studies conducted in the rucaparib clinical program may be 
found in the Investigator’s Brochure. 
3.3.2.1 Rucaparib Monotherapy 
3.3.2.1.1 Study CO-338-010 
Clovis-sponsored study CO-338-010 is a 2-part, open-label, safety, PK, and preliminary efficacy 
study of oral rucaparib administered daily for continuous 21-day cycles. Part 1 is a Phase 1 
portion in patients with any solid tumor, including lymphoma, who have progressed on standard 
treatment. The primary objective of Part 1 is to determine the optimal monotherapy dose for 
orally administered rucaparib. Part 2 is a Phase 2 portion in patients with platinum-sensitive 
relapsed ovarian cancer with evidence of a gBRCA mutation who have received at least 2, but no 
more than 4, prior regimens. The primary objective of Part 2 is to assess the overall objective 
response rate by RECIST v1.1. 
Study CO-338-010 was initiated in Q4 2011. As of 27 June 2014, 56 patients (median age 50 yrs 
[range 2171]; 51 female; 27 breast cancer, 20 ovarian/peritoneal cancer, 9 other tumor) were 
treated at dose levels of 40, 80, 160, 300, and 500 mg once daily (QD), and 240, 360, 480, 600, 
and 840 mg twice daily (BID) rucaparib administered continuously in the Phase 1 portion of the 
study. A total of 50 patients discontinued rucaparib; n=46 due to disease progression; n=2 due to 
an adverse event (unrelated to rucaparib); n=1 due to consent withdrawal; and n=1 due to an 
eligibility criteria violation. One of 6 patients treated with 360 mg BID rucaparib experienced a 
dose-limiting toxicity (DLT) of Common Toxicity Criteria for Adverse Events (CTCAE) 
Grade 3 nausea despite maximal intervention in Cycle 1 of treatment. No DLTs were observed 
during Cycle 1 in the 480 (n=9), 600 (n=5), and 840 mg BID (n=3) cohorts; however, similar to 
other PARP inhibitors, non-DLT myelosuppression was observed beyond Cycle 1. The dose of 
600 mg BID rucaparib was selected as the recommended dose for Phase 2 and Phase 3 studies 
based on the overall safety & tolerability, PK, and clinical activity profile. As of June 27, 2014, 
15 patients (median age=58 [range=45-84]; 9 ECOG PS=0) with platinum-sensitive, relapsed 
ovarian cancer associated with a deleterious BRCA1/2 mutation have been enrolled in the 
Phase 2 portion of the study. One patient has discontinued rucaparib due to disease progression. 
Treatment-related adverse events (all grades) reported in ≥15% of patients treated with 600 mg 
bid rucaparib include gastrointestinal and related symptoms (nausea, vomiting, dysgeusia, 
diarrhea, abdominal pain, and decreased appetite), anemia, fatigue/asthenia, and headache. 
Elevations of ALT and/or AST have been reported. The ALT/AST elevations occur early (within 
first 2-4 weeks of treatment), were generally mild to moderate (Gr 1-2), not accompanied by any 
changes in bilirubin levels, and often transient and resolved to within normal ranges, or stabilize. 
No patient met the laboratory criteria for Hy’s Law.50 As has been observed with rucaparib and 
other PARP inhibitors, myelosuppression may be delayed and observed after a period of 
continuous dosing. All treatment-related adverse events were successfully managed with 
concomitant medication, supportive care, treatment interruption and/or dose reduction. No 
patient discontinued rucaparib treatment due to a treatment-related adverse event. A total of five 
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patients have died on study or within 30 days of last dose of rucaparib; all deaths were due to 
disease progression and were assessed as not related to rucaparib. 
Extensive centrally-reviewed electrocardiogram (ECG) monitoring was conducted in the Phase I 
portion of Study CO-338-010. ECG results (as triplicate reads) are available for all 56 treated 
patients. No patient had a QTcF measurement ≥500 msec at any time during study participation. 
Only one patient had a QTcF measurement ≥480 msec. This measurement occurred in a patient 
receiving 480 mg BID rucaparib and concomitant administration of citalopram, a medication 
with known potential to cause QT prolongation. This patient has continued to receive 
monotherapy rucaparib at a dose of 480 mg BID with no further QTcF measurement ≥480 msec. 
No patient experienced a ≥60 msec increase in QTcF over baseline. The data suggest no 
relationship between QTcF increase and dose or exposure. In addition, there were no adverse 
events suggestive of cardiac arrhythmia (eg, presyncope, syncope, sudden death) in any patient. 
ECG and adverse event data as of the cutoff date in patients receiving monotherapy rucaparib at 
doses up to 840 mg BID suggest there is a minimal risk of QTc prolongation. 
In the Phase 1 portion, 2 patients (1 breast cancer, 1 ovarian cancer, both gBRCAmut) achieved a 
RECIST CR and 7 patients (2 ovarian cancer, 4 breast cancer, 1 pancreatic cancer; all gBRCA 
mut) achieved a RECIST PR (n=2 at 300 mg QD; n=2 at 360 mg BID; n=3 at 480 mg BID; and 
n=2 at 600 mg BID). In addition, 3 patients with ovarian cancer achieved a cancer antigen 125 
(CA-125) response as defined by Gynecologic Cancer InterGroup (GCIG) criteria. The disease 
control rate (CR, PR, or SD>12 wks at doses ≥360 mg BID in evaluable ovarian cancer patients 
is 92% (11/12). Responses have been durable across tumor types. 
Preliminary efficacy data are available for 16 patients in the Phase 2 portion of Study CO-338-
010. Currently, 12 of 16 (75%) patients have achieved a RECIST PR. Response to treatment 
occurs rapidly; the majority of these patients achieved a PR by the first disease assessment (week 
6). All responses are ongoing, with several patients in Cycle 5 of treatment or beyond. The vast 
majority of patients had some level of target lesion measurement reduction as shown in Figure 1. 
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Figure 1 Best Response in Target Lesions – Phase 2 Portion of Study CO-338-010 
 
After once daily oral administration of rucaparib for 15 days, steady state Cmax and AUC0-24 
generally increased dose proportionally. Tmax and t1/2 were independent of dose. Steady state 
exposure increased by an average of 89%, consistent with accumulation expected for a 
compound exhibiting a t1/2 of approximately 17 hours administered once daily. Following BID 
oral administration of rucaparib for 15 days, steady state Cmax and AUC0-24 generally increased 
dose proportionally. Moreover, BID dosing delivered a lower Cmax with a low peak to trough 
plasma concentration variation. The target trough level of 2 µM was achieved in 100% of 
patients (n=14) at ≥240 mg BID with low inter-patient variability (<4-fold) within each dose 
group. Steady state trough levels also exhibited low intra-patient variability (24% CV). No 
sporadically high exposures were observed. The effect of food on rucaparib PK was evaluated at 
40 mg (n=3) and 300 mg (n=6) doses administered once daily. There was no food effect; patients 
may take rucaparib on an empty stomach or with food.  
Updates of study information may be found in the Investigator’s Brochure. 
3.3.2.1.2 Study CO-338-017 
Study CO-338-017 (ARIEL2) is a Phase 2 study of rucaparib as monotherapy treatment for 
relapsed, platinum-sensitive high-grade ovarian, fallopian tube or primary peritoneal cancer. The 
purpose of this study is to define a tumor-based molecular signature of HRD in ovarian cancer 
that correlates with response to rucaparib and enables selection of appropriate ovarian cancer 
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patients for treatment with rucaparib. The trial is enrolling patients with and without a BRCA1/2 
mutation in order to enable identification of this response signature, which will then be 
prospectively applied to the primary analysis of study CO -338-014 (ARIEL3). Tumor HRD 
status is assessed using next generation sequencing, with an algorithm for HRD status based on 
the presence of a BRCA mutation (germline or somatic) and/or degree of tumor genomic loss of 
heterozygosity (LOH), a phenotypic consequence of HRD.  
All patients enrolled into Clinical Study CO-338-017 (ARIEL2) must have received at least 1 
prior platinum-based treatment regimen, received a platinum-based regimen as their last course 
of treatment and have platinum-sensitive disease, defined as disease progression >6 months after 
the last dose of platinum. In addition, all patients must have disease that can be biopsied and is 
measurable by RECIST v1.1. Rucaparib 600 mg BID is administered continuously until disease 
progression. 
Clinical Study CO-338-017 (ARIEL2) was initiated in October 2013. As of 27 June 2014, 72 of 
180 planned patients have been enrolled. The median age is 65.5 years (range 44 – 83) and the 
majority of patients (n= 54, 75%) had Eastern Cooperative Oncology Group (ECOG) 
performance status of 0.  
The most frequent (reported in ≥15% of patients treatment-related adverse events (all grades) as 
of 27 June 2014 are gastrointestinal-related toxicities (nausea, constipation, vomiting, diarrhea, 
and abdominal pain), fatigue, elevations in ALT/AST, decreased appetite, and dysgeusia. 
Transaminase elevations occur early in treatment and are generally transient and resolve or 
stabilize. All patients who experienced adverse events related to rucaparib, including those with 
Grade 3 transaminase elevation, were successfully managed by treatment interruption and/or a 
dose reduction. No patient has discontinued rucaparib due to a treatment-related adverse event. 
No patients have died on study or within 30 days of last dose of rucaparib. 
Response data are preliminary, yet indicate that rucaparib has activity in BRCAwt patients with 
high level of LOH as well as in BRCAmut patients. 
Updates of study information may be found in the Investigator’s Brochure. 
3.3.2.1.3 Study A4991002, A4991005, and A4991014 
Further details of these studies are provided in the Investigator’s Brochure. 
3.3.2.1.4 Safety: Events of Special Interest 
The current list of adverse events of special interest (AESIs) is located in the rucaparib IB. As of 
25 March 2016, there have been 3 events of Myelodysplastic Syndrome (MDS) and 2 events of 
Acute Myeloid Leukemia (AML) reported in patients participating in Clovis-sponsored clinical 
studies. The 2 events of AML were reported in this study (CO-338-014 [ARIEL3]). The 3 events 
of MDS were reported in open-label studies CO-338-017 (ARIEL2) (n=2) and CO-338-010 
(n=1). One of these 5 events was fatal. 
More than 900 patients have received oral rucaparib in Clovis-sponsored studies as of 
25 March 2016, thus these events have been observed in < 0.6% of all patients treated in these 
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trials.  All patients experiencing these events received prior treatment with chemotherapy. While 
the etiology of these events is confounded by prior treatments and the relationship to rucaparib is 
not clear, Clovis has added these potential risks to all informed consent forms and patient 
information sheets. Events of MDS and AML have also been reported with another PARP 
inhibitor.51 
3.4 Rationale for Study 
In vitro studies have shown that cells deficient in BRCA1/2 as well as cells deficient in or 
depleted of homologous recombination proteins other than BRCA1/2 have been associated with 
PARP inhibitor sensitivity in vitro.16, 17, 25-28 Clinical data have shown that ovarian cancer 
patients with and without evidence of a gBRCA mutation benefit from treatment with a PARP 
inhibitor18-22 and that maintenance treatment with a PARP inhibitor following a response to 
platinum-based treatment increases PFS in patients with ovarian cancer.29, 30 While patients with 
a BRCA mutation derived the most benefit, patients without evidence of a BRCA mutation also 
derived significant benefit.21, 30 The purpose of this study is to evaluate PFS of patients with 
platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, fallopian tube, or 
primary peritoneal cancer who receive rucaparib or placebo as switch maintenance therapy 
following a response to platinum-based chemotherapy in order to identify the patients most 
likely to benefit from treatment with rucaparib. It is anticipated that rucaparib will provide 
therapeutic benefit and increase PFS in patients with HRD associated with a BRCA gene 
mutation or other HR gene alteration. 
Patients will be stratified into one of 3 HRD subgroups (tBRCA, nbHRD, and biomarker 
negative) (Appendix A) by Foundation Medicine’s ICTA, which will determine HRD status 
through analysis of homologous recombination gene mutations in tumor tissue. Tumor DNA will 
also be assessed to detect the presence of genomic scars.33-36 Analysis of specific genomic 
scarring patterns may identify tumors with HRD regardless of the underlying mechanism(s). 
Homologous recombination gene mutation analysis and genomic scarring will also be assessed in 
a Phase 2 study (CO-338-017) that will be initiated in parallel with this Phase 3 study. The 
insights from study CO-338-017 will be applied prospectively to the analysis of this Phase 3 
trial. The FCTA analysis plan (gene mutation and/or genomic scarring) and classification of 
HRD subgroups will be finalized and locked down prior to the completion of the Phase 3 study 
and applied prospectively to the analysis of this Phase 3 study. 
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4 STUDY OBJECTIVES 
4.1 Objectives and Endpoints 
This is a double-blind efficacy study of oral rucaparib in patients with platinum-sensitive, 
relapsed high-grade serous or endometrioid epithelial ovarian, fallopian tube, or primary 
peritoneal cancer who receive rucaparib or placebo as switch maintenance therapy following a 
response to platinum-based chemotherapy. 
Primary, secondary, and exploratory objectives and endpoints are shown in Table 1. 
Table 1. Primary, Secondary, and Exploratory Objectives and Endpoints 
Primary Objectives Primary Endpoints 
1. To evaluate PFS by RECIST, as assessed by 
the investigator, in molecularly-defined 
HRD subgroups 
1. Disease progression according to RECIST 
Version 1.1 (v1.1), as assessed by the 
investigator, or death from any cause 
(invPFS), in molecularly defined subgroups 
Secondary Objectives Secondary Endpoints 
1. To evaluate patient-reported outcome (PRO) 
of disease related symptoms utilizing the 
disease-related symptoms – physical 
(DRSP) subscale of the National 
Comprehensive Cancer Network-Functional 
Assessment of Cancer Therapy 
(NCCN-FACT) FACT-Ovarian Symptom 
Index 18 (FOSI-18) 
1. Time to a 4-point decrease in the DSRP 
subscale of the FOSI-18 
2. To evaluate PRO utilizing the complete 
FOSI-18 
2. Time to an 8-point decrease in the total score of 
the FOSI-18 
3. To evaluate survival benefit 3. OS 
4. To evaluate PFS by RECIST, as assessed by 
independent radiology review (IRR), in 
molecularly-defined HRD subgroups 
4. Disease progression according to RECIST v1.1, 
as assessed by IRR, or death from any cause 
(irrPFS), in molecularly defined subgroups 
5. To evaluate safety  5. Incidence of AEs, clinical laboratory 
abnormalities, and dose modifications 
6. To determine the population PK of rucaparib 6. Individual model parameter estimates of 
rucaparib and covariates identification 
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Table 1. Primary, Secondary, and Exploratory Objectives and Endpoints 
(continued) 
Exploratory Objectives Exploratory Endpoints 
1. To evaluate the relationship between cancer 
antigen 125 (CA-125) levels and invPFS 
1. Association between the change from baseline 
in CA-125 measurements and invPFS 
2. To evaluate PFS2 (PFS on the subsequent 
line of treatment) 
2. Time to the next event of disease progression or 
death, as assessed by the investigator 
3. To evaluate ORR 3. ORR per RECIST v1.1, as assessed by both 
investigator and IRR, in patients with 
measureable disease at study entry 
4. To evaluate duration of response (DOR) 4. DOR per RECIST Version 1.1, as assessed by 
both investigator and IRR 
5. To evaluate PRO utilizing the Euro-Quality 
of Life 5D (EQ-5D) 
5. PRO as measured by the total score on the 
EQ-5D 
6. To explore the relationship between 
rucaparib exposure, efficacy, and safety 
6. Rucaparib PK, invPFS, irrPFS, CA-125, AEs, 
clinical laboratory abnormalities, and dose 
modifications 
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5 STUDY DESIGN 
5.1 Overall Study Design and Plan 
This is a double-blind efficacy study of oral rucaparib in patients with platinum-sensitive, 
high-grade serous or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer 
who receive rucaparib or placebo as switch maintenance therapy following a response to 
platinum-based chemotherapy. 
5.1.1 Screening Phase 
All patients will undergo screening assessments within 120 days prior to randomization.  
The study will enroll patients with platinum-sensitive (defined as disease with confirmed 
radiologic relapse > 6 months after the last dose of the penultimate platinum regimen received), 
high-grade serous or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer 
who achieved a response to platinum-based chemotherapy administered for relapsed disease. 
Patients must have received ≥ 2 prior platinum-based treatment regimens, inclusive of the 
regimen that must have been administered immediately prior to maintenance therapy in this trial. 
There is no limit on the number of prior platinum-regimens that may have been received, but the 
patient must have been sensitive to the penultimate platinum regimen received. In addition, up to 
1 prior non-platinum chemotherapy regimen is permitted. Prior hormonal therapy is permitted; 
this treatment will not be counted as a non-platinum regimen. Prior maintenance therapy may 
have been administered with any prior treatment, with the exception of the platinum regimen 
received immediately prior to maintenance in this study. For the last chemotherapy course prior 
to study entry, patients must have received a platinum-based doublet chemotherapy regimen 
(minimum 4 cycles) and have achieved a CR (defined as complete radiologic response by 
RECIST [Appendix B] or PR (defined as partial response by RECIST [Appendix B] and/or a 
GCIG CA-125 response [Appendix C]. All responses require that CA-125 be < ULN. The 
response must be maintained through the completion of chemotherapy and during the interval 
period between completion of chemotherapy and entry in the study.  
Screening assessments will include demographics and medical history, prior treatments for 
serous or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer (and other 
malignancies, if applicable), prior and current medications and procedures, 12 lead 
electrocardiogram (ECG), ECOG performance status, central laboratory hematology, serum 
chemistry, and CA-125 measurement, serum pregnancy (for women of childbearing potential 
only), urinalysis, physical examination, height, weight, and vital signs measurements, adverse 
events, and radiologic assessment by CT or MRI. PRO will be collected using the FOSI-18 and 
EQ-5D instruments.  
Germline BRCA mutation results should be obtained for all patients who are known to have been 
tested prior to enrollment in order to determine whether any mutation was reported and if so, 
whether the mutation was classified as deleterious / pathogenic or other. Enrollment of patients 
with a gBRCA mutation classified as deleterious (i.e. pathogenic), suspected deleterious, or the 
equivalent, on the most recent assessment by a testing laboratory will be limited to 150. Patients 
with a BRCA mutation detected in tumor tissue (tBRCA) will be limited to 200. Once this cap is 
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reached, newly screened patients identified as having a BRCA mutation in tumor tissue will be 
offered treatment in another study. 
The complete results of the Foundation Medicine NGS test, which examines exons of 287 genes 
as well as introns of 19 genes, will be provided to all patients who opt to receive this information 
and provide appropriate consent. Results for the BRCA genes will be provided to patients who 
consent to receive this information upon availability. Results for the remainder of the gene panel 
will be provided to consenting patients upon treatment discontinuation. All results are to be 
disclosed to consenting patients by the study physician as part of an overall clinical discussion. 
In the event a mutation associated with hereditary cancer or other syndrome is detected in tumor 
tissue, the patient will be referred by the investigator for genetic counseling and potential 
germline testing per institutional guidelines. If the patient chooses to have germline BRCA 
testing, this result will be entered into the clinical trial database. The Sponsor will remain blinded 
to all NGS test results (including all tBRCA results), as well as existing BRCA data, until the 
primary efficacy analysis is conducted. 
Mutations detected in tumor tissue may be somatic or germline; however, the NGS test will not 
distinguish between the two. A blood sample will therefore be collected for all patients and 
stored. Prior to final efficacy analysis, genomic DNA may be subjected to exploratory analysis in 
order to determine whether any mutation identified is of germline or somatic origin. This data 
will be generated in a research setting and will not be provided to the investigator or patient. 
Enrollment will require Clovis (or designee) review of eligibility, including, but not limited to: 
• The number of prior therapies and the details for the penultimate and most recent 
platinum-based regimens, including dates administered; 
• documentation supporting platinum sensitivity; 
• documentation supporting a RECIST or GCIG CA-125 response to most recent platinum-
based treatment; 
• confirmation if patient has had local gBRCA testing;  
• confirmation that sufficient tumor tissue was submitted for HRD stratification for 
randomization and storage for potential bridging to a validated companion diagnostic test 
and analysis results were successfully transmitted to IXRS 
5.1.2 Randomization 
Randomization to study treatment must occur within 8 weeks following a patient’s last dose of 
platinum-based chemotherapy, and is described in more detail in Section 7.2. Study treatment 
must be initiated within 3 days of randomization. 
5.1.3 Double-Blind Treatment Phase 
During the double-blind treatment phase (continuous 28-day treatment cycles), patients will be 
monitored for safety and efficacy. Assessments will include AEs, physical examination, vital 
signs and weight measurement, central laboratory hematology, serum chemistry, including 
alpha-1 acid glycoprotein (AAG) analysis on days where a blood sample is taken for PK, and 
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CA-125 measurement, serum pregnancy for women of childbearing potential, concomitant 
medications, therapies and procedures, disease status assessment, study drug administration and 
accountability, and PRO. ECGs and urinalysis will be performed as clinically indicated. Blood 
samples will also be collected for population PK. The purpose of AAG monitoring is to 
determine whether there is an association with rucaparib PK variability. 
Patients will be assessed for disease status per RECIST v1.1 every 12 calendar weeks (up to 1 
week prior is permitted) following initiation of study treatment on Day 1 of Cycle 1. Patients 
experiencing disease progression by RECIST v1.1, as assessed by the investigator, will be 
discontinued from treatment and enter follow-up. Disease progression will only be determined 
by RECIST v1.1. Patients with a CR at study entry will only be considered to have disease 
progression if a new lesion is identified. Patients who meet GCIG CA-125 criteria for disease 
progression should have a radiologic assessment and be assessed by RECIST v1.1. If the 
radiologic assessment does not confirm disease progression, patients should continue on 
treatment and be assessed by RECIST v1.1 per the protocol schedule of assessments. 
All CT scans (and other imaging, as appropriate) performed during the treatment period and at 
treatment discontinuation will be collected for IRR. 
Patients will be continuously monitored for safety. An Independent Data Monitoring Committee 
(IDMC) with multidisciplinary representation will evaluate safety in compliance with a 
prospective charter. 
5.1.4 Treatment Discontinuation 
Upon treatment discontinuation, regardless of reason, patients will have a Treatment 
Discontinuation visit. Assessments will include AEs, physical examination, vital signs and 
weight measurements, central laboratory hematology, serum chemistry, and CA-125 
measurement, serum pregnancy (for women of childbearing potential only), concomitant 
medications, therapies and procedures, disease status assessment, study drug accountability, and 
PRO. Additionally, all patients discontinued from treatment will be followed for 28 days 
following the last dose of study drug for the collection of AEs and PRO. An optional tumor 
biopsy will be collected from patients who experience disease progression and provide 
appropriate consent. 
5.1.5 Follow-Up Phase 
After the Treatment Discontinuation visit, all patients will be followed for AEs up to 28 days 
after last dose of study drug. Patients will also be followed for survival, subsequent treatments, 
and monitoring for secondary malignancy every 12 weeks (± 14 days) until death, loss to follow-
up, withdrawal of consent, or study closure.  
Patients who discontinued treatment for reason other than disease progression or death should 
continue to have tumor scans performed at 12-week intervals from Cycle 1 Day 1 (a window of 
up to 7 days prior is permitted) until disease progression by RECIST v1.1, as assessed by the 
investigator. 
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5.2 Study Schema 
An overview of the study design is provided in Figure 2. 
Figure 2 Study Schema 
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5.3 End of Study 
The trial is monitored on an ongoing basis by an IDMC for the number of PFS events required 
for the primary endpoint and for safety signals. An unblinding of treatment assignment might be 
performed when the study is still ongoing if the IDMC recommends it. However, the study is not 
anticipated to close until all patients are off treatment and sufficient OS follow up has occurred. 
Upon formal closure of the study, individual patients who are continuing to benefit from 
treatment with rucaparib at the time of study closure, and who do not meet any of the criteria for 
withdrawal, will have the option of entering an extension protocol in which they can continue to 
receive rucaparib. 
The sponsor may discontinue the study early for any reason as noted in Section 13.6. 
5.4 Discussion of Study Design 
This is a multicenter, randomized, double-blind, placebo-controlled study. 
Sponsor personnel (with the exception of individuals responsible for clinical supply chain), 
investigator and clinical site staff, and patient will all be blinded to study treatment to avoid bias 
in the interpretation of the efficacy and safety results. To avoid bias between treatment groups, 
patients will be randomized to treatment with active drug or placebo with stratification according 
to HRD classification, interval between completion of penultimate platinum-based regimen and 
disease progression by radiologic assessment, and best response to platinum regimen received 
immediately before initiation of maintenance therapy.  
PFS by RECIST will be assessed by the investigator for the primary endpoint (invPFS) and by a 
blinded independent radiologist for the secondary endpoint (irrPFS). 
Ongoing benefit/risk will be assessed regularly by an IDMC that will have access to unblinded 
datasets. 
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6 STUDY POPULATION 
6.1 Number of Patients and Sites 
Approximately 540 patients with platinum-sensitive, relapsed, high-grade serous or endometrioid 
epithelial ovarian, fallopian tube, or primary peritoneal cancer will be enrolled at approximately 
90 – 100 study sites. A minimum of 180 and a maximum of 200 patients with a deleterious 
tBRCA mutation will be enrolled. Enrollment of patients with a known deleterious gBRCA 
mutation documented in their medical record will not exceed 150. There is no minimum number 
of patients required for each of the nbHRD and biomarker negative subgroups; however, no 
more than 360 total patients will be randomized for stratification into these subgroups combined. 
6.2 Inclusion Criteria 
All patients enrolling into the study must meet all of the following inclusion criteria: 
1. Have signed an Institutional Review Board/Independent Ethics Committee-approved 
informed consent form prior to any study-specific evaluation 
2. Be 18 years of age at the time the informed consent form is signed 
3. Have a histologically confirmed diagnosis of high-grade (Grade 2 or 3) serous or 
endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer  
 For mixed histology, >50% of the primary tumor must be confirmed to be high-grade 
serous or endometrioid 
 Grade 2 tumors classified under a 3-tier system should be re-reviewed by local pathology 
and confirmed as high-grade under the 2-tier system  
4. Received prior platinum-based therapy and have platinum-sensitive disease (i.e. documented 
radiologic disease progression >6 months following the last dose of the penultimate platinum 
administered) 
 Received ≥2 prior platinum-based treatment regimens, including platinum-based regimen 
that must have been administered immediately prior to maintenance therapy in this trial. 
In addition, up to 1 non-platinum chemotherapy regimen is permitted. Prior hormonal 
therapy is permitted; this treatment will not be counted as a non-platinum regimen. 
 There is no upper limit on the number of prior platinum-based regimens that may have 
been received, but the patient must have been sensitive to the penultimate platinum-based 
regimen administered. 
 If both neoadjuvant and adjuvant treatment were administered pre/post any debulking 
surgery, this will be considered 1 treatment regimen 
 Prior maintenance therapy following a prior treatment regimen is permitted, with the 
exception of the regimen received immediately prior to maintenance in this study. No 
anticancer therapy is permitted to be administered as maintenance treatment in the 
interval period between completion of the most recent platinum-based therapy and 
initiation of study drug in this trial. 
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5. Achieved best response of either CR or PR to the most recent platinum-based regimen 
administered and is randomized to study treatment within 8 weeks of the last dose of 
platinum received 
 The most recent platinum-based regimen must have been a chemotherapy doublet. The 
choice of the platinum and the 2nd chemotherapy agent is per Investigator’ discretion. 
 A minimum of 4 cycles of platinum chemotherapy must have been administered. There is 
no cap on the maximum number of cycles; however, additional cycles of treatment 
administered following completion of therapy for the specific purpose of enabling patient 
eligibility and randomization within 8 weeks of the last platinum dose is not permitted. 
 A CR is defined as a complete radiologic response per RECIST v1.1, i.e. absence of any 
detectable disease and CA-125 <ULN* 
 A PR is defined as either a partial response per RECIST v1.1 (if disease was measurable 
prior to chemotherapy) or a serologic response per GCIG CA-125 response criteria (if 
disease was not measurable according to RECIST v1.1)* 
 CA-125 must also be <ULN for all responses classified as a PR 
 R0 surgery (no visible tumor) or R1 surgery (residual disease <1 cm) as a component of 
the most recent treatment regimen is not permitted. The response assessment must be 
determined solely in relation to the chemotherapy regimen administered. The presence of 
measurable disease or CA-125 >2 x ULN immediately prior to the chemotherapy regimen 
is required. 
 Responses must have been maintained through the completion of chemotherapy and 
during the interval period between completion of chemotherapy and entry in the study 
 All disease assessments performed prior to and during this chemotherapy regimen must 
be adequately documented in the patient’s medical record 
6. Have sufficient archival formalin-fixed paraffin-embedded (FFPE) tumor tissue (1 x 4 µm 
section for hematoxylin and eosin [H&E] stain and approximately 8 – 12 x 10 µm sections, 
or equivalent) available for planned analyses. 
 The most recently collected tumor tissue sample should be provided, if available  
 Submission of a tumor block is preferred; if sections are provided, these must all be from 
the same tumor sample 
 Sample must be received at the central laboratory at least 3 weeks prior to planned 
start of treatment in order to enable stratification for randomization 
7. Have CA-125 measurement that is < ULN 
8. Have ECOG performance status of 0 to 1 
9. Have adequate organ function confirmed by the following laboratory values obtained within 
14 days of the first dose of study drug: 
 Bone Marrow Function 
o Absolute neutrophil count (ANC)  1.5 × 109/L 
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o Platelets > 100 × 109/L  
o Hemoglobin  9 g/dL 
 Hepatic Function 
o Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)  3 × ULN; 
if liver metastases, then  5 × ULN 
o Bilirubin  1.5 × ULN (< 2 x ULN if hyperbilirubinemia is due to Gilbert’s 
syndrome) 
 Renal Function  
o Serum creatinine  1.5 × ULN or estimated glomerular filtration rate (GFR) 
≥ 45 mL/min using the Cockcroft Gault formula 
* Note: It is acceptable for sites to utilize local and contemporaneous clinical imaging reports 
to record lesion measurement history and define a burden of disease according to RECIST; it 
is not a requirement to re-read radiological scans to collect this data. 
6.3 Exclusion Criteria 
Patients will be excluded from participation if any of the following criteria apply: 
1. History of a prior malignancy except: 
 Curatively treated non-melanoma skin cancer 
 Breast cancer treated curatively >3 years ago, or other solid tumor treated curatively >5 
years ago, without evidence of recurrence 
 Synchronous endometrioid endometrial cancer (Stage 1A G1/G2) 
2. Prior treatment with any PARP inhibitor, including oral or intravenous rucaparib. Patients 
who previously received iniparib are eligible. 
3. Required drainage of ascites during the final 2 cycles of their last platinum-based regimen 
and/or during the period between the last dose of chemotherapy of that regimen and 
randomization to maintenance treatment in this study 
4. Symptomatic and/or untreated central nervous system (CNS) metastases. Patients with 
asymptomatic previously treated CNS metastases are eligible provided they have been 
clinically stable for at least 4 weeks. 
5. Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the 
opinion of the Investigator, interfere with absorption of study drug 
6. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome 
(AIDS)-related illness, or history of chronic hepatitis B or C 
7. Pregnant or breast feeding. Women of childbearing potential must have a negative serum 
pregnancy test ≤ 3 days prior to first dose of study drug 
8. Received treatment with chemotherapy, radiation, antibody therapy or other immunotherapy, 
gene therapy, vaccine therapy, angiogenesis inhibitors, or experimental drugs  14 days prior 
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to first dose of study drug and/or ongoing adverse effects from such treatment > NCI CTCAE 
Grade 1, with the exception of Grade 2 non-hematologic toxicity such as alopecia, peripheral 
neuropathy, and related effects of prior chemotherapy that are unlikely to be exacerbated by 
treatment with study drug 
 Ongoing hormonal treatment for previously treated breast cancer is permitted 
 Refer also to inclusion criteria #4 for guidelines pertaining to prior maintenance therapy 
9. Received administration of strong CYP1A2 or CYP3A4 inhibitors 7 days prior to first dose 
of study drug or have on-going requirements for these medications (Appendix F) 
10. Non-study related minor surgical procedure 5 days, or major surgical procedure ≤21 days, 
prior to first dose of study drug; in all cases, the patient must be sufficiently recovered and 
stable before treatment administration 
11. Presence of any other condition that may increase the risk associated with study participation 
or may interfere with the interpretation of study results, and, in the opinion of the 
investigator, would make the patient inappropriate for entry into the study 
6.4 Patients or Partners of Patients of Reproductive Potential 
Pregnancy is an exclusion criterion and women of childbearing potential must not be considering 
getting pregnant during the study. Female patients are considered to be of childbearing potential 
unless 1 of the following applies: 
• Postmenopausal, defined as no menses for at least 12 months without an alternative 
medical cause. A high follicle-stimulating hormone (FSH) level consistently in the 
postmenopausal range (30 mIU/mL or higher) may be used to confirm a postmenopausal 
state in women not using hormonal contraception or hormonal replacement therapy; 
however, in the absence of 12 months of amenorrhea, a single FSH measurement is 
insufficient to confirm a postmenopausal state: or  
• Considered to be permanently sterile. Permanent sterilization includes hysterectomy, 
bilateral salpingectomy, and/or bilateral oophorectomy.  
Female patients of childbearing potential must have a negative serum pregnancy test result 
≤ 3 days prior to administration of the first dose of study drug. In addition, a serum pregnancy 
test must be performed within ≤ 3 days prior to Day 1 of every subsequent cycle during the 
treatment phase and at the Treatment Discontinuation visit. All pregnancy testing will be 
performed by the local laboratory. 
Female patients of reproductive potential must practice highly effective methods of 
contraception (failure rate < 1% per year) with their male partners during treatment and for 
6 months following the last dose of study drug. Highly effective contraception includes: 
• Ongoing use of progesterone-only injectable or implantable contraceptives (eg, Depo 
Provera, Implanon, Nexplanon); 
• Placement of an intrauterine device (IUD) or intrauterine system (IUS); 
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• Bilateral tubal occlusion;  
• Male sterilization, with appropriate post-vasectomy documentation of absence of sperm 
in ejaculate; or 
• Sexual abstinence as defined as complete or true abstinence, acceptable only when it is 
the usual and preferred lifestyle of the patient; periodic abstinence (eg, calendar, 
symptothermal, post-ovulation methods) is not acceptable. 
Patients will be instructed to notify the investigator if pregnancy is discovered either during or 
within 6 months of completing treatment with study drug.  
6.5 Waivers of Inclusion/Exclusion Criteria 
No waivers of these inclusion or exclusion criteria will be granted by the investigator and the 
sponsor or its designee for any patient enrolling into the study. 
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7 DESCRIPTION OF STUDY TREATMENTS AND DOSE MODIFICATIONS 
7.1 Description of Investigational Product 
Rucaparib camsylate (also known as CO-338; previously known as PF-01367338-BW) is an oral 
formulation with a molecular weight of 555.67 Daltons. Rucaparib tablets for oral administration 
and matched placebo tablets will be supplied to the study sites by the sponsor. A brief 
description of the investigational product is provided below. 
Drug Name: CO-338 
rINN: rucaparib  
Formulation: Oval tablet; film coated; salmon pink 
How Supplied: 120 mg (as free base) strength in high-density polyethylene bottles or 
equivalent with child-resistant caps 
Storage Conditions: 15–30 °C/ 59-86 ºF 
Placebo tablets will be identical in appearance to the rucaparib tablets. 
Study drug containers containing rucaparib or placebo tablets will be labeled according to 
national regulations for investigational products. Where accepted, the expiry date will not appear 
on the labels, but will be controlled by the use of an Interactive Voice Response 
System/Interactive Web Response System (IVRS/IWRS). 
7.2 Method of Assigning Patients to Treatment Groups 
Following confirmation of eligibility in the screening phase, patients will be randomized 2:1 to 
receive rucaparib or placebo. Randomization will occur by a central randomization procedure 
using IVRS/IWRS. The following will be included as randomization stratification factors at 
study entry to ensure treatment groups are balanced:  
• HRD classification (tBRCA, nbHRD, or biomarker negative) by the ICTA (Appendix A) 
• Interval between completion of the penultimate platinum-based regimen and disease 
progression (6 to 12 or >12 months) by radiologic assessment 
• Best response (CR [defined as complete radiologic response by RECIST] or PR [defined 
as partial response by RECIST and/or a GCIG CA-125 response] to platinum regimen 
received immediately prior to initiation of maintenance therapy. All responses require 
that CA-125 be <ULN. 
Randomization to study treatment must occur within 8 weeks following a patient’s last dose of 
platinum-based chemotherapy. Study treatment must be initiated within 3 days of randomization. 
7.3 Preparation and Administration of Protocol-Specified Treatment 
The investigator or designee will be responsible for distributing study drug to all patients. Study 
drug will be assigned by the IVRS/IWRS according to the patient’s randomization assignment. 
The system must be accessed at each dispensation in order to retrieve the bottle number 
Clovis Oncology, Inc.   Clinical Protocol 
Oral rucaparib (CO-338) CO-338-014 
 7 July 2016  
Amendment 3 53 
 
appropriate to the patient’s treatment. Study sites should follow local guidelines for the handling 
of oral cytotoxic drugs. 
All patients will ingest study drug twice a day. Patients may take study drug on an empty 
stomach or with food (with a regular meal or within 30 minutes after a regular meal). Each dose 
should be taken with at least 8 oz (240 mL) of room temperature water. Tablets should be 
swallowed whole.  
Patients should take study drug doses as close to 12 hours apart as possible, preferably at the 
same times every day. If a patient misses a dose (i.e. does not take it within 4 hours of the 
scheduled time), she should skip the missed dose and resume taking study drug with their next 
scheduled dose. Missed or vomited doses should not be made up. 
A sufficient number of tablets will be provided to the patient to last until the next scheduled visit. 
Patients will be instructed to record daily doses taken or not taken in an electronic dosing diary, 
and will be instructed to bring their study drug tablets, all containers (empty, partially used, 
and/or unopened), and electronic dosing diary to the next scheduled visit for reconciliation by 
site personnel. The electronic dosing diary is a Class 1 listed (i.e. approved) device. 
7.3.1 Dietary Restrictions 
All patients participating in the study should be instructed not to consume any grapefruit 
products or any of the CYP1A2 or CYP3A4 inhibitors noted in Appendix F for 7 days prior to 
their first scheduled dose of oral rucaparib or placebo.  
7.4 Starting Dose and Dose Modifications of Protocol-Specified Treatment 
7.4.1 Starting Dose 
The starting dose in this study will be 600 mg rucaparib or matched placebo, bid. 
7.4.2 Dose Modification Criteria  
Treatment with study drug should be held if any of the following are observed and a dose 
reduction should be considered or implemented: 
• Grade 3 or 4 hematologic toxicity  
Grade 3 or 4 non-hematologic toxicity (except for alopecia, nausea, vomiting, or diarrhea 
adequately controlled with systemic antiemetic/antidiarrheal medication administered in 
standard doses according to the study center routines). Grade 3 or Grade 4 ALT/AST 
elevations should be managed as described below.  
• In addition, and at the discretion of the investigator, the dose of study drug may be held 
and/or reduced for Grade 2 toxicity not adequately controlled by concomitant 
medications and/or supportive care. 
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MANAGEMENT OF STUDY DRUG TREATMENT-EMERGENT ALT/AST 
ELEVATIONS 
• Grade 4 ALT/AST elevations: hold study drug until values have returned to Grade 2 or 
better, then resume study drug with a dose reduction. Monitor liver function tests weekly 
for 3 weeks after study drug has been restarted. 
• Grade 3 ALT/AST elevations, in the absence of other signs of liver dysfunction, should 
be managed as follows:  
– Monitor liver function tests weekly until resolution to ≤ Grade 2. 
– Continuation of study drug with elevation of ALT/AST up to Grade 3 is permitted 
provided bilirubin is < ULN and alkaline phosphatase is < 3 x ULN.  
– If patient has Grade 3 ALT/AST and continues on study drug, and levels do not 
decline within 2 weeks or they continue to rise, treatment interruption and 
resolution to ≤ Grade 2 will be required before study drug can be resumed, either 
at the current dose or at a reduced dose. 
Treatment with study drug should be held until the toxicity resolves to ≤ CTCAE Grade 2. Twice 
daily dosing may then be resumed at either the same dose or a lower dose, per investigator 
discretion. If treatment is resumed at the same dose, and the patient experiences the same 
toxicity, the dose should be reduced following resolution of the event to ≤ CTCAE Grade 2. If 
the patient continues to experience toxicity, additional dose reduction steps are permitted; 
however, the Investigator should consult with the Sponsor’s medical monitor before reducing to 
240 mg BID. If a patient continues to experience toxicity despite two dose reduction steps (ie, to 
a dose of 360 mg BID rucaparib or placebo), or if dosing with study drug is interrupted for > 14 
consecutive days due to toxicity, treatment should be discontinued, unless otherwise agreed 
between the investigator and the sponsor. 
Dose reduction steps are presented in Table 2. 
Dose re-escalation upon resolution of toxicity to ≤ CTCAE Grade 1 is permitted at the discretion 
of the Investigator. 
Table 2. Dose Reduction Steps 
Starting Dose 600 mg BID 
Dose Level -1 480 mg BID 
Dose Level -2 360 mg BID 
Dose Level -3* 240 mg BID 
*Consult with medical monitor before reducing to this dose 
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7.4.3 Criteria for Re-Treatment 
A new cycle of treatment may begin if: 
• ANC ≥1.0 x 109/L 
• Platelet count ≥100 x 109/L 
• Non-hematologic toxicities have returned to baseline or ≤ CTCAE Grade 1 severity (or, 
at the investigator’s discretion, ≤ CTCAE Grade 2 severity if not considered a safety risk 
for the patient). Grade 3 or Grade 4 ALT/AST elevations should be managed as described 
above. 
7.5 Accountability of Protocol-Specified Treatment 
Study personnel will maintain accurate records of study drug receipt, dispensation, use, return, 
destruction, and reconciliation. An IVRS/IWRS will be used to manage study drug inventory at 
all sites. In order to function properly, and to ensure patients receive the correct study drug 
according to the treatment assigned at randomization, the system will require real-time entry of 
study drug receipt, dispensation, or destruction, etc. by study personnel at the study center. 
The site is responsible for the return or destruction of study drug as required. Authorization to 
destroy study drug at the site that has not been dispensed to a patient (eg, expired study drug), 
must be requested from the Sponsor prior to destruction. Any study drug accidentally or 
deliberately destroyed must be accounted for. All study drug containers must be accounted for 
prior to their destruction at the study center, according to institutional procedures for disposal of 
cytotoxic drugs. Unused study drug containers should be destroyed on-site if possible. 
Destruction of damaged or expired study drug at the site requires prior approval by the sponsor. 
If destruction on site is not possible, supply should be returned to the drug depot.  
During the course of the study and at completion of the study, the number of study drug 
containers received, dispensed, returned, and destroyed must be reconciled.  
7.6 Blinding/Masking of Treatment 
Active and placebo tablets will be identical in appearance and supplied in identical containers. 
The medication labeling will ensure that no staff member or patient will be able to identify 
whether the tablets are placebo or contain active medication. 
Patients will take the equivalent number of active or placebo tablets according to the treatment 
assignment and scheduled dose. 
In the event of a medical emergency, an individual patient’s treatment assignment may be 
unblinded using IVRS/IWRS. The module to unblind treatment assignment is accessible only to 
specific authorized study personnel. AEs per se are not a reason to break the treatment code. 
Unblinding should only occur for medical emergencies that require explicit knowledge of the 
treatment administered in order to determine the next course of action. The IVRS/IWRS vendor 
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operates a 24-hour/365-day helpline as a back-up in the rare event the electronic system in 
unavailable when unblinding is required. 
The study will not be unblinded for overall safety evaluation. 
7.7 Treatment Compliance 
Documentation of dosing will be recorded in a study specific electronic dosing diary provided by 
the sponsor (or designee). Study site personnel will review dosing information with the patient 
(or legally authorized representative) on scheduled clinic visit days, providing instructions 
regarding dose, dose frequency and the number of tablets to be taken for each dose. Patients (or 
legally authorized representative) will be instructed to record dosing information for study drug 
taken at home in the electronic dosing diary and to bring the electronic dosing diary and all 
unused tablets with them to scheduled clinic visits. A compliance check and tablet count will be 
performed by study personnel during clinic visits. Every effort should be made to ensure patients 
complete the electronic dosing diary and return their study drug containers at the end of each 
cycle of treatment. 
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8 PRIOR AND CONCOMITANT THERAPIES 
Patients who have received prior treatment with a PARP inhibitor including IV or oral rucaparib, 
are not eligible to participate in this study. Patients having received prior treatment with iniparib 
are eligible. 
During the study, supportive care (eg, antiemetics; analgesics for pain control) may be used at 
the investigator’s discretion and in accordance with institutional procedures.  
All procedures performed (eg, thoracentesis, etc.) and medications used during the study must be 
documented on the eCRF.  
8.1 Anticancer or Experimental Therapy 
No anticancer therapy is permitted to have been administered as maintenance treatment in the 
interval period between completion of the most recent platinum-based chemotherapy and 
initiation of maintenance treatment in this study. 
No other anticancer therapies (including chemotherapy, radiation, hormonal treatment, antibody 
or other immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, or other 
experimental drugs) of any kind will be permitted while the patient is participating in the study, 
with the exception of ongoing hormonal treatment for previously treated breast cancer.  
8.2 Hematopoietic Growth Factors and Blood Products 
Erythropoietin, darbepoetin alfa, and/or hematopoietic colony-stimulating factors for treatment 
of cytopenias should be administered according to institutional guidelines. Transfusion 
thresholds for blood product support will be in accordance with institutional guidelines. 
8.3 CYP450 Isoenzyme Inhibitors, Inducers, and Substrates 
Based on in vitro CYP interaction studies (Please refer to current IB for details), caution should 
be used for concomitant medications with narrow therapeutic windows that are substrates of 
CYP2C19, CYP2C9, and/or CYP3A (Appendix F). Selection of an alternative concomitant 
medication is recommended.  
8.4 Bisphosphonates 
Bisphosphonates are permitted. 
8.5 Anticoagulants 
Caution should be exercised in patients receiving study drug and concomitant warfarin 
(Coumadin) as rucaparib showed a mixed inhibition of CYP2C9 in vitro. If appropriate, low 
molecular weight heparin should be considered as an alternative treatment. Patients taking 
warfarin should have international normalized ratio (INR) monitored regularly per standard 
clinical practice. 
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8.6 Other Concomitant Medications 
Therapies considered necessary for the patient’s well-being may be given at the discretion of the 
investigator and should be documented on the eCRF. Other concomitant medications, except for 
analgesics, chronic treatments for concomitant medical conditions, or agents required for 
life-threatening medical problems, should be avoided. Herbal and complementary therapies 
should not be encouraged because of unknown side effects and potential drug interactions, but 
any taken by the patient should be documented appropriately on the eCRF. 
Because rucaparib is a moderate inhibitor of P-gp in vitro, caution should be exercised for 
patients receiving study drug and requiring concomitant medication with digoxin. Patients taking 
digoxin should have their digoxin levels monitored after starting study drug and then regularly 
per standard clinical practice. Caution should also be exercised for concomitant use of certain 
statin drugs (eg, rosuvastatin and fluvastatin) due to potential increase in exposure from 
inhibition of BCRP and CYP2C9.52 
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9 STUDY PROCEDURES 
9.1 Schedule of Assessments 
Table 3 summarizes the procedures and assessments to be performed for all patients. 
All procedures and assessments are to be completed within ±3 days of the scheduled time point 
unless otherwise stated.  
Imaging guidelines provided in the Bioclinica Site Manual should be followed for the collection 
of images and the radiological assessment of disease.  
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Table 3. Schedule of Assessments 
k = The FOSI-18 and EQ-5D instruments must be completed prior to other scheduled study procedures and dosing (if applicable) at Screening, on Day 1 of each 
treatment cycle, at treatment discontinuation, and at the 28-day post-treatment discontinuation follow-up visit for all patients. If a patient has known brain 
metastases, this disease should be evaluated at each required assessment.  
l = Includes RBC and parameters (Hgb, Hct, MCV, MCH, MCHC) and reticulocyte count, WBC and differential (with ANC), and platelet count. Blood will be 
analyzed by a central laboratory. A duplicate sample may be collected and analyzed by the local laboratory for immediate eligibility/treatment decisions. 
m = Includes total protein, albumin, creatinine or estimated GFR using the Cockcroft Gault formula, BUN or urea, total bilirubin, ALP, ALT, AST, lipid panel (total 
cholesterol, LDL, HDL, and triglycerides), glucose, sodium, potassium, chloride, CO2, calcium, and phosphorus. Blood will be analyzed by a central laboratory. 
A duplicate sample may be collected and analyzed by the local laboratory for immediate eligibility/treatment decisions. 
n = Women of childbearing potential must have a negative serum pregnancy test result ≤ 3 days prior to the first dose of study drug. A serum pregnancy test must 
also be performed ≤ 3 days prior to Day 1 of every cycle during the treatment phase and at the treatment discontinuation visit. All tests will be performed by a 
local laboratory. 
o = Includes dipstick for protein, glucose, blood, pH, and ketones. If dipstick findings abnormal based on Investigator’s judgment, perform microscopic evaluation 
to assess abnormal findings. Urinalysis to be repeated as clinically indicated.  
p = CA-125 measurement should be performed at Screening, on Cycle 1, Day 1, at the start of every 3rd cycle thereafter (i.e. Day 1 of Cycles 4, 7, 10, etc.), at 
treatment discontinuation, and as clinically indicated. All CA-125 measurements will be performed by a central laboratory. 
q = Randomization to study treatment must occur within 8 weeks following a patient’s last dose of platinum-based chemotherapy and study treatment must begin 
within 3 days of randomization. Randomization will occur by a central randomization procedure using an IVRS/IWRS. Patients will be stratified based on HRD 
classification (tBRCA, nbHRD or biomarker negative), interval between completion of penultimate platinum regimen and disease progression (6 to 12 or > 12 
months) by radiologic assessment, and best response (RECIST CR, RECIST PR, or GCIG CA-125 response) to most recent platinum regimen. All responses 
require that CA-125 be <ULN. 
r = If sample is not collected on Day 1 of Cycle 1, it should be collected as soon as possible thereafter. 
s = AEs, SAEs, and AESIs that occur after first administration of study drug through to 28 days after last dose of study drug will be recorded. In addition, AEs that 
were related to a screening procedure will also be recorded. Section 10 includes the details of reporting AEs, SAEs, and AESIs.  
t = Ongoing SAEs/ AESIs will be followed to resolution or stabilization. 
u = PK samples to be collected on Day 15 of Cycle 1 (in morning or afternoon, after dose taken earlier in day), on Day 1 of Cycle 2 (prior to dosing), on Day 15 of 
Cycle 2 (in morning or afternoon, after dose taken earlier in day), and on Day 1 of Cycle 4 and Cycle 7 (prior to dosing). At least one morning post-dose sample 
and one afternoon post-dose sample must be taken for each patient. For example, if on Day 15 of Cycle 1 a PK sample is collected in the morning, then on 
Day 15 of Cycle 2, the PK sample should be collected in the afternoon. Conversely, if on Day 15 of Cycle 1 a PK sample is collected in the afternoon, then on 
Day 15 of Cycle 2, the PK sample should be collected in the morning. There is no requirement for either of these 2 samples to be collected at a specific time 
following the first dose taken on these days (Cycle 1 Day 15 and Cycle 2 Day 15). 
v = Serum AAG sample to be collected on the same day as the PK sample. Sample should be collected at the same time as the hematology and serum chemistry 
samples for central laboratory testing. 
w = An optional tumor biopsy may be collected from patients at time of disease progression. Additional consent is required. Refer to the Pathology Charter for 
detailed sample handling instructions. 
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Table 3. Schedule of Assessments 
x = All patients discontinued from treatment, regardless of reason, should be followed for subsequent treatments, secondary malignancy, and survival every 
12 weeks (± 14 days) from Cycle 1 Day 1 until death, loss to follow-up, withdrawal of consent from study, or closure of the study. Follow-up can be performed 
via the telephone. Diagnosis of any secondary malignancy requires appropriate documentation (i.e. laboratory and/or pathology reports) and should be reported a 
specified in Section 10.8. 
Clovis Oncology, Inc.  Clinical Protocol 
Oral rucaparib (CO-338) CO-338-014 
 7 July 2016 
   
Amendment 3 64 
 
9.2 Screening Phase 
Following written informed consent, and unless otherwise specified, the following assessments 
will be performed prior to randomization. Assessments performed within the specified windows, 
but prior to patient signing informed consent, are acceptable only if confirmed to have been 
standard of care. 
Up to 120 days prior to randomization: 
• Medical history, including demographic information (birth date, race, gender, etc.) and 
smoking status, and oncology history, including date of diagnosis for ovarian, primary 
peritoneal, or fallopian tube cancer (and other malignancy, if applicable), prior treatments 
received, dates of administration, best response achieved, date of progression and how 
assessed, radiology reports, and gBRCA mutation status (if known) 
• FFPE archival tumor tissue sample. Sufficient archival FFPE tumor tissue (enough for 
1 x 4 µm section for H&E and approximately 8 to 12 x 10 µm sections, or equivalent) for 
planned analyses should be provided. Refer to the Pathology Charter for detailed sample 
handling instructions.  
o The most recently collected tumor tissue sample should be provided, if available.  
o Submission of a tumor block preferred; if sections are provided, these must all be 
from the same tumor sample. 
o Tumor content ≥30% is strongly preferred for successful genomic scarring / LOH 
analysis 
o Sample must be submitted to the central laboratory at least 3 weeks prior to 
planned start of treatment in order to enable stratification for randomization 
• AE monitoring (only if related to screening procedure) 
Up to 28 days prior to randomization: 
• PRO collected using the FOSI-18 and EQ-5D instruments 
• Physical examination by body system, including height and weight 
• Vital signs (blood pressure, pulse, and temperature) 
• 12-lead ECG 
• Prior and concomitant medications and any surgical procedures  
• Disease assessment/tumor scans: tumor assessments should consist of clinical examination 
and appropriate imaging techniques (including CT scans of the chest, abdomen, and pelvis 
with appropriate slice thickness per RECIST; other studies (magnetic resonance imaging 
[MRI], X-ray, positron emission tomography [PET], and ultrasound) may be performed if 
required. The same methods used to detect lesions at baseline are to be used to follow lesions 
throughout the clinical study. If a patient has known brain metastases, this disease should be 
evaluated at each required assessment. CT/ MRI scans of the chest, abdomen, and pelvis 
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performed to determine the extent of disease at baseline should also be performed at each 
time of disease assessment, even if the scans were negative at baseline.  
• ECOG performance status (Appendix D) 
• AE monitoring (only if related to screening procedure) 
Up to 14 days prior to randomization: 
• Hematology (RBC and parameters [Hgb, Hct, MCH, MCV, and MCHC] and reticulocyte 
count, white blood cell [WBC] and differential [with ANC], and platelet count 
• Serum chemistry (total protein, albumin, creatinine, or estimated GFR using the Cockcroft 
Gault formula, blood urea nitrogen [BUN] or urea, total bilirubin, ALP, ALT, AST, glucose, 
sodium, potassium, chloride, CO2, calcium, and phosphorus) and lipid panel (total 
cholesterol, low density lipoprotein [LDL], high density lipoprotein [HDL], and 
triglycerides). Note: fasting is not required. 
• Urinalysis performed on freshly voided clean sample (dipstick for protein, glucose, blood, 
pH, and ketones) ≤14 days prior to the first dose of study drug. If dipstick findings are 
abnormal based on investigator judgment, then a microscopic evaluation will be performed to 
assess the abnormal findings 
• CA-125 measurement 
• AE monitoring (only if related to screening procedure) 
Up to 3 days prior to first dose of study drug: 
• Serum pregnancy test for women of childbearing potential 
• AE monitoring (only if related to screening procedure) 
9.3 Treatment Phase 
9.3.1 Day 1 of Cycles 1 and 2 
The following procedures/assessments will be completed before study drug is administered: 
• PRO using the FOSI-18 and EQ-5D instruments 
• Physical examination 
• Weight 
• Vital Signs 
• Concomitant medications and procedures 
• ECOG performance status (Appendix D) 
• Hematology  
• Serum chemistry (fasting is not required) 
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• Serum pregnancy for women of childbearing potential (Cycle 2 only) 
• CA-125 measurement (Cycle 1 only) 
• Blood sample for storage (Cycle 1 only; if sample is not collected on Day 1 of Cycle 1, it 
should be collected as soon as possible thereafter) 
• Study drug dispensation 
• AE monitoring 
• Plasma PK sample (prior to first dose taken that day) (Cycle 2 only; see Section 9.5.1) 
• Serum sample for AAG sample (Cycle 2 only) 
Study drug will be dispensed to the patient in sufficient quantity to last until the next treatment 
cycle. Patients will ingest study drug twice daily at about the same times every day, as close to 
12 hours apart as possible. Each dose of study drug should be taken with at least 8 oz (240 mL) 
of room temperature water. Patients may take study drug on an empty stomach or with food 
(with a regular meal or within 30 minutes after a regular meal). Patients will record dosing 
information in their electronic dosing diary. 
Patients will be instructed to refrain from taking their first dose of study drug at home on the day 
of their clinic visits because certain assessments must be performed prior to dosing. 
9.3.2 Day 15 of Cycles 1 and 2 
The following procedures will be completed: 
• Concomitant medications and procedures 
• Hematology 
• Serum chemistry (fasting is not required) 
• AE monitoring 
• Plasma PK sample (in morning or afternoon following the first dose of study drug taken this 
day; see Section 9.5.1) 
• Serum sample for AAG analysis (note: sample can be collected at the same time as 
hematology and serum chemistry and/or with the PK sample)  
Patients will ingest study drug twice daily at about the same times every day, at close to 12 hours 
apart as possible. Each dose of study drug should be taken with at least 8 oz (240 mL) of room 
temperature water. Patients may take study drug on an empty stomach or with food (with a 
regular meal or within 30 minutes after a regular meal). Patients will record dosing information 
in their electronic dosing diary. 
9.3.3 Day 1 of Cycles 3 and Beyond 
The following procedures will be completed: 
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• PRO using the FOSI-18 and EQ-5D instruments 
• Physical examination 
• Weight 
• Vital signs 
• Concomitant medications and procedures 
• Disease assessment/tumor scans every 12 calendar weeks (within 7 days prior is permitted) 
after start of treatment on Day 1 of Cycle 1 
• ECOG performance status (Appendix D) 
• Hematology 
• Serum chemistry (fasting is not required) 
• Serum pregnancy for women of childbearing potential 
• CA-125 measurement (Day 1 of Cycles 4, 7, 10, etc.) 
• AE monitoring 
• Plasma PK sampling (prior to the first dose of study drug taken this day; Cycles 4 and 7 only; 
see Section 9.5.1) 
• Serum sample for AAG analysis (note: sample can be collected at the same time as 
hematology and serum chemistry and/or with the PK sample) (Cycles 4 and 7 only) 
Study drug will be dispensed to the patient in sufficient quantity to last until the next clinic visit. 
A single dose of study drug will be administered during the current clinic visit with at least 8 oz 
(240 mL) of room temperature water. Patients may take study drug on an empty stomach or with 
food (with a regular meal or within 30 minutes after a regular meal). Patient will record dosing 
information in their electronic dosing diary. 
Patients will continue dosing with study drug at home on an empty stomach or with food (with a 
regular meal or within 30 minutes after a regular meal), taking doses twice daily at about the 
same times every day. Study drug should be taken with at least 8 oz (240 mL) of room 
temperature water. Patients will record dosing information in their electronic dosing diary. 
9.4 Post-Treatment Phase 
9.4.1 Treatment Discontinuation 
Upon treatment discontinuation, regardless of the reason, patients will have a Treatment 
Discontinuation visit. The following procedures will be performed: 
• PRO using the FOSI-18 and EQ-5D instruments 
• Physical examination 
• Weight 
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• Vital signs 
• 12-lead ECG 
• Concomitant medications and procedures 
• Tumor scans (using the same methodology as was used at screening) if reason for treatment 
discontinuation was other than disease progression based on radiologic assessment 
• ECOG performance status (Appendix D) 
• Hematology 
• Serum chemistry (fasting is not required) 
• Serum pregnancy test for women of childbearing potential 
• CA-125 measurement 
• AE monitoring 
• Optional tumor tissue biopsy collection at time of disease progression/treatment 
discontinuation (requires additional consent). Tumor tissue will be processed locally as FFPE 
tissue. Refer to the Pathology Charter for detailed sample handling instructions. 
9.4.2 28-day Follow-up 
The following procedures will be performed for all patients at 28 (±3) days after the last dose of 
study drug: 
• PRO collected using the FOSI-18 and EQ-5D instruments 
• Disease assessment for patients who discontinued treatment for reason other than disease 
progression or death. Tumor scans should continue to be performed at 12-week intervals (up 
to 7 days prior permitted) until radiologic disease progression by RECIST v1.1, as assessed 
by the investigator. 
• AE monitoring 
• Concomitant medications and procedures 
9.4.3 Long-term Follow-up 
• Disease assessment for patients who discontinued treatment for reason other than disease 
progression or death. Tumor scans should continue to be performed at 12-week intervals (up 
to 7 days prior permitted) until radiologic disease progression by RECIST v1.1, as assessed 
by the investigator. 
• Subsequent treatments, secondary malignancy monitoring, and overall survival information 
will be collected for all patients every 12 weeks (± 14 days) until death, loss to follow-up, 
withdrawal of consent from study, or closure of the study. Follow-up can be performed via 
the telephone. Diagnosis of any secondary malignancy requires appropriate documentation 
(i.e. laboratory and/or pathology reports) and should be reported as indicated in Section 10.8. 
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• SAEs related to study drug and all AESIs, irrespective of causality, are to be reported as 
specified in Section 10.8. 
9.5 Methods of Data Collection 
Hematology, serum chemistry, and assays described below will be performed centrally. 
Urinalysis and serum pregnancy, if applicable, will be performed locally. Please refer to the 
Pathology Charter and/or Laboratory Manual for details on collecting and processing all samples 
that will be sent to central/core laboratories. 
9.5.1 Pharmacokinetic Evaluations and AAG Measurement 
For all patients, 4 mL blood samples for rucaparib population PK analysis will be drawn at the 
following time points: 
• Day 15 of Cycle 1 (in morning or afternoon, after dose taken earlier in the day) 
• Day 1 of Cycle 2 (before first dose taken that day) 
• Day 15 of Cycle 2 (in morning or afternoon, after dose taken earlier in the day) 
• Day 1 of Cycle 4 and 7 (before first dose taken that day) 
At least one morning post-dose sample and one afternoon post-dose sample must be taken for 
each patient. 
Serum samples for AAG analysis will be collected on the same day as PK samples. 
Central laboratories will be used for bioanalysis of plasma rucaparib levels and AAG 
measurement. Please refer to the laboratory manual for details on collection and processing of 
blood PK samples. 
9.5.2 Biomarker Analysis – FFPE Tumor Tissue 
Archival tumor tissue must be located during the screening process and submitted to the central 
laboratory directly as soon as possible for determination of HRD status. Archival tumor tissue 
is required for HRD stratification for randomization and for storage for potential bridging to a 
validated companion diagnostic test.  
9.5.3 Biomarker Analysis – Blood 
A blood sample will be collected from all patients and stored. Prior to final analysis, genomic 
DNA may be analyzed in an exploratory fashion in order to determine whether the mutation is 
germline or somatic.  
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9.5.4 Safety Evaluations 
9.5.4.1 Adverse Event Assessment 
The investigator is responsible for assessing the safety of the patients and for compliance with 
the protocol to ensure study integrity. Patients will be monitored for AEs during study 
participation, beginning after the first dose of study drug and until 28 days after the last dose of 
study drug. Any ongoing serious adverse events (SAEs) and AESIs will be followed until 
resolution or stabilization. In addition, any AE/SAE that occurs after informed consent is 
obtained and that is deemed related to a screening procedure for the study should be entered on 
the eCRF. AEs and laboratory abnormalities will be graded according to the NCI CTCAE 
grading system (Version 4.03) and recorded on the eCRF. 
Complete details for monitoring AEs, including the definition of drug-related AEs, are provided 
in Section 10. 
9.5.4.2 Prior and concomitant medications 
Prior concomitant medications will be recorded during screening and concomitant medications 
will be collected from study entry until the Treatment Discontinuation visit. 
9.5.4.3 Clinical Laboratory Investigations 
With the exception of samples for serum pregnancy and urinalysis, all other samples collected 
will be analyzed by a central laboratory; a duplicate sample may be collected and analyzed by 
the local laboratory for immediate eligibility/ treatment decisions. The panels of laboratory tests 
to be performed are shown below: 
Hematology: RBC and parameters (Hgb, Hct, MCV, MCH, and MCHC) and reticulocyte count, 
WBC and differential (with ANC), and platelet count at screening (to be performed ≤14 days 
prior to the first dose of study drug), at clinic visits during treatment, and at the Treatment 
Discontinuation visit. Hematology results must be reviewed by the investigator prior to the start 
of treatment with oral rucaparib or placebo. 
Clinical Chemistry: Total protein, albumin, creatinine, or estimated GFR using the Cockcroft 
Gault formula, BUN or urea, total bilirubin, alkaline phosphatase (ALP), ALT, AST, lipid panel 
(total cholesterol, LDL, HDL, and triglycerides), glucose, sodium, potassium, chloride, CO2, 
calcium, and phosphorus at screening (to be performed ≤14 days prior to the first dose of study 
drug), on Day 1 of each cycle during treatment, and at the Treatment Discontinuation visit. 
Clinical chemistry results must be reviewed by the Investigator prior to the start of initial 
treatment with study drug. 
Urinalysis: Performed on freshly voided clean sample by dipstick for protein, glucose, blood, 
pH, and ketones per the schedule of evaluations. If dipstick findings are abnormal based on 
Investigator’s judgment, then a microscopic evaluation will be performed to assess the abnormal 
findings. Urinalysis will be performed at screening only, but may be repeated if clinically 
indicated.  
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Laboratory reports will be reviewed by the investigator or delegated physician who will then 
comment on out-of-range parameters and assess clinical significance. Clinically significant 
abnormalities and associated panel results, as well as results of any additional tests performed as 
follow-up to the abnormalities, will be documented on the eCRF as an AE per the criteria 
specified in Section 10.5. 
Serum Pregnancy: For women of childbearing potential only. Serum pregnancy testing is to be 
performed ≤ 3 days prior to first dose of study drug, ≤ 3 days prior to the start of every cycle 
during the treatment phase, and at the Treatment Discontinuation visit. 
9.5.4.4 Vital Signs 
Vital signs will include blood pressure, pulse, and body temperature. Vital signs will be 
performed at most study visits.  
9.5.4.5 12-Lead Electrocardiograms 
For all patients, 12-lead ECGs will be taken at screening (within 28 days prior to first dose of 
study drug) and at Treatment Discontinuation. 
The following will be measured or calculated: heart rate, PR, QRS, QT, QTc, and rhythm. The 
investigator will analyze the ECGs locally and assess the results as normal or abnormal 
(clinically significant or not clinically significant). 
ECGs will be repeated as clinically indicated. 
9.5.4.6 Body Weight and Height 
Height will be measured during the Screening visit only. Weight will be measured per 
institutional guidelines at Screening, on Day 1 of each cycle, and at the End of Treatment visit.  
9.5.4.7 Physical Examinations 
Physical examinations will include an assessment of all the major body systems. Physical 
examinations will be performed at screening (complete) and at most study visits (limited as 
appropriate).  
9.5.4.8 ECOG Performance Status 
ECOG performance status (Appendix D) will be assessed at screening, on Day 1 of each cycle, 
and at the Treatment Discontinuation visit. ECOG performance status should be assessed by the 
same study personnel at each visit, if possible. Care will be taken to accurately score 
performance status, especially during screening for study eligibility purposes. Additional 
consideration should be given to borderline ECOG performance status to avoid enrolling patients 
with significant impairment. 
Clovis Oncology, Inc.  Clinical Protocol 
Oral rucaparib (CO-338) CO-338-014 
 7 July 2016 
   
Amendment 3 72 
 
9.5.5 Efficacy Evaluations 
9.5.5.1 Disease Assessments 
Tumor assessment measurements will be performed at screening, at the end of every 12 weeks of 
treatment (up to 1 week prior permitted) relative to Cycle 1 Day 1, at discontinuation of 
treatment, and as clinically indicated. 
Disease assessment will comprise clinical examination and appropriate imaging techniques (CT 
scans of the chest, abdomen, and pelvis with appropriate slice thickness per RECIST); other 
studies (MRI, X-ray, PET, and ultrasound) may be performed if required. If a patient has known 
brain metastases, this disease should be evaluated at each required assessment. The same 
methods used to detect lesions at baseline are to be used to follow the same lesions throughout 
the clinical study. CT/ MRI scans of the chest, abdomen, and pelvis performed to determine the 
extent of disease at baseline should also be performed at each time of disease assessment, even if 
the scans were negative at baseline. Investigators should perform scans of other anatomical sites 
that, in their judgment, are appropriate to assess based on each patient’s tumor status. Imaging 
guidelines provided in the Bioclinica Site Manual should be followed for the collection of 
images and the radiological assessment of disease.  
Tumor response will be interpreted using RECIST v1.1 (Appendix B). Disease progression will 
only be determined by RECIST v1.1. Patients with a CR at study entry will only be considered to 
have disease progression if a new lesion is identified. Patients who meet GCIG CA-125 criteria 
for disease progression should have a radiologic assessment and be assessed by RECIST. If the 
radiologic assessment does not confirm disease progression, patients should continue on 
treatment and continue to be assessed by RECIST v1.1 per the protocol schedule of assessments. 
Patients who discontinued treatment for reason other than disease progression or death should 
continue to have tumor scans performed at 12-week intervals (up to 7 days prior permitted) until 
radiologic disease progression by RECIST v1.1, as assessed by the investigator. 
9.5.5.2 Tumor Markers 
CA-125 measurement will be performed at screening, on Day 1 of Cycle 1, at the start of every 
3rd cycle thereafter (i.e. Day 1 of Cycle 4, Cycle 7, Cycle 10, etc.), at discontinuation of 
treatment, and as clinically indicated. All CA-125 measurements will be performed by a central 
laboratory. 
9.5.6 Patient-Reported Outcomes 
PRO utilizing the FOSI-18 and EQ-5D instruments (see Appendix E) will be assessed at 
screening, on Day 1 of every treatment cycle, at treatment discontinuation, and at the 28-day 
follow-up visit. Patients will complete the instruments on an electronic device before any other 
scheduled study procedures are performed and dosing occurs (if applicable). The electronic 
device is a Class 1 listed (i.e. approved) device. 
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9.5.7 Appropriateness of Measurements 
The assessments planned in the protocol are widely used and recognized as reliable, accurate and 
relevant. 
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10 ADVERSE EVENT MANAGEMENT 
10.1 Definition of an Adverse Event 
An AE is any untoward medical occurrence, including the exacerbation of a pre-existing 
condition, in a patient administered a pharmaceutical product. The pharmaceutical product does 
not necessarily have a causal relationship with the AE. Anticipated fluctuations of pre-existing 
conditions, including the disease under study, that do not represent a clinically significant 
exacerbation or worsening are not considered AEs. 
For the purposes of this study, disease progression of the patient’s tumor with new or worsening 
symptoms must be documented as an AE. However, disease progression documented solely by 
radiographic evidence with no new or worsening symptoms will not require reporting as an AE.  
It is the responsibility of the investigator to document all AEs that occur during the study. AEs 
should be elicited by asking the patient a nonleading question (eg, “Have you experienced any 
new or changed symptoms since we last asked/since your last visit?”). The existence of an AE 
may be concluded from a spontaneous report of the patient; from the physical examination; or 
from special tests such as the ECG, laboratory assessments, or other study-specified procedure 
(source of AE). AEs will be reported on the AE eCRF. Symptoms reported spontaneously by the 
patient during the physical examination will also be documented on the AE eCRF. 
10.2 Definition of a Serious Adverse Event 
An SAE is any untoward medical occurrence that occurs at any dose that: 
• Results in death. 
• Is immediately life-threatening (i.e. the patient is at risk of death at the time of the event; it 
does not refer to an event that hypothetically might have caused death if it were more 
severe). 
• Requires in-patient hospitalization or prolongation of existing hospitalization. 
• Results in a persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions. 
• Results in a congenital anomaly or birth defect. 
• Important medical events that may not result in death, are not life-threatening, or do not 
require hospitalization may be considered SAEs when, based on appropriate medical 
judgment, they may jeopardize the patient and may require medical or surgical intervention 
to prevent one of the outcomes listed in this definition. Examples of such events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at home, or the 
development of drug dependency or drug abuse. 
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10.3 Definition of an Adverse Event of Special Interest 
An AESI (serious or non-serious) is one of scientific and medical concern specific to the 
sponsor’s product or program, for which ongoing monitoring and rapid communication by the 
investigator to the sponsor can be appropriate. Such an event might warrant further investigation 
in order to characterize and understand it. Depending on the nature of the event, rapid 
communication by the trial sponsor to other parties (eg, health authorities or ethics committees) 
might also be warranted.  
Details on the sponsor’s currently agreed list of AESIs for rucaparib can be found in the current 
rucaparib IB. These AESIs are to be reported to the sponsor expeditiously (see Section 10.8 for 
reporting instructions).  
10.4 Exceptions to Serious Adverse Event Reporting 
The following are not considered SAEs and therefore are not required to be reported to the 
Sponsor: 
• Pre-planned or elective hospitalization, including social and/or convenience situations (eg, 
respite care). 
• Hospital visits of less than 24 hours duration (eg, patient presents to the emergency room, but 
is not admitted to a ward).  
• Overdose of either study drug or concomitant medication, unless the event meets SAE 
criteria (eg, hospitalization) as a direct consequence of the overdose. If the event does not 
meet SAE criteria it should still be captured as a non-serious AE on the appropriate eCRF. 
• Events of disease progression of the patient’s underlying cancer as well as events clearly 
related to disease progression (i.e. signs and symptoms) should not be reported as a SAE 
unless the outcome is fatal and occurs during the safety reporting period. If the event has a 
fatal outcome during the safety reporting period, then the event of Progression of Disease 
must be recorded as an AE/SAE with CTC Grade 5 (fatal outcome) indicated. 
• Diagnosis of progression of disease or hospitalization due to signs and symptoms of disease 
progression alone should not be reported as a SAE. 
10.5 Clinical Laboratory Assessments and Other Abnormal Assessments as 
Adverse Events and Serious Adverse Events 
It is the responsibility of the Investigator to assess the clinical significance of all abnormal 
laboratory values as defined by the list of reference ranges from the local laboratory. In some 
cases, significant change in laboratory values within the normal range may require similar 
assessment. 
An abnormal value that is not already associated with an AE is to be recorded as an AE only if 
one of the following criteria is met: 
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• It resulted in treatment modification (reduction of dose, interruption of dosing, or permanent 
discontinuation of study drug) 
• It required intervention / management 
• It is suggestive of organ toxicity 
• The Investigator considers it to be clinically significant 
10.6 Pregnancy or Drug Exposure during Pregnancy 
If a patient becomes pregnant during the course of the study, study drug dosing should be held 
immediately. 
Pregnancy is not considered to be an AE or SAE; however, all pregnancies occurring during 
study participation or within 6 months of last dosing must be reported to the Sponsor using the 
Clinical Pregnancy Report form within the same timelines as for as SAE. 
All pregnancies should be followed through to outcome whenever possible. Once the outcome of 
a pregnancy is known, the Clinical Pregnancy Outcome Report form should be completed and 
submitted to the Sponsor. 
AEs, SAEs, or AESIs that occur during pregnancy will be assessed and processed according to 
the AE or SAE/ AESI processes using the appropriate AE or SAE/ AESI forms.  
10.7 Recording of Adverse Events, Serious Adverse Events, and Adverse Events 
of Special Interest 
All AEs, serious and non-serious, will be fully documented on the appropriate eCRF. For each 
AE, the Investigator must provide duration (start and end dates or ongoing), intensity, 
relationship to study drug, and indicate whether specific action or therapy was required. 
Any AE/SAE that occurs after the first dose of study drug until 28 days after last dose of study 
drug administration will be collected, documented and reported to the Sponsor by the 
Investigator according to the specific definitions and instructions detailed within this protocol, 
whether dosing has occurred or not. In addition, any AE/SAE that occurs after informed consent 
is obtained and is deemed related to a screening procedure for the study should also be reported 
on the AE eCRF and, if applicable, the SAE report form. Events that occur after signing of 
informed consent but prior to initiation of study drug, unless due to a protocol-mandated 
procedure, should be recorded on the Medical History eCRF. In order to avoid vague, 
ambiguous, or colloquial expressions, the AE should be recorded in standard medical 
terminology rather than the patient’s own words. Whenever possible, the investigator should 
combine signs and symptoms that constitute a single disease entity or syndrome into a final 
diagnosis. For example, fever, cough, and shortness of breath may be reported as pneumonia, if 
that is a reasonable diagnosis. 
All SAEs/ AESIs that occur during the study or within 28 days after receiving the last dose of 
study drug, regardless of relationship to study drug, must be reported to the Sponsor/designated 
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safety contact immediately (ie, within 24 hours of the Investigator’s knowledge of the event). 
This should be done by faxing or emailing the completed SAE/ AESI report to the 
Sponsor/designee contact provided on the SAE/ AESI report form. After the 28-day window 
after treatment discontinuation, only SAEs assessed as related to study drug and all AESIs, 
irrespective of causality, should be reported. If a patient is determined to be a screen failure, no 
further AEs/ SAEs are required to be reported once that determination has been made, with the 
exception of AEs/ SAEs deemed related to a protocol-specified procedure. Information on the 
follow-up of AEs, SAEs, and AESIs is provided in Section 10.7.4.  
10.7.1 Intensity of Adverse Events 
Severity refers to the intensity of an AE. The severity of each AE will be categorized using the 
NCI CTCAE, Version 4.03 (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-
14_QuickReference_5x7.pdf).53 
For any term that is not specifically listed in the CTCAE, intensity should be assigned a grade of 
1-5 using the following CTCAE guidelines:  
• Mild (Grade 1): mild or asymptomatic symptoms; clinical or diagnostic observations only; 
intervention not indicated 
• Moderate (Grade 2): limiting age-appropriate instrumental activities of daily living; minimal, 
local or noninvasive intervention indicated 
• Severe (Grade 3): limiting self-care activities of daily living; hospitalization indicated 
• Life threatening (Grade 4): life-threatening consequences; urgent intervention indicated 
• Fatal (Grade 5): results in death 
10.7.2 Causal Relationship of Adverse Events to Study Drug 
Medical judgment should be used to determine the cause of the AE considering all relevant 
factors such as but not limited to: the disease under study, concurrent disease, concomitant 
medication, relevant history, pattern of the AE, temporal relationship to the study medication, 
dechallenge or rechallenge with the study drug. 
Not Related 
To Study Drug 
An AE that is clearly due to extraneous causes (eg, concurrent disease, concomitant 
medication, disease under study, etc.) 
An AE that does not follow a reasonable temporal sequence from administration of 
the study drug. 
An AE that does not follow a known pattern of response to study drug. 
An AE that does not reappear or worsen when study drug is restarted. 
An AE for which an alternative explanation is likely, but not clearly identifiable. 
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Related to 
Study Drug 
An AE that is difficult to assign to alternative causes. 
An AE that follows a strong or reasonable temporal sequence from administration of 
study drug. 
An AE that could not be reasonably explained by the patient’s clinical state, 
concurrent disease, or other concomitant therapy administered to the patient. 
An AE that follows a known response pattern to study drug. 
An AE that is confirmed with a positive rechallenge or supporting laboratory data. 
10.7.3 Outcome  
The investigator will record the outcome for each AE according to the following criteria: 
Outcome 
• Recovered/Resolved 
• Recovered/Resolved with sequelae 
• Improved 
• Ongoing 
• Death 
• Unknown/Lost to follow-up 
10.7.4 Follow-up of Adverse Events, Serious Adverse Events, and Adverse Events of 
Special Interest 
All AEs (including SAEs and AESIs) occurring during the study are to be followed up in 
accordance with good medical practice until resolved; judged no longer clinically significant; or, 
if a chronic condition, until fully characterized until 28 days after the last dose of study 
treatment. Any SAE/ AESI must be followed until the event has resolved, the condition has 
stabilized, or the patient is lost to follow-up. If the patient is lost to follow-up with an ongoing 
SAE/ AESI, this should be captured accordingly on a follow-up SAE/ AESI report.  
10.8 Regulatory Aspects of Adverse Event Reporting 
All SAEs and AESIs, irrespective of relationship to study treatment, as well as all pregnancies, 
must be reported to the Sponsor’s SAE designee within 24 hours of knowledge of the event, 
occurring during the study through 28 days after receiving the last dose of study treatment, 
according to the procedures below. After the 28-day specified window, SAEs considered to be 
treatment-related and all AESIs, regardless of treatment relationship, should be reported if 
occurring. Pregnancies that occur within 6 months of the last dose of study drug should be 
reported. It is important that the investigator provide an assessment of relationship of the 
SAE/ AESI to study treatment at the time of the initial report. The SAE/ AESI Report form must 
be used for reporting SAEs/ AESIs. The contact information for reporting of SAEs/ AESIs can 
be found on the SAE/ AESI Reporting Form and Pregnancy Report Forms. 
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Clovis Oncology, Inc. (Clovis Oncology), or its designee is responsible for submitting reports of 
AEs associated with the use of the drug that are both serious and unexpected to FDA, according 
to 21 Code of Federal Regulations (CFR) 312.32, to the European regulatory authorities 
according to the European Commission Clinical Trials Directive (2001/20/EC); and to other 
regulatory authorities, according to national law and/or local regulations. All investigators 
participating in ongoing clinical studies with the study medication will receive copies of these 
reports for prompt submission to their IRB or IEC. In accordance with the European 
Commission Clinical Trials Directive (2001/20/EC), Clovis Oncology or its designee will notify 
the relevant ethics committees in concerned member states of applicable suspected unexpected 
serious adverse reactions (SUSARs) as individual notifications or through periodic line listings. 
Clovis Oncology or its designee will submit all safety updates and periodic reports to the 
regulatory authorities as required by applicable regulatory requirements. 
10.9 Independent Data Monitoring Committee 
No formal efficacy interim analyses are planned. 
An Independent Data Monitoring Committee (IDMC) will be established to review safety and 
efficacy data in compliance with a prospective charter. The IDMC will be comprised of medical 
oncologists with experience in treating women with ovarian cancer and a statistician, all of 
whom are not otherwise involved in the study as investigators. The IDMC responsibilities, 
authorities, and procedures will be documented in the IDMC charter, which will be endorsed and 
signed by the IDMC prior to the first data review meeting. 
The IDMC will: 
• Review safety and efficacy of rucaparib compared with placebo to ensure the study is 
beneficial to patients 
• Ensure the study is conducted in a high quality manner 
• Monitor the size of the tBRCA subgroup and the known gBRCA group 
Following data review, the IDMC will recommend continuation, revision, or termination of the 
study and/or continuing or halting enrollment into a particular subgroup. The IDMC will meet at 
least semi-annually after sufficient data has been collected. The IDMC chairperson may convene 
formal IDMC meeting if there are safety concerns. The Sponsor can also request an IDMC 
review of safety data. 
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11 STATISTICAL METHODS 
11.1 Analysis Populations 
The following analysis populations are defined for the study: 
Safety Table Population – The safety population will consist of all patients who received at 
least one dose of protocol-specified treatment. 
Intent-to-treat (ITT) Population  The ITT population will consist of all randomized patients. 
Response Evaluable Population  The response evaluable population will consist of all patients 
evaluable for response by RECIST (Appendix B). Patients evaluable for a RECIST response 
must have at least one measureable target lesion at baseline and at least one post-baseline tumor 
assessment. 
11.2 Statistical Methods 
11.2.1 General Considerations 
Variables registered on a continuous scale will be presented using the following descriptive 
statistics: N, mean, standard deviation, median, minimum and maximum. Continuous variables 
may also be presented using frequencies and percentages among appropriate categorizations. 
Categorical variables will be presented using frequencies and percentages. The Kaplan-Meier 
methodology will be used to summarize time-to-event variables. The number of patients with 
events and the number of censored patients will also be presented. The stratified logrank test will 
be used to compare the time-to-event distributions between the randomized treatment groups. In 
addition, the Cox proportional hazards model will be used to estimate the HR between the 
randomized treatment groups. 
The primary and key secondary endpoints will be tested among the tBRCA and all HRD 
subgroups, and all randomized patients, using an ordered step-down multiple comparisons 
procedure. Investigator determined PFS (invPFS) in the tBRCA subgroup will be tested first at a 
one-sided 0.025 significance level. If invPFS in the tBRCA subgroup is statistically significant, 
then invPFS will be tested in the all HRD subgroup followed by invPFS in all randomized 
patients. Continuing in an ordered step-down manner, the PRO of disease symptoms utilizing the 
FOSI-18 DRS-P subscale will be tested at the one-sided 0.025 significance level in the tBRCA, 
all HRD, and all randomized patients subgroups and then for the remaining key secondary 
endpoints of PRO utilizing the FOSI-18 total score and OS. Once statistical significance is not 
achieved for one test the statistical significance will not be declared for all subsequent analyses 
in the ordered step-down procedure.  
PFS by IRR will be evaluated as a stand-alone secondary endpoint. 
All data will be used to their maximum possible extent but without any imputations for missing 
data. 
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All statistical analyses will be conducted with the SAS® System, version 9.1 or higher.  
Unless otherwise specified, baseline is defined as the last measurement on or prior to the first 
day of study drug administration. 
11.2.2 Patient Disposition  
Patient disposition (analysis population allocation, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency counts, and the corresponding 
percentages. 
11.2.3 Baseline Characteristics  
All demographic and baseline characteristics will be summarized for the safety population. 
The following variables will be summarized with frequency tabulations: 
• Time since diagnosis (months): > 12-24, > 24 
• Baseline laboratory parameters: graded based on CTCAE 
• HRD status for stratification at randomization: tBRCA, nbHRD, biomarker negative 
• Interval between completion of penultimate platinum regimen and disease progression (6 
to 12 months of >12 months) by radiologic assessment 
• Best response to most recent platinum-based regimen (CR [defined as complete 
radiologic response by RECIST v1.1 with normalization of CA-125] or PR [defined as 
partial radiologic response by RECIST v1.1 and/or a GCIG CA-125 response]). All 
responses require that CA-125 be <ULN. 
Descriptive statistics may also be used to summarize the continuous variables.  
11.2.4 Efficacy Analyses  
All efficacy evaluations will be conducted using the ITT population. 
11.2.4.1 Primary Efficacy Analysis 
The primary efficacy endpoint for the study is invPFS by RECIST v1.1. Investigator-determined 
PFS is defined as the time from randomization to disease progression, according to RECIST v1.1 
criteria (Appendix B), as assessed by the investigator, or death due to any cause, in molecularly 
defined subgroups. The stratification factors included in the primary analysis of invPFS will be 
as follows: 
• HRD classification (tBRCA or nbHRD or biomarker negative) 
• Interval between completion of penultimate platinum regimen and disease progression (6 
to 12 months or >12 months) by radiologic assessment 
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• Best response to the most recent platinum-based regimen (CR [defined as complete 
radiologic response by RECIST v1.1 with normalization of CA-125] or PR [defined as 
partial response by RECIST v1.1 and/or a GCIG CA-125 response]). All responses 
required that CA-125 be <ULN. 
Tumor HRD status by the FCTA will be determined after randomization, but before the final 
efficacy analysis, so that the primary endpoint (PFS in molecularly-defined HRD subgroups) can 
be assessed prospectively. 
11.2.4.2 Secondary Efficacy Analyses 
Secondary efficacy endpoints are: 
• Time to a 4-point decrease in the FOSI-18 DSRP subscale 
• Time to an 8-point decrease in the FOSI-18 total score 
• OS 
• PFS by RECIST v1.1 as assessed by IRR (irrPFS) 
PRO of disease-related symptoms as measured by the FOSI-18 DRSP subscale 
The time to an event in PRO of worsening of disease symptoms will be defined as the time from 
randomization to a 4-point reduction in the FOSI-18 DRS-P subscale. Patients without a 4-point 
reduction will be censored on the date of their last PRO evaluation.  
PRO as measured by the total score of the FOSI-18 
An event in worsening of PRO utilizing the complete FOSI-18 instrument will be defined as the 
time from randomization to an 8-point reduction in the total score. Patients without an 8-point 
reduction will be censored on the date of their last PRO evaluation. 
Overall survival 
Overall survival (OS) is defined as the number of days from the date of randomization to the date 
of death (due to any cause). Patients without a known date of death will be censored on the date 
the patient was last known to be alive. 
irrPFS 
PFS for secondary efficacy analysis is defined as the time from randomization to disease 
progression, according to RECIST v1.1 criteria as assessed by IRR, or death due to any cause, 
whichever occurs first. 
11.2.5 Safety Analyses  
Safety endpoints are incidence of AEs, clinical laboratory abnormalities, and dose modifications. 
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Data from all patients who receive at least one dose of study drug will be included in the safety 
analyses. AEs, clinical laboratory information, vital signs, ECG results, ECOG performance 
status, body weight, and concomitant medications/procedures will be tabulated and summarized. 
11.2.5.1 Adverse Events 
AEs will be classified using the Medical Dictionary for Drug Regulatory Activities (MedDRA) 
classification system. The severity of the toxicities will be graded according to the NCI CTCAE 
whenever possible. Only treatment-emergent adverse events (TEAEs) will be collected: TEAEs 
are defined as AEs with onset date on or after the date of first dose of study medication until the 
date of the last study medication dose plus 28 days.  
The number and percentage of patients who experienced TEAEs for each system organ class 
(SOC) and preferred term will be presented. Multiple instances of the TEAE in each SOC and 
multiple occurrences of the same preferred term are counted only once per patient. The number 
and percentage of patients with at least one TEAE will also be summarized.  
Separate tables will be presented as follows: 
• All TEAEs 
• TEAEs by CTCAE grade 
• Grade 3 or greater TEAEs 
• Serious TEAEs 
• TEAEs with an outcome of death 
• TEAEs leading to discontinuation of study medication 
• TEAEs resulting in interruption/delay of study medication 
• TEAEs resulting in dose reduction of study medication 
If a patient experiences multiple occurrences of the same AE with different toxicity grades, the 
patient will be counted once for the maximum (most severe) toxicity grade. AEs with a missing 
toxicity grade will be presented in the summary table with a toxicity grade of “Missing.” For 
each toxicity grade, the number and percentage of patients with at least one TEAE of the given 
grade will be summarized.  
11.2.5.2 Clinical Laboratory Evaluations 
Clinical laboratory evaluations include the continuous variables for hematology, serum 
chemistry, and urinalysis. The laboratory values will be presented in SI units. The on-treatment 
period will be defined as the time from the first dose of study drug to 28 days after the last dose 
of study drug. Laboratory values collected during the on-treatment period will be included in the 
summary tables. The laboratory values collected after the on-treatment period will only be 
presented in the data listings.  
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The summary of laboratory data will include shift tables based on CTCAE for shifts in grade 
from baseline to maximum, minimum and last value during the on-treatment period.  
Supporting laboratory data including normal ranges and abnormal laboratory flags will be 
provided using by-patient listings. Separate listings will be produced for clinically significant 
laboratory abnormalities (i.e. those that meet Grade 3 or 4 criteria according to CTCAE). 
11.2.5.3 Vital Sign Measurements 
The on-treatment period will be defined as the time from the first dose of study drug to 28 days 
after the last dose of study drug. Vital sign measurements collected during the on-treatment 
period will be included in the summary tables. The vital sign measurements collected after the 
on-treatment period will only be presented in the data listings.  
The summary of vital sign data will include descriptive statistics (N, mean, SD, minimum, 
median, third quartile and maximum) of the maximum, minimum and last value during the on-
treatment period. Summaries using descriptive statistics (N, mean, SD, minimum, median and 
maximum) of the change from baseline to the maximum, minimum, and last value during the 
on-treatment period will also be given.  
11.2.6 Population PK Analysis 
The PK endpoint is individual model parameter estimates of rucaparib and covariates 
identification. 
A specific population PK data analysis plan will be developed that will outline the detailed 
approach to data handling, model development and diagnostics, individual model parameter 
estimation, exploration of covariate effects, and final model evaluation techniques. 
11.2.7 Exploratory Analyses 
The endpoints for the exploratory analyses are: 
• Change from baseline in CA-125 measurements by the central laboratory 
• PFS2 (PFS on the subsequent line of treatment) defined as the time from randomization 
to the second event of disease progression or death, as assessed by the investigator 
• ORR per RECIST v1.1, as assessed by both the investigator and IRR, in patients with 
measureable disease at study entry 
• DOR per RECIST Version 1.1, as assessed by both the investigator and IRR  
• PRO as measured by the EQ-5D total score 
• Rucaparib PK, invPFS, irrPFS, CA-125, AEs, clinical laboratory abnormalities, and dose 
modifications 
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11.2.7.1 Change from Baseline in CA-125 
Analyses of changes and/or percent changes from baseline will be analyzed for each scheduled 
post-baseline visit and for the final visit for the CA-125 measurements from the central 
laboratory. Patients that do not have both a baseline measurement and at least one post-baseline 
measurement will not be included. 
At a given visit, the change and/or percent change from baseline will be compared between the 
randomized treatment groups using an ANCOVA using the treatment as a categorical factor and 
baseline measurement for the parameter as a continuous covariate. 
The association between the change from baseline in CA-125 measurements and invPFS will be 
evaluated using a Cox proportional hazards model. A measure of CA-125 kinetics such as the 
rate of change from baseline in CA-125 may also be associated with invPFS using a Cox model. 
11.2.7.2 Progression Free Survival 2 (PFS2) 
The second event of PFS, PFS2, is defined as the time from randomization to the second event of 
disease progression as assessed by the investigator, or death due to any cause. The first event of 
disease progression will be captured as the primary endpoint in this study and thus the second 
event will be the next event of disease progression as assessed by the investigator. This second 
event of PFS may be a documented event per RECIST guidelines or may be an event of 
symptomatic progression.  
11.2.7.3 Overall Response Rate 
ORR is defined as a best response of CR or PR using the RECIST v1.1 criteria (Appendix B), as 
assessed by both investigator and IRR, in patients with measurable disease at study entry. ORR 
will be summarized with frequencies and percentages in the safety population. 
11.2.7.4 Duration of Response 
The DOR is measured from the time measurement criteria are met for CR/PR per RECIST v1.1 
criteria (Appendix B), as assessed by both the investigator and IRR, until the first date that 
recurrent or PD is objectively documented. The DOR will be summarized with descriptive 
statistics. Only patients with a response will be included in the summary. 
11.2.7.5 Patient Reported Outcome EQ-5D 
Analyses of changes and/or percent changes from baseline will be analyzed for each scheduled 
post-baseline visit and for the final visit for the EQ-5D instrument. Patients that do not have both 
a baseline measurement and at least one post-baseline measurement will not be included. 
At a given visit, the change and/or percent change from baseline will be compared between the 
randomized treatment groups using an ANCOVA using the treatment as a categorical factor and 
baseline measurement for the parameter as a continuous covariate. 
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11.2.7.6 Relationship between Rucaparib Exposure and Efficacy and Safety 
The primary endpoint of invPFS will be presented for subgroups of patients defined by levels of 
rucaparib exposure. These analyses are exploratory in nature so the definition of relevant 
subgroups may be data-driven.  
11.3 Interim Analysis 
No formal interim efficacy analyses will be performed. 
11.4 Sample Size Considerations 
The total enrollment planned is 540 patients. A minimum of 180 and a maximum of 200 patients 
with a deleterious tBRCA mutation will be enrolled. Enrollment of patients with a known 
deleterious gBRCA mutation documented in their medical record will not exceed 150. There is 
no minimum number of patients required for each of the nbHRD and biomarker negative 
subgroups; however, no more than 360 total patients will be randomized for stratification into 
these subgroups combined. Prior to final efficacy analysis, HRD classification will be 
determined by the FCTA, which will evaluate homologous recombination gene mutations and/or 
extent of genomic scarring in tumor tissue. 
Table 4 below provides estimated sample sizes and power calculations. 
Table 4. Estimated Sample Sizes and Power Calculations 
Group Hazard 
Ratio 
Cumulative 
N  
Minimum 
Number of 
Events 
(70%) 
Median PFS 
Placebo vs 
Rucaparib 
(months) 
Power One-
sided 
Alpha 
BRCA HRD  0.50 180 126 6 vs 12 90% 0.025 
All HRD 
(BRCA + 
nbHRD) 
0.60 300 210 6 vs 10 90% 0.025 
ITT Population 
(BRCA + 
nbHRD + 
Biomarker 
Negative) 
0.70 540 378 6 vs 8.5 90% 0.025 
The study will end after 70% of the patients in the tBRCA subgroup have an observed event of 
investigator-determined disease progression or death. If the minimum number of tBRCA patients 
are enrolled, then the study will end following the 126th event of investigator-determined disease 
progression or death. Similarly, if the maximum number of tBRCA patients are enrolled, then the 
study will end following the 140th event of investigator-determined disease progression or death. 
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The IDMC will inform the Sponsor when the required number of PFS events have been observed 
in order to ensure the Sponsor remains blinded to which patients are in the tBRCA subgroup. If 
the nbHRD and/or biomarker negative subgroups have observed events of invPFS in fewer than 
60% of the patients, the IDMC may recommend that the study continue for up to 6 more months 
if it is likely that the nbHRD and biomarker negative subgroups will observe enough additional 
events of PFS to reach 60%.  
Following the collection of the required number of PFS events, the outstanding queries for all 
visits and events prior to the data cutoff date will be resolved and the database will be locked 
before the blind break and subsequent primary analysis.  
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12 PATIENT DISPOSITION 
12.1 Removal of patients from therapy or assessment 
A patient must be discontinued from treatment with study drug if any of the following apply: 
• Consent withdrawal at the patient’s own request or at the request of their legally 
authorized representative 
• Progression of patient’s underlying disease by RECIST v1.1 as assessed by the 
investigator 
• Any event, adverse or otherwise, that, in the opinion of the investigator, would pose an 
unacceptable safety risk to the patient 
• An intercurrent illness that, in the opinion of the investigator, would affect assessments of 
the clinical status to a significant degree and requires discontinuation of therapy 
• A positive pregnancy test at any time during the study. 
The sponsor may discontinue the trial early for any of the reasons noted in Section 13.6. 
12.2 Procedures for discontinuation 
The sponsor (or designee) should be notified of all study terminations as soon as possible. The 
date and reason for cessation of study drug must be documented in the eCRF and source 
documents. To the extent possible, end-of-study procedures should be performed on all patients 
who receive study drug. The Treatment Discontinuation visit should occur 28 (±3) days 
following the last dose of study drug. Patients will be followed for 28 days after the last dose of 
study drug for safety; those with ongoing SAEs/ AESIs will be followed until either resolution or 
stabilization has been determined. 
Clovis Oncology, Inc.  Clinical Protocol 
Oral rucaparib (CO-338) CO-338-014 
 7 July 2016 
   
Amendment 3 89 
 
13 STUDY ADMINISTRATION 
13.1 Regulatory and Ethical Considerations 
This study will be conducted in compliance with the protocol; Good Clinical Practices (GCPs), 
including International Conference on Harmonization (ICH) Technical Requirements for 
Registration of Pharmaceuticals for Human Use Guidelines; Food and Drug Administration 
(FDA) regulatory requirements; and in accordance with the ethical principles of the Declaration 
of Helsinki.  
13.1.1 Regulatory Authority Approvals 
The sponsor or designee will submit the study protocol plus all relevant study documents to 
concerned regulatory agencies for approval prior to the study start. No patient will be admitted to 
the study until appropriate regulatory approval of the study protocol has been received. 
Each investigator must complete a Form FDA 1572 (or equivalent) and provide the completed 
form according to written instructions to the sponsor (or designee). Each investigator must 
submit to the sponsor (or designee) financial disclosure information according to national law 
and/or local regulations. 
U.S.-generated data will be handled in accordance with the Health Information Portability and 
Accountability Act (HIPAA). The trial will be registered at www.clinicaltrials.gov, EudraCT, 
and other applicable trial registry systems as appropriate. 
13.1.2 Independent Ethics Committee/Institutional Review Board 
This protocol and any material to be provided to the patient (such as advertisements, patient 
information sheets, drug dosing diaries, or descriptions of the study used to obtain informed 
consent) will be submitted by the investigator to an IEC/IRB. This also applies to protocol 
amendments.  
Clovis Oncology will supply relevant data for the investigator to submit the study protocol and 
additional study documents to the IEC/IRB. The principal investigator will submit the study 
protocol for review and approval by an IEC/IRB, according to national law and/or local 
regulations, and will provide the IEC/IRB with all appropriate materials.  
Verification of the IEC’s/IRB’s unconditional approval of the study protocol and the written 
informed consent form will be transmitted to Clovis Oncology. This approval must refer to the 
study by exact study protocol title and number, identify the documents reviewed, and state the 
date of the review. 
No patient will be admitted to the study until appropriate IEC/IRB approval of the study protocol 
has been received, the investigator has obtained the signed and dated informed consent form, and 
the sponsor is notified.  
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The principal investigator will submit appropriate reports on the progress of the study to the 
IEC/IRB at least annually in accordance with applicable national law and/or local regulations 
and in agreement with the policy established by the IEC/IRB and sponsor.  
The IEC/IRB must be informed by the principal investigator of all subsequent study protocol 
amendments and of SAEs or SUSARs occurring during the study that are likely to affect the 
safety of the patients or the conduct of the study. 
13.2 Confidentiality of Information 
The investigator must assure that patients’ anonymity is strictly maintained and that their 
identities are protected from unauthorized parties. Only patient initials and an identification code 
(i.e. not names) should be recorded on any form submitted to the sponsor and the IRB. The 
investigator must record all screened and enrolled patients in the eCRF. The investigator must 
have a list where the identity of all treated patients can be found. 
The investigator agrees that all information received from Clovis Oncology, including, but not 
limited to, the Investigator’s Brochure, this protocol, eCRFs, the protocol-specified treatment, 
and any other study information, remain the sole and exclusive property of the sponsor during 
the conduct of the study and thereafter. This information is not to be disclosed to any third party 
(except employees or agents directly involved in the conduct of the study or as required by law) 
without prior written consent from the sponsor. The investigator further agrees to take all 
reasonable precautions to prevent the disclosure by any employee or agent of the study center to 
any third party or otherwise into the public domain. 
13.3 Patient Informed Consent 
All information about the clinical study, including the patient information and the informed 
consent form, is prepared and used for the protection of the human rights of the patient according 
to ICH GCP guidelines and the Declaration of Helsinki. 
It is the responsibility of the investigator to obtain signed informed consent forms from each 
patient participating in this study after adequate explanation of the aims, methods, objectives, 
and potential hazards of the study and prior to undertaking any study-related procedures.  
The informed consent form, prepared by the investigator with the assistance of the sponsor, must 
be approved along with the study protocol by the IEC/IRB and be acceptable to the sponsor. 
The patient must be provided with the patient information and informed consent form consistent 
with the study protocol version used and approved by the relevant IEC/IRB. The informed 
consent form must be in a language fully comprehensible to the prospective patient. Patients 
(and/or relatives, guardians, or legal representatives, if necessary) must be given sufficient time 
and opportunity to inquire about the details of the study and to discuss and decide on their 
participation in the study with the investigator concerned. The patient and the person explaining 
about the study and with whom they discuss the informed consent will sign and date the 
informed consent form. A copy of the signed informed consent form will be retained by the 
patient and the original will be filed in the investigator file unless otherwise agreed.  
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13.4 Study Monitoring 
On behalf of Clovis Oncology, a CRO monitor will contact and visit the investigator at the study 
center prior to the entry of the first patient (unless Clovis or the CRO has worked with the center 
recently in which case this initial visit maybe waived) and at predetermined appropriate intervals 
during the study until after the last patient is completed. The monitor will also perform a study 
closure visit. Visits may also be conducted by Clovis Oncology personnel. 
In accordance with ICH GCP guidelines, the investigator must ensure provision of sufficient 
time, reasonable space, and adequate qualified personnel for the monitoring visits. The visits are 
for the purpose of verifying adherence to the study protocol and the completeness, consistency, 
and accuracy of data entered on the eCRF and other documents.  
The investigator will make all source data (i.e. the various study records, the eCRFs, laboratory 
test reports, other patient records, drug accountability forms, and other pertinent data) available 
for the monitor and allow access to them throughout the entire study period. Monitoring is done 
by comparing the relevant site records of the patients with the entries on the eCRF (i.e. source 
data verification). It is the monitor’s responsibility to verify the adherence to the study protocol 
and the completeness, consistency, and accuracy of the data recorded on the eCRFs.  
By agreeing to participate in the study, the investigator agrees to cooperate with the monitor to 
ensure that any problems detected in the course of the monitoring visits are resolved. Contact 
information for the study monitor is located in the investigator file. Representatives from Clovis 
Oncology may also contact and visit the investigators and monitor data during the study.  
13.5 Case Report Form 
The data will be collected using an electronic data capture (EDC) system by remote data entry on 
eCRFs. Sites will receive training on the EDC system. All users will be supplied with unique 
login credentials. 
Prior to study start, the investigator will prepare a list showing the signature and handwritten 
initials of all individuals authorized to make or change entries on eCRFs. This “study center 
personnel and delegation list” must be kept current throughout the study. 
For each patient enrolled, an eCRF should be completed and reviewed by the principal 
investigator or co-investigator within a reasonable time period (<2 weeks) after data collection. 
This also applies to records for those patients who fail to complete the study. If a patient 
withdraws from the study, the reason must be noted on the eCRF. If a patient is withdrawn from 
the study because of a treatment-limiting AE, thorough efforts should be made to clearly 
document the outcome. 
All laboratory data and investigator observations on the results and any other clinically 
significant test results must be documented on eCRFs. 
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Full information regarding electronic data capture and completing eCRFs is included in the 
investigator files. All questions or comments related to electronic capture should be directed to 
the assigned monitor. 
13.6 Study Termination and Site Closure 
Both the sponsor and the investigator reserve the right to terminate the study at any time. Should 
this be necessary, both parties will arrange discontinuation procedures. In terminating the study, 
Clovis Oncology and the investigator will assure that adequate consideration is given to the 
protection of the patients’ interests. 
Clovis Oncology reserves the right to discontinue the study at any time for medical or 
administrative reasons. When feasible, a 30 day written notification will be given. 
The entire study will be stopped if: 
• The protocol-specified treatment is considered too toxic to continue the study 
• Evidence has emerged that, in the opinion of the sponsor or the investigator(s), makes the 
continuation of the study unnecessary or unethical 
• The stated objectives of the study are achieved 
• The sponsor discontinues the development of oral rucaparib 
Regardless of the reason for termination, all data available for the patient at the time of 
discontinuation of follow-up must be recorded on the eCRF. All reasons for discontinuation of 
treatment must be documented. In terminating the study, the investigator will ensure that 
adequate consideration is given to the protection of the patients’ interests. 
13.7 Modification of the Study Protocol 
Protocol amendments, except when necessary to eliminate an immediate hazard to patients, must 
be made only with the prior approval of Clovis Oncology. Agreement from the investigator must 
be obtained for all protocol amendments and amendments to the informed consent document. 
The IEC/IRB must be informed of all amendments and give approval prior to their 
implementation. The sponsor will submit any study protocol amendments to the concerned 
regulatory authorities for approval and keep the investigator(s) updated as detailed in the ICH 
GCP guidelines. 
13.8 Retention of Study Documents 
The study site will maintain a study file, which should contain, at minimum, the Investigator’s 
Brochure, the protocol and any amendments, drug accountability records, correspondence with 
the IEC/IRB and Clovis Oncology, and other study-related documents. 
The investigator agrees to keep records and those documents that include (but are not limited to) 
the identification of all participating patients, medical records, study-specific source documents, 
source worksheets, all original signed and dated informed consent forms, copies of all eCRFs, 
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query responses, and detailed records of drug disposition to enable evaluations or audits from 
regulatory authorities and Clovis Oncology or its designees. 
The investigator shall retain records required to be maintained for a period of 5 years following 
the date a marketing application in an ICH region is approved for the drug for the indication for 
which it is being investigated or, if no application is to be filed or if the application is not 
approved for such indication, until at least 5 years after the investigation is discontinued. 
However, these documents should be retained for a longer period if required by the applicable 
regulatory requirement(s) or if needed by Clovis Oncology. In addition, the investigator must 
make provision for the patients’ medical records to be kept for the same period of time. 
No data should be destroyed without the agreement of Clovis Oncology. Should the investigator 
wish to assign the study records to another party or move them to another location, Clovis 
Oncology must be notified in writing of the new responsible person and/or the new location. 
Clovis Oncology will inform the investigator, in writing, when the trial-related records are no 
longer needed. 
Patients’ medical records and other original data will be archived in accordance with the 
archiving regulations or facilities of the investigational site. 
13.9 Clinical Study Report 
A clinical study report will be prepared under the responsibility and supervision of Clovis 
Oncology and signed by the sponsor’s chief medical officer, thereby indicating their agreement 
with the analyses, results, and conclusions of the clinical study report.  
13.10 Study Publication 
The results of this study will be published and/or presented at scientific meetings in a timely 
manner. Any formal publication of study results will be a collaborative effort between the 
sponsor and the investigator(s). All data generated from this study are the property of Clovis 
Oncology and shall be held in strict confidence along with all information furnished by Clovis 
Oncology. Independent analysis and/or publication of these data by the investigator(s) or any 
member of their staff are not permitted without the prior written consent of Clovis Oncology. 
Written permission to the investigator will be contingent on the review by Clovis Oncology of 
the statistical analysis and manuscript, and will provide for nondisclosure of Clovis Oncology 
confidential or proprietary information. In all cases, the parties agree to submit all manuscripts or 
abstracts to all other parties 30 days prior to submission. This will enable all parties to protect 
proprietary information and to provide comments based on information that may not yet be 
available to other parties. The sponsor may request a delay in publication if there are important 
intellectual property concerns relating to publication, but does not have the right to suppress 
publication of the study results indefinitely. 
Result of this pivotal study will also be posted to www.clinicaltrials.gov within 30 days of 
marketing approval for rucaparib in the US and to EudraCT within one year of the end of the 
trial. 
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13.11 Quality Assurance Audits 
An audit visit to clinical centers may be conducted by a quality control auditor appointed by 
Clovis Oncology. The purpose of an audit, which is independent of and separate from routine 
monitoring or quality control functions, is to evaluate trial conduct and compliance with the 
protocol, standard operating procedures (SOPs), ICH GCPs, and the applicable regulatory 
requirements. The investigator and the sponsor may also be subject to an inspection by FDA, 
European Regulatory authorities, or other applicable regulatory authorities at any time. The 
auditor and regulatory authorities will require authorization from the investigator to have direct 
access to the patients’ medical records. It is important that the investigator(s) and their staff 
cooperate with the auditor or regulatory authorities during this audit or inspection.  
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15.1 Appendix A 
List of Homologous Recombination Genes for HRD Stratification by the ICTA 
tBRCA nbHRD Biomarker-negative 
BRCA1 
BRCA2 
ATM 
ATR 
ATRX 
BARD1 
BLM 
BRIP1 
CHEK1 
CHEK2 
FANCA 
FANCC 
FANCD2 
FANCE 
FANCF 
FANCG 
FANCI 
FANCL 
FANCM 
MRE11A 
NBN 
PALB2 
RAD50 
RAD51 
RAD51B 
RAD51C 
RAD51D 
RAD52 
RAD54L 
RPA1 
Genes not included in 
the tBRCA or nbHRD 
groups 
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15.2 Appendix B 
Response Evaluation Criteria in Solid Tumors Criteria 
The RECIST guidelines (Version 1.1) are described in Eisenhauer (2009)31 and at 
http://www.eortc.be/Recist/Default.htm. A short summary is given below. 
Measurable Disease: 
Tumor lesions: measurable lesions are defined as those that can be accurately measured in at 
least one dimension (longest diameter to be recorded) with the following: 
• A minimum size of 10 mm by CT scan (CT scan thickness no greater than 5 mm). 
• A minimum size of 10 mm caliper measurement by clinical exam (lesions that cannot be 
accurately measured with calipers should be recorded as nonmeasurable). 
• A minimum size of 20 mm by chest X-ray. 
All tumor measurements must be recorded n millimeters (or decimal fractions of centimeters). 
Malignant lymph nodes: to be considered pathologically enlarged and measurable, a lymph node 
must be 15 mm in short axis when assessed by CT scan (CT scan slice thickness recommended 
to be not greater than 5 mm). At baseline and in follow-up, only the short axis will be measured 
and followed.  
Nonmeasurable Disease: 
All other lesions (or sites of disease), including small lesions (longest diameter < 10 mm or 
pathological lymph nodes with 10 to <15 mm short axis), as well as truly nonmeasurable 
lesions, are considered nonmeasurable disease. Lesions considered truly nonmeasurable include 
leptomeningeal disease, ascites, pleural/pericardial effusions, inflammatory breast disease, 
lymphangitic involvement of skin and lung, and abdominal masses/abdominal organomegaly 
identified by physical exam that is not measurable by reproducible imaging techniques.  
Bone Lesions 
Bone lesions, cystic lesion, and lesions previously treated with local therapy require particular 
comment. Bone scan, PET scan, or plain films are not considered adequate imaging techniques 
to measure bone lesions. However, these techniques can be used to confirm the presence or 
disappearance of bone lesions. 
Lytic bone lesions or mixed lytic–blastic lesions with identifiable soft tissue components that can 
be evaluated by cross-sectional imaging techniques such as CT or MRI can be considered as 
measurable lesions if the soft tissue component meets the definition of measurability described 
above. 
Blastic bone lesions are nonmeasurable. 
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Cystic Lesions 
Lesions that meet the criteria for radiographically defined simple cysts should not be considered 
as malignant lesions (neither measurable nor nonmeasurable) because they are, by definition, 
simple cysts. 
Cystic lesions thought to represent cystic metastases can be considered as measurable lesions if 
they meet the definition of measurability described above. However, if noncystic lesions are 
present in the same patient, these are preferred as target lesions. 
Lesions with Prior Local Treatment 
Tumor lesions situated in a previous irradiated area or in an area subjected to other locoregional 
therapy are usually not considered measurable unless there has been demonstrated progression in 
the lesion. 
Target Lesions 
All measurable lesions up to a maximum of two lesions per organ and five lesions in total, 
representative of all involved organs, should be identified as target lesions and recorded and 
measured at baseline. Target lesions should be selected on the basis of their size (lesions with the 
longest diameter) and their suitability for accurate repeated measurements (either by imaging 
techniques or clinically). A sum of the longest diameter (LD) for all target lesions will be 
calculated and reported as the baseline sum LD. The baseline sum LD will be used as reference 
by which to characterize the objective tumor response.  
Non target Lesions 
RECIST criteria require unequivocal quantification of the changes in tumor size for adequate 
interpretation of the sum of target lesions. Consequently, when the boundaries of the primary are 
difficult to delineate, this tumor should not be considered a target lesion. 
Guidelines for Evaluation of Measurable Disease 
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up. Imaging-based evaluation is 
preferred to evaluation by clinical examination when both methods have been used to assess the 
antitumor effect of a treatment. 
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Evaluation of Target Lesions 
Complete Response Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or nontarget) must have reduction in short axis to <10 
mm. 
Partial Response At least a 30% decrease in the sum of the LD of target lesions, taking as 
reference the baseline sum LD. 
Stable Disease Neither sufficient shrinkage to qualify for partial response nor sufficient 
increase to qualify for PD, taking as reference the smallest sum LD since 
the treatment started. 
Progressive Disease At least a 20% increase in the sum of the LD of target lesions, taking as 
reference the smallest sum on study (this includes the baseline sum if 
that is the smallest on study). In addition to the relative increase of 20%, 
the sum must also demonstrate an absolute increase of at least 5 mm. 
The appearance of one or more new lesions is also considered 
progression. 
Evaluation of Nontarget Lesions 
Complete Response Disappearance of all nontarget lesions and normalization of tumor 
marker level. 
Stable Disease/Incomplete 
Response 
Persistence of one or more nontarget lesion(s) or/and maintenance of 
tumor marker level above the normal limits. 
Progressive Disease Appearance of one or more new lesions and/or unequivocal progression 
of existing nontarget lesions. 
If tumor markers are initially above the institutional ULN, they must normalize for a patient to 
be considered a complete responder.  
Evaluation of Best Overall Response 
The best overall response is the best response recorded from the start of the treatment until 
disease progression/recurrence (taking as reference for PD the smallest measurements recorded 
since the treatment started). The patient’s best response assignment will depend on the 
achievement of both measurement and confirmation criteria.  
Evaluation of Best Overall Response 
Target Lesions Nontarget Lesions New Lesions Overall Response 
CR CR No CR 
CR Non-CR/non-PD No PR 
CR Not evaluated No PR 
PR Non-PD or not 
evaluated 
No PR 
SD Non-PD or not 
evaluated 
No SD 
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Evaluation of Best Overall Response 
Target Lesions Nontarget Lesions New Lesions Overall Response 
Not Evaluated Non-PD No NE 
PD Any Yes or No PD 
Any PD Yes or No PD 
Any Any Yes PD 
NE = Not evaluable. 
Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be classified as having 
symptomatic deterioration. Every effort should be made to document the objective progression, 
even after discontinuation of treatment. 
In some circumstances, it may be difficult to distinguish residual disease from normal tissue. 
When the evaluation of CR depends on this determination, it is recommended that the residual 
lesion be investigated (fine needle aspiration/biopsy) prior to confirming the complete response 
status. 
Confirmatory Measurement/Duration of Response 
Confirmation 
CT scans are required at screening and at the end of every 3rd cycle of treatment. 
Duration of Overall Response 
The duration of overall response is measured from the time measurement criteria are met for CR 
or PR (whichever is first recorded) until the first date that recurrent or PD is objectively 
documented (taking as reference for PD the smallest measurements recorded since the treatment 
started). 
The duration of overall CR is measured from the time measurement criteria are first met for CR 
until the first date that recurrent disease is objectively documented. 
Duration of Stable Disease 
SD is measured from the start of the treatment until the criteria for progression are met, taking as 
reference the smallest measurements recorded since the treatment started. 
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15.3 Appendix C 
Modified Gynecological Cancer Intergroup (GCIG) Guidelines  
GCIG Guidelines for Response Using CA-12532 (adapted for use in this trial) 
GCIG CA-125 definitions are available at http://gcig.igcs.org/CA-125.html.  
To be evaluable for response by CA-125 requires at least one pre-treatment sample >2 x ULN 
and two post-treatment samples confirming a response 
A response to CA-125 has occurred if there is at least a 50% decrease as the result of the 
treatment. The pre / post treatment samples must satisfy the following criteria: 
1. There must be at least one sample that is >2 x ULN prior to initiation of treatment 
2. The second sample (post-treatment) must be ≤ 50% of the pre-treatment sample; 
3. The confirmatory third sample must be ≥21 days after the second sample and ≤ 110% of 
the second sample; 
4. Any intervening samples between samples 2 and 3 must be ≤ 110% of the previous 
sample unless considered to be increasing because of tumor lysis. 
Per inclusion criteria #5, CA-125 must =be <ULN prior to study entry. This requirement applies 
to all patients, including those who achieved a best response of PR by serologic CA-125 
response criteria. Thus, patients must have achieved a >50% reduction in CA-125 level and also 
have CA-125 <ULN. 
Patients are not evaluable by CA-125 if they have received mouse antibodies or if there has been 
medical or surgical interference with their peritoneum or pleura during the previous 28 days.  
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15.4 Appendix D 
Eastern Cooperative Oncology Group (ECOG) Performance Status Scale 
ECOG Performance Status 
0 Fully active, able to carry on all predisease performance without restriction. 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature (eg, light house work or office work). 
2 Ambulatory and capable of all self care but unable to carry out any work activities. Up and 
about more than 50% of waking hours. 
3 Capable of only limited self care; confined to bed or chair more than 50% of waking hours. 
4 Completely disabled. Cannot carry on any self care. Totally confined to bed or chair. 
5 Dead. 
 
In the event performance status is assessed by the Karnofsky Performance Status scale, the 
following conversion chart applies. 
Karnofsky Performance Status ECOG Performance 
Status 
General Description Score Specific Description Score 
Able to carry on 
normal activity and to 
work; no special care 
needed 
100 Normal; no complaints; no 
evidence of disease 
0 
90 Able to carry on normal activity; 
minor signs or symptoms of 
disease 
1 
80 Normal activity with effort; 
some signs or symptoms of 
disease 
Unable to work; able 
to live at home and 
care for most personal 
needs; varying 
amount of assistance 
needed 
70 Cares for self, unable to carry on 
normal activity or to do active 
work 
2 
60 Requires occasional assistance, 
but is able to care for most of 
personal needs 
50 Requires considerable assistance 
and frequent medical care 
3 
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Karnofsky Performance Status ECOG Performance 
Status 
General Description Score Specific Description Score 
Unable to care for 
self; requires 
equivalent of 
institutional or 
hospital care; disease 
may be progressing 
rapidly 
40 Disabled; requires special care 
and assistance 
30 Severely disabled; hospital 
admission is indicated although 
death not imminent 
4 
20 Very sick; hospital admission 
necessary; active supportive 
treatment necessary 
10 Moribund; fatal processes 
progressing rapidly 
0 Dead 5 
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15.5 Appendix E  
National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy 
(NCCN-FACT) FACT - Ovarian Symptom Index (FOSI-18) instrument (NCCN-FACT 
FOSI-18) – English Version 
Sample form and background available at: http://www.facit.org/FACITOrg/Questionnaires.  
Patients will complete the instrument on an electronic device. This device is a Class 1 listed (i.e. 
approved) device. 
Below is a list of statements that other people with your illness have said are important.  
Please circle or mark one number per line to indicate your response as it applies to  
the past 7 days. 
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I am moderately anxious or depressed   
I am extremely anxious or depressed   
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15.6 Appendix F 
Examples of CYP Substrates with Narrow Therapeutic Range 
CYP Enzyme Substrates with Narrow Therapeutic Rangea 
CYP2C9 Warfarin, phenytoin  
CYP2C19 S-mephenytoin  
CYP3A Alfentanil, astemizole, cisapride, cyclosporine, dihydroergotamine, 
ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, 
terfenadine 
The table is based on the Draft FDA Guidance on Drug Interaction Studies — Study Design, Data Analysis, 
Implications for Dosing, and Labeling Recommendations, 2012 
(http://www fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf).48 
a CYP substrates with narrow therapeutic range refers to drugs whose exposure-response relationship indicates that 
small increases in their exposure levels by the concomitant use of CYP inhibitors may lead to serious safety 
concerns (eg, Torsades de Pointes). 
